Page last updated: 2024-11-04

choline

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Occurs in Manufacturing Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Choline is an essential nutrient that plays a vital role in various physiological processes, including neurotransmission, cell membrane integrity, and lipid metabolism. It is not synthesized in the body and must be obtained through diet or supplementation. Choline is a precursor to acetylcholine, a neurotransmitter involved in muscle contraction, memory, and learning. It is also a component of phosphatidylcholine, a key phospholipid in cell membranes. Choline has been studied for its potential benefits in cognitive function, cardiovascular health, and pregnancy outcomes. Research suggests that adequate choline intake may improve memory, reduce the risk of neural tube defects in newborns, and protect against age-related cognitive decline. However, further research is needed to fully understand its long-term effects. Choline deficiency can lead to various health problems, including liver damage, muscle weakness, and impaired cognitive function.'

Cross-References

ID SourceID
PubMed CID305
CHEMBL ID920
CHEBI ID15354
SCHEMBL ID3142
MeSH IDM0004283

Synonyms (97)

Synonym
CHEBI:15354 ,
n-trimethylethanolamine
trimethylethanolamine
DIVK1C_000107
KBIO1_000107
einecs 200-535-1
brn 1736748
nsc-6393
nsc6393
SPECTRUM_000258
lopac-c-1754
NCGC00015219-01
nsc402838
2-hydroxy-n,n,n-trimethylammonium chloride
2-hydroxyethyl(trimethyl)ammonium
LOPAC0_000180
SPECTRUM5_001579
ethanaminium, 2-hydroxy-n,n,n-trimethyl-
2-hydroxy-n,n,n-trimethylethanaminium
inchi=1/c5h14no/c1-6(2,3)4-5-7/h7h,4-5h2,1-3h3/q+
cholinum
choline ion
ethanaminium, 2-hydroxy-n,n,n-trimethyl- (9ci)
CHT ,
(beta-hydroxyethyl)trimethylammonium
ccris 5847
choline cation
choline (8ci)
ai3-24208
choline ,
bilineurine
C00114
62-49-7
(2-hydroxyethyl)trimethylammonium
n,n,n-trimethylethanol-ammonium
1OBA
vitamin j
DB00122
IDI1_000107
KBIO2_000738
KBIO2_003306
KBIO2_005874
KBIOGR_001533
KBIOSS_000738
SPECTRUM2_001938
NINDS_000107
SPBIO_001975
SPECTRUM4_000867
NCGC00162082-01
2HA3
NCGC00015219-03
CHEMBL920 ,
BMSE000285
choline (dcf)
D07690
2-hydroxyethyl(trimethyl)azanium
bdbm50026220
STL137772
AKOS005721137
BBL005532
BMSE000953
BMSE001003
CCG-204275
NCGC00015219-04
NCGC00015219-02
unii-n91bdp6h0x
n91bdp6h0x ,
3-04-00-00651 (beilstein handbook reference)
nanoveson c
acetylcholine chloride impurity a [ep impurity]
choline [vandf]
choline [mi]
2-hydroxyethyl)trimethylammonium
choline [who-dd]
carbachol impurity a [ep impurity]
(.beta.-hydroxyethyl)trimethylammonium
EPITOPE ID:116046
(2-hydroxyethyl)trimethylazanium
gtpl4551
SCHEMBL3142
2REG
3R6U
3PPQ
OEYIOHPDSNJKLS-UHFFFAOYSA-N
mono-2-hydroxyethyltrimethylammonium
2-hydroxy-n,n,n-trimethyl-ethanaminium
DTXSID8043789
AB00053822_02
SBI-0050168.P003
n,n,n-trimethylethanolammonium
(2-hydroxyethyl)trimethyl ammonium
Q193166
NCGC00015219-10
bilineurine; choline cation; choline ion; nanoveson c; vitamin j
NCGC00015219-07
2-hydroxyethyl-trimethyl-ammonium
carbachol impurity a (ep impurity)

Research Excerpts

Overview

Choline is an essential nutrient under evaluation as a cognitive enhancing treatment for fetal alcohol spectrum disorders (FASD) in clinical trials. Choline is a precursor of the major neurotransmitter acetylcholine and has been demonstrated beneficial in diverse models of cardiovascular disease.

ExcerptReferenceRelevance
"Choline is an essential nutrient under evaluation as a cognitive enhancing treatment for fetal alcohol spectrum disorders (FASD) in clinical trials. "( Effects of prenatal ethanol exposure on choline-induced long-term depression in the hippocampus.
Christie, BR; Fontaine, CJ; Grafe, EL; Thomas, JD, 2021
)
2.33
"Choline is an essential nutrient for humans and is involved in various physiologic functions. "( Assessment of Dietary Choline Intake, Contributing Food Items, and Associations with One-Carbon and Lipid Metabolites in Middle-Aged and Elderly Adults: The Hordaland Health Study.
Brække, MS; Dierkes, J; Haugsgjerd, TR; Karlsson, T; Lysne, V; Nygård, O; Tell, GS; Ueland, PM; Van Parys, A; Vinknes, KJ; Øyen, J, 2022
)
2.48
"Choline is an officially established essential nutrient and precursor of the neurotransmitter acetylcholine. "( Enhanced Electrocatalytic Detection of Choline Based on CNTs and Metal Oxide Nanomaterials.
Fayemi, OE; Uwaya, GE, 2021
)
2.33
"Choline is an important nutrient during the first 1000 days post conception due to its roles in brain function. "( Habitual Choline Intakes across the Childbearing Years: A Review.
Derbyshire, E; Obeid, R; Schön, C, 2021
)
2.48
"Choline is an over-the-counter supplement and essential nutrient that has many health benefits."( Choline supplementation influences ovarian follicular development.
Baracuhy, E; Dingle, S; Fletcher, L; Huber, LA; Li, J; Wang, B; Zhan, X, 2021
)
2.79
"Choline is an important nutrient, playing key roles in numerous metabolic pathways relevant to animal health."( Choline diet improves serum lipid parameters and alters egg composition in breeder ducks.
Li, X; Shi, X; Song, J; Zheng, J, 2022
)
3.61
"Choline is an important factor for regulating human health and is widely present in various foods. "( Choline Oxidase-Integrated Copper Metal-Organic Frameworks as Cascade Nanozymes for One-Step Colorimetric Choline Detection.
Fang, S; Huang, H; Li, Y; Liang, Z; Song, D; Zhang, H; Zhang, W; Zhou, Q, 2022
)
3.61
"Choline is a precursor of the major neurotransmitter acetylcholine and has been demonstrated beneficial in diverse models of cardiovascular disease. "( Choline Protects the Heart from Doxorubicin-Induced Cardiotoxicity through Vagal Activation and Nrf2/HO-1 Pathway.
Guo, F; Hu, R; Jiang, H; Lai, Y; Li, Z; Liu, Z; Wang, J; Wang, M; Wang, Y; Xu, X; Yu, F; Zhou, L; Zhou, Y; Zhou, Z, 2022
)
3.61
"Choline is an essential nutrient linked to hepatic lipid metabolism in many animal species, including cats. "( Dose-response relationship between dietary choline and serum lipid profile, energy expenditure, and respiratory quotient in overweight adult cats fed at maintenance energy requirements.
Bakovic, M; Godfrey, H; Grant, CE; Kirby, G; Rankovic, A; Shoveller, AK; Verbrugghe, A, 2022
)
2.43
"Choline is an essential nutrient important for lipid metabolism in the liver of many mammals. "( Dose-response relationship between dietary choline and serum lipid profile, energy expenditure, and respiratory quotient in overweight adult cats fed at maintenance energy requirements.
Bakovic, M; Godfrey, H; Grant, CE; Kirby, G; Rankovic, A; Shoveller, AK; Verbrugghe, A, 2022
)
2.43
"Choline is an essential nutrient for mammalian cells. "( Metabolic Labeling-Based Chemoproteomics Establishes Choline Metabolites as Protein Function Modulators.
Dixit, A; Jose, GP; Kalia, J; Shanbhag, C; Tagad, N, 2022
)
2.41
"Choline is an amine osmolyte with antioxidant potential. "( Short Report: Choline plasma levels are related to Nrf2 transcriptional expression in chronic kidney disease?
Bergman, P; Cardozo, L; Mafra, D; Ribeiro-Alves, M; Shiels, PG; Stenvinkel, P, 2022
)
2.52
"Choline is an essential nutrient with many roles in brain development and function. "( Choline Improves Neonatal Hypoxia-Ischemia Induced Changes in Male but Not Female Rats.
Adeyemo, T; Banerjee, A; Bumgardner, JG; Jaiyesimi, A; Lohr, C; McKenna, MC; Waddell, J, 2022
)
3.61
"Choline is an essential nutrient that is involved in various developmental processes during pregnancy. "( Inadequate Choline Intake in Pregnant Women in Germany.
Kordowski, A; Roeren, M; Sina, C; Smollich, M, 2022
)
2.55
"Choline is an essential micronutrient that may influence growth and development; however, few studies have examined postnatal choline status and children's growth and development in low- and middle-income countries. "( The association between plasma choline, growth and neurodevelopment among Malawian children aged 6-15 months enroled in an egg intervention trial.
Arnold, CD; Beckner, AG; Bennett, BJ; Bragg, MG; Caswell, BL; DeBolt, MC; George, M; Maleta, KM; Oakes, LM; Prado, EL; Stewart, CP, 2023
)
2.64
"Choline acts as a determinative element for appropriate cell membrane functions."( The Influence of Rumen-Protected Choline and α-tocopherol Supplementation on Early Lactating Dairy Cows Metabolism.
Abdul Ali, A; Ali Yaseen, M; Ameen Baqer, A; Ayad Kareem, H; Hachim, SK; Hamad, DA; Hussein Adhab, Z; Lafta, HA; Salam Karim, Y; Shaker Hamza, I, 2022
)
1.72
"Choline is an essential micronutrient for many physiological processes related to exercise training including biosynthesis of acetylcholine. "( Low Intake of Choline Is Associated with Diminished Strength and Lean Mass Gains in Older Adults.
Bui, S; Chen, VCW; Crouse, SF; Fluckey, JD; Galvan, E; Lee, CW; Lee, TV; Riechman, SE; Smith, SB, 2023
)
2.71
"Choline is an essential nutrient affects brain development in early life. "( Choline Intake and Cognitive Function Among U.S. Older Adults.
An, R; Li, D; Xiang, X,
)
3.02
"Choline is a semi-essential nutrient involved in lipid and one-carbon metabolism that is compromised during MAFLD progression."( Prenatal Choline Supplement in a Maternal Obesity Model Modulates Offspring Hepatic Lipidomes.
Bretter, R; Caviglia, JM; Jiang, X; Johnson, CH; Kadam, I; Korsmo, HW; Reaz, A; Saxena, A, 2023
)
2.05
"Choline is an important metabolite involved in phospholipids synthesis, including serum lipids, and is the immediate precursor of betaine. "( Dietary choline and betaine intake, cardio-metabolic risk factors and prevalence of metabolic syndrome among overweight and obese adults.
Abbasi, MSP; Ardekani, AM; Gharebakhshi, F; Jafarzadeh, F; Manzouri, A; Nikrad, N; Tousi, AZ; Vahdat, S; Yazdani, Y, 2023
)
2.79
"Choline is an essential micronutrient in fetal brain maturation."( Maternal choline supplementation during pregnancy to promote mental health in offspring.
Eijsink, JJH; Hoenders, HJR; Knegtering, H; Spoelstra, SK, 2023
)
2.05
"Choline is an essential nutrient that plays an integral role in all stages of the life cycle, with increasing interest in the relationship between choline and neurodevelopment. "( [Advances in basic research on choline and central nervous system development and related disorders].
Song, YY; Tan, XY; Xia, ZL, 2023
)
2.64
"Choline is an essential nutrient that must be obtained from the diet and its deficiency promotes fatty liver disease in a process dependent on ASM activity."( Modulation of Dietary Choline Uptake in a Mouse Model of Acid Sphingomyelinase Deficiency.
Casas, J; Gaudioso, Á; Ledesma, MD; Moreno-Huguet, P; Schuchman, EH, 2023
)
1.95
"Choline is an essential micronutrient important for fetal brain development. "( [The influence of maternal choline supplementation on fetal brain development and the risk of psychotic symptoms].
Eijsink, JJH; Hoenders, HJR; Knegtering, H; Spoelstra, SK, 2023
)
2.65
"Choline is an essential nutrient that plays a role in the synthesis of the phospholipid membrane, critical for cell functions, and it is the major source of methyl donors relevant for epigenetic modifications of the genome [...]."( Choline: An Essential Nutrient for Human Health.
Gallo, M; Gámiz, F, 2023
)
3.8
"Choline is a precursor of trimethylamine oxide and its role in PH remains unknown."( Circulating choline levels are associated with prognoses in patients with pulmonary hypertension: a cohort study.
Liang, Y; Liu, B; Liu, Z; Luo, Q; Xiong, C; Yang, B; Yang, Y; Zeng, Q; Zhao, Z, 2023
)
2.01
"Choline is an essential nutrient, and its deficiency causes steatohepatitis. "( Intestinal Atp8b1 dysfunction causes hepatic choline deficiency and steatohepatitis.
Abukawa, D; Ando, T; Azuma, Y; Fukuda, A; Hayashi, H; Inui, A; Kaji, S; Kasahara, M; Kusuhara, H; Mizuno, S; Mizuno, T; Nakano, S; Okamoto, T; Sabu, Y; Sakamoto, S; Shimizu, S; Suzuki, M; Takahashi, S; Tamura, R; Zen, Y, 2023
)
2.61
"Choline is a crucial nutrient essential for cellular metabolism, requiring consumption from foods or supplements due to inadequate endogenous synthesis."( Advancing nutrition science to meet evolving global health needs.
Green, M; Griffiths, JC; Ho, E; Huber, LG; Neufeld, LM; Obeid, R; Stout, M; Tzoulis, C, 2023
)
1.63
"Choline-based BIL is a structural precursor of the phospholipid bilayer in the cell membrane."( Bioionic Liquid Conjugation as Universal Approach To Engineer Hemostatic Bioadhesives.
Ellis, E; Hannah, T; Hazelton, J; Kanjilal, B; Kapetanakis, A; Krishnadoss, V; Leijten, J; Masoumi, A; Melillo, A; Noshadi, I; San Roman, J, 2019
)
1.24
"Choline is a positively charged quaternary ammonium compound that requires transporters to pass through the plasma membrane."( Functional Expression of Choline Transporters in the Blood-Brain Barrier.
Inazu, M, 2019
)
1.54
"Choline is a B-like vitamin nutrient found in common foods that is important in various cell functions."( Lifelong choline supplementation ameliorates Alzheimer's disease pathology and associated cognitive deficits by attenuating microglia activation.
Ferreira, E; Fux, C; Knowles, S; Oddo, S; Rodin, A; Velazquez, R; Winslow, W, 2019
)
1.65
"Choline is a vitamin-like essential nutrient, important throughout one's lifespan. "( Natural Choline from Egg Yolk Phospholipids Is More Efficiently Absorbed Compared with Choline Bitartrate; Outcomes of A Randomized Trial in Healthy Adults.
Balvers, MGJ; de Wit, NJW; Esser, D; Obeid, R; Smolders, L; Vissers, MMM, 2019
)
2.39
"Choline is a micronutrient and a methyl donor that is required for normal brain growth and development."( Neuroprotective Effects of Choline and Other Methyl Donors.
Bekdash, RA, 2019
)
1.53
"Choline is an essential nutrient required for normal neuronal and muscular development, as well as homeostatic regulation of hepatic metabolism. "( In Vitro Hepatitis C Virus Infection and Hepatic Choline Metabolism.
Crawley, AM; Fullerton, MD; Ghorbani, P; Gobeil Odai, K; Han, S; Langlois, MA; O'Dwyer, C; Pezacki, JP; Renner, TM; Rezaaifar, M; Russell, RS; Shaw, TA; Steenbergen, R; Tyrrell, DL, 2020
)
2.26
"Choline is an essential nutrient for brain growth and other processes in the developing neonate. "( Total Water-Soluble Choline Concentration Does Not Differ in Milk from Vegan, Vegetarian, and Nonvegetarian Lactating Women.
Allen, LH; Hampel, D; Pawlak, R; Perrin, MT, 2020
)
2.32
"F-choline PET/CT is a potential tool for predicting sPCa in patients with persistently increased PSA levels and previous negative biopsies, and also it could improve the performance of score risk in predicting sPCa."( 18F-choline PET/computed tomography and clinical parameters in the detection of significant prostate cancer in patients with increased prostate-specific antigen levels and previous negative biopsies.
Amo-Salas, M; Fúnez Mayorga, F; García Vicente, AM; Jiménez Londoño, GA; López Guerrero, MA; Noriega Álvarez, E; Pena Pardo, FJ; Soriano Castrejón, ÁM, 2020
)
1.84
"Choline is an essential nutrient for fetal and infant growth and development. "( Serum choline in extremely preterm infants declines with increasing parenteral nutrition.
Hellgren, G; Hellström, A; Löfqvist, C; Lund, AM; Malmodin, D; Nilsson, AK; Pedersen, A; Pupp, IH, 2021
)
2.54
"Choline is an essential micronutrient with a pivotal role in several metabolic pathways contributing to liver, neurological, and hematological homeostasis. "( Choline: An Essential Nutrient for Skeletal Muscle.
Bertone, M; Iolascon, G; Liguori, S; Moretti, A; Paoletta, M; Toro, G, 2020
)
3.44
"Choline is a dietary component that is crucial for normal cellular function."( Effects of choline supplementation on liver biology, gut microbiota, and inflammation in Helicobacter pylori-infected mice.
Cao, M; Chen, J; Huang, M; Li, S; Liu, Y; Wu, D; Wu, M; Yan, S; Yu, Z; Zhao, J; Zhou, J, 2020
)
1.67
"Choline is a water-soluble nutrient essential for human life. "( The Relationship between Choline Bioavailability from Diet, Intestinal Microbiota Composition, and Its Modulation of Human Diseases.
Allison, J; Arboleya, S; Arias, JL; Arias, N; Gueimonde, M; Higarza, SG; Kaliszewska, A, 2020
)
2.3
"Choline is a tightly regulated tissue component in the form of phosphatidylcholine (Ptd'Cho) and sphingomyelin (SPH) in all membranes and many secretions, particularly of liver (bile, lipoproteins) and lung (surfactant, lipoproteins)."( Choline in cystic fibrosis: relations to pancreas insufficiency, enterohepatic cycle, PEMT and intestinal microbiota.
Bernhard, W, 2021
)
2.79
"Choline is a precursor of acetylcholine, phosphatidylcholine, and the methyl-donor betaine. "( Effects of choline on the phenotype of the cultured bovine preimplantation embryo.
Estrada-Cortés, E; Hansen, PJ; Negrón-Peréz, VM; Staples, CR; Tríbulo, P; Zenobi, MG, 2020
)
2.39
"Choline is an important nutrient involved in multiple biosynthesis pathways. "( Circulating choline is associated with coronary artery stenosis in patients with hypertension: A cross-sectional study of Chinese adults.
Guo, F; Li, Z; Ouyang, D; Qiu, X; Tan, Z; Zhu, Y, 2020
)
2.38
"Choline is a critical nutrient for cognitive development, metabolism and liver function, and regulation of homocysteine metabolism. "( [Importance of choline in cognitive function].
Aparicio, A; López-Sobaler, AM; Lorenzo Mora, AM; Ortega, RMª; Peral Suárez, Á; Salas González, MªD, 2021
)
2.42
"Choline is an essential human nutrient that is particular important for proliferating cells, and altered choline metabolism has been associated with cancer transformation. "( Mapping choline metabolites in normal and transformed cells.
Jain, M; Lagerborg, KA; Nilsson, R; Roci, I; Watrous, JD, 2020
)
2.44
"Choline is an essential nutrient and a primary dietary source of methyl groups that are vital for brain development. "( Low Maternal Dietary Intake of Choline Regulates Toll-Like Receptor 4 Expression Via Histone H3K27me3 in Fetal Mouse Neural Progenitor Cells.
Bai, Y; Chen, X; Dai, L; Guan, X; Ma, J; Qu, S; Wang, Y; Zhang, Q, 2021
)
2.35
"Choline is an important nutrient during pregnancy and lactation. "( Liver choline metabolism and gene expression in choline-deficient mice offspring differ with gender.
Akiyama, K; Kumrungsee, T; Miyachi, Y; Tsukuda, Y; Yanaka, N, 2021
)
2.54
"Choline is a dietary precursor to the gut microbial generation of the prothrombotic and proatherogenic metabolite trimethylamine-N-oxide (TMAO). "( Dietary Choline Supplements, but Not Eggs, Raise Fasting TMAO Levels in Participants with Normal Renal Function: A Randomized Clinical Trial.
Fu, X; Graham, B; Hazen, SL; Li, L; Li, XS; Neale, S; O'Laughlin, C; Peterson, K; Shelkay, S; Skye, SM; Tang, WHW; Wilcox, J; Zabell, A, 2021
)
2.5
"Choline is an essential nutrient; however, the associations of choline and its related metabolites with cardiometabolic risk remain unclear."( Associations of circulating choline and its related metabolites with cardiometabolic biomarkers: an international pooled analysis.
Albanes, D; Cai, H; Cai, Q; Eliassen, H; Elliott, P; Fornage, M; Gerszten, RE; Guasch-Ferré, M; Harada, S; Herrington, DM; Karaman, I; Lipworth, LP; Matthews, CE; Menni, C; Meyer, KA; Moore, SC; Ose, J; Palmer, ND; Pan, XF; Shu, XO; Tzoulaki, I; Ulrich, CM; Wagenknecht, LE; Wang, TJ; Yang, JJ; Yu, D; Zheng, W; Zhu, H, 2021
)
2.36
"Choline is an organic water-soluble compound that can regulate a series of vital biological process, including cellular structural integrity and oxidative stress."( Choline attenuates heat stress-induced oxidative injury and apoptosis in bovine mammary epithelial cells by modulating PERK/Nrf-2 signaling pathway.
Ali, I; Kuang, M; Li, L; Li, Y; Tang, Y; Wang, G; Yang, C; Yang, M, 2021
)
2.79
"Choline is a key nutrient in fetal brain development."( Maternal prenatal choline and inflammation effects on 4-year-olds' performance on the Wechsler Preschool and Primary Scale of Intelligence-IV.
Balser, M; D'Alessandro, A; Freedman, R; Hoffman, MC; Hunter, SK; Law, AJ; Noonan, K; Walker, VK, 2021
)
1.68
"Choline is an essential nutrient in laying hen diets and is needed for the formation of phosphatidylcholine (PC), that serves as a rich source of long chain (≥20 C) n-3 fatty acids (FA) in eggs. "( Choline and methionine supplementation in layer hens fed flaxseed: effects on hen production performance, egg fatty acid composition, tocopherol content, and oxidative stability.
Aziza, AE; Beheshti Moghadam, MH; Cherian, G, 2021
)
3.51
"Choline is an essential macronutrient involved in neurotransmitter synthesis, cell-membrane signaling, lipid transport, and methyl-group metabolism. "( Understanding Choline Bioavailability and Utilization: First Step Toward Personalizing Choline Nutrition.
Cheam, G; Goh, YQ; Wang, Y, 2021
)
2.42
"Choline is an essential nutrient for humans. "( Neuroprotective Actions of Dietary Choline.
Blusztajn, JK; Mellott, TJ; Slack, BE, 2017
)
2.17
"Choline is an essential nutrient and methyl donor required for epigenetic regulation. "( Metabolic, Epigenetic, and Transgenerational Effects of Gut Bacterial Choline Consumption.
Amador-Noguez, D; Balskus, EP; Chittim, CL; Kasahara, K; Martinez-Del Campo, A; Rey, FE; Romano, KA; Vivas, EI, 2017
)
2.13
"Choline is an essential nutrient utilized for phosphatidylcholine biosynthesis and lipoprotein packaging and secretion. "( Four-week dietary supplementation with 10- and/or 15-fold basal choline caused decreased body weight in Sprague Dawley rats.
Bagley, BD; Butenhoff, JL; Chang, SC; Ehresman, DJ; Eveland, A; Parker, GA; Peters, JM, 2017
)
2.14
"Choline is a crucial methyl donor necessary for epigenetic regulation. "( Choline Theft-An Inside Job.
Claus, SP; Mora-Ortiz, M, 2017
)
3.34
"Choline is an essential nutrient that is required for synthesis of the main eukaryote phospholipid, phosphatidylcholine. "( Choline transport links macrophage phospholipid metabolism and inflammation.
Bennett, SAL; Fullerton, MD; Ghorbani, P; LeBlond, ND; Margison, KD; Nguyen, T; Nunes, JRC; O'Dwyer, C; Snider, SA; Xu, H, 2018
)
3.37
"Choline is an important nutrient during development. "( Plasma Betaine Is Positively Associated with Developmental Outcomes in Healthy Toddlers at Age 2 Years Who Are Not Meeting the Recommended Adequate Intake for Dietary Choline.
Chau, CMY; Devlin, AM; Dyer, RA; Grunau, RE; Innis, SM; McCarthy, D; Wiedeman, AM; Yurko-Mauro, K, 2018
)
2.12
"Choline deprivation is a recognized experimental approach to nonalcoholic steatohepatitis, while thioacetamide (TAA)-induced liver fibrosis resembles alcoholic liver fibrogenesis. "( "Extracellular matrix remodelling in the liver of rats subjected to dietary choline deprivation and/or thioacetamide administration".
Al-Humadi, H; Al-Saigh, R; Alhumadi, A; Gazouli, M; Lazaris, AC; Liapi, C; Strilakou, A, 2018
)
2.15
"Choline is an essential nutrient for the growth and development of the baby, and therefore it is often added to infant formula. "( Detection of choline and hydrogen peroxide in infant formula milk powder with near infrared upconverting luminescent nanoparticles.
Hou, J; Huang, H; Li, Y; Yin, S; Yu, C; Zhang, L; Zhang, W, 2019
)
2.33
"Choline is an essential nutrient, with increased requirements during development. "( Choline and choline-related nutrients in regular and preterm infant growth.
Bernhard, W; Franz, AR; Poets, CF, 2019
)
3.4
"Choline is a vitamin-like nutrient that is taken up via specific transporters and metabolized by choline kinase, which converts it to phosphocholine needed for de novo synthesis of phosphatidylcholine (PC), the main phospholipid of cellular membranes. "( Choline Uptake and Metabolism Modulate Macrophage IL-1β and IL-18 Production.
Antonucci, L; Booshehri, LM; Guma, M; Hoffman, HM; Karin, M; Lacal, JC; Liu-Bryan, R; Lodi, A; Murphy, AN; Sanchez-Lopez, E; Stubelius, A; Sweeney, SR; Terkeltaub, R; Tiziani, S; Zhong, Z, 2019
)
3.4
"Choline is a vital metabolite in plant and synthesized from phosphocholine by phosphocholine phosphatase. "( Expression and functional characterization of sugar beet phosphoethanolamine/phosphocholine phosphatase under salt stress.
Cha-Um, S; Kito, K; Maeda, T; Rai, V; Sahashi, K; Takabe, T; Tanaka, Y; Yamada-Kato, N, 2019
)
2.18
"Choline is an essential nutrient for proper liver, muscle, and brain functions as well as for lipid metabolism and cellular membrane composition and repair. "( Choline: The Neurocognitive Essential Nutrient of Interest to Obstetricians and Gynecologists.
Blusztajn, JK; Caudill, MA; Klatt, KC; Wallace, TC; Zeisel, SH, 2020
)
3.44
"Choline is an important methyl donor needed for the generation of S-adenosylmethionine."( Choline's role in maintaining liver function: new evidence for epigenetic mechanisms.
Mehedint, MG; Zeisel, SH, 2013
)
2.55
"Choline is a selective agonist at α7-type nicotinic receptors that does not have addictive or sympathetic activating properties."( Oral choline supplementation for postoperative pain.
Davies, S; Flood, P; Mercier, RJ; Nadarajah, A; Rivera, J; Sidhu, N; Virag, L; Wang, S; Whittington, R, 2013
)
1.63
"Choline is a general anti-herbivore and pathogen deterrent."( Metabolic responses of Quercus ilex seedlings to wounding analysed with nuclear magnetic resonance profiling.
Filella, I; Gargallo-Garriga, A; Parella, TJ; Peñuelas, J; Pérez-Trujillo, M; Sardans, J; Seco, R, 2014
)
1.12
"Choline (Ch) is a precursor and metabolite of the neurotransmitter acetylcholine (ACh). "( Voltage sensitivity of M2 muscarinic receptors underlies the delayed rectifier-like activation of ACh-gated K(+) current by choline in feline atrial myocytes.
Aréchiga-Figueroa, IA; Benavides-Haro, DE; Moreno-Galindo, EG; Navarro-Polanco, RA; Rodríguez-Elías, JC; Sachse, FB; Salazar-Fajardo, PD; Sánchez-Chapula, JA; Tristani-Firouzi, M, 2013
)
2.04
"Choline is a water-soluble essential nutrient, used as a dietary supplement in different diseases."( Choline associated hypersexuality in a 79-year-old man.
Bramanti, P; Calabrò, RS; Cordici, F; Genovese, C, 2014
)
2.57
"Choline is an essential nutrient for eukaryotic cells, where it is used as precursor for the synthesis of choline-containing phospholipids, such as phosphatidylcholine (PC). "( Characterization of choline uptake in Trypanosoma brucei procyclic and bloodstream forms.
Bütikofer, P; Macêdo, JP; Mäser, P; Rentsch, D; Schmidt, RS; Sigel, E; Vial, HJ, 2013
)
2.16
"Choline is a precursor for the synthesis of phosphatidylcholine through the CDP-choline pathway. "( Choline transport activity regulates phosphatidylcholine synthesis through choline transporter Hnm1 stability.
Fernández-Murray, JP; McMaster, CR; Ngo, MH, 2013
)
3.28
"Choline is an important component of human breast milk and its content varies considerably among breastfeeding women and lactation periods."( Breast milk choline contents are associated with inflammatory status of breastfeeding women.
Cansev, M; Ozarda, Y; Ulus, IH, 2014
)
2.22
"F-choline PET/CT is an important diagnostic tool in the management of patients with prostate cancer (PC). "( (18)F-choline PET/CT pitfalls in image interpretation: an update on 300 examined patients with prostate cancer.
Calabria, F; Chiaravalloti, A; Schillaci, O, 2014
)
1.6
"Choline is an essential nutrient, and choline deficiency has been associated with cardiovascular morbidity. "( Carnitine modulates crucial myocardial adenosine triphosphatases and acetylcholinesterase enzyme activities in choline-deprived rats.
Kalafatakis, KG; Karkalousos, PL; Koulouris, AV; Liapi, CA; Mourouzis, IS; Strilakou, AA; Stylianaki, AT; Tsakiris, ST, 2014
)
2.08
"Choline is an essential nutrient that is required for normal human liver and muscle functions and important for normal fetal development."( Effect of egg ingestion on trimethylamine-N-oxide production in humans: a randomized, controlled, dose-response study.
Bennett, BJ; Blevins, T; Corbin, KD; da Costa, KA; Galanko, JA; Miller, CA; O'Connor, A; Zeisel, SH; Zhang, S; Zhao, X, 2014
)
1.12
"Choline is an essential nutrient required for the biosynthesis of membrane lipid phosphatidylcholine (PtdCho). "( Palmitic acid and oleic acid differentially regulate choline transporter-like 1 levels and glycerolipid metabolism in skeletal muscle cells.
Bakovic, M; Schenkel, LC, 2014
)
2.09
"Choline is a precursor of the neurotransmitter acetylcholine, whereas PA functions as an intracellular lipid mediator of diverse biological functions."( Detection of choline and phosphatidic acid (PA) catalyzed by phospholipase D (PLD) using MALDI-QIT-TOF/MS with 9-aminoacridine matrix.
Daitoku, H; Fukamizu, A; Kako, K; Kim, JD; Matsui, M; Nagashima, Y; Park, GG; Park, KE, 2014
)
1.49
"Choline is a fundamental nutrient for brain development and high choline intake during prenatal and/or early postnatal periods is neuroprotective."( High maternal choline consumption during pregnancy and nursing alleviates deficits in social interaction and improves anxiety-like behaviors in the BTBR T+Itpr3tf/J mouse model of autism.
Blusztajn, JK; Krykbaeva, M; Langley, EA; Mellott, TJ, 2015
)
1.5
"Choline kinase (CK) is a homodimeric enzyme that catalyses the transfer of the ATP γ-phosphate to choline, generating phosphocholine and ADP in the presence of magnesium. "( Choline kinase active site provides features for designing versatile inhibitors.
Carrasco, MP; Entrena, A; Hurtado-Guerrero, R; López-Cara, LC; Macchiarulo, A; Marco, C; Nuti, R; Ríos-Marco, P; Serran-Aguilera, L, 2014
)
3.29
"Choline is a water-soluble nutrient essential for human life. "( Intestinal microbiota composition modulates choline bioavailability from diet and accumulation of the proatherogenic metabolite trimethylamine-N-oxide.
Amador-Noguez, D; Rey, FE; Romano, KA; Vivas, EI, 2015
)
2.12
"Choline is an essential nutrient, and its deficiency is related to PN-associated organ diseases."( Choline Alleviates Parenteral Nutrition-Associated Duodenal Motility Disorder in Infant Rats.
Cai, W; Guo, Y; Huang, H; Lu, T; Tang, Q; Wu, Y; Zhu, J, 2016
)
2.6
"Choline is an essential nutrient, and the amount needed in the diet is modulated by several factors. "( Evidence for negative selection of gene variants that increase dependence on dietary choline in a Gambian cohort.
Corbin, KD; da Costa, KA; Dominguez-Salas, P; Hellenthal, G; Hennig, BJ; Moore, SE; Owen, J; Prentice, AM; Silver, MJ; Zeisel, SH, 2015
)
2.08
"Choline is a water-soluble essential nutrient included as a member of the vitamin B12 group owing to its structural similarities with that of the other members of the group. "( Importance of choline as essential nutrient and its role in prevention of various toxicities.
Biswas, S; Giri, S, 2015
)
2.22
"Choline is an essential nutrient, but many diets in the USA are choline deficient."( Choline Ameliorates Deficits in Balance Caused by Acute Neonatal Ethanol Exposure.
Bearer, CF; He, M; Mooney, SM; Tang, N; Wellmann, KA, 2015
)
2.58
"Choline is a precursor to phosphatidylcholine (PC), a structural molecule in cellular membranes that is crucial for cell growth and function. "( Choline deficiency impairs intestinal lipid metabolism in the lactating rat.
Curtis, JM; da Silva, RP; Field, CJ; Goruk, S; Jacobs, RL; Kelly, KB; Leonard, KA; Lewis, ED; Proctor, SD; Vine, DF, 2015
)
3.3
"Choline is a precursor of both betaine and acetylcholine and might, therefore, influence cardiovascular and cognitive outcomes. "( Effects of choline on health across the life course: a systematic review.
Bautista, PK; Bramer, WM; Chowdhury, R; Darweesh, SK; Felix, JF; Franco, OH; Gorman, D; Kiefte-de Jong, JC; Leermakers, ET; Moreira, EM; Visser, T; Voortman, T, 2015
)
2.25
"¹⁸F-choline PET/CT is a valuable and an established functional diagnostic imaging method for staging and restaging prostate cancer. "( The nonspecific lymph node uptake of 18F-choline in patients with prostate cancer--a prospective observational study.
Golubić, AT; Huić, D; Mutvar, A; Žuvić, M, 2015
)
1.24
"Choline is an important nutrient for humans. "( Dietary intake and food sources of choline in European populations.
D'Addezio, L; Dubuisson, C; Dumas, C; Héraud, F; Ioannidou, S; Lindtner, O; Mattison, I; Mensink, GB; Ocké, MC; Siksna, I; Tlustos, C; Valsta, LM; Vennemann, FB; Virtanen, SM, 2015
)
2.14
"Choline is a quaternary ammonium salt, and being an essential component of different membrane phospholipids (PLs) contributes to the structural integrity of cell membranes. "( Choline-Containing Phospholipids: Structure-Activity Relationships Versus Therapeutic Applications.
Amenta, F; Buccioni, M; Marucci, G; Santinelli, C; Tayebati, SK, 2015
)
3.3
"Choline (Ch) is an essential nutrient that acts as a cognitive facilitator when administered during perinatal periods, and it has been recognised as a 'pharmacological' agent that can ease cognitive dysfunctions provoked by exposure to damaging stimuli during early developmental stages. "( Dietary choline during periadolescence attenuates cognitive damage caused by neonatal maternal separation in male rats.
Carías Picón, D; de Brugada Sauras, I; Moreno Gudiño, H, 2017
)
2.33
"Choline is an important source of phospholipids and methyl groups in mammalian cells. "( Choline-phospholipids inter-conversion is altered in elderly patients with prostate cancer.
Awwad, HM; Aziz, R; Geisel, J; Obeid, R; Ohlmann, CH; Stoeckle, M, 2016
)
3.32
"Choline is an essential nutrient and plays a critical role in brain development, cell signaling, nerve impulse transmission, and lipid transport and metabolism. "( Assessment of Total Choline Intakes in the United States.
Fulgoni, VL; Wallace, TC, 2016
)
2.2
"Choline is an essential nutrient and betaine is an osmolyte and methyl donor. "( Higher Dietary Choline and Betaine Intakes Are Associated with Better Body Composition in the Adult Population of Newfoundland, Canada.
Gao, X; Gulliver, W; Pedram, P; Randell, E; Sun, G; Wang, Y; Yi, Y, 2016
)
2.23
"Choline is an essential nutrient for cell structure, cell signaling, neurotransmission, lipid transport, and bone formation. "( The association of serum choline with linear growth failure in young children from rural Malawi.
Ferrucci, L; Gonzalez-Freire, M; Maleta, KM; Manary, MJ; Moaddel, R; Ordiz, MI; Semba, RD; Trehan, I; Zhang, P, 2016
)
2.18
"Choline is a dietary component and precursor of acetylcholine, a crucial neurotransmitter for memory-related brain functions. "( No Acute Effects of Choline Bitartrate Food Supplements on Memory in Healthy, Young, Human Adults.
Lippelt, DP; Naber, M; van der Kint, S; van Herk, K, 2016
)
2.2
"Choline is a quaternary ammonium base that represents an essential component of phospholipids and cell membranes. "( Biochemical and Pathophysiological Premises to Positron Emission Tomography With Choline Radiotracers.
Castoria, G; Cuccurullo, V; Di Stasio, GD; Evangelista, L; Mansi, L, 2017
)
2.12
"Choline is an essential nutrient that is required for normal development of the brain. "( Choline and the Brain: An Epigenetic Perspective.
Bekdash, RA, 2016
)
3.32
"Choline is an essential nutrient involved in one-carbon metabolism, but its role in mechanisms underlying meiotic non-disjunction is poorly known. "( Choline metabolic pathway gene polymorphisms and risk for Down syndrome: An association study in a population with folate-homocysteine metabolic impairment.
Chauhan, A; Jaiswal, SK; Kumar, A; Lakhotia, AR; Rai, AK; Sukla, KK, 2017
)
3.34
"Choline is an essential nutrient, a cell membrane constituent, a precursor in the biosynthesis of acetylcholine, and a selective natural alpha7nAChR agonist."( Modulation of TNF release by choline requires alpha7 subunit nicotinic acetylcholine receptor-mediated signaling.
Al-Abed, Y; Chavan, S; Czura, CJ; Gallowitsch-Puerta, M; Goldstein, RS; Hudson, L; Johnson, SM; Lin, X; Miller, EJ; Ochani, K; Ochani, M; Parrish, WR; Patel, N; Pavlov, VA; Rosas-Ballina, M; Tracey, KJ; Yang, LH,
)
1.14
"11C-choline is a potential tracer to complement 18F-FDG in detection of HCC lesions."( Detection of hepatocellular carcinoma using 11C-choline PET: comparison with 18F-FDG PET.
Deguchi, A; Kaji, M; Kameyama, R; Kashiwagi, H; Nishiyama, Y; Ohkawa, M; Okano, K; Yamamoto, Y, 2008
)
1.08
"Choline is an essential nutrient that seems to be involved in a wide variety of metabolic reactions and functions, that affect the developing brain. "( Equilibrated diet restores the effects of early age choline-deficient feeding on rat brain antioxidant status and enzyme activities: the role of homocysteine, L-phenylalanine and L-alanine.
Carageorgiou, H; Feskou, I; Galanopoulou, P; Liapi, C; Tsakiris, S; Zarros, A, 2008
)
2.04
"Choline is a selective agonist for the alpha7 nicotinic receptor which appears in development before acetylcholine is present."( Perinatal choline deficiency produces abnormal sensory inhibition in Sprague-Dawley rats.
Adams, CE; Kisley, MA; Mellott, TJ; Robbins, E; Stevens, KE, 2008
)
1.47
"Choline is an essential nutrient whose availability during the second half of gestation produces long-lasting cognitive effects. "( Prenatal choline supplementation in rats increases the expression of IGF2 and its receptor IGF2R and enhances IGF2-induced acetylcholine release in hippocampus and frontal cortex.
Blusztajn, JK; Mellott, TJ; Napoli, I, 2008
)
2.21
"Choline is an essential nutrient that is critical during fetal brain development. "( Genetic polymorphisms in methyl-group metabolism and epigenetics: lessons from humans and mouse models.
Zeisel, SH, 2008
)
1.79
"C-11 choline PET/CT is a valuable noninvasive imaging technology in the diagnosis of PCa. "( C-11 choline PET/CT imaging for differentiating malignant from benign prostate lesions.
Jin, X; Li, J; Li, X; Liu, Q; Liu, S; Wang, M; Yao, S, 2008
)
1.37
"Choline is an essential nutrient that, via its metabolite betaine, serves as a donor of methyl groups used in fetal development to establish the epigenetic DNA and histone methylation patterns. "( Gestational choline supply regulates methylation of histone H3, expression of histone methyltransferases G9a (Kmt1c) and Suv39h1 (Kmt1a), and DNA methylation of their genes in rat fetal liver and brain.
Blusztajn, JK; Davison, JM; Kovacheva, VP; Mellott, TJ, 2009
)
2.17
"Choline is an essential nutrient that serves as a donor of metabolic methyl groups used during gestation to establish the epigenetic DNA methylation patterns that modulate tissue-specific gene expression. "( Raising gestational choline intake alters gene expression in DMBA-evoked mammary tumors and prolongs survival.
Blusztajn, JK; Davison, JM; Kovacheva, VP; Mellott, TJ; O'Brien, MJ; Rogers, AE; Yang, S, 2009
)
2.12
"Choline is a required nutrient with roles in liver and brain function, lipid metabolism, and fetal development. "( Genetic variants in phosphatidylethanolamine N-methyltransferase and methylenetetrahydrofolate dehydrogenase influence biomarkers of choline metabolism when folate intake is restricted.
Caudill, MA; Hinkis, S; Ivanov, A; Nash-Barboza, S, 2009
)
2
"Choline is an essential nutrient for phospholipids and acetylcholine biosynthesis in normal development of fetus. "( Choline transport via choline transporter-like protein 1 in conditionally immortalized rat syncytiotrophoblast cell lines TR-TBT.
Choi, HM; Kang, YS; Lee, NY, 2009
)
3.24
"As choline is a marker of membrane phospholipid metabolism, the elevated choline in patients may indicate increased membrane breakdown in the brain regions examined."( Increased choline-containing compounds in the orbitofrontal cortex and hippocampus in euthymic patients with bipolar disorder: a proton magnetic resonance spectroscopy study.
Hall, GB; MacQueen, GM; Milne, AM; Senaratne, R, 2009
)
1.27
"Choline is a quaternary amino cationic organic alcohol that is oxidized to betaine in liver and kidney mitochondria. "( Control of choline oxidation in rat kidney mitochondria.
Clarke, KJ; Donagh, R; O'Donoghue, N; Porter, RK; Sweeney, T, 2009
)
2.19
"Choline is an essential nutrient which is difficult to measure because it has no native absorbance or fluorescence and only relatively unreactive functional groups. "( Measurement of plasma free choline by high performance liquid chromatography with fluorescence detection following derivatization with 1-naphthyl isocyanate.
Lever, M; McEntyre, CJ; Slow, S, 2009
)
2.09
"Choline is an essential nutrient necessary for synthesis of membrane phospholipids, cell signalling molecules and acetylcholine. "( Detection of choline transporter-like 1 protein CTL1 in neuroblastoma x glioma cells and in the CNS, and its role in choline uptake.
Dolezal, V; Dove, R; Lisá, V; Machová, E; Meunier, FM; Newcombe, J; O'Regan, S; Prentice, J, 2009
)
2.16
"Choline is an essential nutrient that influences brain and behavioral development."( Prenatal choline supplementation mitigates the adverse effects of prenatal alcohol exposure on development in rats.
Abou, EJ; Dominguez, HD; Thomas, JD,
)
1.27
"Cholinergic neurons are a major constituent of the mammalian central nervous system. "( Determination of high-affinity choline uptake (HACU) and choline acetyltransferase (ChAT) activity in the same population of cultured cells.
Lahiri, DK; Ray, B; Simon, JR, 2009
)
2.08
"Choline is a quaternary amine endogenously synthesized from the amino acid methionine or absorbed via the portal circulation. "( The addition of choline to parenteral nutrition.
Buchman, AL, 2009
)
2.14
"Choline is a candidate marker to aid decision making in the emergency room in the upcoming era of sensitive troponin tests and the growing need to differentiate between ischemic and nonischemic etiologies of troponin elevations."( Choline in acute coronary syndrome: an emerging biomarker with implications for the integrated assessment of plaque vulnerability.
Danne, O; Möckel, M, 2010
)
2.52
"Choline is an essential nutrient, and deficiency causes liver and muscle dysfunction. "( Metabolomic profiling can predict which humans will develop liver dysfunction when deprived of dietary choline.
Berger, A; da Costa, KA; Fischer, LM; Jia, W; Lawton, KA; Milburn, MV; Sha, W; Zeisel, SH, 2010
)
2.02
"Choline is an essential nutrient, but is also formed by de novo synthesis. "( Choline and betaine in health and disease.
Ueland, PM, 2011
)
3.25
"Choline is a dietary supplement that activates alpha7 nicotinic receptors. "( Antinociceptive and anti-inflammatory effects of choline in a mouse model of postoperative pain.
Flood, P; Greenidge, E; McKinstry, A; Rowley, TJ; Smith, W, 2010
)
2.06
"Choline (Cho) is an essential nutrient for humans as well as the precursor of glycine betaine (GlyBet), an important compatible solute in eukaryotes that protects cells from osmotic stress caused by dehydrating conditions. "( Choline and osmotic-stress tolerance induced in Arabidopsis by the soil microbe Bacillus subtilis (GB03).
Dowd, SE; Jeter, RM; Kim, MS; Murzello, C; Paré, PW; Sun, Y; Xie, X; Zak, JC; Zhang, H, 2010
)
3.25
"Choline is an essential nutrient that influences brain and behavioral development."( Prenatal choline supplementation mitigates behavioral alterations associated with prenatal alcohol exposure in rats.
Dominguez, HD; Idrus, NM; Monk, BR; Thomas, JD, 2010
)
1.5
"Choline is an essential amino acid, which is needed for the synthesis of membrane phospholipids. "( Colchicine must be stopped before imaging with [18F]-methylcholine PET/CT.
Roef, MJ; van der Laken, CJ; van der Poel, H; Vogel, WV, 2010
)
2.05
"Choline is an important constituent of acetylcholine. "( Plasma choline depletion is associated with decreased peripheral blood leukocyte acetylcholine in children with cystic fibrosis.
Bay, BN; Davidson, AG; Hasman, D; Innis, SM; Slack, PJ, 2011
)
2.27
"Choline is an essential nutrient in humans, and is an important methyl group donor."( What choline metabolism can tell us about the underlying mechanisms of fetal alcohol spectrum disorders.
Zeisel, SH, 2011
)
1.6
"Low choline intake is a major risk factor for liver and several neurological disorders."( Use of canonical variate analysis biplot in examination of choline content data of some foods.
Alkan, B; Atakan, C, 2011
)
1.09
"Choline is a α7 nicotinic receptor agonist that has antinociceptive effects in a variety of pain models."( Pharmacological action of choline and aspirin coadministration on acute inflammatory pain.
Hai, W; Hai-Tao, Y; Jin-Da, W; Ru-Huan, W; Xiang-Di, Z; Yong-Ping, S, 2011
)
1.39
"Choline is an essential nutrient for humans, and part of this requirement is met by endogenous synthesis catalyzed by hepatic phosphatidylethanolamine N-methyltransferase (PEMT). "( Docosahexaenoic acid in plasma phosphatidylcholine may be a potential marker for in vivo phosphatidylethanolamine N-methyltransferase activity in humans.
da Costa, KA; Fischer, LM; Sanders, LM; Zeisel, SH, 2011
)
2.07
"Choline is a vital nutrient needed during early development for both humans and rodents. "( Prenatal choline deficiency does not enhance hippocampal vulnerability after kainic acid-induced seizures in adulthood.
Blusztajn, JK; Glenn, MJ; Mellott, TJ; Tognoni, CM; Williams, CL; Wong-Goodrich, SJ, 2011
)
2.23
"Choline is an important component of the human diet and is required for the endogenous synthesis of choline-containing phospholipids, acetylcholine and betaine. "( Plasma choline concentration varies with different dietary levels of vitamins B6, B12 and folic acid in rats maintained on choline-adequate diets.
Böhlke, M; Broersen, LM; Hageman, RJ; Kamphuis, PJ; Maher, TJ; van Wijk, N; Watkins, CJ; Wurtman, RJ, 2012
)
2.28
"Choline is a micronutrient essential for the structural integrity of cellular membranes, and its presence at synapses follows either depolarization-induced pre-synaptic release or degradation of acetylcholine. "( Choline-mediated depression of hippocampal synaptic transmission.
Ahuja, TK; Comas, T; Mealing, GA; Mielke, JG, 2011
)
3.25
"Choline is an essential nutrient and the liver is a central organ responsible for choline metabolism. "( Choline metabolism provides novel insights into nonalcoholic fatty liver disease and its progression.
Corbin, KD; Zeisel, SH, 2012
)
3.26
"Choline is an essential nutrient and can also be obtained by de novo synthesis via an oestrogen responsive pathway. "( Choline supplementation and measures of choline and betaine status: a randomised, controlled trial in postmenopausal women.
Bonham, MP; Duffy, ME; McCormack, JM; McNulty, H; Molloy, AM; Robson, PJ; Scott, JM; Strain, JJ; Ueland, PM; Wallace, JM; Walsh, PM; Ward, M, 2012
)
3.26
"Choline is a quaternary amine that is synthesized in the body or consumed through the diet. "( Analytical approaches to determination of total choline in foods and dietary supplements.
Phillips, MM, 2012
)
2.08
"Choline is a new PET tracer that is useful for the detection of malignant tumor. "( Usefulness of Choline-PET for the detection of residual hemangiopericytoma in the skull base: comparison with FDG-PET.
Fujimaki, M; Hanaguri, M; Ikeda, K; Ito, S; Kazuo, K; Ohba, S; Yazawa, M; Yokoyama, J; Yoshimoto, H, 2012
)
2.18
"Choline is a water-soluble nutrient important for infants' brain and neural development. "( Determination of total choline by liquid chromatography-electrospray ionization-tandem mass spectrometry in infant formulas.
Fu, S; Lai, S; Tao, B; Yiping, R; Zhang, J,
)
1.88
"Choline is a zwitter ion that is positively charged at certain pH, which necessitates transport systems to allow this amine to cross the phospholipid bilayer of cellular membranes. "( The ubiquitous choline transporter SLC44A1.
Bakovic, M; Michel, V, 2012
)
2.17
"Choline is a ubiquitous water soluble nutrient, often associated with the B vitamins; however, not yet officially defined as a B vitamin. "( An introduction to the nutrition and metabolism of choline.
Hollenbeck, CB, 2012
)
2.07
"Choline is an essential nutrient for humans. "( Choline nutrition programs brain development via DNA and histone methylation.
Blusztajn, JK; Mellott, TJ, 2012
)
3.26
"Choline (Ch) is an important nutrient that is involved in many physiological functions. "( Choline deprivation: an overview of the major hepatic metabolic response pathways.
Al-Humadi, H; Al-Saigh, R; Kyriakaki, A; Liapi, C; Zarros, A, 2012
)
3.26
"Choline is an essential nutrient with a wide range of biological functions, and current studies are aimed at refining our understanding of its requirements and, importantly, on defining the molecular mechanisms that mediate its effects in instances of suboptimal dietary intake."( The nutrigenetics and nutrigenomics of the dietary requirement for choline.
Corbin, KD; Zeisel, SH, 2012
)
1.34
"Cholinesterase is a key protein overexpressed in Alzheimer's disease, and therefore, the present system may have potential for the delivery of Alzheimer's disease drugs."( Cholinesterase-responsive supramolecular vesicle.
Guo, DS; Liu, Y; Wang, K; Wang, YX, 2012
)
2.54
"Choline is an essential nutrient that is necessary for cell membrane synthesis and phospholipid metabolism and functions as an important methyl donor. "( The role of choline in prostate cancer.
Awwad, HM; Geisel, J; Obeid, R, 2012
)
2.2
"Choline is an integral part of folate and methylation pathways."( Plasma choline and betaine correlate with serum folate, plasma S-adenosyl-methionine and S-adenosyl-homocysteine in healthy volunteers.
Barto, R; Blom, HJ; Imbard, A; Jakobs, C; Kok, RM; Smith, DE; Smulders, YM, 2013
)
1.57
"Choline is an essential nutrient that is found in many food sources and plays a critical role in the development of the central nervous system. "( Choline status and neurodevelopmental outcomes at 5 years of age in the Seychelles Child Development Nutrition Study.
Bonham, MP; Davidson, PW; Henderson, J; Kobrosly, RW; McAfee, AJ; McSorley, EM; Mulhern, MS; Myers, GJ; Shamlaye, CF; Strain, JJ; Thurston, SW; Ueland, PM; van Wijngaarden, E; Wallace, JM; Watson, GE, 2013
)
3.28
"Choline is an essential nutrient for humans. "( Neuroprotective actions of perinatal choline nutrition.
Blusztajn, JK; Mellott, TJ, 2013
)
2.11
"Choline acetate is an ionic liquid composed of a kosmotropic anion and a chaotropic cation. "( Choline acetate enhanced the catalytic performance of Candida rogusa lipase in AOT reverse micelles.
Huang, X; Li, Y; Qu, Y; Sun, Y; Xue, L; Yan, K; Yu, L; Zhao, Y, 2013
)
3.28
"Choline is an essential nutrient required for early development. "( Long-lasting effects of prenatal dietary choline availability on object recognition memory ability in adult rats.
Carias, D; de Brugada, I; Gallo, M; Moreno, HC, 2013
)
2.1
"Choline is an essential nutrient for humans and is derived from the diet as well as from de novo synthesis involving methylation of phosphatidylethanolamine catalysed by the enzyme phosphatidylethanolamine N -methyltransferase (PEMT). "( Phosphatidylethanolamine N-methyltransferase (PEMT) knockout mice have hepatic steatosis and abnormal hepatic choline metabolite concentrations despite ingesting a recommended dietary intake of choline.
Edwards, LJ; Mar, MH; Song, J; Zeisel, SH; Zhu, X, 2003
)
1.97
"TDBzcholine acts as a nAChR competitive antagonist that binds at equilibrium with equal affinity to both agonist sites (K(D) approximately 10 microM)."( Identification of amino acids in the nicotinic acetylcholine receptor agonist binding site and ion channel photolabeled by 4-[(3-trifluoromethyl)-3H-diazirin-3-yl]benzoylcholine, a novel photoaffinity antagonist.
Chiara, DC; Cohen, JB; Sullivan, D; Trinidad, JC; Wang, D; Ziebell, MR, 2003
)
1.05
"11C-choline PET is a feasible technique for evaluation of treatment for localized prostate cancer. "( 11C-choline positron emission tomography for the evaluation after treatment of localized prostate cancer.
de Jong, IJ; Elsinga, PH; Mensink, HJ; Pruim, J; Vaalburg, W, 2003
)
1.44
"Choline is a ubiquitous molecule, found throughout almost every tissue in the body. "( The blood-brain barrier choline transporter as a brain drug delivery vector.
Allen, DD; Lockman, PR, 2003
)
2.07
"Choline is an agonist at alpha7 nAChRs but is not the sole agonist in this system, as inhibition of acetylcholinesterase by echothiophate failed to reduce calcium transients."( Rapid activation of presynaptic nicotinic acetylcholine receptors by nerve-released transmitter.
Rogers, M; Sargent, PB, 2003
)
1.3
"Choline is an essential nutrient for animals and humans. "( Prenatal choline supplementation advances hippocampal development and enhances MAPK and CREB activation.
Blusztajn, JK; Meck, WH; Mellott, TJ; Williams, CL, 2004
)
2.18
"Choline is a nutrient in milk that is essential for the nourishment and growth of newborns. "( Hormone regulation of choline uptake and incorporation in mouse mammary gland explants.
Rillema, JA, 2004
)
2.08
"Choline is a required nutrient and is derived from the diet as well as from de novo synthesis catalyzed by phosphatidylethanolamine N-methyltransferase (PEMT). "( Deletion of the Pemt gene increases progenitor cell mitosis, DNA and protein methylation and decreases calretinin expression in embryonic day 17 mouse hippocampus.
Mar, MH; Song, J; Zeisel, SH; Zhu, X, 2004
)
1.77
"Choline is an important methyl donor and a component of membrane phospholipids. "( Choline availability modulates human neuroblastoma cell proliferation and alters the methylation of the promoter region of the cyclin-dependent kinase inhibitor 3 gene.
Niculescu, MD; Yamamuro, Y; Zeisel, SH, 2004
)
3.21
"Choline is an important nutrient that penetrates infected erythrocyte membranes through the endogenous carrier and through parasite-induced permeability pathways, but nothing is known about its transport into the intracellular parasite."( Characterization of the choline carrier of Plasmodium falciparum: a route for the selective delivery of novel antimalarial drugs.
Biagini, GA; Bray, PG; De Koning, HP; Hughes, R; O'Neill, PM; Pasini, EM; Vial, HJ; Ward, SA, 2004
)
1.35
"[11C]Choline is a potential tracer to detect tumors, especially brain and prostate cancers. "( Radiolabeled choline as a proliferation marker: comparison with radiolabeled acetate.
Fujibayashi, Y; Furukawa, T; Obata, A; Waki, A; Yonekura, Y; Yoshimoto, M, 2004
)
1.21
"Choline is a dietary component essential for normal function of all cells. "( Nutritional importance of choline for brain development.
Zeisel, SH, 2004
)
2.07
"Choline is an essential nutrient for humans that is used to synthesize membrane phospholipids and the neurotransmitter acetylcholine. "( Ad libitum choline intake in healthy individuals meets or exceeds the proposed adequate intake level.
Blanchard, RT; Busby, MG; Fischer, LM; Macintosh, BA; Mar, MH; Patel, JR; Scearce, JA; Zeisel, SH, 2005
)
2.16
"Choline, via betaine, is an important folate-independent source of methyl groups for remethylating homocysteine in liver."( Choline and homocysteine interrelations in umbilical cord and maternal plasma at delivery.
Brody, LC; Conley, M; Cox, C; Daly, SF; Kirke, PN; Mills, JL; Molloy, AM; Scott, JM; Ueland, PM, 2005
)
2.49
"Choline is a required nutrient, and some humans deplete quickly when fed a low-choline diet, whereas others do not. "( Genetic variation of folate-mediated one-carbon transfer pathway predicts susceptibility to choline deficiency in humans.
da Costa, KA; Fischer, LM; Kohlmeier, M; Zeisel, SH, 2005
)
1.99
"Choline is an essential nutrient and a precursor of neurotransmitter acetylcholine (ACh) and is produced at synapses during depolarization, upon hydrolysis of ACh via acetylcholinesterase, and under conditions of injury and trauma. "( Subtype-specific inhibition of nicotinic acetylcholine receptors by choline: a regulatory pathway.
Albuquerque, EX; Alkondon, M, 2006
)
2.03
"Choline is an essential nutrient for all cells because it plays a role in the synthesis of the membrane phospholipid components of the cell membranes, as a methyl-group donor in methionine metabolism as well as in the synthesis of the neurotransmitter acetylcholine. "( Choline transport for phospholipid synthesis.
Bakovic, M; Michel, V; Ramsubir, S; Yuan, Z, 2006
)
3.22
"Choline is an essential nutrient for humans and its availability during pregnancy is important for optimal fetal development. "( Dietary intake of choline and plasma choline concentrations in pregnant women in Jamaica.
Fletcher, H; Gossell-Williams, M; Jacob, A; McFarlane-Anderson, N; Patel, J; Zeisel, S, 2005
)
2.1
"Choline deficiency is a significant risk factor for development of catheter thrombosis in patients with intestinal failure who require PN."( Choline deficiency is associated with increased risk for venous catheter thrombosis.
Ahn, C; Ament, ME; Buchman, AL; Jenden, DJ,
)
3.02
"Choline is an essential nutrient needed for the structural integrity and signaling functions of cell membranes; for normal cholinergic neurotransmission; for normal muscle function; for lipid transport from liver; and it is the major source of methyl groups in the diet. "( Choline: critical role during fetal development and dietary requirements in adults.
Zeisel, SH, 2006
)
3.22
"Choline oxidase is a flavin-dependent enzyme that catalyzes the oxidation of choline to glycine-betaine, with oxygen as electron acceptor. "( Trapping choline oxidase in a nonfunctional conformation by freezing at low pH.
Gadda, G; Hoang, JV, 2007
)
2.2
"Choline is an essential nutrient and it is also a methyl donor critical for the maintenance of cell membrane integrity and methyl metabolism."( CHKA and PCYT1A gene polymorphisms, choline intake and spina bifida risk in a California population.
Enaw, JO; Finnell, RH; Lammer, EJ; Lu, W; Shaw, GM; Yang, W; Zhu, H, 2006
)
1.33
"Choline peak in vivo is a specific but not sensitive marker of malignancy."( Evaluation of spectral selected press sequence in breast lesion characterization.
Bao, RX; Liu, PF; Lu, H; Sun, F, 2006
)
1.06
"Choline is an important nutrient for mammals. "( Choline redistribution during adaptation to choline deprivation.
Agellon, LB; Li, Z; Vance, DE, 2007
)
3.23
"Choline is an important nutrient for humans and animals. "( Choline cannot be replaced by propanolamine in mice.
Li, Z; Vance, DE, 2007
)
3.23
"Choline is a major dietary source of methyl-groups (one of choline's metabolites, betaine, participates in the methylation of homocysteine to form methionine); also choline is needed for the biosynthesis of cell membranes, bioactive phospholipids and the neurotransmitter acetylcholine."( Gene response elements, genetic polymorphisms and epigenetics influence the human dietary requirement for choline.
Zeisel, SH, 2007
)
1.27
"Choline is an essential nutrient for cell survival and proliferation, however, the expression and function of choline transporters have not been well identified in cancer. "( Choline transporters in human lung adenocarcinoma: expression and functional implications.
Chen, F; Gu, J; He, X; Li, J; Wan, D; Wang, T; Zhao, Y, 2007
)
3.23
"Choline is an essential nutrient required for methyl group metabolism, but its role in carcinogenesis and tumor progression is not well understood. "( Choline metabolism and risk of breast cancer in a population-based study.
Bradshaw, PT; Chen, J; Gammon, MD; Lee, YL; Neugut, AI; Santella, RM; Teitelbaum, SL; Wetmur, JG; Xu, X; Zeisel, SH, 2008
)
3.23
"Choline is a precursor of cellular phospholipid metabolism that provides Magnetic Resonance (MR) and Positron Emission Tomography (PET) biomarkers for cancer detection and response assessment. "( Therapeutic target metabolism observed using hyperpolarized 15N choline.
Eykyn, TR; Gabellieri, C; Lavie, A; Leach, MO; Payne, GS; Reynolds, S, 2008
)
2.03
"Choline is an important nutrient that is actively transported from mother to fetus across the placenta and from mother to infant across the mammary gland. "( Pregnancy and lactation are associated with diminished concentrations of choline and its metabolites in rat liver.
da Costa, KA; Mar, MH; Zeisel, SH; Zhou, Z, 1995
)
1.97
"Choline entry is a limiting step in this metabolic pathway and occurs by a facilitated-diffusion system involving an asymmetric carrier operating according to a cyclic model."( Infected erythrocyte choline carrier inhibitors: exploring some potentialities inside Plasmodium phospholipid metabolism for eventual resistance acquisition.
Ancelin, ML; Elabbadi, N; Gumila, C; Orcel, H; Vial, HJ; Yeo, HJ, 1994
)
1.33
"Choline is a crucial intermediate in several clinically relevant neurochemical processes. "( Choline ingestion increases the resonance of choline-containing compounds in human brain: an in vivo proton magnetic resonance study.
Cohen, BM; De Micheli, E; Pillay, SS; Renshaw, PF; Stoll, AL; Wurtman, R, 1995
)
3.18
"Choline is an essential precursor for the synthesis of phosphatidylcholine, the most abundant phospholipid classes in renal cells, as well as for the synthesis of the osmolyte glycerophosphorylcholine. "( Transport of choline by Madin-Darby canine kidney cells.
Blais, A; Le Grimellec, C; Loiseau, A; Moll, G; Zlatkine, P, 1993
)
2.1
"Choline is an essential metabolite for the growth of filamentous fungi. "( Choline: its role in the growth of filamentous fungi and the regulation of mycelial morphology.
Bainbridge, BW; Markham, P; Robson, GD; Trinci, AP, 1993
)
3.17
"Choline is an essential nutrient for fetal development and may be utilized to form phospholipids such as phosphatidylcholine and sphingomyelin; to synthesize the neurotransmitter, acetylcholine; and to donate methyl groups after being oxidized to betaine. "( Characterization of choline metabolism and secretion by human placental trophoblasts in culture.
Chou, SC; Coleman, RA; Garner, SC; Mar, MH; Zeisel, SH, 1993
)
2.05
"Choline is a constituent of cell membranes, surfactant and acetylcholine and is also a major source of methyl groups for the regeneration of methionine from homocysteine. "( Glycerophosphocholine and phosphocholine are the major choline metabolites in rat milk.
Garner, SC; Mar, MH; Rohlfs, EM; Zeisel, SH, 1993
)
2.09
"Choline is a primary degradation product of succinylcholine chloride. "( Determination of choline in pharmaceutical formulations by reversed-phase high-performance liquid chromatography and postcolumn suppression conductivity detection.
Chen, S; Soneji, V; Webster, J, 1996
)
2.08
"Choline is a major donor of methyl groups, a precursor for membrane synthesis, and a component of the neurotransmitter acetylcholine. "( Prolonged fasting in humans results in diminished plasma choline concentrations but does not cause liver dysfunction.
Mar, MH; Savendahl, L; Underwood, LE; Zeisel, SH, 1997
)
1.98
"Choline is an important substrate in alveolar epithelia for both surfactant production and cellular maintenance. "( Conductive choline transport by alveolar epithelial plasma membrane vesicles.
Oelberg, DG; Xu, F, 1998
)
2.13
"Choline is an essential nutrient, and its absence induces apoptosis."( Choline deficiency-induced apoptosis in PC12 cells is associated with diminished membrane phosphatidylcholine and sphingomyelin, accumulation of ceramide and diacylglycerol, and activation of a caspase.
Mar, MH; Yen, CL; Zeisel, SH, 1999
)
2.47
"Choline is a necessary substrate of the lipid membrane and for acetylcholine synthesis. "( Choline modulates cardiac membrane repolarization by activating an M3 muscarinic receptor and its coupled K+ channel.
Lu, Y; Shi, H; Wang, H; Wang, Z; Yang, B, 1999
)
3.19
"Choline is an important membrane phospholipid constituent and a neurotransmitter precursor that is minimally synthesized in brain. "( Blood-brain barrier choline transport in the senescent rat.
Allen, DD; Smith, QR, 1999
)
2.07
"Choline is an essential constituent of membrane phospholipids in great demand in the developing brain and liver. "( Changes in the choline content of human breast milk in the first 3 weeks after birth.
Holmes, HC; Iles, RA; Snodgrass, GJ, 2000
)
2.1
"Choline is an important metabolite in all cells due to the major contribution of phosphatidylcholine to the production of membranes, but it takes on an added role in cholinergic neurons where it participates in the synthesis of the neurotransmitter acetylcholine. "( An electric lobe suppressor for a yeast choline transport mutation belongs to a new family of transporter-like proteins.
Cha, N; Compaore, D; Meunier, FM; O'Regan, S; Ruat, M; Traiffort, E, 2000
)
2.02
"Choline is a dietary component essential for normal function of all cells. "( Choline: needed for normal development of memory.
Zeisel, SH, 2000
)
3.19
"Choline is an essential nutrient for rats and humans, and its availability during fetal development has long-lasting cognitive effects (Blusztajn, 1998). "( Protective effects of prenatal choline supplementation on seizure-induced memory impairment.
Blusztajn, JK; Cermak, JM; Holmes, GL; Liu, Z; Neill, JC; Sarkisian, MR; Stafstrom, CE; Tandon, P; Yang, Y, 2000
)
2.04
"Choline is an essential nutrient participating as the initial substrate in major metabolic pathways. "( Differential routing of choline in implanted breast cancer and normal organs.
Degani, H; Katz-Brull, R; Margalit, R, 2001
)
2.06
"Choline is an essential nutrient in methylation, acetylcholine and phospholipid biosynthesis, and in cell signaling. "( Inhibitors of choline uptake and metabolism cause developmental abnormalities in neurulating mouse embryos.
Fisher, MC; Mar, MH; Sadler, TW; Zeisel, SH, 2001
)
2.11
"Choline deficiency is a significant contributor to the development of TPN-associated liver disease. "( Choline deficiency causes reversible hepatic abnormalities in patients receiving parenteral nutrition: proof of a human choline requirement: a placebo-controlled trial.
Ahn, C; Ament, ME; Awal, M; Buchman, AL; Dubin, M; Farley, W; Jenden, DJ; Pownall, H; Roch, M; Sohel, M,
)
3.02
"Choline (Ch) is an essential nutrient as the biosynthetic precursor of acetylcholine (ACh) and phospholipids. "( A homeostatic mechanism counteracting K(+) -evoked choline release in adult brain.
Dvorak, C; Klein, J; Löffelholz, K; Ruhr, J; Weichel, O, 2002
)
2.01
"Choline is an important metabolite in all cells because of the major contribution of phosphatidylcholine and sphingomyelin to the production of membranes."( Changes in mRNA for choline transporter-like protein following facial nerve transection.
Che, YH; Higuchi, H; Tohyama, M; Yamashita, T, 2002
)
1.36
"Choline is a conditionally essential nutrient in this population."( Lecithin increases plasma free choline and decreases hepatic steatosis in long-term total parenteral nutrition patients.
Ament, ME; Buchman, AL; Dubin, M; Eckhert, CD; Gornbein, J; Jenden, D; Moukarzel, A; Rice, K; Roch, MH, 1992
)
1.29
"Choline is a quaternary ammonium compound that is normally reabsorbed by the renal proximal tubule, despite its acknowledged role as a substrate for the renal organic cation (OC) secretory pathway. "( A choline transporter in renal brush-border membrane vesicles: energetics and structural specificity.
Wright, SH; Wunz, TM; Wunz, TP, 1992
)
2.45
"Choline is an essential nutrient for some mammals; it is used for membrane and neurotransmitter synthesis. "( Plasma choline concentration in humans fed parenterally.
Bistrian, BR; Blackburn, GL; Sheard, NF; Tayek, JA; Zeisel, SH, 1986
)
2.17
"Choline is an important precursor for the biosynthesis of acetylcholine, phosphatidylcholine and sphingomyelin. "( Fewer metabolites of dietary choline reach the blood of rats after treatment with lithium.
O'Connor, SC; Pomfret, EA; Zeisel, SH; Zola, TH, 1988
)
2.01
"Choline is a precursor for the biosynthesis of phosphatidylcholine (lecithin), sphingomyelin, and choline plasmalogens--all essential constituents of membranes. "( Choline, phosphatidylcholine and sphingomyelin in human and bovine milk and infant formulas.
Char, D; Sheard, NF; Zeisel, SH, 1986
)
3.16
"1. Choline kinase is a mitochondrial enzyme in Cuscuta reflexa. "( Choline kinase in Cuscuta reflexa.
Krishnan, PS; Setty, PN, 1972
)
2.31
"2. Choline is a potent inhibitor of ethanolamine phosphorylation, but ethanolamine has little effect on choline phosphorylation."( Phosphorylation of choline and ethanolamine in Ehrlich ascites-carcinoma cells.
Johnstone, RM; Sung, CP, 1967
)
1.09

Effects

Choline PET has a role in the diagnosis of malignancies. Choline biosensor has a lower potential dependence. C-choline imaging has a certain rate of false positivity and false negativity.

Choline deficiency has numerous negative health consequences. Choline and betaine have been suggested to play a pivotal role in neurotransmitter synthesis, cell membrane integrity, and methyl-group metabolism, exerting neuroprotective effects in patients with various neurological disorders.

ExcerptReferenceRelevance
"The cholinergic system has a crucial role to play in visual function. "( Cholinergic nervous system and glaucoma: From basic science to clinical applications.
Chan, KC; Faiq, MA; Schuman, JS; Wollstein, G, 2019
)
2.51
"Choline PET has a role in the diagnosis of malignancies. "( Fluorocholine PET/computed tomography: physiologic uptake, benign findings, and pitfalls.
Beheshti, M; Bomanji, JB; Haroon, A; Langsteger, W, 2014
)
2.33
"Choline-PET/CT has a high global sensitivity while WB-DW-MRI has a high specificity, and so they are complementary techniques. "( Whole-body diffusion-weighted magnetic resonance imaging (WB-DW-MRI) vs choline-positron emission tomography-computed tomography (choline-PET/CT) for selecting treatments in recurrent prostate cancer.
Broseta-Torres, R; Conde-Moreno, AJ; Cozar-Santiago, MP; Ferrer-Albiach, C; Ferrer-Rebolleda, J; García-Piñón, F; Herrando-Parreño, G; Muelas-Soria, R, 2017
)
2.13
"The choline biosensor has a lower potential dependence."( Improvement in selectivity and storage stability of a choline biosensor fabricated from poly(aniline-co-o-aminophenol).
Mu, S; Shan, D; Zhang, J, 2007
)
1.07
"C-choline imaging has a certain rate of false positivity and false negativity. "( Misdiagnoses of 11C-choline combined with 18F-FDG PET imaging in brain tumours.
Guan, Y; Huang, Z; Lin, X; Liu, P; Xue, F; Zhang, Z; Zuo, C, 2008
)
1.39
"This choline transport has a Km of 12 microM, is Na+ and energy independent, and is relatively insensitive to hemicholinium-3 (IC50 approximately 50 microM)."( Choline and acetylcholine metabolism in PC12 secretory cells.
Howard, BD; Melega, WP, 1981
)
2.16
"Choline kinase (ChoK) has been well documented as a major enzyme involved in the anomalous cellular lipid metabolic profile of chronic inflammatory disorders. "( Choline kinase: An underappreciated rheumatoid arthritis therapeutic target.
Miriam Jose, A; Rasool, M, 2022
)
3.61
"Choline has been shown to exert atherogenic effects in Apoe"( Choline and butyrate beneficially modulate the gut microbiome without affecting atherosclerosis in APOE*3-Leiden.CETP mice.
Boon, MR; Fan, X; Li, Z; Liu, C; Rensen, PCN; Schönke, M; Shao, H; Song, Z; Wang, Y, 2022
)
3.61
"Choline has been inversely related to CRC risk but findings are inconsistent."( Dietary choline and sphingomyelin choline moiety intake and risk of colorectal cancer: a case-control study.
Boffetta, P; Collatuzzo, G; Crispo, A; Fiori, F; Giacosa, A; Hannun, Y; Khalifeh, M; La Vecchia, C; Luberto, C; Negri, E; Parpinel, M; Pelucchi, C; Rossi, M; Serraino, D, 2023
)
2.07
"Choline deficiency has been well studied in the context of liver disease; however, less is known about the effects of choline supplementation in HCC."( Dietary Choline Supplementation Attenuates High-Fat-Diet-Induced Hepatocellular Carcinoma in Mice.
Allende, DS; Brown, AL; Conrad, K; Gromovsky, AD; Helsley, RN; Neumann, CK; Owens, AP; Tranter, M; Zhang, R, 2020
)
1.71
"Choline salicylate has been qualified as practically stable in neutral and acid media, stable in an alkaline medium, very stable in an oxidizing environment, and photolabile in solution."( Choline Salicylate Analysis: Chemical Stability and Degradation Product Identification.
Dereziński, P; Muszalska-Kolos, I; Plewa, S; Wróblewska, KB, 2019
)
2.68
"Choline deficiency has numerous negative health consequences; although the preponderance of the US population consumes less than the recommended Adequate Intake (AI), clinical assessment of choline status is difficult. "( Two methods for assessment of choline status in a randomized crossover study with varying dietary choline intake in people: isotope dilution MS of plasma and in vivo single-voxel magnetic resonance spectroscopy of liver.
Friday, WB; Horita, DA; Hwang, S; Kirchner, DR; Stegall, JM; Zeisel, SH, 2021
)
2.35
"Choline and betaine have been suggested to play a pivotal role in neurotransmitter synthesis, cell membrane integrity, and methyl-group metabolism, exerting neuroprotective effects in patients with various neurological disorders. "( Plasma choline and betaine and risks of cardiovascular events and recurrent stroke after ischemic stroke.
Bu, X; Che, B; Du, J; He, J; Ju, Z; Miao, M; Peng, H; Wang, A; Xu, T; Zhang, J; Zhang, Y; Zhong, C, 2021
)
2.52
"Choline PET/CT has shown favorable results in detection of hyperfunctioning parathyroid tissue and may replace conventional technetium-99m-sestamibi scintigraphy in preoperative planning of parathyroid surgery."( Choline PET/CT in parathyroid imaging: a systematic review.
Broos, WAM; Knol, RJJ; van der Zant, FM; Wondergem, M, 2019
)
2.68
"Choline status has been positively associated with weight and fat mass in animal and human studies. "( Prospective associations of maternal choline status with offspring body composition in the first 5 years of life in two large mother-offspring cohorts: the Southampton Women's Survey cohort and the Growing Up in Singapore Towards healthy Outcomes cohort.
Aris, IM; Barker, M; Chong, MFF; Chong, YS; Cooper, C; Crozier, SR; Fortier, MV; Gluckman, PD; Godfrey, KM; Harvey, NC; Inskip, HM; Lee, YS; Michael, N; Quah, PL; Robinson, SM; Sadananthan, SA; Shek, LP; Tan, KH; Tint, MT; van Lee, L; Velan, SS; Yap, F, 2019
)
2.23
"The cholinergic system has a crucial role to play in visual function. "( Cholinergic nervous system and glaucoma: From basic science to clinical applications.
Chan, KC; Faiq, MA; Schuman, JS; Wollstein, G, 2019
)
2.51
"Choline PET/CT has shown limitations for the detection of primary prostate cancer and nodal metastatic disease, mainly due to limited sensitivity and specificity. "( Role of choline PET/CT in guiding target volume delineation for irradiation of prostate cancer.
Gocke, Ch; Hildebrandt, G; Krause, BJ; Kuhnt, T; Kurth, J; Schwarzenböck, SM, 2013
)
2.27
"Choline PET has a role in the diagnosis of malignancies. "( Fluorocholine PET/computed tomography: physiologic uptake, benign findings, and pitfalls.
Beheshti, M; Bomanji, JB; Haroon, A; Langsteger, W, 2014
)
2.33
"Choline has been shown to have direct BP-reducing effects in humans and animals."( Increased systolic blood pressure in rat offspring following a maternal low-protein diet is normalized by maternal dietary choline supplementation.
Bai, SY; Briggs, DI; Vickers, MH, 2012
)
1.31
"11C-choline has been reported as a suitable tracer for neuroimaging application."( Clinical applications of choline PET/CT in brain tumors.
Ciarmiello, A; Gaeta, MC; Giovannini, E; Lazzeri, P; Milano, A, 2015
)
1.2
"Choline deficiency has been shown to induce liver fat accumulation in both rodent and human studies. "( Higher dietary choline intake is associated with lower risk of nonalcoholic fatty liver in normal-weight Chinese women.
Gao, YT; Li, H; Shu, XO; Xiang, YB; Yang, G; Yu, D; Zhang, X; Zheng, W, 2014
)
2.2
"11C-choline has been used in the diagnosis and follow-up of patients with prostate cancer for years. "( [11C-choline PET/CT in the diagnosis of prostate cancer -- Hungarian experience].
Berczi, C; Farkas, B; Flaskó, T; Galuska, L; Garai, I; Oszlánszki, A, 2015
)
1.49
"The cholinergic system has been found to be crucially involved in cognitive function, with cholinergic dysfunction playing a pivotal role in the pathophysiology of dementia."( Cholinergic imaging in dementia spectrum disorders.
Niccolini, F; Pagano, G; Politis, M; Roy, R, 2016
)
2.36
"Choline PET-CT has its potential as a diagnostic modality enabling the detection of occult prostate cancer recurrence and to differentiate localised disease from systemic disease thus guiding management. "( A pilot study of the utility of choline PET-CT in prostate cancer biochemical relapse following radical prostatectomy.
Francis, RJ; Joseph, D; Leong, E; Loh, NK; McCarthy, M; Morandeau, L; Segard, T; Siew, T; Tan, H; Trevenen, M, 2016
)
2.16
"Choline has been shown to mediate damage of the chondrocyte matrix and degradation enzymes of mice exposed to fluoride (F). "( Effect of Choline on the Composition and Degradation Enzyme of Extracellular Matrix of Mice Chondrocytes Exposed to Fluoride.
Hao, J; Wang, J; Zhao, Y, 2017
)
2.3
"Choline-PET/CT has a high global sensitivity while WB-DW-MRI has a high specificity, and so they are complementary techniques. "( Whole-body diffusion-weighted magnetic resonance imaging (WB-DW-MRI) vs choline-positron emission tomography-computed tomography (choline-PET/CT) for selecting treatments in recurrent prostate cancer.
Broseta-Torres, R; Conde-Moreno, AJ; Cozar-Santiago, MP; Ferrer-Albiach, C; Ferrer-Rebolleda, J; García-Piñón, F; Herrando-Parreño, G; Muelas-Soria, R, 2017
)
2.13
"Choline has been identified as a promising marker of coronary inflammation, plaque destabilisation and ischaemia. "( Choline for diagnosis and prognostication of acute coronary syndromes in the Emergency Department.
Body, R; Carley, S; Ferguson, J; Griffith, CA; Keevil, B; Mackway-Jones, K; McDowell, G, 2009
)
3.24
"11C-choline has the potential to provide information about atherosclerotic plaques independent of calcification measurement."( Evaluation and comparison of 11C-choline uptake and calcification in aortic and common carotid arterial walls with combined PET/CT.
Ikeda, M; Ishigaki, T; Kato, K; Kies, P; Naganawa, S; Schäfers, M; Schober, O; Stegger, L, 2009
)
1.12
"Choline has been used widely as an agonist for the investigation of gain-of-function mutants of the nicotinic acetylcholine receptor. "( Agonist and blocking actions of choline and tetramethylammonium on human muscle acetylcholine receptors.
Colquhoun, D; Krashia, P; Lape, R; Sivilotti, LG, 2009
)
2.08
"Choline PET has the potential to determine whether a PDT-treated tumor responds to treatment within 48 h after therapy."( Choline PET for monitoring early tumor response to photodynamic therapy.
Chiu, SM; Fei, B; Wang, H; Wu, C, 2010
)
2.52
"Choline has many physiological functions throughout the body that are dependent on its available local supply. "( The transport of choline.
Allen, DD; Lockman, PR, 2002
)
2.1
"[11C]Choline has been evaluated as a potential positron emission tomography (PET) marker for imaging of breast cancer. "( [11C]Choline as a potential PET marker for imaging of breast cancer athymic mice.
Fei, X; Glick-Wilson, BE; Hutchins, GD; Liu, X; Miller, KD; Mock, BH; Sledge, GW; Stone, KL; Wang, JQ; Zheng, QH, 2002
)
1.34
"Choline has been shown to be a specific agonist at alpha7 nicotinic acetylcholine receptors, which are the most Ca(2+) permeable of the ionotropic receptor channels. "( Choline induces Ca2+ entry in cultured sympathetic neurones isolated from rat superior cervical ganglion.
Bradaïa, A; Seddik, R; Trouslard, J, 2003
)
3.2
"The choline biosensor has a lower potential dependence."( Improvement in selectivity and storage stability of a choline biosensor fabricated from poly(aniline-co-o-aminophenol).
Mu, S; Shan, D; Zhang, J, 2007
)
1.07
"C-choline imaging has a certain rate of false positivity and false negativity. "( Misdiagnoses of 11C-choline combined with 18F-FDG PET imaging in brain tumours.
Guan, Y; Huang, Z; Lin, X; Liu, P; Xue, F; Zhang, Z; Zuo, C, 2008
)
1.39
"The choline carrier has been solubilized and incorporated into an artificial membrane system (liposomes)."( The activation of presynaptic choline uptake by acetylcholine release.
Marchbanks, RM, 1982
)
1.03
"This choline transport has a Km of 12 microM, is Na+ and energy independent, and is relatively insensitive to hemicholinium-3 (IC50 approximately 50 microM)."( Choline and acetylcholine metabolism in PC12 secretory cells.
Howard, BD; Melega, WP, 1981
)
2.16
"s-1. Choline influx has been studied after pre-loading synaptosomes with choline."( The effect of acetylcholine release on choline fluxes in isolated synaptic terminals.
Marchbanks, RM; Rubio, MA; Wonnacott, S, 1981
)
1.04
"Choline supplements have been advocated as a means of preventing the decline in acetylcholine production purported to occur during exercise; this decline may reduce the transmission of contraction-generating impulses across the skeletal muscle, an effect that could impair one's ability to perform muscular work."( Antioxidants, carnitine, and choline as putative ergogenic aids.
Kanter, MM; Williams, MH, 1995
)
1.3
"Choline dehydrogenase has been purified using hydrophobic chromatography 250-fold from a Pseudomonas strain. "( Use of hydrophobic chromatography for purification of the membrane-located choline dehydrogenase from a Pseudomonas strain.
Russell, R; Scopes, RK, 1994
)
1.96
"Choline kinase which has been previously described as a target of ras-transfection in fibroblasts was unaffected."( c-Ha-ras oncogene expression increases choline uptake, CTP: phosphocholine cytidylyltransferase activity and phosphatidylcholine biosynthesis in the immortalized human keratinocyte cell line HaCaT.
Boremski, S; Geilen, CC; Orfanos, CE; Wieder, T; Wieprecht, M, 1996
)
1.28
"Choline cotransport has been shown to be up-regulated by neuronal activity."( Hemicholinium-3 mustard reveals two populations of cycling choline cotransporters in Limulus.
Ivy, MT; Karim, MR; Mtshali, CM; Newkirk, RF; Townsel, JG, 2001
)
1.28
"Choline transport has been characterized by multiple mechanisms including the blood-brain barrier (BBB), and high- and low-affinity systems. "( Inhibition of the rat blood-brain barrier choline transporter by manganese chloride.
Allen, DD; Lockman, PR; Roder, KE, 2001
)
2.02
"Choline has recently been recognized as an essential nutrient, in part based on deficiency data in long-term home total parenteral nutrition (TPN) patients. "( Choline and vitamin B12 deficiencies are interrelated in folate-replete long-term total parenteral nutrition patients.
Buzby, GP; Compher, CW; Kinosian, BP; Lentine, DC; Stoner, NE,
)
3.02
"CDP-choline, which has been identified for the first time in epidermis, accumulates when skin is deprived of glucose."( The central role of phosphorylcholine in the metabolism of epidermis in the guinea-pig, Cavia porcellus.
Godfrey, G, 1978
)
1.03
"Choline uptake has also been shown to be altered in ethanol-dependent animals, and these effects may be coupled to alterations in dopamine neurons which are produced by chronic ethanol feeding and withdrawal."( Regional differences in high-affinity choline uptake in brain after acute and chronic treatment with ethanol.
Hunt, WA; Majchrowicz, E,
)
1.12
"Choline esters have been found to cause vasoconstriction of perfused systemic blood vessels of common Indian toad, Bufo melanostictus. "( Receptor mechanisms in vasoconstrictor responses to choline esters in Bufo melanostictus.
Gambhir, SS; Singh, RK, 1992
)
1.98
"Choline has both a nutritional and osmoregulatory role in Rhizobium meliloti (T. "( Characterization of three choline transport activities in Rhizobium meliloti: modulation by choline and osmotic stress.
Bernard, T; Le Rudulier, D; Pocard, JA; Smith, LT, 1989
)
2.02
"The choline uptake system has been characterized in the albino rat iris. "( Acute effects of cholinesterase inhibitors on uptake of choline in the rat iris.
Giacobini, E; Mattio, TG; Richardson, JS, 1985
)
1.17
"The choline influx has two components, one that is linear and one that is saturable with increasing choline concentration."( The uptake of [14C] choline into synaptosomes in vitro.
Marchbanks, RM, 1968
)
1.05

Actions

Choline-derived TMAO promotes osteogenic differentiation through ER and mitochondrial stress pathways in vitro and aortic valve lesions in vivo. Choline plays an essential role in the integrity of cell membranes, methylation reactions, and memory development. Cholinergic signaling plays an important role in regulating the growth and regeneration of axons in the nervous system.

ExcerptReferenceRelevance
"CHOLINE had lower mean daily FI and lower rates of BW accretion (P<0.05) in contrast to CONTROL."( Dietary choline in gonadectomized kittens improved food intake and body composition but not satiety, serum lipids, or energy expenditure.
Abood, SK; Bakovic, M; Godfrey, H; Grant, CE; Rankovic, A; Shoveller, AK; Verbrugghe, A, 2022
)
1.88
"Choline plays an important role in neurogenesis and neural migration during fetal development, potentially influencing the development and prognosis of neurological disorders, but its mechanism of action is not yet clear."( [Advances in basic research on choline and central nervous system development and related disorders].
Song, YY; Tan, XY; Xia, ZL, 2023
)
1.92
"Choline plays an integral role in one-carbon metabolism in the body, but it is unclear whether genetic polymorphisms are associated with variations in plasma choline and its metabolites."( Associations between Plasma Choline Metabolites and Genetic Polymorphisms in One-Carbon Metabolism in Postmenopausal Women: The Women's Health Initiative Observational Study.
Bailey, LB; Beresford, SAA; Caudill, MA; Cheng, TD; Duggan, DJ; Ilozumba, MN; Liu, S; Malysheva, O; Miller, JW; Neuhouser, ML; Shadyab, AH; Song, X; Toriola, AT; Ulrich, CM; Zheng, Y, 2020
)
2.29
"Choline plays a crucial role in lipid metabolism for fish, and its deficiency in aquafeed has been linked to compromised health and growth performance. "( Effects of dietary choline on liver lipid composition, liver histology and plasma biochemistry of juvenile yellowtail kingfish (
Booth, MA; Codabaccus, BM; Francis, DS; Liu, A; Pirozzi, I; Sammut, J; Stephens, F, 2021
)
2.39
"The cholinergic system plays a crucial role in learning and memory processes."( Choline Plus Working Memory Training Improves Prenatal Alcohol-Induced Deficits in Cognitive Flexibility and Functional Connectivity in Adulthood in Rats.
Hill, E; Jiang, L; Mooney, SM; Tang, S; Waddell, J; Xu, S, 2020
)
2.48
"Choline plays an important role in eye health and disease."( Role of Choline in Ocular Diseases.
Hwang, JS; Shin, YJ, 2021
)
1.78
"Choline-derived TMAO promotes osteogenic differentiation through ER and mitochondrial stress pathways in vitro and aortic valve lesions in vivo."( Trimethylamine N-oxide induces osteogenic responses in human aortic valve interstitial cells in vitro and aggravates aortic valve lesions in mice.
Ao, L; Lai, W; Li, J; Liu, Z; Meng, X; Ren, H; Xian, G; Xiong, Z; Xu, D; Zeng, Q; Zhan, Q, 2022
)
2.16
"Choline was 34.8% lower in OAB compared with the controls (P = 0.014)."( Evaluation of Urine Choline Levels in Women With and Without Overactive Bladder Syndrome.
Dawodu, K; El-Nashar, S; Hazlett, FE; Hijaz, AK; Mahajan, ST; Mangel, JM; Petrikovets, A; Sheyn, D, 2020
)
1.6
"Choline chloride plays a dominant role in the system and the complexes formed with curcumin are the most stable among all possible homo- and hetero-molecular pairs that can be found in NADES-curcumin systems."( Natural Deep Eutectic Solvents as Agents for Improving Solubility, Stability and Delivery of Curcumin.
Cysewski, P; Jeliński, T; Przybyłek, M, 2019
)
1.24
"Choline plays an essential role in the integrity of cell membranes, methylation reactions, and memory development."( Umbilical choline and related methylamines betaine and dimethylglycine in relation to birth weight.
Blom, HJ; den Heijer, M; Hogeveen, M; Semmekrot, BA; Sporken, JM; Ueland, PM, 2013
)
1.51
"Choline diet promotes improvement of the brain cognitive functions in rats with moderate-to-severe traumatic brain injury. "( Optimization of choline administration regimen for correction of cognitive functions in rats after brain injury.
Gusev, VB; Guseva, MV; Kamenskii, AA, 2013
)
2.18
"Cholinergic signaling plays an important role in regulating the growth and regeneration of axons in the nervous system. "( Axon targeting of the alpha 7 nicotinic receptor in developing hippocampal neurons by Gprin1 regulates growth.
Clark, SG; Del Negro, CA; Kabbani, N; Kodama, N; Nordman, JC; Phillips, WS, 2014
)
1.85
"Choline plays a lipotropic role in lipid metabolism as an essential nutrient. "( The effects of choline on hepatic lipid metabolism, mitochondrial function and antioxidative status in human hepatic C3A cells exposed to excessive energy substrates.
Cai, W; Leng, Y; Tang, Q; Wu, Y; Zhu, J, 2014
)
2.2
"This choline-induced increase was abolished by the α7 nAChR antagonist MLA and the calcium chelator BAPTA, suggesting that the cAMP increase depends on the α7 nAChR activation and subsequent intracellular calcium rise."( Activation of α7 nicotinic acetylcholine receptors increases intracellular cAMP levels via activation of AC1 in hippocampal neurons.
Cheng, Q; Yakel, JL, 2015
)
1.15
"Choline plays a critical role in systemic lipid metabolism and hepatic function. "( Choline supplementation restores substrate balance and alleviates complications of Pcyt2 deficiency.
Bakovic, M; Schenkel, LC; Sivanesan, S; Taylor, A; Verbrugghe, A; Wuyts, B; Zhang, J, 2015
)
3.3
"Choline (Ch) plays an important role in brain neurotransmission, while Ch-deprivation (CD) has been linked to various pathophysiological states. "( Effects of adult-onset choline deprivation on the activities of acetylcholinesterase, (Na+,K+)- and Mg2+-ATPase in crucial rat brain regions.
Al-Humadi, H; Anifantaki, F; Gkrouzman, E; Kyriakaki, A; Liapi, C; Margaritis, M; Skandali, N; Stolakis, V; Tsakiris, S; Zarros, A, 2009
)
2.11
"Choline did not inhibit NMDA or alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors in CA1 SR interneurons."( Subtype-specific inhibition of nicotinic acetylcholine receptors by choline: a regulatory pathway.
Albuquerque, EX; Alkondon, M, 2006
)
1.31
"The choline-induced flow increase was attenuated by alpha-bungarotoxin and mecamylamine, but not by dihydro-beta-erythroidine."( Regulation of the common carotid arterial blood flow by nicotinic receptors in the medulla of cats.
Cheng, CC; Chiu, YT; Gong, CL; Kuo, JS; Lee, TJ; Lin, NN; Lin, SZ, 2006
)
0.81
"Choline plays a central role in many physiological pathways, including neurotransmitter synthesis (acetylcholine), cell-membrane signaling (phospholipids), lipid transport (lipoproteins), and methyl-group metabolism (homocysteine reduction). "( Choline: an important micronutrient for maximal endurance-exercise performance?
Manore, MM; Penry, JT, 2008
)
3.23
"CDP-choline alone did not produce behavioral changes in these rats."( Effects of CDP-choline on striatal dopamine level and behavior in rats.
Fujiwara, M; Hidaka, H; Kageyama, N; Shibuya, M; Taniguchi, T, 1981
)
1.1
"Choline did not increase lipid mobilization or piglet survival."( The influence of sow dietary lipids and choline on piglet survival, milk and carcass composition.
McCampbell, HC; Seerley, RW; Snyder, RA, 1981
)
1.25
"choline can increase blood pressure in rats made hypotensive by acute chemical sympathectomy through the activation of central nicotinic receptors by presynaptic mechanisms."( Intracerebroventricular choline reverses hypotension induced by acute chemical sympathectomy.
Gürün, MS; Savci, V; Ulus, IH, 1997
)
1.33
"Choline was able to activate postsynaptic and presynaptic alpha7 nAChRs, with the latter action resulting in the release of other neurotransmitters."( Choline is a selective agonist of alpha7 nicotinic acetylcholine receptors in the rat brain neurons.
Albuquerque, EX; Alkondon, M; Cortes, WS; Maelicke, A; Pereira, EF, 1997
)
2.46
"Choline values were lower in chronic radiation necrosis than in solid anaplastic tumors (P < .001)."( Mapping of brain tumor metabolites with proton MR spectroscopic imaging: clinical relevance.
Alger, JR; Bizzi, A; Di Chiro, G; Dietz, MJ; Dwyer, AJ; Frank, JA; Fulham, MJ; Raman, R; Shih, HH; Sobering, GS, 1992
)
1

Treatment

Choline treatment of ID neurons (ID + Cho) significantly increased overall dendrite complexity. Choline treatments could restore the membrane lipids, repair cellular organelles and protect mutant cells from acute iron overload.

ExcerptReferenceRelevance
"Choline treatment of ID neurons (ID + Cho) significantly increased overall dendrite complexity (150, 160, 180, and 210 μm from the soma) compared with untreated ID neurons to a level of complexity that was no longer significantly different from IS neurons. "( Choline Supplementation Partially Restores Dendrite Structural Complexity in Developing Iron-Deficient Mouse Hippocampal Neurons.
Bastian, TW; Georgieff, MK; Kaus, OR; Lanier, LM; von Hohenberg, WC, 2022
)
3.61
"The choline treatments were control (no additional choline added, 1.2 × RA), 2 × RA, 4 × RA, 6 × RA, and 8 × RA."( Dose-response relationship between dietary choline and serum lipid profile, energy expenditure, and respiratory quotient in overweight adult cats fed at maintenance energy requirements.
Bakovic, M; Godfrey, H; Grant, CE; Kirby, G; Rankovic, A; Shoveller, AK; Verbrugghe, A, 2022
)
1.46
"Choline-treatment started twice a day on the first day of gestation until PND 21."( Effects of choline supplementation in mothers with hypothyroidism on the brain-derived neurotrophic factor gene expression changes in pre-pubertal offspring rats.
Aghazadeh, R; Bagheri, M; Derafshpour, L; Saboory, E; Sayyadi, H; Sheikhi, S, 2023
)
2.02
"Choline treatments could restore the membrane lipids, repair cellular organelles and protect mutant cells from acute iron overload."( Choline transporter-like 1 deficiency causes a new type of childhood-onset neurodegeneration.
Agarwal, P; Bakovic, M; Brady, L; Distelmaier, F; Dolinsky, VW; Fagerberg, CR; Gade, E; Hejbøl, EK; Jamra, RA; Kibæk, M; Klee, D; Larsen, MJ; Markovic, L; Nagy, P; Rouse, N; Schrøder, HD; Seibt, A; Tarnopolsky, M; Taylor, A; Wieczorek, D, 2020
)
2.72
"Choline treatment alters the NSP response to LPS."( Nasal secretory protein changes following intravenous choline administration in calves with experimentally induced endotoxaemia.
Baykal, AT; Cansev, M; Ceron, JJ; Inan, OE; Kocaturk, M; Sahin, B; Tvarijonaviciute, A; Ulus, IH; Yilmaz, Z, 2021
)
1.59
"Choline treatment was administered in the mice till the end of the experiment."( [Choline improves lipopolysaccharide-induced central nervous system inflammatory response and cognitive dysfunction in mice].
DU, CY; Feng, ZG; Jin, SY; Wang, H; Yu, J; Zhang, N; Zhang, WD; Zhao, WX, 2017
)
2.09
"Choline treatment significantly ameliorated myocardial IR-induced autophagic activity characterized by repression of beclin-1 over-activation, the reduction of autophagosomes, the LC3-II/LC3-I ratio, and p62 protein abundance."( Choline Inhibits Ischemia-Reperfusion-Induced Cardiomyocyte Autophagy in Rat Myocardium by Activating Akt/mTOR Signaling.
Chen, T; Du, Z; Hang, P; Su, Z; Sun, H; Zhao, J; Zhao, L, 2018
)
2.64
"Choline treatment may represent a new therapeutic strategy for optimizing myocardial metabolism in the context of hypertrophy and heart failure."( Choline ameliorates cardiac hypertrophy by regulating metabolic remodelling and UPRmt through SIRT3-AMPK pathway.
Cui, YL; Lu, Y; Wu, Q; Xu, M; Xue, RQ; Yong, SY; Yu, XJ; Zang, WJ; Zhao, M; Zuo, XT, 2019
)
2.68
"Choline treatment partly restored the DMRs in SHRs, which were related to 131 genes."( Regulation of DNA methylation and 2-OG/TET signaling by choline alleviated cardiac hypertrophy in spontaneously hypertensive rats.
He, X; Liu, J; Liu, L; Wang, S; Yang, S; Yu, X; Zang, W; Zhao, M, 2019
)
1.48
"Choline treatment did not attenuate hyperglycaemic development. "( Choline treatment affects the liver reticuloendothelial system and plasma fatty acid composition in diabetic rats.
Al-Saeedi, FJ; Cheng, B, 2013
)
3.28
"Choline treatment affected hepatic reticuloendothelial function and plasma fatty acid composition, but not hepatobiliary function, in diabetic rats. "( Choline treatment affects the liver reticuloendothelial system and plasma fatty acid composition in diabetic rats.
Al-Saeedi, FJ; Cheng, B, 2013
)
3.28
"Choline pretreatment of CGN significantly reduces the disruption of L1 function by EtOH, but does not completely return L1 function to baseline. "( Choline partially prevents the impact of ethanol on the lipid raft dependent functions of l1 cell adhesion molecule.
Bamford, P; Bearer, CF; He, M; Jones, J; Kane, MA; Mooney, SM; Tang, N, 2014
)
3.29
"Choline treatment attenuated I/R-induced vascular dysfunction, blocked elevations in the levels of reactive oxygen species (ROS) and decreased the up-regulated expression of oxidised CaMKII and phosphorylated CaMKII. "( Activation of M3 cholinoceptors attenuates vascular injury after ischaemia/reperfusion by inhibiting the Ca2+/calmodulin-dependent protein kinase II pathway.
Bi, XY; He, X; Lu, XZ; Xu, M; Yu, XJ; Zang, WJ; Zhao, M; Zhao, ZH, 2015
)
1.86
"Choline pre-treatment increased the distance crossed by males, and both pre- and post-treatment with choline significantly increased total distance crossed for females and males."( Choline Ameliorates Deficits in Balance Caused by Acute Neonatal Ethanol Exposure.
Bearer, CF; He, M; Mooney, SM; Tang, N; Wellmann, KA, 2015
)
2.58
"Choline treatment failed to attenuate alcohol-related overactivity in the open field and deficits in Morris water maze performance."( Adolescent Choline Supplementation Attenuates Working Memory Deficits in Rats Exposed to Alcohol During the Third Trimester Equivalent.
Schneider, RD; Thomas, JD, 2016
)
1.55
"Choline treatment attenuated actin alpha cardiac muscle-1 overexpression after LPS."( Changes in serum proteins after endotoxin administration in healthy and choline-treated calves.
Baykal, AT; Cansev, M; Ceron, J; Eralp Inan, O; Hacariz, O; Hatipoglu, I; Kocaturk, M; Tvarijonaviciute, A; Ulus, IH; Yilmaz, Z, 2016
)
1.39
"Choline treatment reduced changes in serum MMPs, TIMPs and markers of organ damage, and prevented the hypoimmunoglobulinemia in LPS+C."( Effects of choline treatment in concentrations of serum matrix metalloproteinases (MMPs), MMP tissue inhibitors (TIMPs) and immunoglobulins in an experimental model of canine sepsis.
Cansev, M; Ceron, JJ; Eralp-Inan, O; Kahraman, MM; Kocaturk, M; Ozyigit, MO; Tvarijonaviciute, A; Yilmaz, Z, 2016
)
1.55
"Choline treatment prior to endotoxin resulted in a significantly improved survival rate as compared with saline-treated endotoxemic controls."( Modulation of TNF release by choline requires alpha7 subunit nicotinic acetylcholine receptor-mediated signaling.
Al-Abed, Y; Chavan, S; Czura, CJ; Gallowitsch-Puerta, M; Goldstein, RS; Hudson, L; Johnson, SM; Lin, X; Miller, EJ; Ochani, K; Ochani, M; Parrish, WR; Patel, N; Pavlov, VA; Rosas-Ballina, M; Tracey, KJ; Yang, LH,
)
1.14
"Choline treatment improved survival rate of rats in lethal endotoxin shock."( Choline or CDP-choline alters serum lipid responses to endotoxin in dogs and rats: involvement of the peripheral nicotinic acetylcholine receptors.
Cansev, M; Ilcol, YO; Ulus, IH; Yilmaz, Z, 2009
)
2.52
"Choline treatment in sensitised mice before OVA challenge via oral/intranasal routes significantly inhibited eosinophilic airway inflammation and eosinophil peroxidase activity."( Effect of choline chloride in allergen-induced mouse model of airway inflammation.
Arora, N; Gaur, SN; Mehta, AK; Singh, BP, 2007
)
1.46
"CDP-choline treatment was not able to reverse the effect of hypoxia on DNA labeling, but it was able to remove the effect of hypoxia on RNA and protein labeling."( Effect of CDP-choline on the biosynthesis of nucleic acids and proteins in brain regions during hypoxia.
Alberghina, M; Giuffrida, AM; Mistretta, A; Serra, I; Viola, M, 1981
)
1.1
"CDP-Choline-treated cats exhibited a statistically significant increase in resistance to the effects of mechanical compression of the brain when compared with the vehicle-treated group."( Study of the effects of oral administration of CDP-choline on EEG changes and lethality induced by epidural compression in the anaesthetised cat.
Algate, DR; Beard, DJ; Davies, JE; Ortiz, JA; Sacristán, A, 1983
)
1
"CDP-choline treatment showed a significant improvement of rigidity and bradykinesia and a less important amelioration of tremor."( New strategies in the management of Parkinson's disease: a biological approach using a phospholipid precursor (CDP-choline).
Agnoli, A; Bruno, G; Denaro, A; Ruggieri, S, 1982
)
0.96
"Choline treatment did not change brain choline content, and was not associated with clinical or radiological improvement."( One-methyl group metabolism in non-ketotic hyperglycinaemia: mildly elevated cerebrospinal fluid homocysteine levels.
Bottiglieri, T; Charles, HC; Gray, L; Hyland, K; Jaeken, J; Kahler, SG; Lazeyras, F; Van Hove, JL; Zeisel, SH, 1998
)
1.02
"The choline treatment affected retention of the PA task on PND 18."( Postnatal choline supplementation in preweanling mice: sexually dimorphic behavioral and neurochemical effects.
Berger-Sweeney, J; Ricceri, L, 1998
)
1.18
"The choline-treated EC males were the most influenced by their experience seeing a demonstrator swim to a platform location."( The influences of sex, rearing environment, and neonatal choline dietary supplementation on spatial and nonspatial learning and memory in adult rats.
Tees, RC, 1999
)
1.03
"Choline-treated old animals made more perservation errors, i.e., responses with interresponse times (IRTs) < 2 s, than the untreated old control rats."( Chronic dietary choline enrichment affects DRL responding of old, but not of adult CPBB rats.
Collijn, D; Kerbusch, S; Raaijmakers, W; van der Staay, FJ, 1992
)
1.35
"Choline treatment was able to reduce the amount of accumulated Rb+ in old rats."( Chronic choline treatment improves the "in vivo" membrane permeability of old hepatocytes to Rb+.
Pieri, C, 1989
)
1.43
"Choline treatment was able to reduce the amount of accumulated Rb+ in the old rats."( Chronic dietary choline influences the permeability of nerve cell membranes as revealed by in vivo Rb+ uptake and release.
Giuli, C; Marcheselli, F; Pieri, C, 1989
)
1.34
"CDP-choline treatment, thus exerts favourable effects especially in the acute treatment, by reducing platelet reactivity."( Effects of CDP-choline on platelet aggregation and the antiaggregatory activity of arterial wall in the rat.
Galli, C; Giani, E; Masi, I, 1986
)
1.1
"Treatment with choline reduced the number of upregulated (32 proteins) and downregulated proteins (33 proteins) in the NSPs induced by LPS."( Nasal secretory protein changes following intravenous choline administration in calves with experimentally induced endotoxaemia.
Baykal, AT; Cansev, M; Ceron, JJ; Inan, OE; Kocaturk, M; Sahin, B; Tvarijonaviciute, A; Ulus, IH; Yilmaz, Z, 2021
)
1.21
"Post-treatment 11C-Choline-PET showed metabolic complete response in 17 metastases (44,7%), partial response in 9 metastases (38%)."( 11C-Choline-Pet Guided Stereotactic Body Radiation Therapy for Lymph Node Metastases in Oligometastatic Prostate Cancer.
Chiti, A; D'Agostino, GR; Di Brina, L; Franzese, C; Lopci, E; Mancosu, P; Navarria, P; Scorsetti, M; Tomatis, S, 2017
)
1.33
"The treatment with choline showed significant reduction in symptom/drug score and improvement in PC(20) FEV1 compared to baseline or standard pharmacotherapy (p<0.01)."( Choline attenuates immune inflammation and suppresses oxidative stress in patients with asthma.
Arora, N; Gaur, SN; Mehta, AK; Singh, BP, 2010
)
2.12
"Treatment with choline or cytidine alone led to a less marked improvement in SFI score and failed to increase axon count."( CDP-choline and its endogenous metabolites, cytidine and choline, promote the nerve regeneration and improve the functional recovery of injured rat sciatic nerves.
Aslan, E; Bekar, A; Kocaeli, H; Tolunay, S; Ulus, IH, 2011
)
1.27
"Pre-treatment with choline (> or =1 mM) alone or in combination with corticosterone markedly reduced subsequent NMDA toxicity, effects blocked by co-exposure to methyllycaconitine (100 nM), an antagonist active at nAChRs expressing the alpha7 subunit."( Choline exposure reduces potentiation of N-methyl-D-aspartate toxicity by corticosterone in the developing hippocampus.
Harris, BR; Littleton, JM; Mulholland, PJ; Prendergast, MA; Self, RL, 2004
)
2.09
"Pretreatment with choline totally prevented the depletion of ACh induced by pentylenetetrazol in the striatum."( Exogenous choline enhances the synthesis of acetylcholine only under conditions of increased cholinergic neuronal activity.
Schmidt, DE; Trommer, BA; Wecker, L, 1982
)
0.99
"Rats treated with a choline-free diet that contained the false cholinergic precursor N-aminodeanol showed great deficit in PPI."( Cholinergic mechanisms in startle and prepulse inhibition: effects of the false cholinergic precursor N-aminodeanol.
Fairchild, MD; Jenden, DJ; Siegel, JM; Wu, MF, 1993
)
2.04
"Rats treated with a cholinergic blocker (ethylcholine aziridium) have been used as a model for cholinergic deficits."( Neuroprotective strategy for Alzheimer disease: intranasal administration of a fatty neuropeptide.
Bardea, A; Brenneman, DE; Fridkin, M; Gozes, I; Reshef, A; Rubinraut, S; Zamostiano, R; Zhukovsky, S, 1996
)
0.61
"Pretreatment with choline chloride, PAH, furosemide and ethacrynic acid reduced the nephrotoxic action of CP in rat but did not prevent the accumulation of platinum in renal tissue which appeared to be a function of the dose injected to investigated animals."( Cisplatin: nephrotoxic action in vertebrates and its prevention.
Bakhteeva, VT; Brovtsyn, VK; Myazina, EM; Reznik, LV, 1989
)
0.6
"Pretreatment with choline was not effective."( Amnesia produced by intracerebroventricular injections of hemicholinium-3 in mice was prevented by pretreatment with piracetam-like compounds.
Franklin, SR; Sethy, VH; Tang, AH, 1986
)
0.59
"Treatment with choline theophyllinate had no effect on either the occurrence or the severity of transient nocturnal hypoxaemic episodes or apnoeas or hypopnoeas."( Sustained release choline theophyllinate in nocturnal asthma.
Connaughton, JJ; Douglas, NJ; Flenley, DC; McFie, J; Rhind, GB, 1985
)
0.94
"Pre-treatment with choline salicylate and colchicine reduced swelling while pre-treatment with dipyridamole increased edema following cryoglobulin inoculation."( Cryoglobulin-induced inflammation.
Denko, CW, 1985
)
0.59

Toxicity

The toxic effect of AF64A correlated well with the affinity of the choline transport system detected in each cell type. A third population of cholinergic cells, located towards the middle of the inner nuclear layer, was resistant to the toxic effects of ECMA.

ExcerptReferenceRelevance
"Tests on a culture of embryonal fibroblast cells furnished preliminary data on a possible use of vitamins C, PP, folic acid and methionine in preventing the toxic effects of phosphamide and acrex."( [Protective action of vitamins and amino acids against the cytotoxic effect of phosphamide and Acrex].
Dorofeev, VM; Zolotnikova, GP,
)
0.13
" Mouse toxicity studies (LD50) indicate that 2 is approximately as toxic as HC-3 (1), whereas 3, 4, and 5 are 14."( Synthesis and structure-toxicity relationships of three new stable analogues of acetyl-seco-hemicholinium-3.
Charles, HC; Chihal, DM; Domer, FR; Haarstad, VB; Rege, AB, 1976
)
0.26
" A third population of cholinergic cells, located towards the middle of the inner nuclear layer, was resistant to the toxic effects of ECMA."( The toxic effects of ethylcholine mustard aziridinium ion on cholinergic cells in the chicken retina.
Boelen, M; Epstein, ML; Ishimoto, I; Johnson, CD; Millar, TJ; Morgan, IG, 1987
)
0.88
" A fixed dose of Ch (100 mg/kg) altered neither the expression of toxic cholinergic signs produced by varying doses (from 75."( The effects of choline on soman-induced analgesia and toxicity.
Romano, JA; Shih, TM,
)
0.72
" In rats, the LD50 of HPC was 606 mumol/kg; the maximum tolerable dose over four weeks was 39 mumol/kg."( Alkyl phosphocholines: toxicity and anticancer properties.
Berger, MR; Eibl, HJ; Garzon, FT; Muschiol, C; Scherf, HR; Schmähl, D; Schuler, B; Unger, C; Zeller, WJ, 1987
)
0.64
" Supplementation of the ethionine-containing diet with either choline or betaine ameliorated the growth depression, although neither compound was able to completely overcome the toxic effects of ethionine."( Amelioration of ethionine toxicity in the chick.
Baker, DH; Lowry, KR, 1987
)
0.51
" After 24 h, some neurons survived but with attenuated arbors; in contrast, astrocytes appeared intact, suggesting that glial cells are more resistant than neurons to the toxic effects of AF64A."( Cholinergic neurotoxicity induced by ethylcholine aziridinium (AF64A) in neuron-enriched cultures.
Davies, DL; Sakellaridis, N; Valcana, T; Vernadakis, A, 1986
)
1.71
"The LD50 and LD0 of choline HCl and cytidine diphosphate choline (CDP-choline, citicoline, Somazina) by oral and intravenous route at equivalent doses of choline for both compounds were determined."( Dissimilar effects in acute toxicity studies of CDP-choline and choline.
Agut, J; Font, E; Ortiz, JA; Sacristán, A, 1983
)
0.84
" LD50 values were determined according to the cumulative method by Reed-Muench for mortality rate, and Pizzi's method for calculation of standard error."( CDP-choline: acute toxicity study.
Grau, T; Ortiz, JA; Romero, A; Sacristán, A, 1983
)
0.82
" It can therefore be concluded that CDP-choline does not cause any toxic effects under the chosen experimental conditions."( CDP-choline: 6-month study on toxicity in dogs.
Grau, T; Ortiz, JA; Romero, A; Sacristán, A, 1983
)
1.09
" The toxic effect of AF64A correlated well with the affinity of the choline transport system detected in each cell type."( Direct cytotoxicity of ethylcholine mustard aziridinium in cerebral microvascular endothelial cells.
Estrada, C; Galea, E; Gómez, C; Martín, C, 1993
)
0.82
" They interfered with subsequent steps in the toxic process."( Neurotoxicity of ammonia and glutamate: molecular mechanisms and prevention.
Felipo, V; Hermenegildo, C; Llansola, M; Miñana, MD; Montoliu, C,
)
0.13
" The results obtained warrant the further search for the novel types of safe neuroprotectors among the synthetic NAS/melatonin derivatives."( N-acetylserotonin, melatonin and their derivatives improve cognition and protect against beta-amyloid-induced neurotoxicity.
Afanasiev, A; Bachurin, S; Beznosko, B; Lermontova, N; Mukhina, T; Oxenkrug, G; Serkova, T; Shevtzova, E; Vankin, G, 1999
)
0.3
" Pretreatment, cotreatment, or delayed treatment with acetylcholine or choline prevented the adverse effects of DMAE."( The sea urchin embryo as a model for mammalian developmental neurotoxicity: ontogenesis of the high-affinity choline transporter and its role in cholinergic trophic activity.
Buznikov, GA; Lauder, JM; Nikitina, LA; Qiao, D; Seidler, FJ; Slotkin, TA, 2003
)
0.77
" But there are apprehensions regarding adverse effects of choline when given orally in high doses."( Acute toxicity assessment of choline by inhalation, intraperitoneal and oral routes in Balb/c mice.
Arora, N; Gaur, SN; Mehta, AK; Singh, BP, 2009
)
0.89
"Thallium (Tl) is a toxic heavy metal and its exposure to the human body causes physiological and biochemical changes due to its interference with potassium-dependent biological reactions."( Study of acute biochemical effects of thallium toxicity in mouse urine by NMR spectroscopy.
Bhatnagar, D; Chaturvedi, S; Devi, MM; Khan, AR; Khushu, S; Rana, P; Tripathi, RP; Tyagi, R, 2011
)
0.37
" Toxic signs and survival were evaluated at key times for up to 72 h following soman exposure."( Diet composition exacerbates or attenuates soman toxicity in rats: implied metabolic control of nerve agent toxicity.
Langston, JL; Myers, TM, 2011
)
0.37
"It was previously demonstrated that diet potently modulates the toxic effects of an acute lethal dose of the nerve agent soman."( Diet composition modifies the toxicity of repeated soman exposure in rats.
Langston, JL; Myers, TM, 2011
)
0.37
"Paraquat (PQ) is a widely used, highly toxic and non-selective contact herbicide, which has been associated with central neurotoxic effects, namely the development of Parkinson's disease, but whose effects to the blood-brain barrier (BBB) itself have rarely been studied."( RBE4 cells are highly resistant to paraquat-induced cytotoxicity: studies on uptake and efflux mechanisms.
Bastos, ML; Carvalho, F; Guedes-de-Pinho, P; Remião, F; Silva, R; Vilas-Boas, V, 2014
)
0.4
" No grade 3 adverse events or chronic lymphedema at extremities were observed."( Toxicity and quality of life after choline-PET/CT directed salvage lymph node dissection and adjuvant radiotherapy in nodal recurrent prostate cancer.
Grosu, AL; Henne, K; Jilg, CA; Kirste, S; Leifert, A; Rischke, HC; Schlager, D; Schnell, D; Schultze-Seemann, W; Volegova-Neher, N; Wieser, G, 2014
)
0.68
"ART after extended LND in PCa relapse is justifiable with respect to adverse effects and toxicity."( Toxicity and quality of life after choline-PET/CT directed salvage lymph node dissection and adjuvant radiotherapy in nodal recurrent prostate cancer.
Grosu, AL; Henne, K; Jilg, CA; Kirste, S; Leifert, A; Rischke, HC; Schlager, D; Schnell, D; Schultze-Seemann, W; Volegova-Neher, N; Wieser, G, 2014
)
0.68
" In this work, cholinium-based DESs comprised of choline chloride (ChCl) and choline acetate (ChAc) as the salt and urea (U), acetamide (A), glycerol (G) and ethylene glycol (EG) as the HBD were evaluated for their toxic effects on different living organisms such as Escherichia coli (a bacterium), Allium sativum (garlic, a plant) and hydra (an invertebrate), and their biodegradabilities were assessed by means of closed bottle tests."( Assessing the toxicity and biodegradability of deep eutectic solvents.
Chen, JX; Tang, YL; Wang, J; Wen, Q; Yang, Z, 2015
)
0.67
") provide potentially toxic amounts of manganese, copper, and chromium, and neonatal/pediatric multi-TE products provide potentially toxic amounts of manganese and chromium."( A Call to Action to Bring Safer Parenteral Micronutrient Products to the U.S. Market.
Borum, P; Buchman, A; Fessler, TA; Howard, L; Shenkin, A; Valentine, CJ; Vanek, VW, 2015
)
0.42
" DESs were found to be less toxic than their mixture or individual components."( Toxicity profile of choline chloride-based deep eutectic solvents for fungi and Cyprinus carpio fish.
Hayyan, M; Juneidi, I; Mohd Ali, O, 2016
)
0.76
"11C-choline-PET/CT-guided HTT is safe and effective in the treatment of LN relapses of prostate cancer in previously treated patients."( Toxicity and efficacy of salvage carbon 11-choline positron emission tomography/computed tomography-guided radiation therapy in patients with lymph node recurrence of prostate cancer.
Berardi, G; Busnardo, E; Calandrino, R; Cozzarini, C; Dell'Oca, I; Di Muzio, NG; Fiorino, C; Fodor, A; Gianolli, L; Incerti, E; Kirienko, M; Mangili, P; Pasetti, M; Picchio, M, 2017
)
1.28
" Stable O/W emulsions and gels were prepared containing the less toxic choline-based ILs and caffeine."( Choline- versus imidazole-based ionic liquids as functional ingredients in topical delivery systems: cytotoxicity, solubility, and skin permeation studies.
Araújo, MEM; Baby, AR; Fernandes, AS; Júlio, A; Mota, JP; Rosado, C; Santos de Almeida, T; Saraiva, N, 2017
)
2.13
" In this study, we report our results relating to the efficacy of this intervention in mitigating adverse effects of prenatal alcohol exposure (PAE) on infant growth and cognitive function."( Efficacy of Maternal Choline Supplementation During Pregnancy in Mitigating Adverse Effects of Prenatal Alcohol Exposure on Growth and Cognitive Function: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial.
Carter, RC; Dodge, NC; Duggan, CP; Herbert, JS; Hoyme, HE; Jacobson, JL; Jacobson, SW; Lewis, CE; Lindinger, NM; Meintjes, EM; Molteno, CD; Stanton, ME; Zeisel, SH, 2018
)
0.8
"This exploratory study is the first to provide evidence that a high dose of choline administered early in pregnancy can mitigate adverse effects of heavy PAE on EBC, postnatal growth, and cognition in human infants."( Efficacy of Maternal Choline Supplementation During Pregnancy in Mitigating Adverse Effects of Prenatal Alcohol Exposure on Growth and Cognitive Function: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial.
Carter, RC; Dodge, NC; Duggan, CP; Herbert, JS; Hoyme, HE; Jacobson, JL; Jacobson, SW; Lewis, CE; Lindinger, NM; Meintjes, EM; Molteno, CD; Stanton, ME; Zeisel, SH, 2018
)
1.03
" Further, apart from PMPy [triflate], ChC1 and TMAA had a significant adverse effect on the hatching rate of the treated embryos at concentrations of 200 mg/L."( Toxicity evaluation of selected ionic liquid compounds on embryonic development of Zebrafish.
Al-Asmakh, M; Altamash, T; Khraisheh, M; Nasrallah, GK; Pintus, G; Salem, R; Younes, N, 2018
)
0.48
" Clinical assessments, including DCNVA and adverse events (AEs), were recorded at each study visit."( Topical lipoic acid choline ester eye drop for improvement of near visual acuity in subjects with presbyopia: a safety and preliminary efficacy trial.
Burns, W; Chen, BL; Evans, DG; Korenfeld, MS; Rauchman, SH; Robertson, SM; Sall, KN; Stein, JM; Venkataraman, S; Wuttke, M, 2021
)
0.94
"UNR844 administration (n = 50) produced no safety concerns and was well-tolerated, with no clinically-relevant changes in best-corrected distance visual acuity, pupil size, intraocular pressure, or discontinuations due to adverse events."( Topical lipoic acid choline ester eye drop for improvement of near visual acuity in subjects with presbyopia: a safety and preliminary efficacy trial.
Burns, W; Chen, BL; Evans, DG; Korenfeld, MS; Rauchman, SH; Robertson, SM; Sall, KN; Stein, JM; Venkataraman, S; Wuttke, M, 2021
)
0.94
" In this work, we report a stable, safe and potent alternative artemisinin-based injectable nanocomplex consisting of dimeric artesunate-choline conjugate (dACC) micelles coated with hyaluronic acid (HA)."( Dimeric artesunate-choline conjugate micelles coated with hyaluronic acid as a stable, safe and potent alternative anti-malarial injection of artesunate.
Dogovski, C; Du, Y; He, W; Hu, R; Li, C; Li, X; Tao, Z; Wang, J; Wang, Y; Yao, C, 2021
)
1.15
" Serious adverse events from supplements with these ingredients are rare and typically involve unusually high intakes."( Dietary Supplements for Weight Management: A Narrative Review of Safety and Metabolic Health Benefits.
Blumberg, JB; Chen, O; Liska, DJ; Mah, E, 2022
)
0.72
" These solvents are a new generation of green solvents showing excellent potential for different purposes, where they are used as environmentally acceptable substitute for toxic and volatile organic solvents."( Environmentally Friendly Approach to the Synthesis of 3-[Benzylideneamino]-2-methylquinazolin-4(3H)-one Derivatives and Calculation of Their Toxicity.
Gazivoda Kraljević, T; Komar, M; Molnar, M; Pavić, V; Rastija, V, 2023
)
0.91

Pharmacokinetics

The aim of this study was to assess the biodistribution and pharmacokinetic characteristics of a novel choline-bound GNP (choline-GNP) stabilized with polyethelenimine (PEI) A rapid, simple, and sensitive high performance liquid chromatography-tandem mass spectrometry method (LC-ESI-MS) was used.

ExcerptReferenceRelevance
" The mean elimination half-life was 14 +/- 7 hours."( Pharmacokinetic study of controlled-release choline theophyllinate in elderly patients.
Beck, PR; Clarke, I; Gregory, J; le Cotonnec, JY; Mondal, BK, 1990
)
0.54
" In the remaining 13 patients, optimal concentrations of the drug were attained during most of the 24 hours, and there were only minor pharmacokinetic differences between the two periods of treatment."( The pharmacokinetics and efficacy of slow-release theophylline with asymmetric dosing in asthmatic Chinese.
Pang, JA; Swaminathan, R; Zhang, YG, 1988
)
0.27
" Salicylate levels were not sustained between doses and elimination rates and half-life were similar for both preparations."( A pharmacokinetic comparison of choline magnesium trisalicylate and soluble aspirin.
Berry, D; Gibson, T; Helliwell, M; Volans, G, 1984
)
0.55
" Oxtriphylline syrup demonstrated no appreciable change in the pharmacokinetic parameter of half-life in this young age group."( Pharmacokinetics and taste acceptance of an alcohol-free oxtriphylline solution.
Ellenberg, D; Ha, L; Jarboe, CH; Kadlec, GJ; Karibo, JM; Katsampes, C; Pollard, S; Simon, T; Sublett, J, 1980
)
0.26
" An intravenous infusion of tracer quantities of [2H4]-Ch, serial measurements of blood [2H0]-Ch and [2H4]-Ch, and a simple pharmacokinetic model were used to assess the bidirectional flux of choline between the central pool and peripheral pools before, during and after a period of imposed hypoxia, in rats ranging from 56 to 780 days of age."( The influence of aging on whole body choline release and clearance.
Jenden, DJ; Li, G; Roch, M; Scremin, OU, 1996
)
0.76
"There is an urgent need to develop non-invasive pharmacodynamic endpoints for the evaluation of new molecular therapeutics that inhibit signal transduction."( Use of radiolabelled choline as a pharmacodynamic marker for the signal transduction inhibitor geldanamycin.
Aboagye, EO; Hutchinson, OC; Liu, D; Osman, S; Price, P; Workman, P, 2002
)
0.63
" Corresponding DCE kinetics was measured from each voxel, and analyzed with a 2-compartmental model to obtain pharmacokinetic parameters Ktrans and k(ep)."( Comparison of choline and pharmacokinetic parameters in breast cancer measured by MR spectroscopic imaging and dynamic contrast enhanced MRI.
Baik, HM; Chen, JH; Mehta, RS; Nalcioglu, O; Su, MY; Yu, HJ, 2006
)
0.69
"To assess which specific morphologic features, enhancement patterns, or pharmacokinetic parameters on breast Magnetic Resonance Imaging (MRI) could predict a false-negative outcome of Proton MR Spectroscopy ((1)H MRS) exam in patients with invasive breast cancer."( MRI and (1)H MRS of the breast: presence of a choline peak as malignancy marker is related to K21 value of the tumor in patients with invasive ductal carcinoma.
Birdwell, RL; Fong, KJ; Geraghty, PR; Herfkens, RJ; Hunjan, S; Ikeda, DM; Spielman, DM; Stables, LA; van den Bosch, MA; Zakhour, M,
)
0.39
" To identify pharmacodynamic markers for the therapeutic evaluation of ChoK down-regulation, we investigated the uptake and efflux of [(3)H]choline, a natural substrate of ChoK, and two other important metabolic indicators of malignancy, namely, [(3)H]thymidine and [(3)H]fluorodeoxyglucose, which measure proliferation and glucose metabolic changes, respectively, in ChoK-downregulated cells."( Pharmacodynamic markers for choline kinase down-regulation in breast cancer cells.
Bhujwalla, ZM; Glunde, K; Nimmagadda, S; Pomper, MG, 2009
)
0.85
"A rapid, simple, and sensitive high performance liquid chromatography-tandem mass spectrometry method (LC-ESI-MS/MS) was developed and validated for the determination and pharmacokinetic investigation of choline (CL), active metabolite of citicoline in human plasma using metformin (MF) as IS."( A rapid LC-ESI-MS/MS method for the quantitation of choline, an active metabolite of citicoline: Application to in vivo pharmacokinetic and bioequivalence study in Indian healthy male volunteers.
Dastidar, SG; Ghosh, D; Gupta, B; Haldar, D; Pal, TK; Sarkar, AK; Sarkar, P, 2012
)
0.82
" The aim of this study was to assess the biodistribution and pharmacokinetic characteristics of a novel choline-bound GNP (choline-GNP) stabilized with polyethelenimine (PEI)."( The biodistribution and pharmacokinetic evaluation of choline-bound gold nanoparticles in a human prostate tumor xenograft model.
Amanie, J; Bédard, EL; Moore, RB; Pervez, N; Razzak, R; Roa, WH; Shaw, A; Yang, X; Zhou, J, 2013
)
0.85

Compound-Compound Interactions

Choline and acetylcholine (ACh) concentrations in the brain of rats. 11C-choline PET for localising and evaluating cancer lesions in patients with prostate cancer.

ExcerptReferenceRelevance
" The results indicate that theophylline alone has only a moderate acute bronchodilating effect at recommended plasma concentrations but gives a good effect when combined with inhaled beta 2-adrenostimulants."( Bioavailability of theophylline from three different tablets in asthmatic patients and their bronchodilating effects in combination with terbutaline inhalation.
Mellstrand, T; Svedmyr, K; Svedmyr, N, 1982
)
0.26
"A sensitive and rapid flow-injection analysis (FIA) of total choline-containing phospholipids (PLs) and a selective FIA method for the class assay of choline-containing PLs combined with preparative HPLC were described."( Sensitive flow-injection method with peroxyoxalate chemiluminescence detection combined with preparative high-performance liquid chromatography for determination of choline-containing phospholipids in human serum.
Akiyama, S; Imai, K; Kuroda, N; Nakashima, K; Wada, M, 1996
)
0.73
"We investigated the effects of egg phosphatidylcholine (PC) combined with vitamin B12 on memory in the Morris water maze task, and on choline and acetylcholine (ACh) concentrations in the brain of rats."( EGG phosphatidylcholine combined with vitamin B12 improved memory impairment following lesioning of nucleus basalis in rats.
Ikeda, H; Inoue, S; Kokubu, T; Masuda, Y; Yamashita, M, 1998
)
0.9
"In the present work, acetylcholine(ACh) and choline(Ch) in the microdialysates from three brain areas of anesthetized rats and from hippocampus and frontal cortex of freely moving rats were simultaneously measured by high performance liquid chromatography(HPLC) with electrochemical detection combined with a post-column immobilized enzyme reactor(IMER)."( [Determination of acetylcholine and choline in microdialysates from rat brain by high performance liquid chromatography with electrochemical detection combined with a post-column immobilized enzyme reactor].
Ma, X; Mei, Z; Ye, W, 1998
)
0.9
" The present study aimed to clarify the utility of 11C-choline PET for localising and evaluating cancer lesions in patients with prostate cancer by conducting a prospective comparison with magnetic resonance (MR) imaging combined with proton MR spectroscopy."( Prostate cancer: a comparative study of 11C-choline PET and MR imaging combined with proton MR spectroscopy.
Endou, H; Inoue, T; Kubota, Y; Lee, J; Oka, T; Sasaki, T; Shizukuishi, K; Takahashi, N; Uemura, H; Yamaguchi, T, 2005
)
0.84
"PET and MR imaging combined with proton MR spectroscopy were performed in 20 patients with prostate cancer."( Prostate cancer: a comparative study of 11C-choline PET and MR imaging combined with proton MR spectroscopy.
Endou, H; Inoue, T; Kubota, Y; Lee, J; Oka, T; Sasaki, T; Shizukuishi, K; Takahashi, N; Uemura, H; Yamaguchi, T, 2005
)
0.59
" To suppress these lipid signals, short inversion time (TI) inversion recovery (STIR) was combined with STEAM (STIR-STEAM)."( In vivo localized 1H MR spectroscopy of rat testes: stimulated echo acquisition mode (STEAM) combined with short TI inversion recovery (STIR) improves the detection of metabolite signals.
Minami, M; Mitsumori, F; Takaya, N; Watanabe, H; Yamaguchi, M, 2006
)
0.33
"Using discriminant analysis, this study found that MR spectroscopy in combination with ADC ratio, rather than ADC value, can improve the ability to differentiate recurrent glioma and radiation injury."( Distinction between recurrent glioma and radiation injury using magnetic resonance spectroscopy in combination with diffusion-weighted imaging.
Feng, DC; Li, CF; Liu, H; Zeng, QS; Zhen, JH, 2007
)
0.34
" Anti-proliferative effects of sorafenib were evidenced by (1)H MRS and (18)F-FLT PET after 2 days of treatment with sorafenib, with no additional effect of the combination with radiation therapy, results that are in agreement with Ki67 staining."( Multimodal imaging of tumor response to sorafenib combined with radiation therapy: comparison between diffusion-weighted MRI, choline spectroscopy and 18F-FLT PET imaging.
Bol, A; Bouzin, C; Danhier, P; Feron, O; Gallez, B; Grégoire, V; Jordan, BF; Karmani, L; Karroum, O; Kengen, J; Labar, D; Levêque, P; Magat, J; Mignion, L,
)
0.34
"We validated the utility of SPM8 plus DARTEL (VSRAD) combined with magnetic resonance spectroscopy (1H MRS) as an adjunct screening technique for dementia due to Alzheimer's disease (AD)."( Utility of SPM8 plus DARTEL (VSRAD) combined with magnetic resonance spectroscopy as adjunct techniques for screening and predicting dementia due to Alzheimer's disease in clinical practice.
Arai, H; Fujii, C; Hata, S; Higuchi, S; Igarashi, K; Ishii, R; Iwai, N; Moriya, M; Ohrui, T; Suzuki, T; Tokuda, T; Uemura, K; Waragai, M; Yoshida, M, 2014
)
0.4
"This study investigated the effects of dietary inclusion of rumen-protected methionine alone or in combination with rumen-protected choline and betaine on: (i) milk yield, chemical composition and fatty acids (FA) profile and (ii) blood plasma glutathione transferase (GST) activity of periparturient ewes."( The effect of dietary supplementation with rumen-protected methionine alone or in combination with rumen-protected choline and betaine on sheep milk and antioxidant capacity.
Chatzikonstantinou, M; Kalogeropoulos, T; Koutsouli, P; Labrou, N; Mavrommatis, A; Sotirakoglou, K; Tsiplakou, E; Zervas, G, 2017
)
0.87

Bioavailability

The effects TMA-producing microbes have on the bioavailability of dietary choline remain largely unknown. This work identifies members of the human gut microbiota responsible for both the accumulation of trimethylamine (TMA), the precursor of the proatherogenic compound TMAO.

ExcerptReferenceRelevance
" The qualities of both drugs as to their bioavailability and effect on airway obstruction shall be examined by means of another comparative study."( [Comparative examination of theophylline-serum-concentrations and bronchospasmolytic effect of cholintheophyllinate (euspirax) and theophyllin-aethylendiamine (euphyllin retard) in patients with obstructive airway diseases (author's transl)].
Oellerich, M; Schnitker, J; Wettengel, R, 1979
)
0.26
" The bioavailability of a radiolabeled form of the product seemed to be advantageous (slow blood clearance and no significant concentration in tissues)."( Basic biochemical investigations as rationale for the design of original antimalarial drugs. An example of phospholipid metabolism.
Angelin, ML; Calas, M; Cordinas, G; Elabbadi, N; Giral, L; Vial, HJ, 1992
)
0.28
" The absolute bioavailability of nasal tetraethylammonium administration was 79%."( Nasal absorption of tetraethylammonium in rats.
Kato, Y; Kimura, R; Miwa, M; Sato, M; Yamada, S,
)
0.13
" At a low concentration, TMA was absorbed rapidly from the in situ intestinal lumen without being metabolized in the tissue and the rate of absorption was dependent upon the concentration used."( Intestinal absorption of tetramethylammonium and its derivatives in rats.
Komai, T; Tsubaki, H, 1986
)
0.27
"During perfusion of a plasma-like solution, colonic absorption rate of chloride was much higher than the secretion rate of bicarbonate (34 vs."( Evaluation of chloride/bicarbonate. Exchange in the human colon in vivo.
Davis, GR; Fordtran, JS; Morawski, SG; Santa Ana, CA, 1983
)
0.27
"In this work, the bioavailability of the 14C-methyl-labelled cytidine diphosphate choline (CDP-Choline, citicoline, Somazina), has been studied by oral route, leading to the result that it is slowly and completely absorbed, with a very low urinary and fecal elimination, thus producing maintained blood levels."( Bioavailability of methyl-14C CDP-choline by oral route.
Agut, J; Font, E; Ortiz, JA; Sacristán, A, 1983
)
0.77
"The bioavailability of three different theophylline tablets (microcrystallinic theophylline, Theolair, Nuelin, 3M Riker), choline theophyllinate as a new film-coated tablet (Teovent, Ferrosan, Sweden) and theophyllaminopropanol (Oxyphylline, Draco, Sweden) was investigated in eight adult asthmatics and a randomized, double-blind, cross-over study."( Bioavailability of theophylline from three different tablets in asthmatic patients and their bronchodilating effects in combination with terbutaline inhalation.
Mellstrand, T; Svedmyr, K; Svedmyr, N, 1982
)
0.47
"Two experiments were conducted to determine the bioavailability for young pigs of Fe from ferric choline citrate or from a commercial mixture of Fe, Cu and Co choline citrate salts."( Bioavailability of iron from ferric choline citrate and a ferric copper cobalt choline citrate complex for young pigs.
Ku, PK; Miller, ER; Parsons, MJ; Ullrey, DE, 1981
)
0.76
" These results are consistent with saturable active secretion and provide an explanation for the dose-dependent bioavailability of celiprolol."( Transport of celiprolol across human intestinal epithelial (Caco-2) cells: mediation of secretion by multiple transporters including P-glycoprotein.
Artursson, P; Karlsson, J; Kuo, SM; Ziemniak, J, 1993
)
0.29
"Attempts to determine choline bioavailability have encountered criticism of experimental diets and protocol."( Development of an experimental diet for determining bioavailable choline concentration and its application in studies with soybean lecithin.
Baker, DH; Emmert, JL; Garrow, TA, 1996
)
0.85
" A substantial portion of choline in SBM, CM and PM is unavailable, and overheating does not appear to decrease the bioavailability of choline in these products."( A chick bioassay approach for determining the bioavailable choline concentration in normal and overheated soybean meal, canola meal and peanut meal.
Baker, DH; Emmert, JL, 1997
)
0.84
" The results showed that huperzine A had high bioavailability and more selective inhibition on AChE activity in cortex and hippocampus."( Comparative studies of huperzine A, E2020, and tacrine on behavior and cholinesterase activities.
Cheng, DH; Tang, XC, 1998
)
0.53
" This study was designed to assess 1) neuroprotection after intranasal administration of ADNF-9 and NAP to rats treated with the cholinotoxin ethylcholine aziridium; and 2) bioavailability and pharmacokinetics after intranasal administration."( Activity-dependent neurotrophic factor: intranasal administration of femtomolar-acting peptides improve performance in a water maze.
Bardea, A; Brenneman, DE; Giladi, E; Gozes, I; Pinhasov, A, 2000
)
0.51
" Further research is needed to clarify the role of choline and methionine concentration and the importance of the reduced folate carrier and the folate receptor in determining the relative bioavailability of 5-MeTHF and FA with regard to genome stability."( A comparison of folic acid and 5-methyltetrahydrofolate for prevention of DNA damage and cell death in human lymphocytes in vitro.
Fenech, M; Wang, X, 2003
)
0.57
" It is apparent that SMM in foods and feeds has methylation bioactivity, and this has implications for proper assessment of dietary Met and choline requirements as well as their bioavailability in foods and feeds."( Dietary S-methylmethionine, a component of foods, has choline-sparing activity in chickens.
Augspurger, NR; Baker, DH; Garrow, TA; Scherer, CS, 2005
)
0.78
" Such a relation is biologically plausible because ethanol impedes the bioavailability of dietary folate and is known to inhibit select folate-dependent biochemical reactions."( Effects of alcohol on folate metabolism: implications for carcinogenesis.
Choi, SW; Mason, JB, 2005
)
0.33
" Choline-stabilized orthosilicic acid (ch-OSA) was found to have a high bioavailability compared to other Si supplements."( Partial prevention of long-term femoral bone loss in aged ovariectomized rats supplemented with choline-stabilized orthosilicic acid.
Behets, GJ; Calomme, M; D'Haese, P; Demeester, N; Geusens, P; Sindambiwe, JB; Van Hoof, V; Vanden Berghe, D, 2006
)
1.46
" These graft copolymer nanoparticles enhanced the absorption and improved the bioavailability of insulin via the gastrointestinal (GI) tract of normal male Sprague-Dawley (SD) strain rats to a greater extent than that of the phosphate buffer solution (PBS) of insulin."( Chitosan graft copolymer nanoparticles for oral protein drug delivery: preparation and characterization.
Cui, F; Ding, J; Qian, F; Tang, C; Yin, C, 2006
)
0.33
" We also investigated possible uses of DES in solubilizing poorly soluble compounds for enhanced bioavailability in early drug development such as toxicology studies."( Characterization of thermal behavior of deep eutectic solvents and their potential as drug solubilization vehicles.
Morrison, HG; Neervannan, S; Sun, CC, 2009
)
0.35
"We investigated the effects of folate-enriched egg yolk powder on folate and homocysteine levels in plasma and liver of rats fed the folate- and choline-deficient diet to determine bioavailability in vivo."( The beneficial effect of folate-enriched egg on the folate and homocysteine levels in rats fed a folate- and choline-deficient diet.
Awaji, H; Horie, K; Kim, M; Nakata, R; Sugiyama, A, 2012
)
0.79
" A monolayer of enterocyte-differentiated Caco-2 cell is often used to assess the intestinal bioavailability of nutrients."( Extracellular metabolism-dependent uptake of lysolipids through cultured monolayer of differentiated Caco-2 cells.
Inaba, M; Kishino, E; Matusda, R; Murota, K; Nikawadori, M; Ohkubo, T; Takagi, M; Tanaka, T; Terao, J; Tokumura, A, 2014
)
0.4
", genotype) and diet affect TMA production and colonization of these microbes, and the effects TMA-producing microbes have on the bioavailability of dietary choline remain largely unknown."( Intestinal microbiota composition modulates choline bioavailability from diet and accumulation of the proatherogenic metabolite trimethylamine-N-oxide.
Amador-Noguez, D; Rey, FE; Romano, KA; Vivas, EI, 2015
)
0.88
" This work identifies members of the human gut microbiota responsible for both the accumulation of trimethylamine (TMA), the precursor of the proatherogenic compound TMAO, and subsequent decreased choline bioavailability to the host."( Intestinal microbiota composition modulates choline bioavailability from diet and accumulation of the proatherogenic metabolite trimethylamine-N-oxide.
Amador-Noguez, D; Rey, FE; Romano, KA; Vivas, EI, 2015
)
0.87
"The objective of this study was to develop a novel fenofibric acid-loaded controlled release pellet showing enhanced, or equivalent to, bioavailability compared with two commercially available products containing fenofibrate or choline fenofibrate."( Novel fenofibric acid-loaded controlled release pellet bioequivalent to choline fenofibrate-loaded commercial product in beagle dogs.
Choi, HG; Jin, SG; Kim, DW; Kim, JO; Kim, KS; Kim, YH; Mustapha, O; Woo, JS; Yong, CS; Yousaf, AM, 2015
)
0.83
" In addition to free choline, phosphatidylcholine has been identified as a substrate for trimethylamine production by certain intestinal bacteria, thereby reducing host choline bioavailability and providing an additional link to the increased risk of cardiovascular disease faced by those with NAFLD."( Choline, Its Potential Role in Nonalcoholic Fatty Liver Disease, and the Case for Human and Bacterial Genes.
Adams, LA; O'Sullivan, TA; Oddo, JL; Properzi, C; Sherriff, JL, 2016
)
2.2
" While the rich bioavailability research of curcumin, BDMC is the poor studies."( Hepatoprotective Effect and Synergism of Bisdemethoycurcumin against MCD Diet-Induced Nonalcoholic Fatty Liver Disease in Mice.
Ahn, YS; Cha, SW; Han, SH; Kang, OH; Kim, SB; Kong, R; Kwon, DY; Lee, YS; Seo, YS, 2016
)
0.43
" We also evaluated markers for choline bioavailability by examining relationships between net portal absorption of choline and choline metabolites in plasma and milk."( Choline absorption and evaluation of bioavailability markers when supplementing choline to lactating dairy cows.
Artegoitia, VM; Campagna, SR; de Veth, MJ; Girard, CL; Harte, F; Lapierre, H, 2016
)
2.16
" Several works reported that the bioavailability of DHA to the brain is higher when DHA is acylated to phospholipid."( Docosahexaenoic acid-containing choline phospholipid modulates LPS-induced neuroinflammation in vivo and in microglia in vitro.
Bernoud-Hubac, N; Fourrier, C; Greenhalgh, AD; Guichardant, M; Joffre, C; Lagarde, M; Layé, S; Remus-Borel, J, 2017
)
0.74
" The solubility of curcumin in simulated gastrointestinal fluids revealed that the significant increase of bioavailability takes place in the small intestinal fluid."( Natural Deep Eutectic Solvents as Agents for Improving Solubility, Stability and Delivery of Curcumin.
Cysewski, P; Jeliński, T; Przybyłek, M, 2019
)
0.51
" Dependent on the structure of choline in different sources, absorption and metabolism may differ and strongly impact the bioavailability of circulating choline."( Plasma Kinetics of Choline and Choline Metabolites After A Single Dose of Superba
Hals, PA; Mödinger, Y; Schön, C; Wilhelm, M, 2019
)
1.13
" In conclusion, this study indicates that the bioavailability of OST was improved by using the OST-NE via the nasal route."( Osthole-Loaded Nanoemulsion Enhances Brain Target in the Treatment of Alzheimer's Disease via Intranasal Administration.
Hao, J; Hao, Q; Hou, X; Song, Y; Wang, J; Wang, X, 2021
)
0.62
" A major challenge lies in the lack of knowledge about the bioavailability and pharmacodynamic effects of bioactive compounds in this model organism."( Pharmacometabolic Effects of Pteryxin and Valproate on Pentylenetetrazole-Induced Seizures in Zebrafish Reveal Vagus Nerve Stimulation.
Budzyńska, B; Gertsch, J; Kozioł, E; Lee, SM; Morozova, V; Pellegata, D; Skalicka-Woźniak, K; Skiba, A, 2023
)
0.91

Dosage Studied

8 nmol caused a 46% decrease in striatal choline acetyltransferase (CAT) activity. Acetylpyrrolcholine and acetylmorpholinecholine are full cholinoceptor agonists with dose-response curves parallel to that of acetylcholine.

ExcerptRelevanceReference
" The dose-response relationship between feed intake, liver hemorrhagic score and liver lipid content was again demonstrated."( Effect of inositol, lecithin, vitamins (B12 with choline and E), and iodinated casein on induced fatty liver-hemorrhagic syndrome in laying chickens.
Polin, D; Wolford, JH, 1975
)
0.51
" The dose-response curves to acetylpyrrolidinecholine were shifted to the right in a parallel manner by atropine and (+)-tubocurarine."( Some pharmacological properties of the false cholinergic transmitter acetylpyrrolidinecholine and its precursor pyrrolidinecholine.
Kilbinger, H; Wagner, A; Zerban, R, 1976
)
0.77
" Based on the co-operative and independent model, theoretical dose-response curves were computed using as parameters the Hill coefficient nH, maximum conductance gmax."( Determination of dose-response curves by quantitative ionophoresis at the frog neuromuscular junction.
Dreyer, F; Peper, K; Sterz, R, 1978
)
0.26
" In 6 rheumatoid arthritis patients receiving choline magnesium trisalicylate, mean steady-state serum levels were the same, and the ranges of hourly mean concentrations during 8 and 12 hour dosage intervals were 19 to 27 mg/dl and 17 to 30 mg/dl, respectively."( Steady-state serum salicylate levels in hospitalized patients with rheumatoid arthritis. Comparison of two dosage schedules of choline magnesium trisalicylate.
Cassell, S; Dromgoole, S; Furst, D; Paulus, H, 1979
)
0.72
"Tissue samples were taken from pregnant ewes and their 3-month fetuses 96 hours after intraruminal dosing of the ewes with tritiated choline."( Fate of labeled choline administered intraruminally to pregnant ewes given manganese-deficient or -supplemented rations.
Hidiroglou, M; Kramer, JK; Williams, CJ, 1979
)
0.81
"A total of twenty-nine patients have thus far been treated with deanol in various dosage levels for periods ranging from five to thirty days."( Deanol acetamidobenzoate (Deaner) in tardive dyskinesia.
Fann, WE; Stafford, JR, 1977
)
0.26
" The dose-response curve for the effect of carbachol gave a half-maximal value of 72 muM."( Sodium entry in rat diaphragm induced by depolarizing drugs.
Creese, R; Franklin, GI; Mitchell, LD, 1977
)
0.26
" 2 Acetylpyrrolcholine and acetylmorpholinecholine are full cholinoceptor agonists with dose-response curves parallel to that of acetylcholine."( The pharmacological properties of the cholinergic false transmitter, N-2-acetoxyethyl-N-methylpyrrolidinium, and its precursor, N-2-hydroxyethyl-N-methylpyrrolidinium.
Von Schwarzenfeld, I; Whittaker, VP, 1977
)
0.88
"On the basis of curves illustrating the effects of dosage on experimental animals, it was shown that glucocorticoids inhibit as well as stimulate lecithin synthesis in the fetal lung."( [Experimental investigations in regard to the optimal stimulation of lecithin synthesis in the fetal lung via glucocorticoids (author's transl)].
Gerner, R; Halberstadt, E, 1976
)
0.26
" Drug potency was obtained from log dose-response curves."( Factors determining the potency of mydriatic drugs in man.
Smith, SA, 1976
)
0.26
" All these compounds led to abnormalities of the cervical vertebrae; at higher dosage interference with normal morphogenesis involved the whole vertebral column."( Cholinomimetic teratogens: studies with chicken embryos.
Landauer, W, 1975
)
0.25
" The results provide a basis for further studies to establish a dosage schedule suitable for prolonged therapy."( Plasma level and broncholytic effect of choline theophyllinate after a single dose of a press-coated tablet formulation.
Bülow, KB; Larsson, H; Leideman, T, 1975
)
0.52
" Dose-response curves for these nucleotides revealed a potency order consistent with mediation by purinergic receptors of the P2Y type."( Phospholipid base exchange activity in rat liver plasma membranes. Evidence for regulation by G-protein and P2y-purinergic receptor.
Exton, JH; Siddiqui, RA, 1992
)
0.28
" The dose-response curve for choline generation and DNA synthesis were comparable."( Activation of phospholipase D by platelet-derived growth factor (PDGF) in rat C6 glioma cells: possible role in mitogenic signal transduction.
Nakashima, T; Nozawa, Y; Okano, Y; Sakai, N; Yamada, H; Zhang, W, 1992
)
0.57
" These data show that NSAIDs can affect the disposition of methotrexate, possibly increasing the potential for toxicity and necessitating dosage adjustments."( The effects of a salicylate, ibuprofen, and naproxen on the disposition of methotrexate in patients with rheumatoid arthritis.
Bradley, JD; Brater, DC; Hall, SD; Jones, DR; Krohn, K; Tracy, TS, 1992
)
0.28
" The dosage form was one tablet every 12 hours for four days."( Pharmacokinetic study of controlled-release choline theophyllinate in elderly patients.
Beck, PR; Clarke, I; Gregory, J; le Cotonnec, JY; Mondal, BK, 1990
)
0.54
" Dose-response curves for inhibition of choline transport by A-5 and HC-3 were not changed by a 24-hr pre-exposure of the cells to each inhibitor."( Characterization of the effect of two 4-methyl piperidine derivatives of hemicholinium-3, A-4 and A-5, on choline transport.
Long, JP; Sheff, KY; Yorek, MA, 1990
)
0.76
" CLN and CCK-8 was found to have a complex effect on the acetylcholine and choline contents depending on the brain region, dosage and treatment time."( Effects of caerulein and cholecystokinin-octapeptide on acetylcholine and choline contents in the brains of intact and vagotomized mice.
Miyate, H, 1990
)
0.76
" Male rats were dosed once a week or three times a week and at 24 h after 2, 4 or 6 weeks of dosing, selected brain tissues and behavior were examined."( Effects of repeated injection of sublethal doses of soman on behavior and on brain acetylcholine and choline concentrations in the rat.
Lenz, DE; Maxwell, DM; Shih, TM, 1990
)
0.5
" The dose-response curve for 0-10% CO2 was S-shaped."( Regulation of lung surfactant secretion by intracellular pH.
Chander, A, 1989
)
0.28
" The overall effect was a modulation of the antigen dose-response curve for antibody production, eliminating the sharp increases in dose response mediated by isolated T cell clones."( Collaboration of Th1 and Th2 T cell clones in specific antibody responses: regulation of the IgM response to phosphorylcholine.
Currier, PF; Infante, AJ, 1989
)
0.49
" In most cases the dose-response curves were biphasic and changes in coronary flow paralleled those in oxygen consumption."( The effect of cholinergic agonists on coronary flow rate and oxygen consumption in isolated perfused rat heart.
Erecińska, M; Nuutinen, EM; Wilson, DF, 1985
)
0.63
" After irreversible dopamine (DA) receptor inactivation with N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline (EEDQ), neither the ED50 nor the slope of the dose-response curve for NPA was altered, whereas the maximal response was reduced to 56% of control."( Absence of receptor reserve at striatal dopamine receptors regulating cholinergic neuronal activity.
Enz, A; Goldstein, M; Meller, E, 1988
)
0.51
"1% respectively; the dose-response curve for NE inhibitory action is described."( Quantitative evaluation of alpha- and beta-adrenoceptor modulation of [3H]choline release in guinea pig superior cervical ganglia.
Belluzzi, O; Bonifazzi, C; Perri, V; Travagli, RA, 1987
)
0.5
" Time-course and dose-response evaluations of the 1,25-(OH)2D3 effect revealed that the decrease in [14C]choline incorporation was seen within 12 h of incubation and occurred with as little as 10(-9) M, respectively."( Effect of 1,25-dihydroxyvitamin D3 on phospholipid metabolism in cultured bovine parathyroid cells.
Morrissey, J; Ritter, C; Slatopolsky, E; Sugimoto, T, 1988
)
0.49
" A dose-response relationship was seen after daily oral treatment with complete suppression of tumor growth at doses of 46."( Characterization of the antitumor activity of hexadecylphosphocholine (D 18506).
Berger, MR; Eibl, H; Engel, J; Hilgard, P; Schumacher, W; Stekar, J; Unger, C; Voegeli, R, 1988
)
0.52
" We have attempted to determine the occupancy-response relationships of three muscarinic agonists (carbachol, arecoline, and pilocarpine) by comparing their dose-response curves in these preparations with occupancy curves obtained under the same conditions."( Muscarinic acetylcholine receptors linked to the inhibition of adenylate cyclase activity in membranes from the rat striatum and myocardium can be distinguished on the basis of agonist efficacy.
Keen, M; Nahorski, SR, 1988
)
0.61
" We conclude that asymmetric dosing regimens of slow-release theophylline are effective and rational in maintenance therapy for asthma and that lower total daily dosages may be more appropriate in Chinese patients when compared to those recommended for white subjects."( The pharmacokinetics and efficacy of slow-release theophylline with asymmetric dosing in asthmatic Chinese.
Pang, JA; Swaminathan, R; Zhang, YG, 1988
)
0.27
" Ruminal dosing of steers with 27 g/d supplemental choline in Experiment 3 increased duodenal choline flow by only 3 g/d."( Dietary choline effects on milk yield and duodenal choline flow in dairy cattle.
Atkins, KB; Erdman, RA; Vandersall, JH, 1988
)
0.96
" This dosing regimen produced no alterations of striatal or cortical ChAT activity."( AF64A (ethylcholine aziridinium ion), a cholinergic neurotoxin, selectively impairs working memory in a multiple component T-maze task.
Chrobak, JJ; Hanin, I; Walsh, TJ, 1987
)
0.65
" Treatment with propylbenzilylcholine mustard (PrBCM), to inactivate irreversibly muscarinic receptors, caused a large dose dependent rightward shift of the dose-response curve to three agonistic furtrethonium derivatives with a concomitant decrease in maximal response."( The effect of propylbenzilylcholine mustard on contraction and radioligand binding parameters of muscarinic receptors in guinea pig ileum.
Rodrigues de Miranda, JF; Salden, HJ; van Ginneken, CA, 1987
)
0.86
" Methionine, either dietary or in the dosing solution, had no effect on in situ intestinal absorption or 203PbCl2."( Lead toxicity in chicks: interactions with dietary methionine and choline.
Donaldson, WE; Latta, DM, 1986
)
0.51
" Dose-response relationships were determined for these drugs and the drugs' potencies at inhibiting HACU correlated well with their anticonvulsant potencies."( Effects of anticonvulsants in vivo on high affinity choline uptake in vitro in mouse hippocampal synaptosomes.
Miller, JA; Richter, JA, 1985
)
0.52
" In this study, using the conventional dosage schedule as practised in Singapore, SRT has distinct advantages over CT in the treatment of chronic asthma."( A comparative study of the use of choline theophyllinate and a sustained-release theophylline in adults with chronic asthma.
Chan, KW; Feng, PH; Lee, HS; Tan, TH; Ti, TY, 1985
)
0.55
" Different dose-response curves were obtained for cytostasis and inhibition of [(3)H]-nucleoside incorporation, and changes in [(3)H]thymidine uptake were detected within 15 min of treatment with the inhibitors."( Rapid changes in nucleoside transport induced by growth inhibitors. Studies with neoplastic mast cells.
Lingwood, CA; Thomas, DB, 1974
)
0.25
" The dose-response curve was shifted to the right as the rubidium concentration increased and a plateau was obtained with rubidium only below 1 mM at 10(-5)M ouabain."( Rubidium, sodium and ouabain interactions on the influx of rubidium in rat red blood cells.
Beaugé, LA; Ortíz, O, 1970
)
0.25
" Log dose-response curves for acetylcholine and carbachol were constructed in the presence of triethylcholine, tubocurarine and physostigmine, in both innervated and denervated chick biventer cervicis muscles."( Actions of acetylcholine and carbachol on the chick biventer cervicis muscle.
Marshall, IG, 1971
)
0.86
"Biogenic amines in pons and striatum have been dosed in twenty-four months old Wistar male rats."( [Biochemical changes in 24-month-old Wistar rats].
Della Zuana, O; Duhault, J; Lonchampt, M; Roman, F; Saint Romas, G, 1984
)
0.27
" In a dose-response study (2-26 nmol), 8 nmol caused a 46% decrease in striatal choline acetyltransferase (CAT) activity with minimal effects on the activities of glutamate decarboxylase (GAD) and tyrosine hydroxylase (TH) at 7 days."( Selective cholinergic neurotoxin: AF64A's effects in rat striatum.
Coyle, JT; Fisher, A; Hanin, I; Sandberg, K, 1984
)
0.9
" Further, each dosing paradigm has been evaluated with a view to experimental error and interactive variables."( Effects of early lead exposure on neurotransmitter systems in the brain. A review with commentary.
Shellenberger, MK, 1984
)
0.27
"A randomized and double blind experiment has been made over 50 patients and 25 checks, by giving a dosage of 3 Fosfolip (calcium salt of phosphorylcholine chlorid with pantethine) capsules a day."( [Clinical study of the lipotropic activity of the preparation Fosfolip].
Chiti, D; Ligas, B; Proietti, C, 1983
)
0.47
" The 24-h area under the salicylate curve (AUC0-24 h) after the final 3000-mg salicylate dose averaged about twice the mean 12-h AUC after the last 1500-mg dose, indicating that the two dosing regimens were equally bioavailable."( Choline magnesium trisalicylate: comparative pharmacokinetic study of once-daily and twice-daily dosages.
Kann, J; Levitt, MJ, 1984
)
1.71
"Claims that twice-daily dosage of choline magnesium trisalicylate (CMT) may alter salicylate disposal kinetics and result in sustained plasma levels were examined."( A pharmacokinetic comparison of choline magnesium trisalicylate and soluble aspirin.
Berry, D; Gibson, T; Helliwell, M; Volans, G, 1984
)
0.83
" Male Fischer-F344 rats dosed with either 15 or 30 nmol of AF64A reacted 29-62% faster than CSF-injected controls in a hot-plate test 14 (but not 1, 7, 21 or 28) days following dosing."( AF64A, a cholinergic neurotoxin, selectively depletes acetylcholine in hippocampus and cortex, and produces long-term passive avoidance and radial-arm maze deficits in the rat.
DeHaven, DL; Fisher, A; Hanin, I; Mailman, RB; Tilson, HA; Walsh, TJ, 1984
)
0.68
"The isolated-ventilated-perfused neonatal rabbit lung model was used to study pulse dosed 14C-choline incorporation into 14C-phosphatidylcholine (PC) and 14C-disaturated phosphatidylcholine (DSPC)."( Conversion of choline to phosphatidylcholine in the isolated-ventilated-perfused neonatal rabbit lung.
Cotter, PW; Tsao, FH; Zachman, RD, 1983
)
0.85
" The tested compounds did not show any significant activity; some of them, in particular the isoxazole derivative (X), shift the dose-response curve of norepinephrine to the left."( Synthesis and biological activity of heterocyclic acyl-cholines.
De Amici, M; De Micheli, C; Grana, E; Santagostino Barbone, MG; Zonta, F, 1983
)
0.51
" Dose-response studies demonstrated that choline was also stimulatory for megakaryocyte colony formation (CFU-Mk), 26% at 5 mM."( The influence of choline chloride on murine hematopoiesis in vivo and in vitro.
Chen, MG; Gallicchio, VS; Gamba-Vitalo, C; Watts, TD, 1983
)
0.87
" Likewise, the simultaneous dosing of both drugs, which causes an evident loss of weight in the animals, has demonstrated that an activation on the dopaminergic system is produced."( Effect of oral CDP-choline on acrylamide-induced lesion.
Agut, J; Font, E; Ortiz, JA; Sacristán, A, 1983
)
0.59
" Young males showed greater responsiveness to both drugs than young females, this being reflected in higher maxima of the dose-response curves obtained for the males."( The responsiveness of human eccrine sweat glands to choline and carbachol. Application to the study of peripheral cholinergic functioning in Alzheimer-type dementia.
Bradshaw, CM; Lamb, K; Szabadi, E, 1983
)
0.52
" In each instance, hemicholinium-3 causes a significant inhibition of control activity at a concentration of 30 microM, a dosage that causes complete photoreceptor outer segment degeneration in mammalian retinas."( Alteration of retinal choline metabolism in an experimental model for photoreceptor cell degeneration.
Anderson, RE; Pu, GA, 1983
)
0.58
" At the mid-range dosage tested (400 micrograms), dexamethasone depressed DNA (51%) appreciably more than total phosphatidylcholine (28%) and disaturated phosphatidylcholine (33%)."( Fetal lung disaturated phosphatidylcholine. Ostensible increase following exposure to dexamethasone.
Funkhouser, JD; Hughes, ER, 1980
)
0.74
"A comparison was made of muscarinic receptor occupancy by the irreversible antagonist benzilylcholine mustard (BCM) as determined from shifts in the dose-response curve to a muscarinic agonist and from 3H-QNB binding to homogenates of BCM-treated tissue."( Benzilylcholine mustard and spare receptors in guinea pig ileum.
Siegel, H; Triggle, DJ, 1982
)
0.92
" 2) beta-Methylcholine, the product of carnitine decarboxylase, was not excreted, even when animals were heavily dosed with both carnitine isomers, with or without starvation."( [Catabolism of carnitine: products of carnitine decarboxylase and carnitine dehydrogenase in vivo].
Löster, H; Seim, H; Strack, E, 1980
)
0.61
" In vitro ethanol dose-response curves (0-1."( Norepinephrine, gamma-aminobutyric acid, and choline reuptake kinetics and the effects of ethanol in long-sleep and short-sleep mice.
Collins, AC; Howerton, TC; Marks, MJ, 1982
)
0.52
" 4 The dose-response curve following intraventricular administration demonstrated that hemicholinium-3 was not as lethal after central administration as it was after peripheral administration."( Peripheral toxicity of hemicholinium-3 in mice.
Freeman, JJ; Kosh, JW; Parrish, JS, 1982
)
0.26
"The effect of a forced long-term barbital treatment (daily dosage about 200 mg/kg for 32 weeks) on cholinergic brain mechanisms was studied on days 53 and 81 - 83 after withdrawal."( Changes in cholinergic function in rat brain late in abstinence after chronic barbital treatment.
Nordberg, A; Wahlström, G, 1981
)
0.87
" Combination chemotherapy of tumor bearing mice with thiamine and mechlorethamine increased the mechlorethamine dosage required for a 50 to 60 percent increase in survival time but did not improve survival over that obtained with mechlorethamine alone."( Thiamine protection of murine L1210 leukemia cells against mechlorethamine cytotoxicity and its relation to the choline uptake system.
Naujokaitis, SA, 1981
)
0.47
"The pharmacokinetics of two unmatched populations of asthmatic children, one from an asthmatic convalescent center in Denver and the other from an urban outpatient clinic, are compared after single and repeated dosing of a new asthma formulation, oxtriphylline syrup."( Theophylline pharmacokinetics: variations between two similar study populations using oral oxtriphylline syrup.
Bell, T; Danish, M; Katsampes, C; Lecks, H; Ragni, M; Rasmussen, C; Simon, T; Yaffe, S, 1980
)
0.26
" Similar studies were conducted with rats treated at the highest lead dosage which did not result in weight loss (100 microgram lead as lead acetate/g body weight/day via intubation)."( Developmental studies of the uptake of choline, GABA and dopamine by crude synaptosomal preparations after in vivo or in vitro lead treatment.
Krigman, MR; Morell, P; Ramsay, PB, 1980
)
0.53
"Eighteen healthy volunteers were administered single doses of commercially available solid dosage forms of aspirin, magnesium salicylate (I), and choline magnesium trisalicylate (II), equivalent to approximately 500 mg of salicylic acid, in a randomized, complete crossover design."( Comparative plasma salicylate and urine salicylurate levels following administration of aspirin, magnesium salicylate, and choline magnesium trisalicylate.
Mason, WD, 1980
)
0.67
" Nicotine enhanced release, with a bell-shaped dose-response curve."( Lesion with the neurotoxin AF64A alters hippocampal cholinergic receptor function.
Potter, PE; Thorne, B, 1995
)
0.54
" 25-Hydroxycholesterol dose-response curves for activation of sphingomyelin synthesis, suppression of sterol-regulated transcription, and activation of cholesteryl ester synthesis were also similar."( 25-Hydroxycholesterol stimulates sphingomyelin synthesis in Chinese hamster ovary cells.
Ridgway, ND, 1995
)
0.29
" The cholecystokinin dose-response with a somatostatin-14 background was then repeated with the addition of atropine (10 micrograms/kg/h)."( Somatostatin inhibits cholecystokinin-induced pancreatic protein secretion via cholinergic pathways.
Brodish, RJ; Fink, AS; Kuvshinoff, BW; McFadden, DW, 1995
)
0.52
" The results indicate that the TS16 condition in mice significantly modified the cholinergic function in brain, and to a lesser degree in spinal cord, suggesting that the higher gene dosage inherent to the trisomic condition affects cholinergic neurons in different regions of the central nervous system in a differential fashion."( Regional alteration of cholinergic function in central neurons of trisomy 16 mouse fetuses, an animal model of human trisomy 21 (Down syndrome).
Caviedes, P; Caviedes, R; Epstein, CJ; Fiedler, JL; Rapoport, SI, 1994
)
0.83
" In addition, the dose-response relation for halothane on [methyl-3H]choline uptake was studied."( Volatile anesthetic agents inhibit choline uptake into rat synaptosomes.
Boyle, E; Greiff, JM; Griffiths, R; Norman, RI; Rowbotham, DJ, 1994
)
0.8
" PTX caused a similar shift in the dose-response curve for LPA-induced PA formation."( Lysophosphatidic acid activation of phosphatidylcholine-hydrolysing phospholipase D and actin polymerization by a pertussis toxin-sensitive mechanism.
Exton, JH; Ha, KS; Yeo, EJ, 1994
)
0.54
" Dose-response curves for the effect of NPPB on swelling-activated choline transport and the swelling-activated transport of taurine, a sulfonic amino acid, were superimposable."( Two pathways for choline transport in eel erythrocytes: a saturable carrier and a volume-activated channel.
Joyner, SE; Kirk, K, 1994
)
0.86
" In contrast, in CMD diet fed rats, serum or pathology data showed no obvious time- or dose-response to mycotoxin treatment, extensive hepatic lipidosis in response to dietary treatment being the only predominant lesion in this diet group."( Acute hepatic response to aflatoxin B1 in rats fed a methyl-deficient, amino acid-defined diet.
Campbell, JS; Laver, GW; Mehta, R; Mueller, R; Stapley, R, 1993
)
0.29
" For all of the substrates tested the order of potency of these three inhibitors was the same (NPPB > furosemide > niflumate) and dose-response curves for the effect of these inhibitors on malaria-induced choline transport were similar to those for malaria-induced thymidine transport."( Transport of diverse substrates into malaria-infected erythrocytes via a pathway showing functional characteristics of a chloride channel.
Elford, BC; Ellory, JC; Horner, HA; Kirk, K; Newbold, CI, 1994
)
0.48
"8 mg/kg as free TRH) produced a sustained increase in immunoreactive plasma TRH levels up to about 2 weeks after dosing in rats."( Effects of sustained release formulation of thyrotropin-releasing hormone on learning impairments caused by scopolamine and AF64A in rodents.
Hirai, K; Kato, K; Miyamoto, M; Nagaoka, A; Nishiyama, M; Okada, H; Takahashi, H, 1993
)
0.29
" Dose-response studies revealed that enhancement of neuronal ChAT activity occurred at low concentrations of NGF with an EC50 of 7 ng/ml, with no enhancement of high-affinity choline transport observed at NGF concentrations up to 100 ng/ml."( Differential effects of nerve growth factor on expression of choline acetyltransferase and sodium-coupled choline transport in basal forebrain cholinergic neurons in culture.
Pongrac, JL; Rylett, RJ, 1996
)
0.73
" In the crossover study, the higher dosage of citicoline was clearly associated with improved immediate and delayed logical memory."( Citicoline improves verbal memory in aging.
Hochanadel, GS; Lieberman, HR; Myers, D; Spiers, PA; Wurtman, RJ, 1996
)
0.29
" When the dose was expressed in K1 multiples, all drugs (except AQ-RA 741 at the two highest concentrations) were found to be on the same linear dose-response curve."( Effects of M2 antagonists on in vivo hippocampal acetylcholine levels.
Galli, RL; Levy, A; Lieberman, HR; Shukitt-Hale, B; Stillman, MJ, 1996
)
0.54
" Excitoxins when infused directly into the Nbm destroy non-specifically cell bodies but spare axons passing the injection site, whereas the specificity of AF64A to destroy cholinergic neurons depends on both the dosage applied and the site of injection."( Immunolesion by 192IgG-saporin of rat basal forebrain cholinergic system: a useful tool to produce cortical cholinergic dysfunction.
Bigl, V; Rossner, S; Schliebs, R, 1996
)
0.74
" Blood levels of DEA reflected the dosing method used; oral greater than dermal with access greater than dermal without access."( Potential mechanisms of tumorigenic action of diethanolamine in mice.
Bartels, MJ; Brzak, KA; Mar, M; Markham, DA; Stott, WT; Thornton, CM; Zeisel, SH, 2000
)
0.31
" The small size of the molecules, the low dosage required, the noninvasive administration route, and the demonstrated activity in a relevant paradigm suggest NAP as a lead compound for future drug design."( Activity-dependent neurotrophic factor: intranasal administration of femtomolar-acting peptides improve performance in a water maze.
Bardea, A; Brenneman, DE; Giladi, E; Gozes, I; Pinhasov, A, 2000
)
0.31
" Dose-response curves conducted at 30-min incubation time showed that chlorpromazine potently inhibited labelling of diacylglycerol and diacyglycerol-derived lipids (triacyglycerol and phosphatidylcholine) by the 3H-labelled precursors."( Chlorpromazine and human platelet glycerolipid metabolism: precursor specificity and significance of drug-platelet interaction time.
Daasvatn, KO; Holmsen, H, 1999
)
0.49
" Finally, we find that increased dosage of enzymes that catalyze phospholipase D-independent turnover of PtdCho, via mechanisms that do not result in a direct production of phosphatidic acid or diacylglycerol, effect a partial rescue of sec14-1(ts)-associated growth defects."( Evidence for an intrinsic toxicity of phosphatidylcholine to Sec14p-dependent protein transport from the yeast Golgi complex.
Bankaitis, VA; Fang, M; Xie, Z, 2001
)
0.56
" There was negative linear correlation between the dosage of carnitine and formation of [(3)H]AFB(1)-DNA adducts in the hepatocytes; however, the partitioning of AFB(1) into cellular compartments was not affected by carnitine."( Carnitine alters binding of aflatoxin to DNA and proteins in rat hepatocytes and cell-free systems.
Sachan, DS; Yatim, AM, 2001
)
0.31
" At P42, rats were given a convulsant dosage of KA."( Seizure-induced memory impairment is reduced by choline supplementation before or after status epilepticus.
Blusztajn, JK; Cermak, JM; Holmes, GL; Liu, Z; Neill, JC; Sarkisian, MR; Stafstrom, CE; Yang, Y, 2002
)
0.57
" Seven oral doses of the toxicant, ranging in dosage from 12."( [Neurotoxicity in sodium azide poisoning].
Fujimura, T; Hara, S; Kobayashi, H; Sato, I; Suzuki, T, 2002
)
0.31
" The contributions of the metabolites to the separation of control from dosed liver tissues varied depending on the type of spectral editing method used."( Spectral editing and pattern recognition methods applied to high-resolution magic-angle spinning 1H nuclear magnetic resonance spectroscopy of liver tissues.
Antti, H; Beckonert, O; Bollard, ME; Ebbels, TM; Holmes, E; Keun, H; Lindon, JC; Nicholson, JK; Tang, H; Wang, Y, 2003
)
0.32
" Groups of female B6C3F1 mice were administered 0 (vehicle) or a maximum tolerated dosage (MTD) of 1000 mg/kg/day TEA (Trial I) and 0, 10, 100, 300, or 1000 mg/kg/day TEA (Trial II) in acetone vehicle via skin painting 5 days/week for 3 weeks."( Evaluation of the potential of triethanolamine to alter hepatic choline levels in female B6C3F1 mice.
Linscombe, VA; Mar, MH; Radtke, BJ; Stott, WT; Zeisel, SH, 2004
)
0.56
" Notably, adjusted (for age and sex) dose-response curves for the postmethionine increase in homocysteine or fasting homocysteine versus betaine showed that the inverse associations were most pronounced at low serum folate, an observation that was confirmed by analyses of interaction."( Betaine and folate status as cooperative determinants of plasma homocysteine in humans.
Blom, HJ; den Heijer, M; Holm, PI; Keijzer, MB; Midttun, Ø; Ueland, PM; Vollset, SE, 2005
)
0.33
"Although no difference was found between groups with RBD and IPD without dream enactment behavior in demographic characteristics, duration of disease, mean levodopa dosage and duration of levodopa use, all UPDRS scores (total, motor and cognitive) were worse in RBD group (p<0."( Brainstem 1H-MR spectroscopy in patients with Parkinson's disease with REM sleep behavior disorder and IPD patients without dream enactment behavior.
Dincer, A; Hanoglu, L; Meral, H; Ozer, F, 2006
)
0.33
" These pyrethroids had no significant effect on ChAT in the cortex and hippocampus, but striatal ChAT was increased at higher dosage (60 mg/kg) by all three compounds."( Neuromechanical effects of pyrethroids, allethrin, cyhalothrin and deltamethrin on the cholinergic processes in rat brain.
Hossain, MM; Kobayashi, H; Sato, I; Suzuki, K; Suzuki, T; Takewaki, T, 2005
)
0.55
" The dose-response for choline (0-50 microM) was established in buffer and was applicable to the quantification of choline in human plasma."( Rapid high-throughput detection of peroxide with an acridinium-9-carboxamide: a homogeneous chemiluminescent assay for plasma choline.
Adamczyk, M; Brashear, RJ; Mattingly, PG, 2006
)
0.85
" PI showed a significant dose-response relationship with cumulative exposure index (CEI) (r=0."( Effect of occupational manganese exposure on the central nervous system of welders: 1H magnetic resonance spectroscopy and MRI findings.
Cheong, HK; Choi, DS; Kang, DM; Kim, EA; Park, I; Ryoo, JW; Sakong, J, 2007
)
0.34
" This study was designed to establish the dose-response relationships for this effect of DEA."( Dose response effects of dermally applied diethanolamine on neurogenesis in fetal mouse hippocampus and potential exposure of humans.
Craciunescu, CN; Fischer, L; Guo, Z; Johnson, AR; Niculescu, MD; Zeisel, SH, 2009
)
0.35
" Choline citrate was administered with a dosage of 1200mg/ 2x week for a period of 3 months."( The effectiveness of choline citrate infusions monitored by lymphocyte transformation test (LTT) in multiple sclerosis. A new approach to the diagnosis and treatment of the disease.
Muss, C; Stejskal, V; Titel, E, 2009
)
1.58
" The results showed that piperine at all dosage range used in this study significantly improved memory impairment and neurodegeneration in hippocampus."( Piperine, the main alkaloid of Thai black pepper, protects against neurodegeneration and cognitive impairment in animal model of cognitive deficit like condition of Alzheimer's disease.
Chonpathompikunlert, P; Muchimapura, S; Wattanathorn, J, 2010
)
0.36
"A dose-response effect of rs12325817 on the risk of choline-related organ dysfunction was observed in premenopausal women: 80%, 43%, and 13% of women with 2, 1, or 0 alleles, respectively, developed organ dysfunction."( Dietary choline requirements of women: effects of estrogen and genetic variation.
da Costa, KA; Fischer, LM; Galanko, J; Kwock, L; Zeisel, SH, 2010
)
1.05
" As conventional anatomically based pharmacological endpoints may be inadequate to monitor the tumor response to these targeted treatments, the identification and use of more appropriate, noninvasive pharmacodynamic biomarkers appear to be crucial to optimize the design, dosage and schedule of these novel therapeutic approaches."( MR evaluation of response to targeted treatment in cancer cells.
Canese, R; Canevari, S; Iorio, E; Pisanu, ME; Podo, F; Ricci, A, 2011
)
0.37
" Rats were fed one of four distinct diets (standard, choline-enriched, glucose-enriched, or ketogenic) for four weeks prior to and throughout a repeated soman dosing and recovery regimen."( Diet composition modifies the toxicity of repeated soman exposure in rats.
Langston, JL; Myers, TM, 2011
)
0.62
" However, to our knowledge, no dose-response studies have been conducted to evaluate the effects of pregnancy or maternal choline intake on biomarkers of choline metabolism."( Maternal choline intake modulates maternal and fetal biomarkers of choline metabolism in humans.
Allen, RH; Caudill, MA; Devapatla, S; Jiang, X; Malysheva, OV; Perry, CA; Pressman, E; Stabler, SP; Vermeylen, F; West, AA; Yan, J, 2012
)
1
" As an extension of a 12-wk dose-response choline feeding study conducted in third-trimester pregnant women, we investigated the effect of maternal choline intake (930 vs."( Maternal choline intake alters the epigenetic state of fetal cortisol-regulating genes in humans.
Caudill, MA; Devapatla, S; Jiang, X; Malysheva, OV; Perry, CA; Pressman, E; Vermeylen, F; West, AA; Yan, J, 2012
)
1.06
" A generalised additive regression model showed a positive dose-response relationship between the m-MMSE and choline (P=0·012 from a corresponding linear regression model)."( Plasma free choline, betaine and cognitive performance: the Hordaland Health Study.
Bjelland, I; Drevon, CA; Engedal, K; Nurk, E; Nygaard, HA; Refsum, H; Smith, DA; Tell, GS; Ueland, PM; Vollset, SE, 2013
)
0.98
" Dose-response assays with Cho or PCho revealed that both metabolites at physiological concentrations are able to induce the translational repression of a mORF located downstream of the intact uORF30, without significantly altering its mRNA levels."( Translational regulation of Arabidopsis XIPOTL1 is modulated by phosphocholine levels via the phylogenetically conserved upstream open reading frame 30.
Alatorre-Cobos, F; Alva-Cortés, E; Chauvin, AL; Cruz-Ramírez, A; Hayden, CA; Herrera-Estrella, L; Ibarra-Laclette, E; Jorgensen, RA; Pérez-Torres, CA, 2012
)
0.61
" Exposure to a high dosage of dietary choline increased TMA synthesis in the cecum, suppressed activity of FMO3 in liver, and consequently aggravated the burden of TMA metabolism, especially in TT hens."( Effect of dietary choline supplementation under different flavin-containing monooxygenase 3 genotypes on trimethylamine metabolism in laying hens.
Ji, F; Qi, GH; Wang, J; Wu, SG; Xia, ZQ; Xu, L; Yue, HY; Zhang, HJ, 2012
)
0.98
" We examined dose-response relationships in 12 males and 12 females to incremental doses of acetylcholine (ACh) and methylcholine (MCh) for sweating (ventilated capsule), as well as to ACh and sodium nitroprusside (SNP) for cutaneous vasodilation (laser-Doppler)."( Sex differences in postsynaptic sweating and cutaneous vasodilation.
Crandall, CG; Gagnon, D; Kenny, GP, 2013
)
0.61
"There were no significant dose-response relations between any plasma- or FFQ-measured dietary factors and relative telomere length in multivariate analyses."( One-carbon metabolism factors and leukocyte telomere length.
De Vivo, I; Giovannucci, E; Hankinson, SE; Liu, JJ; Prescott, J; Rosner, B, 2013
)
0.39
" Dosing solutions were adjusted by maternal body weight to provide 30, 70, or 100 mg/kg RA."( Metabolic characterization of all-trans-retinoic acid (ATRA)-induced craniofacial development of murine embryos using in vivo proton magnetic resonance spectroscopy.
Hu, X; Peng, L; Qin, F; Shen, Z; Tang, S; Wu, R; Zhang, G, 2014
)
0.4
" A dose-response experiment with 6 dietary choline concentrations (0, 342, 779, 1285, 1662 and 1962 mg/kg) was conducted with male White Pekin ducks to estimate the choline requirement from 21 to 42 d of age."( Choline requirements of male White Pekin ducks from 21 to 42 d of age.
Feng, YL; Guo, YM; Hou, SS; Huang, W; Tang, J; Wen, ZG; Xie, M, 2014
)
2.11
"A dose-response experiment with 8 dietary choline levels (302, 496, 778, 990, 1,182, 1,414, 1,625, and 1,832 mg/kg) was conducted with male White Pekin ducks to estimate the choline requirement from hatch to 21 d of age."( Choline requirements of White Pekin ducks from hatch to 21 days of age.
Guo, YM; Hou, SS; Huang, W; Tang, J; Wen, ZG; Xie, M, 2014
)
2.11
" However, dose-response relationships between egg intake and such cancers are unclear."( Egg intake and cancers of the breast, ovary and prostate: a dose-response meta-analysis of prospective observational studies.
Aune, D; Giovannucci, EL; Greenwood, DC; Keum, N; Lee, DH; Liu, H; Marchand, N; Oh, H, 2015
)
0.42
" The half maximal inhibitory concentration (IC50) was calculated from dose-response curves."( [Assessment of Antimalarial Activity of Choline Derivatives against Plasmodium falciparum Growth in vitro by SYBR Green I Method].
Cheng, HF; Gao, J; Wang, RL; Zhang, SQ; Zhao, Q, 2015
)
0.68
" However, the effects of RPC on health and reproduction are equivocal, which could reflect the lack of sufficient dose-response studies."( The role of rumen-protected choline in hepatic function and performance of transition dairy cows.
Al Jassim, R; D'Occhio, MJ; Shahsavari, A, 2016
)
0.73
" The suitable dosage and supplementation periods of choline await further exploration."( Choline supplementation alleviates fluoride-induced testicular toxicity by restoring the NGF and MEK expression in mice.
Liang, C; Wang, J; Wang, N; Zhang, J; Zhang, Y; Zheng, H, 2016
)
2.13
"92) through a dose-response analysis."( Choline and betaine consumption lowers cancer risk: a meta-analysis of epidemiologic studies.
Du, H; Du, M; Li, X; Ren, A; Shu, Y; Sun, S; Wang, W; Zhu, L, 2016
)
1.88
" Quantitative differences between sampling events are suggestive of a dose-response relationship observable at the cellular level which, if harnessed, may be useful for assigning levels of concern based on the degree of change in a multi-parameter set of metabolite biomarkers."( Untargeted NMR-based metabolomics for field-scale monitoring: Temporal reproducibility and biomarker discovery in mosquitofish (Gambusia holbrooki) from a metal(loid)-contaminated wetland.
Bennett, WW; Carroll, AR; Doriean, NJC; Lanctôt, CM; Melvin, SD, 2018
)
0.48
" Since the patient declined surgery, and zoledronate was unfit owing to areas of rarefaction of the jaw, the calcimimetic cinacalcet was started; the dosage was progressively titrated up to 120 mg/day with normalisation of calcium levels over time."( Primary Hyperparathyroidism Manifesting with Severe Hypercalcemia in a Nonagenarian Man: Pitfall of Common Imaging Techniques, Localization by 18F-Choline Positron Emission Tomography/Computed Tomography and Successful Management with Calcimimetics.
Bottoni, G; Foppiani, L; Piccardo, A, 2019
)
0.71
"Conventional antidepressants typically require weeks of daily dosing to achieve full antidepressant response in antidepressant responders."( Involvement of muscarinic receptor mechanisms in antidepressant drug action.
Brooks, EA; Golani, LK; Martin, AE; Smith, JL; Witkin, JM, 2020
)
0.56
"Findings will provide timely information on the safety, efficacy, and optimal dosing of t-PA to treat moderate/severe COVID-19-induced ARDS, which can be rapidly adapted to a phase III trial (NCT04357730; FDA IND 149634)."(
Abbasi, S; Abd El-Wahab, A; Abdallah, M; Abebe, G; Aca-Aca, G; Adama, S; Adefegha, SA; Adidigue-Ndiome, R; Adiseshaiah, P; Adrario, E; Aghajanian, C; Agnese, W; Ahmad, A; Ahmad, I; Ahmed, MFE; Akcay, OF; Akinmoladun, AC; Akutagawa, T; Alakavuklar, MA; Álava-Rabasa, S; Albaladejo-Florín, MJ; Alexandra, AJE; Alfawares, R; Alferiev, IS; Alghamdi, HS; Ali, I; Allard, B; Allen, JD; Almada, E; Alobaid, A; Alonso, GL; Alqahtani, YS; Alqarawi, W; Alsaleh, H; Alyami, BA; Amaral, BPD; Amaro, JT; Amin, SAW; Amodio, E; Amoo, ZA; Andia Biraro, I; Angiolella, L; Anheyer, D; Anlay, DZ; Annex, BH; Antonio-Aguirre, B; Apple, S; Arbuznikov, AV; Arinsoy, T; Armstrong, DK; Ash, S; Aslam, M; Asrie, F; Astur, DC; Atzrodt, J; Au, DW; Aucoin, M; Auerbach, EJ; Azarian, S; Ba, D; Bai, Z; Baisch, PRM; Balkissou, AD; Baltzopoulos, V; Banaszewski, M; Banerjee, S; Bao, Y; Baradwan, A; Barandika, JF; Barger, PM; Barion, MRL; Barrett, CD; Basudan, AM; Baur, LE; Baz-Rodríguez, SA; Beamer, P; Beaulant, A; Becker, DF; Beckers, C; Bedel, J; Bedlack, R; Bermúdez de Castro, JM; Berry, JD; Berthier, C; Bhattacharya, D; Biadgo, B; Bianco, G; Bianco, M; Bibi, S; Bigliardi, AP; Billheimer, D; Birnie, DH; Biswas, K; Blair, HC; Bognetti, P; Bolan, PJ; Bolla, JR; Bolze, A; Bonnaillie, P; Borlimi, R; Bórquez, J; Bottari, NB; Boulleys-Nana, JR; Brighetti, G; Brodeur, GM; Budnyak, T; Budnyk, S; Bukirwa, VD; Bulman, DM; Burm, R; Busman-Sahay, K; Butcher, TW; Cai, C; Cai, H; Cai, L; Cairati, M; Calvano, CD; Camacho-Ordóñez, A; Camela, E; Cameron, T; Campbell, BS; Cansian, RL; Cao, Y; Caporale, AS; Carciofi, AC; Cardozo, V; Carè, J; Carlos, AF; Carozza, R; Carroll, CJW; Carsetti, A; Carubelli, V; Casarotta, E; Casas, M; Caselli, G; Castillo-Lora, J; Cataldi, TRI; Cavalcante, ELB; Cavaleiro, A; Cayci, Z; Cebrián-Tarancón, C; Cedrone, E; Cella, D; Cereda, C; Ceretti, A; Ceroni, M; Cha, YH; Chai, X; Chang, EF; Chang, TS; Chanteux, H; Chao, M; Chaplin, BP; Chaturvedi, S; Chaturvedi, V; Chaudhary, DK; Chen, A; Chen, C; Chen, HY; Chen, J; Chen, JJ; Chen, K; Chen, L; Chen, Q; Chen, R; Chen, SY; Chen, TY; Chen, WM; Chen, X; Chen, Y; Cheng, G; Cheng, GJ; Cheng, J; Cheng, YH; Cheon, HG; Chew, KW; Chhoker, S; Chiu, WN; Choi, ES; Choi, MJ; Choi, SD; Chokshi, S; Chorny, M; Chu, KI; Chu, WJ; Church, AL; Cirrincione, A; Clamp, AR; Cleff, MB; Cohen, M; Coleman, RL; Collins, SL; Colombo, N; Conduit, N; Cong, WL; Connelly, MA; Connor, J; Cooley, K; Correa Ramos Leal, I; Cose, S; Costantino, C; Cottrell, M; Cui, L; Cundall, J; Cutaia, C; Cutler, CW; Cuypers, ML; da Silva Júnior, FMR; Dahal, RH; Damiani, E; Damtie, D; Dan-Li, W; Dang, Z; Dasa, SSK; Davin, A; Davis, DR; de Andrade, CM; de Jong, PL; de Oliveira, D; de Paula Dorigam, JC; Dean, A; Deepa, M; Delatour, C; Dell'Aiera, S; Delley, MF; den Boer, RB; Deng, L; Deng, Q; Depner, RM; Derdau, V; Derici, U; DeSantis, AJ; Desmarini, D; Diffo-Sonkoue, L; Divizia, M; Djenabou, A; Djordjevic, JT; Dobrovolskaia, MA; Domizi, R; Donati, A; Dong, Y; Dos Santos, M; Dos Santos, MP; Douglas, RG; Duarte, PF; Dullaart, RPF; Duscha, BD; Edwards, LA; Edwards, TE; Eichenwald, EC; El-Baba, TJ; Elashiry, M; Elashiry, MM; Elashry, SH; Elliott, A; Elsayed, R; Emerson, MS; Emmanuel, YO; Emory, TH; Endale-Mangamba, LM; Enten, GA; Estefanía-Fernández, K; Estes, JD; Estrada-Mena, FJ; Evans, S; Ezra, L; Faria de, RO; Farraj, AK; Favre, C; Feng, B; Feng, J; Feng, L; Feng, W; Feng, X; Feng, Z; Fernandes, CLF; Fernández-Cuadros, ME; Fernie, AR; Ferrari, D; Florindo, PR; Fong, PC; Fontes, EPB; Fontinha, D; Fornari, VJ; Fox, NP; Fu, Q; Fujitaka, Y; Fukuhara, K; Fumeaux, T; Fuqua, C; Fustinoni, S; Gabbanelli, V; Gaikwad, S; Gall, ET; Galli, A; Gancedo, MA; Gandhi, MM; Gao, D; Gao, K; Gao, M; Gao, Q; Gao, X; Gao, Y; Gaponenko, V; Garber, A; Garcia, EM; García-Campos, C; García-Donas, J; García-Pérez, AL; Gasparri, F; Ge, C; Ge, D; Ge, JB; Ge, X; George, I; George, LA; Germani, G; Ghassemi Tabrizi, S; Gibon, Y; Gillent, E; Gillies, RS; Gilmour, MI; Goble, S; Goh, JC; Goiri, F; Goldfinger, LE; Golian, M; Gómez, MA; Gonçalves, J; Góngora-García, OR; Gonul, I; González, MA; Govers, TM; Grant, PC; Gray, EH; Gray, JE; Green, MS; Greenwald, I; Gregory, MJ; Gretzke, D; Griffin-Nolan, RJ; Griffith, DC; Gruppen, EG; Guaita, A; Guan, P; Guan, X; Guerci, P; Guerrero, DT; Guo, M; Guo, P; Guo, R; Guo, X; Gupta, J; Guz, G; Hajizadeh, N; Hamada, H; Haman-Wabi, AB; Han, TT; Hannan, N; Hao, S; Harjola, VP; Harmon, M; Hartmann, MSM; Hartwig, JF; Hasani, M; Hawthorne, WJ; Haykal-Coates, N; Hazari, MS; He, DL; He, P; He, SG; Héau, C; Hebbar Kannur, K; Helvaci, O; Heuberger, DM; Hidalgo, F; Hilty, MP; Hirata, K; Hirsch, A; Hoffman, AM; Hoffmann, JF; Holloway, RW; Holmes, RK; Hong, S; Hongisto, M; Hopf, NB; Hörlein, R; Hoshino, N; Hou, Y; Hoven, NF; Hsieh, YY; Hsu, CT; Hu, CW; Hu, JH; Hu, MY; Hu, Y; Hu, Z; Huang, C; Huang, D; Huang, DQ; Huang, L; Huang, Q; Huang, R; Huang, S; Huang, SC; Huang, W; Huang, Y; Huffman, KM; Hung, CH; Hung, CT; Huurman, R; Hwang, SM; Hyun, S; Ibrahim, AM; Iddi-Faical, A; Immordino, P; Isla, MI; Jacquemond, V; Jacques, T; Jankowska, E; Jansen, JA; Jäntti, T; Jaque-Fernandez, F; Jarvis, GA; Jatt, LP; Jeon, JW; Jeong, SH; Jhunjhunwala, R; Ji, F; Jia, X; Jia, Y; Jian-Bo, Z; Jiang, GD; Jiang, L; Jiang, W; Jiang, WD; Jiang, Z; Jiménez-Hoyos, CA; Jin, S; Jobling, MG; John, CM; John, T; Johnson, CB; Jones, KI; Jones, WS; Joseph, OO; Ju, C; Judeinstein, P; Junges, A; Junnarkar, M; Jurkko, R; Kaleka, CC; Kamath, AV; Kang, X; Kantsadi, AL; Kapoor, M; Karim, Z; Kashuba, ADM; Kassa, E; Kasztura, M; Kataja, A; Katoh, T; Kaufman, JS; Kaupp, M; Kehinde, O; Kehrenberg, C; Kemper, N; Kerr, CW; Khan, AU; Khan, MF; Khan, ZUH; Khojasteh, SC; Kilburn, S; Kim, CG; Kim, DU; Kim, DY; Kim, HJ; Kim, J; Kim, OH; Kim, YH; King, C; Klein, A; Klingler, L; Knapp, AK; Ko, TK; Kodavanti, UP; Kolla, V; Kong, L; Kong, RY; Kong, X; Kore, S; Kortz, U; Korucu, B; Kovacs, A; Krahnert, I; Kraus, WE; Kuang, SY; Kuehn-Hajder, JE; Kurz, M; Kuśtrowski, P; Kwak, YD; Kyttaris, VC; Laga, SM; Laguerre, A; Laloo, A; Langaro, MC; Langham, MC; Lao, X; Larocca, MC; Lassus, J; Lattimer, TA; Lazar, S; Le, MH; Leal, DB; Leal, M; Leary, A; Ledermann, JA; Lee, JF; Lee, MV; Lee, NH; Leeds, CM; Leeds, JS; Lefrandt, JD; Leicht, AS; Leonard, M; Lev, S; Levy, K; Li, B; Li, C; Li, CM; Li, DH; Li, H; Li, J; Li, L; Li, LJ; Li, N; Li, P; Li, T; Li, X; Li, XH; Li, XQ; Li, XX; Li, Y; Li, Z; Li, ZY; Liao, YF; Lin, CC; Lin, MH; Lin, Y; Ling, Y; Links, TP; Lira-Romero, E; Liu, C; Liu, D; Liu, H; Liu, J; Liu, L; Liu, LP; Liu, M; Liu, T; Liu, W; Liu, X; Liu, XH; Liu, Y; Liuwantara, D; Ljumanovic, N; Lobo, L; Lokhande, K; Lopes, A; Lopes, RMRM; López-Gutiérrez, JC; López-Muñoz, MJ; López-Santamaría, M; Lorenzo, C; Lorusso, D; Losito, I; Lu, C; Lu, H; Lu, HZ; Lu, SH; Lu, SN; Lu, Y; Lu, ZY; Luboga, F; Luo, JJ; Luo, KL; Luo, Y; Lutomski, CA; Lv, W; M Piedade, MF; Ma, J; Ma, JQ; Ma, JX; Ma, N; Ma, P; Ma, S; Maciel, M; Madureira, M; Maganaris, C; Maginn, EJ; Mahnashi, MH; Maierhofer, M; Majetschak, M; Malla, TR; Maloney, L; Mann, DL; Mansuri, A; Marelli, E; Margulis, CJ; Marrella, A; Martin, BL; Martín-Francés, L; Martínez de Pinillos, M; Martínez-Navarro, EM; Martinez-Quintanilla Jimenez, D; Martínez-Velasco, A; Martínez-Villaseñor, L; Martinón-Torres, M; Martins, BA; Massongo, M; Mathew, AP; Mathews, D; Matsui, J; Matsumoto, KI; Mau, T; Maves, RC; Mayclin, SJ; Mayer, JM; Maynard, ND; Mayr, T; Mboowa, MG; McEvoy, MP; McIntyre, RC; McKay, JA; McPhail, MJW; McVeigh, AL; Mebazaa, A; Medici, V; Medina, DN; Mehmood, T; Mei-Li, C; Melku, M; Meloncelli, S; Mendes, GC; Mendoza-Velásquez, C; Mercadante, R; Mercado, MI; Merenda, MEZ; Meunier, J; Mi, SL; Michels, M; Mijatovic, V; Mikhailov, V; Milheiro, SA; Miller, DC; Ming, F; Mitsuishi, M; Miyashita, T; Mo, J; Mo, S; Modesto-Mata, M; Moeller, S; Monte, A; Monteiro, L; Montomoli, J; Moore, EE; Moore, HB; Moore, PK; Mor, MK; Moratalla-López, N; Moratilla Lapeña, L; Moreira, R; Moreno, MA; Mörk, AC; Morton, M; Mosier, JM; Mou, LH; Mougharbel, AS; Muccillo-Baisch, AL; Muñoz-Serrano, AJ; Mustafa, B; Nair, GM; Nakanishi, I; Nakanjako, D; Naraparaju, K; Nawani, N; Neffati, R; Neil, EC; Neilipovitz, D; Neira-Borrajo, I; Nelson, MT; Nery, PB; Nese, M; Nguyen, F; Nguyen, MH; Niazy, AA; Nicolaï, J; Nogueira, F; Norbäck, D; Novaretti, JV; O'Donnell, T; O'Dowd, A; O'Malley, DM; Oaknin, A; Ogata, K; Ohkubo, K; Ojha, M; Olaleye, MT; Olawande, B; Olomo, EJ; Ong, EWY; Ono, A; Onwumere, J; Ortiz Bibriesca, DM; Ou, X; Oza, AM; Ozturk, K; Özütemiz, C; Palacio-Pastrana, C; Palaparthi, A; Palevsky, PM; Pan, K; Pantanetti, S; Papachristou, DJ; Pariani, A; Parikh, CR; Parissis, J; Paroul, N; Parry, S; Patel, N; Patel, SM; Patel, VC; Pawar, S; Pefura-Yone, EW; Peixoto Andrade, BCO; Pelepenko, LE; Peña-Lora, D; Peng, S; Pérez-Moro, OS; Perez-Ortiz, AC; Perry, LM; Peter, CM; Phillips, NJ; Phillips, P; Pia Tek, J; Piner, LW; Pinto, EA; Pinto, SN; Piyachaturawat, P; Poka-Mayap, V; Polledri, E; Poloni, TE; Ponessa, G; Poole, ST; Post, AK; Potter, TM; Pressly, BB; Prouty, MG; Prudêncio, M; Pulkki, K; Pupier, C; Qian, H; Qian, ZP; Qiu, Y; Qu, G; Rahimi, S; Rahman, AU; Ramadan, H; Ramanna, S; Ramirez, I; Randolph, GJ; Rasheed, A; Rault, J; Raviprakash, V; Reale, E; Redpath, C; Rema, V; Remucal, CK; Remy, D; Ren, T; Ribeiro, LB; Riboli, G; Richards, J; Rieger, V; Rieusset, J; Riva, A; Rivabella Maknis, T; Robbins, JL; Robinson, CV; Roche-Campo, F; Rodriguez, R; Rodríguez-de-Cía, J; Rollenhagen, JE; Rosen, EP; Rub, D; Rubin, N; Rubin, NT; Ruurda, JP; Saad, O; Sabell, T; Saber, SE; Sabet, M; Sadek, MM; Saejio, A; Salinas, RM; Saliu, IO; Sande, D; Sang, D; Sangenito, LS; Santos, ALSD; Sarmiento Caldas, MC; Sassaroli, S; Sassi, V; Sato, J; Sauaia, A; Saunders, K; Saunders, PR; Savarino, SJ; Scambia, G; Scanlon, N; Schetinger, MR; Schinkel, AFL; Schladweiler, MC; Schofield, CJ; Schuepbach, RA; Schulz, J; Schwartz, N; Scorcella, C; Seeley, J; Seemann, F; Seinige, D; Sengoku, T; Seravalli, J; Sgromo, B; Shaheen, MY; Shan, L; Shanmugam, S; Shao, H; Sharma, S; Shaw, KJ; Shen, BQ; Shen, CH; Shen, P; Shen, S; Shen, Y; Shen, Z; Shi, J; Shi-Li, L; Shimoda, K; Shoji, Y; Shun, C; Silva, MA; Silva-Cardoso, J; Simas, NK; Simirgiotis, MJ; Sincock, SA; Singh, MP; Sionis, A; Siu, J; Sivieri, EM; Sjerps, MJ; Skoczen, SL; Slabon, A; Slette, IJ; Smith, MD; Smith, S; Smith, TG; Snapp, KS; Snow, SJ; Soares, MCF; Soberman, D; Solares, MD; Soliman, I; Song, J; Sorooshian, A; Sorrell, TC; Spinar, J; Staudt, A; Steinhart, C; Stern, ST; Stevens, DM; Stiers, KM; Stimming, U; Su, YG; Subbian, V; Suga, H; Sukhija-Cohen, A; Suksamrarn, A; Suksen, K; Sun, J; Sun, M; Sun, P; Sun, W; Sun, XF; Sun, Y; Sundell, J; Susan, LF; Sutjarit, N; Swamy, KV; Swisher, EM; Sykes, C; Takahashi, JA; Talmor, DS; Tan, B; Tan, ZK; Tang, L; Tang, S; Tanner, JJ; Tanwar, M; Tarazi, Z; Tarvasmäki, T; Tay, FR; Teketel, A; Temitayo, GI; Thersleff, T; Thiessen Philbrook, H; Thompson, LC; Thongon, N; Tian, B; Tian, F; Tian, Q; Timothy, AT; Tingle, MD; Titze, IR; Tolppanen, H; Tong, W; Toyoda, H; Tronconi, L; Tseng, CH; Tu, H; Tu, YJ; Tung, SY; Turpault, S; Tuynman, JB; Uemoto, AT; Ugurlu, M; Ullah, S; Underwood, RS; Ungell, AL; Usandizaga-Elio, I; Vakonakis, I; van Boxel, GI; van den Beucken, JJJP; van der Boom, T; van Slegtenhorst, MA; Vanni, JR; Vaquera, A; Vasconcellos, RS; Velayos, M; Vena, R; Ventura, G; Verso, MG; Vincent, RP; Vitale, F; Vitali, S; Vlek, SL; Vleugels, MPH; Volkmann, N; Vukelic, M; Wagner Mackenzie, B; Wairagala, P; Waller, SB; Wan, J; Wan, MT; Wan, Y; Wang, CC; Wang, H; Wang, J; Wang, JF; Wang, K; Wang, L; Wang, M; Wang, S; Wang, WM; Wang, X; Wang, Y; Wang, YD; Wang, YF; Wang, Z; Wang, ZG; Warriner, K; Weberpals, JI; Weerachayaphorn, J; Wehrli, FW; Wei, J; Wei, KL; Weinheimer, CJ; Weisbord, SD; Wen, S; Wendel Garcia, PD; Williams, JW; Williams, R; Winkler, C; Wirman, AP; Wong, S; Woods, CM; Wu, B; Wu, C; Wu, F; Wu, P; Wu, S; Wu, Y; Wu, YN; Wu, ZH; Wurtzel, JGT; Xia, L; Xia, Z; Xia, ZZ; Xiao, H; Xie, C; Xin, ZM; Xing, Y; Xing, Z; Xu, S; Xu, SB; Xu, T; Xu, X; Xu, Y; Xue, L; Xun, J; Yaffe, MB; Yalew, A; Yamamoto, S; Yan, D; Yan, H; Yan, S; Yan, X; Yang, AD; Yang, E; Yang, H; Yang, J; Yang, JL; Yang, K; Yang, M; Yang, P; Yang, Q; Yang, S; Yang, W; Yang, X; Yang, Y; Yao, JC; Yao, WL; Yao, Y; Yaqub, TB; Ye, J; Ye, W; Yen, CW; Yeter, HH; Yin, C; Yip, V; Yong-Yi, J; Yu, HJ; Yu, MF; Yu, S; Yu, W; Yu, WW; Yu, X; Yuan, P; Yuan, Q; Yue, XY; Zaia, AA; Zakhary, SY; Zalwango, F; Zamalloa, A; Zamparo, P; Zampini, IC; Zani, JL; Zeitoun, R; Zeng, N; Zenteno, JC; Zepeda-Palacio, C; Zhai, C; Zhang, B; Zhang, G; Zhang, J; Zhang, K; Zhang, Q; Zhang, R; Zhang, T; Zhang, X; Zhang, Y; Zhang, YY; Zhao, B; Zhao, D; Zhao, G; Zhao, H; Zhao, Q; Zhao, R; Zhao, S; Zhao, T; Zhao, X; Zhao, XA; Zhao, Y; Zhao, Z; Zheng, Z; Zhi-Min, G; Zhou, CL; Zhou, HD; Zhou, J; Zhou, W; Zhou, XQ; Zhou, Z; Zhu, C; Zhu, H; Zhu, L; Zhu, Y; Zitzmann, N; Zou, L; Zou, Y, 2022
)
0.72
" The restricted cubic spline model was used for the dose-response analysis."( Relationship between dietary choline intake and diabetes mellitus in the National Health and Nutrition Examination Survey 2007-2010.
Li, S; Li, X; Peng, Y; Wen, X; Zhao, L; Zhou, L, 2021
)
0.91
"A linear dose-response relationship between dietary choline intake and the odds of DM was found after adjustment for multiple potential confounding factors."( Relationship between dietary choline intake and diabetes mellitus in the National Health and Nutrition Examination Survey 2007-2010.
Li, S; Li, X; Peng, Y; Wen, X; Zhao, L; Zhou, L, 2021
)
1.16
" Besides, the impact of various additives on pretreated substrate enzymatic hydrolysis confirmed that Tween 80 was the best enzymatic additive, which could significantly improve the glucose produced from pretreated SCB and remarkably reduce the hydrolysis time (from 72 h to 48 h) and enzyme dosage (from 20 FPU/g pretreated solid to 10 FPU/g pretreated solid)."( Investigation of choline chloride-formic acid pretreatment and Tween 80 to enhance sugarcane bagasse enzymatic hydrolysis.
Jin, Y; Ling, R; Wei, W; Wu, W; Yuan, Y, 2021
)
0.96
" Improvements in DCNVA were sustained at 5 and 7 months after UNR844 dosing ceased."( Topical lipoic acid choline ester eye drop for improvement of near visual acuity in subjects with presbyopia: a safety and preliminary efficacy trial.
Burns, W; Chen, BL; Evans, DG; Korenfeld, MS; Rauchman, SH; Robertson, SM; Sall, KN; Stein, JM; Venkataraman, S; Wuttke, M, 2021
)
0.94
" Additional larger, dose-response DHA trials accounting for usual intakes and baseline DHA status are needed to determine how to best achieve target breast milk DHA levels and to identify additional modifiers of the variable breast milk DHA response to maternal DHA supplementation."( Baseline red blood cell and breast milk DHA levels affect responses to standard dose of DHA in lactating women on a controlled feeding diet.
Caudill, MA; Harris, WS; Jackson, KH; Klatt, KC; Malysheva, OV; McDougall, MQ; Perry, CA; West, AA, 2021
)
0.62
"Cantharidin (CTD) is a promising anticancer drug; however, its dosage is limited by hepatotoxicity."( Protective mechanism of Astragalus Polysaccharides against Cantharidin-induced liver injury determined in vivo by liquid chromatography/mass spectrometry metabolomics.
Chen, Y; Huang, X; Li, W; Lin, C; Liu, J; Sa, Z; Tang, W; Wang, L; Xu, M; Yang, C, 2021
)
0.62
" mI/Cr ratio correlated with cumulative glucocorticoids dosage (r = 0."( Axonal dysfunction is associated with interferon-γ levels in childhood-onset systemic lupus erythematosus: a multivoxel magnetic resonance spectroscopy study.
Appenzeller, S; Castellano, G; Cendes, F; Fernandes, PT; Frittoli, RB; Lapa, AT; Marini, R; Niewold, TB; Pereira, DR; Postal, M; Rittner, L; Sinicato, NA, 2022
)
0.72
" The aim of this work was to use dose-response curves to evaluate the hormesis effect provided by sub-doses of the herbicide 2,4-D choline salt on the productivity of cotton at different phenological stages."( Hormesis of 2,4-D choline salt in productive aspects of cotton.
Araújo, PPS; Marchi, SR; Marques, RF; Martins, D; Pinheiro, GHR; Souza, RM, 2021
)
1.16
" In the study of the dose-response relationship, an L-shaped relationship between dietary choline and depressive symptoms was found."( Dietary choline is inversely associated with depressive symptoms: A cross-sectional study of the National Health and Nutrition Examination Survey (NHANES) 2011 to 2018.
Kang, X; Li, J; Luo, J; Zhang, D; Zhang, L, 2022
)
1.38
" An L-shape dose-response relationship between those two was found."( Dietary choline is inversely associated with depressive symptoms: A cross-sectional study of the National Health and Nutrition Examination Survey (NHANES) 2011 to 2018.
Kang, X; Li, J; Luo, J; Zhang, D; Zhang, L, 2022
)
1.16
" The current experiment was designed to study the effect of daily dosing of a molybdenum compound, bis-choline tetrathiomolybdate (TTM), in Sprague Dawley rats using laser ablation inductively coupled plasma time-of-flight mass spectrometry (LA-ICP-ToF-MS) and two dosing levels of TTM for up to 3 months."( Accumulation of molybdenum in major organs following repeated oral administration of bis-choline tetrathiomolybdate in the Sprague Dawley rat.
Billimoria, K; Del Castillo Busto, ME; Foster, JR; Goenaga-Infante, H; Morley, TJ; Strekopytov, S, 2022
)
1.16
"020) for ischemic stroke in an essentially linear dose-response fashion."( Associations of plasma TMAO and its precursors with stroke risk in the general population: A nested case-control study.
Gu, S; Liu, D; Ma, Z; Zhou, Z; Zuo, H, 2023
)
0.91
" Restricted cubic splines were plotted to evaluate the dose-response relationship between dietary OCM-related nutrient intake and the risk of PE."( One-carbon metabolism-related nutrients intake is associated with lower risk of preeclampsia in pregnant women: a matched case-control study.
Bo, Y; Cao, Y; Dou, W; Duan, D; Fu, W; Liu, Y; Lyu, Q; Ma, S; Zeng, F; Zhao, X, 2022
)
0.72
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Occurs in Manufacturing (35 Items)

ItemProcessFrequency
Boissonscore-ingredient2
Produits déshydratéscore-ingredient2
Beveragescore-ingredient2
Laits pour bébécore-ingredient2
Aliments pour bébécore-ingredient2
Vitamin waterscore-ingredient1
Waterscore-ingredient1
Laits en poudrecore-ingredient1
Boissons sans sucre ajoutécore-ingredient1
Boissons lyophiliséescore-ingredient1
Produits lyophilisés à reconstituercore-ingredient1
Laitscore-ingredient1
Substituts du laitcore-ingredient1
Substituts de produits laitierscore-ingredient1
Produits laitierscore-ingredient1
Aliments et boissons à base de végétauxcore-ingredient1
Lait 1er âge en poudre solublecore-ingredient1
Laits infantiles en poudrecore-ingredient1
Laits 1er âgecore-ingredient1
Energy drinkscore-ingredient1
Artificially sweetened beveragescore-ingredient1
en:baby-milkscore-ingredient1
Energy drink with sugarcore-ingredient1
Instant formulacore-ingredient1
Baby drinkscore-ingredient1
Snacks and desserts for babiescore-ingredient1
Baby milkscore-ingredient1
Milkscore-ingredient1
Baby foodscore-ingredient1
Dairiescore-ingredient1
Vitaminscore-ingredient1
Dietary supplementscore-ingredient1
Boissons avec sucre ajoutécore-ingredient1
Boisson énergisante sucréecore-ingredient1
énergisantescore-ingredient1

Roles (9)

RoleDescription
neurotransmitterAn endogenous compound that is used to transmit information across the synapse between a neuron and another cell.
nutrientA nutrient is a food component that an organism uses to survive and grow.
human metaboliteAny mammalian metabolite produced during a metabolic reaction in humans (Homo sapiens).
plant metaboliteAny eukaryotic metabolite produced during a metabolic reaction in plants, the kingdom that include flowering plants, conifers and other gymnosperms.
Daphnia magna metaboliteA Daphnia metabolite produced by the species Daphnia magna.
Saccharomyces cerevisiae metaboliteAny fungal metabolite produced during a metabolic reaction in Baker's yeast (Saccharomyces cerevisiae).
Escherichia coli metaboliteAny bacterial metabolite produced during a metabolic reaction in Escherichia coli.
mouse metaboliteAny mammalian metabolite produced during a metabolic reaction in a mouse (Mus musculus).
allergenA chemical compound, or part thereof, which causes the onset of an allergic reaction by interacting with any of the molecular pathways involved in an allergy.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
cholinesA quaternary ammonium ion based on the choline ion and its substituted derivatives thereof.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (2,157)

PathwayProteinsCompounds
Transport of small molecules39295
SLC-mediated transmembrane transport13567
Transport of bile salts and organic acids, metal ions and amine compounds4928
Metabolism14961108
Metabolism of lipids500463
Phospholipid metabolism12242
Glycerophospholipid biosynthesis7439
Synthesis of PA2215
Synthesis of PC2017
Hydrolysis of LPC34
Synthesis of PS23
Synthesis of PG38
PI Metabolism4911
Glycerophospholipid catabolism77
Amino acid and derivative metabolism250260
Choline catabolism614
Neuronal System16650
Transmission across Chemical Synapses12250
Neurotransmitter release cycle3133
Acetylcholine Neurotransmitter Release Cycle139
Neurotransmitter clearance725
Betaine Metabolism818
Methionine Metabolism1637
Phospholipid Biosynthesis2529
Cystathionine beta-Synthase Deficiency1637
Hypermethioninemia1637
S-Adenosylhomocysteine (SAH) Hydrolase Deficiency1637
Glycine N-Methyltransferase Deficiency1637
Methylenetetrahydrofolate Reductase Deficiency (MTHFRD)1637
Methionine Adenosyltransferase Deficiency1637
Homocystinuria-Megaloblastic Anemia Due to Defect in Cobalamin Metabolism, cblG Complementation Type1637
Sarcosine Oncometabolite Pathway1321
Choline Metabolism1827
Lysolipid Incorporation into ER1023
Lysolipid Incorporation into ER PC(10:0/10:0)1016
Lysolipid Incorporation into ER PC(14:0/14:0)1023
Lysolipid Incorporation into ER PC(16:0/16:0)1024
Lysolipid Incorporation into ER PC(16:1(9Z)/16:1(9Z))1024
Lysolipid Incorporation into ER PC(16:1(11Z)/16:1(11Z))1017
Lysolipid Incorporation into ER PC(18:0/18:0)1024
Lysolipid Incorporation into ER PC(18:1(9Z)/18:1(9Z))1023
Lysolipid Incorporation into ER PC(18:2(9Z,11Z)/18:2(9Z,11Z))1019
Lysolipid Incorporation into ER PC(20:4(5Z,8Z,11Z,14Z)/20:4(5Z,8Z,11Z,14Z))1023
Choline Biosynthesis I415
Choline Biosynthesis II618
Glycine Betaine Biosynthesis I621
Glycine Betaine Biosynthesis II824
Phosphatidylcholine Biosynthesis615
Phosphatidylcholine Biosynthesis PC(14:0/14:0)620
Phosphatidylcholine Biosynthesis PC(14:0/14:1(9Z))620
Phosphatidylcholine Biosynthesis PC(14:0/15:0)620
Phosphatidylcholine Biosynthesis PC(14:0/16:0)620
Phosphatidylcholine Biosynthesis PC(14:0/16:1(9Z))620
Phosphatidylcholine Biosynthesis PC(14:0/18:0)620
Phosphatidylcholine Biosynthesis PC(14:0/18:1(11Z))620
Phosphatidylcholine Biosynthesis PC(14:0/18:1(9Z))620
Phosphatidylcholine Biosynthesis PC(14:0/18:2(9Z,12Z))620
Phosphatidylcholine Biosynthesis PC(14:0/18:3(6Z,9Z,12Z))620
Phosphatidylcholine Biosynthesis PC(14:0/18:3(9Z,12Z,15Z))620
Phosphatidylcholine Biosynthesis PC(14:0/18:4(6Z,9Z,12Z,15Z))620
Phosphatidylcholine Biosynthesis PC(14:0/20:0)620
Phosphatidylcholine Biosynthesis PC(14:0/20:1(11Z))620
Phosphatidylcholine Biosynthesis PC(14:0/20:2(11Z,14Z))620
Phosphatidylcholine Biosynthesis PC(14:0/20:3(5Z,8Z,11Z))620
Phosphatidylcholine Biosynthesis PC(14:0/20:3(8Z,11Z,14Z))620
Phosphatidylcholine Biosynthesis PC(14:0/20:4(5Z,8Z,11Z,14Z))620
Phosphatidylcholine Biosynthesis PC(14:0/20:4(8Z,11Z,14Z,17Z))620
Phosphatidylcholine Biosynthesis PC(14:0/20:5(5Z,8Z,11Z,14Z,17Z))620
Phosphatidylcholine Biosynthesis PC(14:0/22:0)620
Phosphatidylcholine Biosynthesis PC(14:0/22:1(13Z))620
Phosphatidylcholine Biosynthesis PC(14:0/22:2(13Z,16Z))620
Phosphatidylcholine Biosynthesis PC(14:0/22:4(7Z,10Z,13Z,16Z))620
Phosphatidylcholine Biosynthesis PC(14:0/22:5(4Z,7Z,10Z,13Z,16Z))620
Phosphatidylcholine Biosynthesis PC(14:0/22:5(7Z,10Z,13Z,16Z,19Z))620
Phosphatidylcholine Biosynthesis PC(14:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))620
Phosphatidylcholine Biosynthesis PC(14:0/24:0)620
Phosphatidylcholine Biosynthesis PC(14:0/24:1(15Z))620
Phosphatidylcholine Biosynthesis PC(14:1(9Z)/14:0)620
Phosphatidylcholine Biosynthesis PC(14:1(9Z)/14:1(9Z))620
Phosphatidylcholine Biosynthesis PC(14:1(9Z)/15:0)620
Phosphatidylcholine Biosynthesis PC(14:1(9Z)/16:0)620
Phosphatidylcholine Biosynthesis PC(14:1(9Z)/16:1(9Z))620
Phosphatidylcholine Biosynthesis PC(14:1(9Z)/18:0)620
Phosphatidylcholine Biosynthesis PC(14:1(9Z)/18:1(11Z))620
Phosphatidylcholine Biosynthesis PC(14:1(9Z)/18:1(9Z))620
Phosphatidylcholine Biosynthesis PC(14:1(9Z)/18:2(9Z,12Z))620
Phosphatidylcholine Biosynthesis PC(14:1(9Z)/18:3(6Z,9Z,12Z))620
Phosphatidylcholine Biosynthesis PC(14:1(9Z)/18:3(9Z,12Z,15Z))620
Phosphatidylcholine Biosynthesis PC(14:1(9Z)/18:4(6Z,9Z,12Z,15Z))620
Phosphatidylcholine Biosynthesis PC(14:1(9Z)/20:0)620
Phosphatidylcholine Biosynthesis PC(14:1(9Z)/20:1(11Z))620
Phosphatidylcholine Biosynthesis PC(14:1(9Z)/20:2(11Z,14Z))620
Phosphatidylcholine Biosynthesis PC(14:1(9Z)/20:3(5Z,8Z,11Z))620
Phosphatidylcholine Biosynthesis PC(14:1(9Z)/20:3(8Z,11Z,14Z))620
Phosphatidylcholine Biosynthesis PC(14:1(9Z)/20:4(5Z,8Z,11Z,14Z))620
Phosphatidylcholine Biosynthesis PC(14:1(9Z)/20:4(8Z,11Z,14Z,17Z))620
Phosphatidylcholine Biosynthesis PC(14:1(9Z)/20:5(5Z,8Z,11Z,14Z,17Z))620
Phosphatidylcholine Biosynthesis PC(14:1(9Z)/22:0)620
Phosphatidylcholine Biosynthesis PC(14:1(9Z)/22:1(13Z))620
Phosphatidylcholine Biosynthesis PC(14:1(9Z)/22:2(13Z,16Z))620
Phosphatidylcholine Biosynthesis PC(14:1(9Z)/22:4(7Z,10Z,13Z,16Z))620
Phosphatidylcholine Biosynthesis PC(14:1(9Z)/22:5(4Z,7Z,10Z,13Z,16Z))620
Phosphatidylcholine Biosynthesis PC(14:1(9Z)/22:5(7Z,10Z,13Z,16Z,19Z))620
Phosphatidylcholine Biosynthesis PC(14:1(9Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))620
Phosphatidylcholine Biosynthesis PC(14:1(9Z)/24:0)620
Phosphatidylcholine Biosynthesis PC(14:1(9Z)/24:1(15Z))620
Phosphatidylcholine Biosynthesis PC(15:0/14:0)620
Phosphatidylcholine Biosynthesis PC(15:0/14:1(9Z))620
Phosphatidylcholine Biosynthesis PC(15:0/15:0)620
Phosphatidylcholine Biosynthesis PC(15:0/16:0)620
Phosphatidylcholine Biosynthesis PC(15:0/16:1(9Z))620
Phosphatidylcholine Biosynthesis PC(15:0/18:0)620
Phosphatidylcholine Biosynthesis PC(15:0/18:1(11Z))620
Phosphatidylcholine Biosynthesis PC(15:0/18:1(9Z))620
Phosphatidylcholine Biosynthesis PC(15:0/18:2(9Z,12Z))620
Phosphatidylcholine Biosynthesis PC(15:0/18:3(6Z,9Z,12Z))620
Phosphatidylcholine Biosynthesis PC(15:0/18:3(9Z,12Z,15Z))620
Phosphatidylcholine Biosynthesis PC(15:0/18:4(6Z,9Z,12Z,15Z))620
Phosphatidylcholine Biosynthesis PC(15:0/20:0)620
Phosphatidylcholine Biosynthesis PC(15:0/20:1(11Z))620
Phosphatidylcholine Biosynthesis PC(15:0/20:2(11Z,14Z))620
Phosphatidylcholine Biosynthesis PC(15:0/20:3(5Z,8Z,11Z))620
Phosphatidylcholine Biosynthesis PC(15:0/20:3(8Z,11Z,14Z))620
Phosphatidylcholine Biosynthesis PC(15:0/20:4(5Z,8Z,11Z,14Z))620
Phosphatidylcholine Biosynthesis PC(15:0/20:4(8Z,11Z,14Z,17Z))620
Phosphatidylcholine Biosynthesis PC(15:0/20:5(5Z,8Z,11Z,14Z,17Z))620
Phosphatidylcholine Biosynthesis PC(15:0/22:0)620
Phosphatidylcholine Biosynthesis PC(15:0/22:1(13Z))620
Phosphatidylcholine Biosynthesis PC(15:0/22:2(13Z,16Z))620
Phosphatidylcholine Biosynthesis PC(15:0/22:4(7Z,10Z,13Z,16Z))620
Phosphatidylcholine Biosynthesis PC(15:0/22:5(4Z,7Z,10Z,13Z,16Z))620
Phosphatidylcholine Biosynthesis PC(15:0/22:5(7Z,10Z,13Z,16Z,19Z))620
Phosphatidylcholine Biosynthesis PC(15:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))620
Phosphatidylcholine Biosynthesis PC(15:0/24:0)620
Phosphatidylcholine Biosynthesis PC(15:0/24:1(15Z))620
Phosphatidylcholine Biosynthesis PC(16:0/14:0)620
Phosphatidylcholine Biosynthesis PC(16:0/14:1(9Z))620
Phosphatidylcholine Biosynthesis PC(16:0/15:0)620
Phosphatidylcholine Biosynthesis PC(16:0/16:0)620
Phosphatidylcholine Biosynthesis PC(16:0/16:1(9Z))620
Phosphatidylcholine Biosynthesis PC(16:0/18:0)620
Phosphatidylcholine Biosynthesis PC(16:0/18:1(11Z))620
Phosphatidylcholine Biosynthesis PC(16:0/18:1(9Z))620
Phosphatidylcholine Biosynthesis PC(16:0/18:2(9Z,12Z))620
Phosphatidylcholine Biosynthesis PC(16:0/18:3(6Z,9Z,12Z))620
Phosphatidylcholine Biosynthesis PC(16:0/18:3(9Z,12Z,15Z))620
Phosphatidylcholine Biosynthesis PC(16:0/18:4(6Z,9Z,12Z,15Z))620
Phosphatidylcholine Biosynthesis PC(16:0/20:0)620
Phosphatidylcholine Biosynthesis PC(16:0/20:1(11Z))620
Phosphatidylcholine Biosynthesis PC(16:0/20:2(11Z,14Z))620
Phosphatidylcholine Biosynthesis PC(16:0/20:3(5Z,8Z,11Z))620
Phosphatidylcholine Biosynthesis PC(16:0/20:3(8Z,11Z,14Z))620
Phosphatidylcholine Biosynthesis PC(16:0/20:4(5Z,8Z,11Z,14Z))620
Phosphatidylcholine Biosynthesis PC(16:0/20:4(8Z,11Z,14Z,17Z))620
Phosphatidylcholine Biosynthesis PC(16:0/20:5(5Z,8Z,11Z,14Z,17Z))620
Phosphatidylcholine Biosynthesis PC(16:0/22:0)620
Phosphatidylcholine Biosynthesis PC(16:0/22:1(13Z))620
Phosphatidylcholine Biosynthesis PC(16:0/22:2(13Z,16Z))620
Phosphatidylcholine Biosynthesis PC(16:0/22:4(7Z,10Z,13Z,16Z))620
Phosphatidylcholine Biosynthesis PC(16:0/22:5(4Z,7Z,10Z,13Z,16Z))620
Phosphatidylcholine Biosynthesis PC(16:0/22:5(7Z,10Z,13Z,16Z,19Z))620
Phosphatidylcholine Biosynthesis PC(16:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))620
Phosphatidylcholine Biosynthesis PC(16:0/24:0)620
Phosphatidylcholine Biosynthesis PC(16:0/24:1(15Z))620
Phosphatidylcholine Biosynthesis PC(16:1(9Z)/14:0)620
Phosphatidylcholine Biosynthesis PC(16:1(9Z)/14:1(9Z))620
Phosphatidylcholine Biosynthesis PC(16:1(9Z)/15:0)620
Phosphatidylcholine Biosynthesis PC(16:1(9Z)/16:0)620
Phosphatidylcholine Biosynthesis PC(16:1(9Z)/16:1(9Z))620
Phosphatidylcholine Biosynthesis PC(16:1(9Z)/18:0)620
Phosphatidylcholine Biosynthesis PC(16:1(9Z)/18:1(11Z))620
Phosphatidylcholine Biosynthesis PC(16:1(9Z)/18:1(9Z))620
Phosphatidylcholine Biosynthesis PC(16:1(9Z)/18:2(9Z,12Z))620
Phosphatidylcholine Biosynthesis PC(16:1(9Z)/18:3(6Z,9Z,12Z))620
Phosphatidylcholine Biosynthesis PC(16:1(9Z)/18:3(9Z,12Z,15Z))620
Phosphatidylcholine Biosynthesis PC(16:1(9Z)/18:4(6Z,9Z,12Z,15Z))620
Phosphatidylcholine Biosynthesis PC(16:1(9Z)/20:0)620
Phosphatidylcholine Biosynthesis PC(16:1(9Z)/20:1(11Z))620
Phosphatidylcholine Biosynthesis PC(16:1(9Z)/20:2(11Z,14Z))620
Phosphatidylcholine Biosynthesis PC(16:1(9Z)/20:3(5Z,8Z,11Z))620
Phosphatidylcholine Biosynthesis PC(16:1(9Z)/20:3(8Z,11Z,14Z))620
Phosphatidylcholine Biosynthesis PC(16:1(9Z)/20:4(5Z,8Z,11Z,14Z))620
Phosphatidylcholine Biosynthesis PC(16:1(9Z)/20:4(8Z,11Z,14Z,17Z))620
Phosphatidylcholine Biosynthesis PC(16:1(9Z)/20:5(5Z,8Z,11Z,14Z,17Z))620
Phosphatidylcholine Biosynthesis PC(16:1(9Z)/22:0)620
Phosphatidylcholine Biosynthesis PC(16:1(9Z)/22:1(13Z))620
Phosphatidylcholine Biosynthesis PC(16:1(9Z)/22:2(13Z,16Z))620
Phosphatidylcholine Biosynthesis PC(16:1(9Z)/22:4(7Z,10Z,13Z,16Z))620
Phosphatidylcholine Biosynthesis PC(16:1(9Z)/22:5(4Z,7Z,10Z,13Z,16Z))620
Phosphatidylcholine Biosynthesis PC(16:1(9Z)/22:5(7Z,10Z,13Z,16Z,19Z))620
Phosphatidylcholine Biosynthesis PC(16:1(9Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))620
Phosphatidylcholine Biosynthesis PC(16:1(9Z)/24:0)620
Phosphatidylcholine Biosynthesis PC(16:1(9Z)/24:1(15Z))620
Phosphatidylcholine Biosynthesis PC(18:0/14:0)620
Phosphatidylcholine Biosynthesis PC(18:0/14:1(9Z))620
Phosphatidylcholine Biosynthesis PC(18:0/15:0)620
Phosphatidylcholine Biosynthesis PC(18:0/16:0)620
Phosphatidylcholine Biosynthesis PC(18:0/16:1(9Z))620
Phosphatidylcholine Biosynthesis PC(18:0/18:0)620
Phosphatidylcholine Biosynthesis PC(18:0/18:1(11Z))620
Phosphatidylcholine Biosynthesis PC(18:0/18:1(9Z))620
Phosphatidylcholine Biosynthesis PC(18:0/18:2(9Z,12Z))620
Phosphatidylcholine Biosynthesis PC(18:0/18:3(6Z,9Z,12Z))620
Phosphatidylcholine Biosynthesis PC(18:0/18:3(9Z,12Z,15Z))620
Phosphatidylcholine Biosynthesis PC(18:0/18:4(6Z,9Z,12Z,15Z))620
Phosphatidylcholine Biosynthesis PC(18:0/20:0)620
Phosphatidylcholine Biosynthesis PC(18:0/20:1(11Z))620
Phosphatidylcholine Biosynthesis PC(18:0/20:2(11Z,14Z))620
Phosphatidylcholine Biosynthesis PC(18:0/20:3(5Z,8Z,11Z))620
Phosphatidylcholine Biosynthesis PC(18:0/20:3(8Z,11Z,14Z))620
Phosphatidylcholine Biosynthesis PC(18:0/20:4(5Z,8Z,11Z,14Z))620
Phosphatidylcholine Biosynthesis PC(18:0/20:4(8Z,11Z,14Z,17Z))620
Phosphatidylcholine Biosynthesis PC(18:0/20:5(5Z,8Z,11Z,14Z,17Z))620
Phosphatidylcholine Biosynthesis PC(18:0/22:0)620
Phosphatidylcholine Biosynthesis PC(18:0/22:1(13Z))620
Phosphatidylcholine Biosynthesis PC(18:0/22:2(13Z,16Z))620
Phosphatidylcholine Biosynthesis PC(18:0/22:4(7Z,10Z,13Z,16Z))620
Phosphatidylcholine Biosynthesis PC(18:0/22:5(4Z,7Z,10Z,13Z,16Z))620
Phosphatidylcholine Biosynthesis PC(18:0/22:5(7Z,10Z,13Z,16Z,19Z))620
Phosphatidylcholine Biosynthesis PC(18:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))620
Phosphatidylcholine Biosynthesis PC(18:0/24:0)620
Phosphatidylcholine Biosynthesis PC(18:0/24:1(15Z))620
Phosphatidylcholine Biosynthesis PC(18:1(11Z)/14:0)620
Phosphatidylcholine Biosynthesis PC(18:1(11Z)/14:1(9Z))620
Phosphatidylcholine Biosynthesis PC(18:1(11Z)/15:0)620
Phosphatidylcholine Biosynthesis PC(18:1(11Z)/16:0)620
Phosphatidylcholine Biosynthesis PC(18:1(11Z)/16:1(9Z))620
Phosphatidylcholine Biosynthesis PC(18:1(11Z)/18:0)620
Phosphatidylcholine Biosynthesis PC(18:1(11Z)/18:1(11Z))620
Phosphatidylcholine Biosynthesis PC(18:1(11Z)/18:1(9Z))620
Phosphatidylcholine Biosynthesis PC(18:1(11Z)/18:2(9Z,12Z))620
Phosphatidylcholine Biosynthesis PC(18:1(11Z)/18:3(6Z,9Z,12Z))620
Phosphatidylcholine Biosynthesis PC(18:1(11Z)/18:3(9Z,12Z,15Z))620
Phosphatidylcholine Biosynthesis PC(18:1(11Z)/18:4(6Z,9Z,12Z,15Z))620
Phosphatidylcholine Biosynthesis PC(18:1(11Z)/20:0)620
Phosphatidylcholine Biosynthesis PC(18:1(11Z)/20:1(11Z))620
Phosphatidylcholine Biosynthesis PC(18:1(11Z)/20:2(11Z,14Z))620
Phosphatidylcholine Biosynthesis PC(18:1(11Z)/20:3(5Z,8Z,11Z))620
Phosphatidylcholine Biosynthesis PC(18:1(11Z)/20:3(8Z,11Z,14Z))620
Phosphatidylcholine Biosynthesis PC(18:1(11Z)/20:4(5Z,8Z,11Z,14Z))620
Phosphatidylcholine Biosynthesis PC(18:1(11Z)/20:4(8Z,11Z,14Z,17Z))620
Phosphatidylcholine Biosynthesis PC(18:1(11Z)/20:5(5Z,8Z,11Z,14Z,17Z))620
Phosphatidylcholine Biosynthesis PC(18:1(11Z)/22:0)620
Phosphatidylcholine Biosynthesis PC(18:1(11Z)/22:1(13Z))620
Phosphatidylcholine Biosynthesis PC(18:1(11Z)/22:2(13Z,16Z))620
Phosphatidylcholine Biosynthesis PC(18:1(11Z)/22:4(7Z,10Z,13Z,16Z))620
Phosphatidylcholine Biosynthesis PC(18:1(11Z)/22:5(4Z,7Z,10Z,13Z,16Z))620
Phosphatidylcholine Biosynthesis PC(18:1(11Z)/22:5(7Z,10Z,13Z,16Z,19Z))620
Phosphatidylcholine Biosynthesis PC(18:1(11Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))620
Phosphatidylcholine Biosynthesis PC(18:1(11Z)/24:0)620
Phosphatidylcholine Biosynthesis PC(18:1(11Z)/24:1(15Z))620
Phosphatidylcholine Biosynthesis PC(18:1(9Z)/14:0)620
Phosphatidylcholine Biosynthesis PC(18:1(9Z)/14:1(9Z))620
Phosphatidylcholine Biosynthesis PC(18:1(9Z)/15:0)620
Phosphatidylcholine Biosynthesis PC(18:1(9Z)/16:0)620
Phosphatidylcholine Biosynthesis PC(18:1(9Z)/16:1(9Z))620
Phosphatidylcholine Biosynthesis PC(18:1(9Z)/18:0)620
Phosphatidylcholine Biosynthesis PC(18:1(9Z)/18:1(11Z))620
Phosphatidylcholine Biosynthesis PC(18:1(9Z)/18:1(9Z))620
Phosphatidylcholine Biosynthesis PC(18:1(9Z)/18:2(9Z,12Z))620
Phosphatidylcholine Biosynthesis PC(18:1(9Z)/18:3(6Z,9Z,12Z))620
Phosphatidylcholine Biosynthesis PC(18:1(9Z)/18:3(9Z,12Z,15Z))620
Phosphatidylcholine Biosynthesis PC(18:1(9Z)/18:4(6Z,9Z,12Z,15Z))620
Phosphatidylcholine Biosynthesis PC(18:1(9Z)/20:0)620
Phosphatidylcholine Biosynthesis PC(18:1(9Z)/20:1(11Z))620
Phosphatidylcholine Biosynthesis PC(18:1(9Z)/20:2(11Z,14Z))620
Phosphatidylcholine Biosynthesis PC(18:1(9Z)/20:3(5Z,8Z,11Z))620
Phosphatidylcholine Biosynthesis PC(18:1(9Z)/20:3(8Z,11Z,14Z))620
Phosphatidylcholine Biosynthesis PC(18:1(9Z)/20:4(5Z,8Z,11Z,14Z))620
Phosphatidylcholine Biosynthesis PC(18:1(9Z)/20:4(8Z,11Z,14Z,17Z))620
Phosphatidylcholine Biosynthesis PC(18:1(9Z)/20:5(5Z,8Z,11Z,14Z,17Z))620
Phosphatidylcholine Biosynthesis PC(18:1(9Z)/22:0)620
Phosphatidylcholine Biosynthesis PC(18:1(9Z)/22:1(13Z))620
Phosphatidylcholine Biosynthesis PC(18:1(9Z)/22:2(13Z,16Z))620
Phosphatidylcholine Biosynthesis PC(18:1(9Z)/22:4(7Z,10Z,13Z,16Z))620
Phosphatidylcholine Biosynthesis PC(18:1(9Z)/22:5(4Z,7Z,10Z,13Z,16Z))620
Phosphatidylcholine Biosynthesis PC(18:1(9Z)/22:5(7Z,10Z,13Z,16Z,19Z))620
Phosphatidylcholine Biosynthesis PC(18:1(9Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))620
Phosphatidylcholine Biosynthesis PC(18:1(9Z)/24:0)620
Phosphatidylcholine Biosynthesis PC(18:2(9Z,12Z)/14:0)620
Phosphatidylcholine Biosynthesis PC(18:2(9Z,12Z)/14:1(9Z))620
Phosphatidylcholine Biosynthesis PC(18:2(9Z,12Z)/15:0)620
Phosphatidylcholine Biosynthesis PC(18:2(9Z,12Z)/16:0)620
Phosphatidylcholine Biosynthesis PC(18:2(9Z,12Z)/16:1(9Z))620
Phosphatidylcholine Biosynthesis PC(18:2(9Z,12Z)/18:0)620
Phosphatidylcholine Biosynthesis PC(18:2(9Z,12Z)/18:1(11Z))620
Phosphatidylcholine Biosynthesis PC(18:2(9Z,12Z)/18:1(9Z))620
Phosphatidylcholine Biosynthesis PC(18:2(9Z,12Z)/18:2(9Z,12Z))620
Phosphatidylcholine Biosynthesis PC(18:2(9Z,12Z)/18:3(6Z,9Z,12Z))620
Phosphatidylcholine Biosynthesis PC(18:2(9Z,12Z)/18:3(9Z,12Z,15Z))620
Phosphatidylcholine Biosynthesis PC(18:2(9Z,12Z)/18:4(6Z,9Z,12Z,15Z))620
Phosphatidylcholine Biosynthesis PC(18:2(9Z,12Z)/20:0)620
Phosphatidylcholine Biosynthesis PC(18:2(9Z,12Z)/20:1(11Z))620
Phosphatidylcholine Biosynthesis PC(18:2(9Z,12Z)/20:2(11Z,14Z))620
Phosphatidylcholine Biosynthesis PC(18:2(9Z,12Z)/20:3(5Z,8Z,11Z))620
Phosphatidylcholine Biosynthesis PC(18:2(9Z,12Z)/20:3(8Z,11Z,14Z))620
Phosphatidylcholine Biosynthesis PC(18:2(9Z,12Z)/20:4(5Z,8Z,11Z,14Z))620
Phosphatidylcholine Biosynthesis PC(18:2(9Z,12Z)/20:4(8Z,11Z,14Z,17Z))620
Phosphatidylcholine Biosynthesis PC(18:2(9Z,12Z)/20:5(5Z,8Z,11Z,14Z,17Z))620
Phosphatidylcholine Biosynthesis PC(18:2(9Z,12Z)/22:0)620
Phosphatidylcholine Biosynthesis PC(18:2(9Z,12Z)/22:1(13Z))620
Phosphatidylcholine Biosynthesis PC(18:2(9Z,12Z)/22:2(13Z,16Z))620
Phosphatidylcholine Biosynthesis PC(18:2(9Z,12Z)/22:4(7Z,10Z,13Z,16Z))620
Phosphatidylcholine Biosynthesis PC(18:2(9Z,12Z)/22:5(4Z,7Z,10Z,13Z,16Z))620
Phosphatidylcholine Biosynthesis PC(18:2(9Z,12Z)/22:5(7Z,10Z,13Z,16Z,19Z))620
Phosphatidylcholine Biosynthesis PC(18:2(9Z,12Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))620
Phosphatidylcholine Biosynthesis PC(18:2(9Z,12Z)/24:0)620
Phosphatidylcholine Biosynthesis PC(18:2(9Z,12Z)/24:1(15Z))620
Phosphatidylcholine Biosynthesis PC(18:3(6Z,9Z,12Z)/14:0)620
Phosphatidylcholine Biosynthesis PC(18:3(6Z,9Z,12Z)/14:1(9Z))620
Phosphatidylcholine Biosynthesis PC(18:3(6Z,9Z,12Z)/15:0)620
Phosphatidylcholine Biosynthesis PC(18:3(6Z,9Z,12Z)/16:0)620
Phosphatidylcholine Biosynthesis PC(18:3(6Z,9Z,12Z)/16:1(9Z))620
Phosphatidylcholine Biosynthesis PC(18:3(6Z,9Z,12Z)/18:0)620
Phosphatidylcholine Biosynthesis PC(18:3(6Z,9Z,12Z)/18:1(11Z))620
Phosphatidylcholine Biosynthesis PC(18:3(6Z,9Z,12Z)/18:1(9Z))620
Phosphatidylcholine Biosynthesis PC(18:3(6Z,9Z,12Z)/18:2(9Z,12Z))620
Phosphatidylcholine Biosynthesis PC(18:3(6Z,9Z,12Z)/18:3(6Z,9Z,12Z))620
Phosphatidylcholine Biosynthesis PC(18:3(6Z,9Z,12Z)/18:3(9Z,12Z,15Z))620
Phosphatidylcholine Biosynthesis PC(18:3(6Z,9Z,12Z)/18:4(6Z,9Z,12Z,15Z))620
Phosphatidylcholine Biosynthesis PC(18:3(6Z,9Z,12Z)/20:0)620
Phosphatidylcholine Biosynthesis PC(18:3(6Z,9Z,12Z)/20:1(11Z))620
Phosphatidylcholine Biosynthesis PC(18:3(6Z,9Z,12Z)/20:2(11Z,14Z))620
Phosphatidylcholine Biosynthesis PC(18:3(6Z,9Z,12Z)/20:3(5Z,8Z,11Z))620
Phosphatidylcholine Biosynthesis PC(18:3(6Z,9Z,12Z)/20:3(8Z,11Z,14Z))620
Phosphatidylcholine Biosynthesis PC(18:3(6Z,9Z,12Z)/20:4(5Z,8Z,11Z,14Z))620
Phosphatidylcholine Biosynthesis PC(18:3(6Z,9Z,12Z)/20:4(8Z,11Z,14Z,17Z))620
Phosphatidylcholine Biosynthesis PC(18:3(6Z,9Z,12Z)/20:5(5Z,8Z,11Z,14Z,17Z))620
Phosphatidylcholine Biosynthesis PC(18:3(6Z,9Z,12Z)/22:0)620
Phosphatidylcholine Biosynthesis PC(18:3(6Z,9Z,12Z)/22:1(13Z))620
Phosphatidylcholine Biosynthesis PC(18:3(6Z,9Z,12Z)/22:2(13Z,16Z))620
Phosphatidylcholine Biosynthesis PC(18:3(6Z,9Z,12Z)/22:4(7Z,10Z,13Z,16Z))620
Phosphatidylcholine Biosynthesis PC(18:3(6Z,9Z,12Z)/22:5(4Z,7Z,10Z,13Z,16Z))620
Phosphatidylcholine Biosynthesis PC(18:3(6Z,9Z,12Z)/22:5(7Z,10Z,13Z,16Z,19Z))620
Phosphatidylcholine Biosynthesis PC(18:3(6Z,9Z,12Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))620
Phosphatidylcholine Biosynthesis PC(18:3(6Z,9Z,12Z)/24:0)620
Phosphatidylcholine Biosynthesis PC(18:3(6Z,9Z,12Z)/24:1(15Z))620
Phosphatidylcholine Biosynthesis PC(18:3(9Z,12Z,15Z)/14:0)620
Phosphatidylcholine Biosynthesis PC(18:3(9Z,12Z,15Z)/14:1(9Z))620
Phosphatidylcholine Biosynthesis PC(18:3(9Z,12Z,15Z)/15:0)620
Phosphatidylcholine Biosynthesis PC(18:3(9Z,12Z,15Z)/16:0)620
Phosphatidylcholine Biosynthesis PC(18:3(9Z,12Z,15Z)/16:1(9Z))620
Phosphatidylcholine Biosynthesis PC(18:3(9Z,12Z,15Z)/18:0)620
Phosphatidylcholine Biosynthesis PC(18:3(9Z,12Z,15Z)/18:1(11Z))620
Phosphatidylcholine Biosynthesis PC(18:3(9Z,12Z,15Z)/18:1(9Z))620
Phosphatidylcholine Biosynthesis PC(18:3(9Z,12Z,15Z)/18:2(9Z,12Z))620
Phosphatidylcholine Biosynthesis PC(18:3(9Z,12Z,15Z)/18:3(6Z,9Z,12Z))620
Phosphatidylcholine Biosynthesis PC(18:3(9Z,12Z,15Z)/18:3(9Z,12Z,15Z))620
Phosphatidylcholine Biosynthesis PC(18:3(9Z,12Z,15Z)/18:4(6Z,9Z,12Z,15Z))620
Phosphatidylcholine Biosynthesis PC(18:3(9Z,12Z,15Z)/20:0)620
Phosphatidylcholine Biosynthesis PC(18:3(9Z,12Z,15Z)/20:1(11Z))620
Phosphatidylcholine Biosynthesis PC(18:3(9Z,12Z,15Z)/20:2(11Z,14Z))620
Phosphatidylcholine Biosynthesis PC(18:3(9Z,12Z,15Z)/20:3(5Z,8Z,11Z))620
Phosphatidylcholine Biosynthesis PC(18:3(9Z,12Z,15Z)/20:3(8Z,11Z,14Z))620
Phosphatidylcholine Biosynthesis PC(18:3(9Z,12Z,15Z)/20:4(5Z,8Z,11Z,14Z))620
Phosphatidylcholine Biosynthesis PC(18:3(9Z,12Z,15Z)/20:4(8Z,11Z,14Z,17Z))620
Phosphatidylcholine Biosynthesis PC(18:3(9Z,12Z,15Z)/20:5(5Z,8Z,11Z,14Z,17Z))620
Phosphatidylcholine Biosynthesis PC(18:3(9Z,12Z,15Z)/22:0)620
Phosphatidylcholine Biosynthesis PC(18:3(9Z,12Z,15Z)/22:1(13Z))620
Phosphatidylcholine Biosynthesis PC(18:3(9Z,12Z,15Z)/22:2(13Z,16Z))620
Phosphatidylcholine Biosynthesis PC(18:3(9Z,12Z,15Z)/22:4(7Z,10Z,13Z,16Z))620
Phosphatidylcholine Biosynthesis PC(18:3(9Z,12Z,15Z)/22:5(4Z,7Z,10Z,13Z,16Z))620
Phosphatidylcholine Biosynthesis PC(18:3(9Z,12Z,15Z)/22:5(7Z,10Z,13Z,16Z,19Z))620
Phosphatidylcholine Biosynthesis PC(18:3(9Z,12Z,15Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))620
Phosphatidylcholine Biosynthesis PC(18:3(9Z,12Z,15Z)/24:0)620
Phosphatidylcholine Biosynthesis PC(18:3(9Z,12Z,15Z)/24:1(15Z))620
Phosphatidylcholine Biosynthesis PC(18:4(6Z,9Z,12Z,15Z)/14:0)620
Phosphatidylcholine Biosynthesis PC(18:4(6Z,9Z,12Z,15Z)/14:1(9Z))620
Phosphatidylcholine Biosynthesis PC(18:4(6Z,9Z,12Z,15Z)/15:0)620
Phosphatidylcholine Biosynthesis PC(18:4(6Z,9Z,12Z,15Z)/16:0)620
Phosphatidylcholine Biosynthesis PC(18:4(6Z,9Z,12Z,15Z)/16:1(9Z))620
Phosphatidylcholine Biosynthesis PC(18:4(6Z,9Z,12Z,15Z)/18:0)620
Phosphatidylcholine Biosynthesis PC(18:4(6Z,9Z,12Z,15Z)/18:1(11Z))620
Phosphatidylcholine Biosynthesis PC(18:4(6Z,9Z,12Z,15Z)/18:1(9Z))620
Phosphatidylcholine Biosynthesis PC(18:4(6Z,9Z,12Z,15Z)/18:2(9Z,12Z))620
Phosphatidylcholine Biosynthesis PC(18:4(6Z,9Z,12Z,15Z)/18:3(6Z,9Z,12Z))620
Phosphatidylcholine Biosynthesis PC(18:4(6Z,9Z,12Z,15Z)/18:3(9Z,12Z,15Z))620
Phosphatidylcholine Biosynthesis PC(18:4(6Z,9Z,12Z,15Z)/18:4(6Z,9Z,12Z,15Z))620
Phosphatidylcholine Biosynthesis PC(18:4(6Z,9Z,12Z,15Z)/20:0)620
Phosphatidylcholine Biosynthesis PC(18:4(6Z,9Z,12Z,15Z)/20:1(11Z))620
Phosphatidylcholine Biosynthesis PC(18:4(6Z,9Z,12Z,15Z)/20:2(11Z,14Z))620
Phosphatidylcholine Biosynthesis PC(18:4(6Z,9Z,12Z,15Z)/20:3(5Z,8Z,11Z))620
Phosphatidylcholine Biosynthesis PC(18:4(6Z,9Z,12Z,15Z)/20:3(8Z,11Z,14Z))620
Phosphatidylcholine Biosynthesis PC(18:4(6Z,9Z,12Z,15Z)/20:4(5Z,8Z,11Z,14Z))620
Phosphatidylcholine Biosynthesis PC(18:4(6Z,9Z,12Z,15Z)/20:4(8Z,11Z,14Z,17Z))620
Phosphatidylcholine Biosynthesis PC(18:4(6Z,9Z,12Z,15Z)/20:5(5Z,8Z,11Z,14Z,17Z))620
Phosphatidylcholine Biosynthesis PC(18:4(6Z,9Z,12Z,15Z)/22:0)620
Phosphatidylcholine Biosynthesis PC(18:4(6Z,9Z,12Z,15Z)/22:1(13Z))620
Phosphatidylcholine Biosynthesis PC(18:4(6Z,9Z,12Z,15Z)/22:2(13Z,16Z))620
Phosphatidylcholine Biosynthesis PC(18:4(6Z,9Z,12Z,15Z)/22:4(7Z,10Z,13Z,16Z))620
Phosphatidylcholine Biosynthesis PC(18:4(6Z,9Z,12Z,15Z)/22:5(4Z,7Z,10Z,13Z,16Z))620
Phosphatidylcholine Biosynthesis PC(18:4(6Z,9Z,12Z,15Z)/22:5(7Z,10Z,13Z,16Z,19Z))620
Phosphatidylcholine Biosynthesis PC(18:4(6Z,9Z,12Z,15Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))620
Phosphatidylcholine Biosynthesis PC(18:4(6Z,9Z,12Z,15Z)/24:0)620
Phosphatidylcholine Biosynthesis PC(18:4(6Z,9Z,12Z,15Z)/24:1(15Z))620
Phosphatidylcholine Biosynthesis PC(20:0/14:0)620
Phosphatidylcholine Biosynthesis PC(20:0/14:1(9Z))620
Phosphatidylcholine Biosynthesis PC(20:0/15:0)620
Phosphatidylcholine Biosynthesis PC(20:0/16:0)620
Phosphatidylcholine Biosynthesis PC(20:0/16:1(9Z))620
Phosphatidylcholine Biosynthesis PC(20:0/18:0)620
Phosphatidylcholine Biosynthesis PC(20:0/18:1(11Z))620
Disease1278231
Phosphatidylcholine Biosynthesis PC(20:0/18:1(9Z))620
Phosphatidylcholine Biosynthesis PC(20:0/18:2(9Z,12Z))620
Phosphatidylcholine Biosynthesis PC(20:0/18:3(6Z,9Z,12Z))620
Phosphatidylcholine Biosynthesis PC(20:0/18:3(9Z,12Z,15Z))620
Phosphatidylcholine Biosynthesis PC(20:0/18:4(6Z,9Z,12Z,15Z))620
Phosphatidylcholine Biosynthesis PC(20:0/20:0)620
Phosphatidylcholine Biosynthesis PC(20:0/20:1(11Z))620
Phosphatidylcholine Biosynthesis PC(20:0/20:2(11Z,14Z))620
Phosphatidylcholine Biosynthesis PC(20:0/20:3(5Z,8Z,11Z))620
Phosphatidylcholine Biosynthesis PC(20:0/20:3(8Z,11Z,14Z))620
Phosphatidylcholine Biosynthesis PC(20:0/20:4(5Z,8Z,11Z,14Z))620
Phosphatidylcholine Biosynthesis PC(20:0/20:4(8Z,11Z,14Z,17Z))620
Phosphatidylcholine Biosynthesis PC(20:0/20:5(5Z,8Z,11Z,14Z,17Z))620
Phosphatidylcholine Biosynthesis PC(20:0/22:0)620
Phosphatidylcholine Biosynthesis PC(20:0/22:1(13Z))620
Phosphatidylcholine Biosynthesis PC(20:0/22:2(13Z,16Z))620
Phosphatidylcholine Biosynthesis PC(20:0/22:4(7Z,10Z,13Z,16Z))620
Phosphatidylcholine Biosynthesis PC(20:0/22:5(4Z,7Z,10Z,13Z,16Z))620
Phosphatidylcholine Biosynthesis PC(20:0/22:5(7Z,10Z,13Z,16Z,19Z))620
Phosphatidylcholine Biosynthesis PC(20:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))620
Phosphatidylcholine Biosynthesis PC(20:0/24:0)620
Phosphatidylcholine Biosynthesis PC(20:0/24:1(15Z))620
Phosphatidylcholine Biosynthesis PC(20:1(11Z)/14:0)620
Phosphatidylcholine Biosynthesis PC(20:1(11Z)/14:1(9Z))620
Phosphatidylcholine Biosynthesis PC(20:1(11Z)/15:0)620
Phosphatidylcholine Biosynthesis PC(20:1(11Z)/16:0)620
Phosphatidylcholine Biosynthesis PC(20:1(11Z)/16:1(9Z))620
Phosphatidylcholine Biosynthesis PC(20:1(11Z)/18:0)620
Phosphatidylcholine Biosynthesis PC(20:1(11Z)/18:1(11Z))620
Phosphatidylcholine Biosynthesis PC(20:1(11Z)/18:1(9Z))620
Phosphatidylcholine Biosynthesis PC(20:1(11Z)/18:2(9Z,12Z))620
Phosphatidylcholine Biosynthesis PC(20:1(11Z)/18:3(6Z,9Z,12Z))620
Phosphatidylcholine Biosynthesis PC(20:1(11Z)/18:3(9Z,12Z,15Z))620
Phosphatidylcholine Biosynthesis PC(20:1(11Z)/18:4(6Z,9Z,12Z,15Z))620
Phosphatidylcholine Biosynthesis PC(20:1(11Z)/20:0)620
Phosphatidylcholine Biosynthesis PC(20:1(11Z)/20:1(11Z))620
Phosphatidylcholine Biosynthesis PC(20:1(11Z)/20:2(11Z,14Z))620
Phosphatidylcholine Biosynthesis PC(20:1(11Z)/20:3(5Z,8Z,11Z))620
Phosphatidylcholine Biosynthesis PC(20:1(11Z)/20:3(8Z,11Z,14Z))620
Phosphatidylcholine Biosynthesis PC(20:1(11Z)/20:4(5Z,8Z,11Z,14Z))620
Phosphatidylcholine Biosynthesis PC(20:1(11Z)/20:4(8Z,11Z,14Z,17Z))620
Phosphatidylcholine Biosynthesis PC(20:1(11Z)/20:5(5Z,8Z,11Z,14Z,17Z))620
Phosphatidylcholine Biosynthesis PC(20:1(11Z)/22:0)620
Phosphatidylcholine Biosynthesis PC(20:1(11Z)/22:1(13Z))620
Phosphatidylcholine Biosynthesis PC(20:1(11Z)/22:2(13Z,16Z))620
Phosphatidylcholine Biosynthesis PC(20:1(11Z)/22:4(7Z,10Z,13Z,16Z))620
Phosphatidylcholine Biosynthesis PC(20:1(11Z)/22:5(4Z,7Z,10Z,13Z,16Z))620
Phosphatidylcholine Biosynthesis PC(20:1(11Z)/22:5(7Z,10Z,13Z,16Z,19Z))620
Phosphatidylcholine Biosynthesis PC(20:1(11Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))620
Phosphatidylcholine Biosynthesis PC(20:1(11Z)/24:0)620
Phosphatidylcholine Biosynthesis PC(20:1(11Z)/24:1(15Z))620
Phosphatidylcholine Biosynthesis PC(20:2(11Z,14Z)/14:0)620
Phosphatidylcholine Biosynthesis PC(20:2(11Z,14Z)/14:1(9Z))620
Phosphatidylcholine Biosynthesis PC(20:2(11Z,14Z)/15:0)620
Phosphatidylcholine Biosynthesis PC(20:2(11Z,14Z)/16:0)620
Phosphatidylcholine Biosynthesis PC(20:2(11Z,14Z)/16:1(9Z))620
Phosphatidylcholine Biosynthesis PC(20:2(11Z,14Z)/18:0)620
Phosphatidylcholine Biosynthesis PC(20:2(11Z,14Z)/18:1(11Z))620
Phosphatidylcholine Biosynthesis PC(20:2(11Z,14Z)/18:1(9Z))620
Phosphatidylcholine Biosynthesis PC(20:2(11Z,14Z)/18:2(9Z,12Z))620
Phosphatidylcholine Biosynthesis PC(20:2(11Z,14Z)/18:3(6Z,9Z,12Z))620
Phosphatidylcholine Biosynthesis PC(20:2(11Z,14Z)/18:3(9Z,12Z,15Z))620
Phosphatidylcholine Biosynthesis PC(20:2(11Z,14Z)/18:4(6Z,9Z,12Z,15Z))620
Phosphatidylcholine Biosynthesis PC(20:2(11Z,14Z)/20:0)620
Phosphatidylcholine Biosynthesis PC(20:2(11Z,14Z)/20:1(11Z))620
Phosphatidylcholine Biosynthesis PC(20:2(11Z,14Z)/20:2(11Z,14Z))620
Phosphatidylcholine Biosynthesis PC(20:2(11Z,14Z)/20:3(5Z,8Z,11Z))620
Phosphatidylcholine Biosynthesis PC(20:2(11Z,14Z)/20:3(8Z,11Z,14Z))620
Phosphatidylcholine Biosynthesis PC(20:2(11Z,14Z)/20:4(5Z,8Z,11Z,14Z))620
Phosphatidylcholine Biosynthesis PC(20:2(11Z,14Z)/20:4(8Z,11Z,14Z,17Z))620
Phosphatidylcholine Biosynthesis PC(20:2(11Z,14Z)/20:5(5Z,8Z,11Z,14Z,17Z))620
Phosphatidylcholine Biosynthesis PC(20:2(11Z,14Z)/22:0)620
Phosphatidylcholine Biosynthesis PC(20:2(11Z,14Z)/22:1(13Z))620
Phosphatidylcholine Biosynthesis PC(20:2(11Z,14Z)/22:2(13Z,16Z))620
Phosphatidylcholine Biosynthesis PC(20:2(11Z,14Z)/22:4(7Z,10Z,13Z,16Z))620
Phosphatidylcholine Biosynthesis PC(20:2(11Z,14Z)/22:5(4Z,7Z,10Z,13Z,16Z))620
Phosphatidylcholine Biosynthesis PC(20:2(11Z,14Z)/22:5(7Z,10Z,13Z,16Z,19Z))620
Phosphatidylcholine Biosynthesis PC(20:2(11Z,14Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))620
Phosphatidylcholine Biosynthesis PC(20:2(11Z,14Z)/24:0)620
Phosphatidylcholine Biosynthesis PC(20:2(11Z,14Z)/24:1(15Z))620
Phosphatidylcholine Biosynthesis PC(20:3(5Z,8Z,11Z)/14:0)620
Phosphatidylcholine Biosynthesis PC(20:3(5Z,8Z,11Z)/14:1(9Z))620
Phosphatidylcholine Biosynthesis PC(20:3(5Z,8Z,11Z)/15:0)620
Phosphatidylcholine Biosynthesis PC(20:3(5Z,8Z,11Z)/16:0)620
Phosphatidylcholine Biosynthesis PC(20:3(5Z,8Z,11Z)/16:1(9Z))620
Phosphatidylcholine Biosynthesis PC(20:3(5Z,8Z,11Z)/18:0)620
Phosphatidylcholine Biosynthesis PC(20:3(5Z,8Z,11Z)/18:1(11Z))620
Phosphatidylcholine Biosynthesis PC(20:3(5Z,8Z,11Z)/18:1(9Z))620
Phosphatidylcholine Biosynthesis PC(20:3(5Z,8Z,11Z)/18:2(9Z,12Z))620
Phosphatidylcholine Biosynthesis PC(20:3(5Z,8Z,11Z)/18:3(6Z,9Z,12Z))620
Phosphatidylcholine Biosynthesis PC(20:3(5Z,8Z,11Z)/18:3(9Z,12Z,15Z))620
Phosphatidylcholine Biosynthesis PC(20:3(5Z,8Z,11Z)/18:4(6Z,9Z,12Z,15Z))620
Phosphatidylcholine Biosynthesis PC(20:3(5Z,8Z,11Z)/20:0)620
Phosphatidylcholine Biosynthesis PC(20:3(5Z,8Z,11Z)/20:1(11Z))620
Phosphatidylcholine Biosynthesis PC(20:3(5Z,8Z,11Z)/20:2(11Z,14Z))620
Phosphatidylcholine Biosynthesis PC(20:3(5Z,8Z,11Z)/20:3(5Z,8Z,11Z))620
Phosphatidylcholine Biosynthesis PC(20:3(5Z,8Z,11Z)/20:3(8Z,11Z,14Z))620
Phosphatidylcholine Biosynthesis PC(20:3(5Z,8Z,11Z)/20:4(5Z,8Z,11Z,14Z))620
Phosphatidylcholine Biosynthesis PC(20:3(5Z,8Z,11Z)/20:4(8Z,11Z,14Z,17Z))620
Phosphatidylcholine Biosynthesis PC(20:3(5Z,8Z,11Z)/20:5(5Z,8Z,11Z,14Z,17Z))620
Phosphatidylcholine Biosynthesis PC(20:3(5Z,8Z,11Z)/22:0)620
Phosphatidylcholine Biosynthesis PC(20:3(5Z,8Z,11Z)/22:1(13Z))620
Phosphatidylcholine Biosynthesis PC(20:3(5Z,8Z,11Z)/22:2(13Z,16Z))620
Phosphatidylcholine Biosynthesis PC(20:3(5Z,8Z,11Z)/22:4(7Z,10Z,13Z,16Z))620
Phosphatidylcholine Biosynthesis PC(20:3(5Z,8Z,11Z)/22:5(4Z,7Z,10Z,13Z,16Z))620
Phosphatidylcholine Biosynthesis PC(20:3(5Z,8Z,11Z)/22:5(7Z,10Z,13Z,16Z,19Z))620
Phosphatidylcholine Biosynthesis PC(20:3(5Z,8Z,11Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))620
Phosphatidylcholine Biosynthesis PC(20:3(5Z,8Z,11Z)/24:0)620
Phosphatidylcholine Biosynthesis PC(20:3(5Z,8Z,11Z)/24:1(15Z))620
Phosphatidylcholine Biosynthesis PC(20:3(8Z,11Z,14Z)/14:0)620
Phosphatidylcholine Biosynthesis PC(20:3(8Z,11Z,14Z)/14:1(9Z))620
Phosphatidylcholine Biosynthesis PC(20:3(8Z,11Z,14Z)/15:0)620
Phosphatidylcholine Biosynthesis PC(20:3(8Z,11Z,14Z)/16:0)620
Phosphatidylcholine Biosynthesis PC(20:3(8Z,11Z,14Z)/16:1(9Z))620
Phosphatidylcholine Biosynthesis PC(20:3(8Z,11Z,14Z)/18:0)620
Phosphatidylcholine Biosynthesis PC(20:3(8Z,11Z,14Z)/18:1(11Z))620
Phosphatidylcholine Biosynthesis PC(20:3(8Z,11Z,14Z)/18:1(9Z))620
Phosphatidylcholine Biosynthesis PC(20:3(8Z,11Z,14Z)/18:2(9Z,12Z))620
Phosphatidylcholine Biosynthesis PC(20:3(8Z,11Z,14Z)/18:3(6Z,9Z,12Z))620
Phosphatidylcholine Biosynthesis PC(20:3(8Z,11Z,14Z)/18:3(9Z,12Z,15Z))620
Phosphatidylcholine Biosynthesis PC(20:3(8Z,11Z,14Z)/18:4(6Z,9Z,12Z,15Z))620
Phosphatidylcholine Biosynthesis PC(20:3(8Z,11Z,14Z)/20:0)620
Phosphatidylcholine Biosynthesis PC(20:3(8Z,11Z,14Z)/20:1(11Z))620
Phosphatidylcholine Biosynthesis PC(20:3(8Z,11Z,14Z)/20:2(11Z,14Z))620
Phosphatidylcholine Biosynthesis PC(20:3(8Z,11Z,14Z)/20:3(5Z,8Z,11Z))620
Phosphatidylcholine Biosynthesis PC(20:3(8Z,11Z,14Z)/20:3(8Z,11Z,14Z))620
Phosphatidylcholine Biosynthesis PC(20:3(8Z,11Z,14Z)/20:4(5Z,8Z,11Z,14Z))620
Phosphatidylcholine Biosynthesis PC(20:3(8Z,11Z,14Z)/20:4(8Z,11Z,14Z,17Z))620
Phosphatidylcholine Biosynthesis PC(20:3(8Z,11Z,14Z)/20:5(5Z,8Z,11Z,14Z,17Z))620
Phosphatidylcholine Biosynthesis PC(20:3(8Z,11Z,14Z)/22:0)620
Phosphatidylcholine Biosynthesis PC(20:3(8Z,11Z,14Z)/22:1(13Z))620
Phosphatidylcholine Biosynthesis PC(20:3(8Z,11Z,14Z)/22:2(13Z,16Z))620
Phosphatidylcholine Biosynthesis PC(20:3(8Z,11Z,14Z)/22:4(7Z,10Z,13Z,16Z))620
Phosphatidylcholine Biosynthesis PC(20:3(8Z,11Z,14Z)/22:5(4Z,7Z,10Z,13Z,16Z))620
Phosphatidylcholine Biosynthesis PC(20:3(8Z,11Z,14Z)/22:5(7Z,10Z,13Z,16Z,19Z))620
Phosphatidylcholine Biosynthesis PC(20:3(8Z,11Z,14Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))620
Phosphatidylcholine Biosynthesis PC(20:3(8Z,11Z,14Z)/24:0)620
Phosphatidylcholine Biosynthesis PC(20:3(8Z,11Z,14Z)/24:1(15Z))620
Phosphatidylcholine Biosynthesis PC(20:4(5Z,8Z,11Z,14Z)/14:0)620
Phosphatidylcholine Biosynthesis PC(20:4(5Z,8Z,11Z,14Z)/14:1(9Z))620
Phosphatidylcholine Biosynthesis PC(20:4(5Z,8Z,11Z,14Z)/15:0)620
Phosphatidylcholine Biosynthesis PC(20:4(5Z,8Z,11Z,14Z)/16:0)620
Phosphatidylcholine Biosynthesis PC(20:4(5Z,8Z,11Z,14Z)/16:1(9Z))620
Phosphatidylcholine Biosynthesis PC(20:4(5Z,8Z,11Z,14Z)/18:0)620
Phosphatidylcholine Biosynthesis PC(20:4(5Z,8Z,11Z,14Z)/18:1(11Z))620
Phosphatidylcholine Biosynthesis PC(20:4(5Z,8Z,11Z,14Z)/18:1(9Z))620
Phosphatidylcholine Biosynthesis PC(20:4(5Z,8Z,11Z,14Z)/18:2(9Z,12Z))620
Phosphatidylcholine Biosynthesis PC(20:4(5Z,8Z,11Z,14Z)/18:3(6Z,9Z,12Z))620
Phosphatidylcholine Biosynthesis PC(20:4(5Z,8Z,11Z,14Z)/18:3(9Z,12Z,15Z))620
Phosphatidylcholine Biosynthesis PC(20:4(5Z,8Z,11Z,14Z)/18:4(6Z,9Z,12Z,15Z))620
Phosphatidylcholine Biosynthesis PC(20:4(5Z,8Z,11Z,14Z)/20:0)620
Phosphatidylcholine Biosynthesis PC(20:4(5Z,8Z,11Z,14Z)/20:1(11Z))620
Phosphatidylcholine Biosynthesis PC(20:4(5Z,8Z,11Z,14Z)/20:2(11Z,14Z))620
Phosphatidylcholine Biosynthesis PC(20:4(5Z,8Z,11Z,14Z)/20:3(5Z,8Z,11Z))620
Phosphatidylcholine Biosynthesis PC(20:4(5Z,8Z,11Z,14Z)/20:3(8Z,11Z,14Z))620
Phosphatidylcholine Biosynthesis PC(20:4(5Z,8Z,11Z,14Z)/20:4(5Z,8Z,11Z,14Z))620
Phosphatidylcholine Biosynthesis PC(20:4(5Z,8Z,11Z,14Z)/20:4(8Z,11Z,14Z,17Z))620
Phosphatidylcholine Biosynthesis PC(20:4(5Z,8Z,11Z,14Z)/20:5(5Z,8Z,11Z,14Z,17Z))620
Phosphatidylcholine Biosynthesis PC(20:4(5Z,8Z,11Z,14Z)/22:0)620
Phosphatidylcholine Biosynthesis PC(20:4(5Z,8Z,11Z,14Z)/22:1(13Z))620
Phosphatidylcholine Biosynthesis PC(20:4(5Z,8Z,11Z,14Z)/22:2(13Z,16Z))620
Phosphatidylcholine Biosynthesis PC(20:4(5Z,8Z,11Z,14Z)/22:4(7Z,10Z,13Z,16Z))620
Phosphatidylcholine Biosynthesis PC(20:4(5Z,8Z,11Z,14Z)/22:5(4Z,7Z,10Z,13Z,16Z))620
Phosphatidylcholine Biosynthesis PC(20:4(5Z,8Z,11Z,14Z)/22:5(7Z,10Z,13Z,16Z,19Z))620
Phosphatidylcholine Biosynthesis PC(20:4(5Z,8Z,11Z,14Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))620
Phosphatidylcholine Biosynthesis PC(20:4(5Z,8Z,11Z,14Z)/24:0)620
Phosphatidylcholine Biosynthesis PC(20:4(5Z,8Z,11Z,14Z)/24:1(15Z))620
Phosphatidylcholine Biosynthesis PC(20:4(8Z,11Z,14Z,17Z)/14:0)620
Phosphatidylcholine Biosynthesis PC(20:4(8Z,11Z,14Z,17Z)/14:1(9Z))620
Phosphatidylcholine Biosynthesis PC(20:4(8Z,11Z,14Z,17Z)/15:0)620
Phosphatidylcholine Biosynthesis PC(20:4(8Z,11Z,14Z,17Z)/16:0)620
Phosphatidylcholine Biosynthesis PC(20:4(8Z,11Z,14Z,17Z)/16:1(9Z))620
Phosphatidylcholine Biosynthesis PC(20:4(8Z,11Z,14Z,17Z)/18:0)620
Phosphatidylcholine Biosynthesis PC(20:4(8Z,11Z,14Z,17Z)/18:1(11Z))620
Phosphatidylcholine Biosynthesis PC(20:4(8Z,11Z,14Z,17Z)/18:1(9Z))620
Phosphatidylcholine Biosynthesis PC(20:4(8Z,11Z,14Z,17Z)/18:2(9Z,12Z))620
Phosphatidylcholine Biosynthesis PC(20:4(8Z,11Z,14Z,17Z)/18:3(6Z,9Z,12Z))620
Phosphatidylcholine Biosynthesis PC(20:4(8Z,11Z,14Z,17Z)/18:3(9Z,12Z,15Z))620
Phosphatidylcholine Biosynthesis PC(20:4(8Z,11Z,14Z,17Z)/18:4(6Z,9Z,12Z,15Z))620
Phosphatidylcholine Biosynthesis PC(20:4(8Z,11Z,14Z,17Z)/20:0)620
Phosphatidylcholine Biosynthesis PC(20:4(8Z,11Z,14Z,17Z)/20:1(11Z))620
Phosphatidylcholine Biosynthesis PC(20:4(8Z,11Z,14Z,17Z)/20:2(11Z,14Z))620
Phosphatidylcholine Biosynthesis PC(20:4(8Z,11Z,14Z,17Z)/20:3(5Z,8Z,11Z))620
Phosphatidylcholine Biosynthesis PC(20:4(8Z,11Z,14Z,17Z)/20:3(8Z,11Z,14Z))620
Phosphatidylcholine Biosynthesis PC(20:4(8Z,11Z,14Z,17Z)/20:4(5Z,8Z,11Z,14Z))620
Phosphatidylcholine Biosynthesis PC(20:4(8Z,11Z,14Z,17Z)/20:4(8Z,11Z,14Z,17Z))620
Phosphatidylcholine Biosynthesis PC(20:4(8Z,11Z,14Z,17Z)/20:5(5Z,8Z,11Z,14Z,17Z))620
Phosphatidylcholine Biosynthesis PC(20:4(8Z,11Z,14Z,17Z)/22:0)620
Phosphatidylcholine Biosynthesis PC(20:4(8Z,11Z,14Z,17Z)/22:1(13Z))620
Phosphatidylcholine Biosynthesis PC(20:4(8Z,11Z,14Z,17Z)/22:2(13Z,16Z))620
Phosphatidylcholine Biosynthesis PC(20:4(8Z,11Z,14Z,17Z)/22:4(7Z,10Z,13Z,16Z))620
Phosphatidylcholine Biosynthesis PC(20:4(8Z,11Z,14Z,17Z)/22:5(4Z,7Z,10Z,13Z,16Z))620
Phosphatidylcholine Biosynthesis PC(20:4(8Z,11Z,14Z,17Z)/22:5(7Z,10Z,13Z,16Z,19Z))620
Phosphatidylcholine Biosynthesis PC(20:4(8Z,11Z,14Z,17Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))620
Phosphatidylcholine Biosynthesis PC(20:4(8Z,11Z,14Z,17Z)/24:0)620
Phosphatidylcholine Biosynthesis PC(20:4(8Z,11Z,14Z,17Z)/24:1(15Z))620
Phosphatidylcholine Biosynthesis PC(20:5(5Z,8Z,11Z,14Z,17Z)/14:0)620
Phosphatidylcholine Biosynthesis PC(20:5(5Z,8Z,11Z,14Z,17Z)/14:1(9Z))620
Phosphatidylcholine Biosynthesis PC(20:5(5Z,8Z,11Z,14Z,17Z)/15:0)620
Phosphatidylcholine Biosynthesis PC(20:5(5Z,8Z,11Z,14Z,17Z)/16:0)620
Phosphatidylcholine Biosynthesis PC(20:5(5Z,8Z,11Z,14Z,17Z)/16:1(9Z))620
Phosphatidylcholine Biosynthesis PC(20:5(5Z,8Z,11Z,14Z,17Z)/18:0)620
Phosphatidylcholine Biosynthesis PC(20:5(5Z,8Z,11Z,14Z,17Z)/18:1(11Z))620
Phosphatidylcholine Biosynthesis PC(20:5(5Z,8Z,11Z,14Z,17Z)/18:1(9Z))620
Phosphatidylcholine Biosynthesis PC(20:5(5Z,8Z,11Z,14Z,17Z)/18:2(9Z,12Z))620
Phosphatidylcholine Biosynthesis PC(20:5(5Z,8Z,11Z,14Z,17Z)/18:3(6Z,9Z,12Z))620
Phosphatidylcholine Biosynthesis PC(20:5(5Z,8Z,11Z,14Z,17Z)/18:3(9Z,12Z,15Z))620
Phosphatidylcholine Biosynthesis PC(20:5(5Z,8Z,11Z,14Z,17Z)/18:4(6Z,9Z,12Z,15Z))620
Phosphatidylcholine Biosynthesis PC(20:5(5Z,8Z,11Z,14Z,17Z)/20:0)620
Phosphatidylcholine Biosynthesis PC(20:5(5Z,8Z,11Z,14Z,17Z)/20:1(11Z))620
Phosphatidylcholine Biosynthesis PC(20:5(5Z,8Z,11Z,14Z,17Z)/20:2(11Z,14Z))620
Phosphatidylcholine Biosynthesis PC(20:5(5Z,8Z,11Z,14Z,17Z)/20:3(5Z,8Z,11Z))620
Phosphatidylcholine Biosynthesis PC(20:5(5Z,8Z,11Z,14Z,17Z)/20:3(8Z,11Z,14Z))620
Phosphatidylcholine Biosynthesis PC(20:5(5Z,8Z,11Z,14Z,17Z)/20:4(5Z,8Z,11Z,14Z))620
Phosphatidylcholine Biosynthesis PC(20:5(5Z,8Z,11Z,14Z,17Z)/20:4(8Z,11Z,14Z,17Z))620
Phosphatidylcholine Biosynthesis PC(20:5(5Z,8Z,11Z,14Z,17Z)/20:5(5Z,8Z,11Z,14Z,17Z))620
Phosphatidylcholine Biosynthesis PC(20:5(5Z,8Z,11Z,14Z,17Z)/22:0)620
Phosphatidylcholine Biosynthesis PC(20:5(5Z,8Z,11Z,14Z,17Z)/22:1(13Z))620
Phosphatidylcholine Biosynthesis PC(20:5(5Z,8Z,11Z,14Z,17Z)/22:2(13Z,16Z))620
Phosphatidylcholine Biosynthesis PC(20:5(5Z,8Z,11Z,14Z,17Z)/22:4(7Z,10Z,13Z,16Z))620
Phosphatidylcholine Biosynthesis PC(20:5(5Z,8Z,11Z,14Z,17Z)/22:5(4Z,7Z,10Z,13Z,16Z))620
Phosphatidylcholine Biosynthesis PC(20:5(5Z,8Z,11Z,14Z,17Z)/22:5(7Z,10Z,13Z,16Z,19Z))620
Phosphatidylcholine Biosynthesis PC(20:5(5Z,8Z,11Z,14Z,17Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))620
Phosphatidylcholine Biosynthesis PC(20:5(5Z,8Z,11Z,14Z,17Z)/24:0)620
Phosphatidylcholine Biosynthesis PC(20:5(5Z,8Z,11Z,14Z,17Z)/24:1(15Z))620
Phosphatidylcholine Biosynthesis PC(22:0/14:0)620
Phosphatidylcholine Biosynthesis PC(22:0/14:1(9Z))620
Phosphatidylcholine Biosynthesis PC(22:0/15:0)620
Phosphatidylcholine Biosynthesis PC(22:0/16:0)620
Phosphatidylcholine Biosynthesis PC(22:0/16:1(9Z))620
Phosphatidylcholine Biosynthesis PC(22:0/18:0)620
Phosphatidylcholine Biosynthesis PC(22:0/18:1(11Z))620
Phosphatidylcholine Biosynthesis PC(22:0/18:1(9Z))620
Phosphatidylcholine Biosynthesis PC(22:0/18:2(9Z,12Z))620
Phosphatidylcholine Biosynthesis PC(22:0/18:3(6Z,9Z,12Z))620
Phosphatidylcholine Biosynthesis PC(22:0/18:3(9Z,12Z,15Z))620
Phosphatidylcholine Biosynthesis PC(22:0/18:4(6Z,9Z,12Z,15Z))620
Phosphatidylcholine Biosynthesis PC(22:0/20:0)620
Phosphatidylcholine Biosynthesis PC(22:0/20:1(11Z))620
Phosphatidylcholine Biosynthesis PC(22:0/20:2(11Z,14Z))620
Phosphatidylcholine Biosynthesis PC(22:0/20:3(5Z,8Z,11Z))620
Phosphatidylcholine Biosynthesis PC(22:0/20:3(8Z,11Z,14Z))620
Phosphatidylcholine Biosynthesis PC(22:0/20:4(5Z,8Z,11Z,14Z))620
Phosphatidylcholine Biosynthesis PC(22:0/20:4(8Z,11Z,14Z,17Z))620
Phosphatidylcholine Biosynthesis PC(22:0/20:5(5Z,8Z,11Z,14Z,17Z))620
Phosphatidylcholine Biosynthesis PC(22:0/22:0)620
Phosphatidylcholine Biosynthesis PC(22:0/22:1(13Z))620
Phosphatidylcholine Biosynthesis PC(22:0/22:2(13Z,16Z))620
Phosphatidylcholine Biosynthesis PC(22:0/22:4(7Z,10Z,13Z,16Z))620
Phosphatidylcholine Biosynthesis PC(22:0/22:5(4Z,7Z,10Z,13Z,16Z))620
Phosphatidylcholine Biosynthesis PC(22:0/22:5(7Z,10Z,13Z,16Z,19Z))620
Phosphatidylcholine Biosynthesis PC(22:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))620
Phosphatidylcholine Biosynthesis PC(22:0/24:0)620
Phosphatidylcholine Biosynthesis PC(22:0/24:1(15Z))620
Phosphatidylcholine Biosynthesis PC(22:1(13Z)/14:0)620
Phosphatidylcholine Biosynthesis PC(22:1(13Z)/14:1(9Z))620
Phosphatidylcholine Biosynthesis PC(22:1(13Z)/15:0)620
Phosphatidylcholine Biosynthesis PC(22:1(13Z)/16:0)620
Phosphatidylcholine Biosynthesis PC(22:1(13Z)/16:1(9Z))620
Phosphatidylcholine Biosynthesis PC(22:1(13Z)/18:0)620
Phosphatidylcholine Biosynthesis PC(22:1(13Z)/18:1(11Z))620
Phosphatidylcholine Biosynthesis PC(22:1(13Z)/18:1(9Z))620
Phosphatidylcholine Biosynthesis PC(22:1(13Z)/18:2(9Z,12Z))620
Phosphatidylcholine Biosynthesis PC(22:1(13Z)/18:3(6Z,9Z,12Z))620
Phosphatidylcholine Biosynthesis PC(22:1(13Z)/18:3(9Z,12Z,15Z))620
Phosphatidylcholine Biosynthesis PC(22:1(13Z)/18:4(6Z,9Z,12Z,15Z))620
Phosphatidylcholine Biosynthesis PC(22:1(13Z)/20:0)620
Phosphatidylcholine Biosynthesis PC(22:1(13Z)/20:1(11Z))620
Phosphatidylcholine Biosynthesis PC(22:1(13Z)/20:2(11Z,14Z))620
Phosphatidylcholine Biosynthesis PC(22:1(13Z)/20:3(5Z,8Z,11Z))620
Phosphatidylcholine Biosynthesis PC(22:1(13Z)/20:3(8Z,11Z,14Z))620
Phosphatidylcholine Biosynthesis PC(22:1(13Z)/20:4(5Z,8Z,11Z,14Z))620
Phosphatidylcholine Biosynthesis PC(22:1(13Z)/20:4(8Z,11Z,14Z,17Z))620
Phosphatidylcholine Biosynthesis PC(22:1(13Z)/20:5(5Z,8Z,11Z,14Z,17Z))620
Phosphatidylcholine Biosynthesis PC(22:1(13Z)/22:0)620
Phosphatidylcholine Biosynthesis PC(22:1(13Z)/22:1(13Z))620
Phosphatidylcholine Biosynthesis PC(22:1(13Z)/22:2(13Z,16Z))620
Phosphatidylcholine Biosynthesis PC(22:1(13Z)/22:4(7Z,10Z,13Z,16Z))620
Phosphatidylcholine Biosynthesis PC(22:1(13Z)/22:5(4Z,7Z,10Z,13Z,16Z))620
Phosphatidylcholine Biosynthesis PC(22:1(13Z)/22:5(7Z,10Z,13Z,16Z,19Z))620
Phosphatidylcholine Biosynthesis PC(22:1(13Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))620
Phosphatidylcholine Biosynthesis PC(22:1(13Z)/24:0)620
Phosphatidylcholine Biosynthesis PC(22:1(13Z)/24:1(15Z))620
Phosphatidylcholine Biosynthesis PC(22:2(13Z,16Z)/14:0)620
Phosphatidylcholine Biosynthesis PC(22:2(13Z,16Z)/14:1(9Z))620
Phosphatidylcholine Biosynthesis PC(22:2(13Z,16Z)/15:0)620
Phosphatidylcholine Biosynthesis PC(22:2(13Z,16Z)/16:0)620
Phosphatidylcholine Biosynthesis PC(22:2(13Z,16Z)/16:1(9Z))620
Phosphatidylcholine Biosynthesis PC(22:2(13Z,16Z)/18:0)620
Phosphatidylcholine Biosynthesis PC(22:2(13Z,16Z)/18:1(11Z))620
Phosphatidylcholine Biosynthesis PC(22:2(13Z,16Z)/18:1(9Z))620
Phosphatidylcholine Biosynthesis PC(22:2(13Z,16Z)/18:2(9Z,12Z))620
Phosphatidylcholine Biosynthesis PC(22:2(13Z,16Z)/18:3(6Z,9Z,12Z))620
Phosphatidylcholine Biosynthesis PC(22:2(13Z,16Z)/18:3(9Z,12Z,15Z))620
Phosphatidylcholine Biosynthesis PC(22:2(13Z,16Z)/18:4(6Z,9Z,12Z,15Z))620
Phosphatidylcholine Biosynthesis PC(22:2(13Z,16Z)/20:0)620
Phosphatidylcholine Biosynthesis PC(22:2(13Z,16Z)/20:1(11Z))620
Phosphatidylcholine Biosynthesis PC(22:2(13Z,16Z)/20:2(11Z,14Z))620
Phosphatidylcholine Biosynthesis PC(22:2(13Z,16Z)/20:3(5Z,8Z,11Z))620
Phosphatidylcholine Biosynthesis PC(22:2(13Z,16Z)/20:3(8Z,11Z,14Z))620
Phosphatidylcholine Biosynthesis PC(22:2(13Z,16Z)/20:4(5Z,8Z,11Z,14Z))620
Phosphatidylcholine Biosynthesis PC(22:2(13Z,16Z)/20:4(8Z,11Z,14Z,17Z))620
Phosphatidylcholine Biosynthesis PC(22:2(13Z,16Z)/20:5(5Z,8Z,11Z,14Z,17Z))620
Phosphatidylcholine Biosynthesis PC(22:2(13Z,16Z)/22:0)620
Phosphatidylcholine Biosynthesis PC(22:2(13Z,16Z)/22:1(13Z))620
Phosphatidylcholine Biosynthesis PC(22:2(13Z,16Z)/22:2(13Z,16Z))620
Phosphatidylcholine Biosynthesis PC(22:2(13Z,16Z)/22:4(7Z,10Z,13Z,16Z))620
Phosphatidylcholine Biosynthesis PC(22:2(13Z,16Z)/22:5(4Z,7Z,10Z,13Z,16Z))620
Phosphatidylcholine Biosynthesis PC(22:2(13Z,16Z)/22:5(7Z,10Z,13Z,16Z,19Z))620
Phosphatidylcholine Biosynthesis PC(22:2(13Z,16Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))620
Phosphatidylcholine Biosynthesis PC(22:2(13Z,16Z)/24:0)620
Phosphatidylcholine Biosynthesis PC(22:2(13Z,16Z)/24:1(15Z))620
Phosphatidylcholine Biosynthesis PC(22:4(7Z,10Z,13Z,16Z)/14:0)620
Phosphatidylcholine Biosynthesis PC(22:4(7Z,10Z,13Z,16Z)/14:1(9Z))620
Phosphatidylcholine Biosynthesis PC(22:4(7Z,10Z,13Z,16Z)/15:0)620
Phosphatidylcholine Biosynthesis PC(22:4(7Z,10Z,13Z,16Z)/16:0)620
Phosphatidylcholine Biosynthesis PC(22:4(7Z,10Z,13Z,16Z)/16:1(9Z))620
Phosphatidylcholine Biosynthesis PC(22:4(7Z,10Z,13Z,16Z)/18:0)620
Phosphatidylcholine Biosynthesis PC(22:4(7Z,10Z,13Z,16Z)/18:1(11Z))620
Phosphatidylcholine Biosynthesis PC(22:4(7Z,10Z,13Z,16Z)/18:1(9Z))620
Phosphatidylcholine Biosynthesis PC(22:4(7Z,10Z,13Z,16Z)/18:2(9Z,12Z))620
Phosphatidylcholine Biosynthesis PC(22:4(7Z,10Z,13Z,16Z)/18:3(6Z,9Z,12Z))620
Phosphatidylcholine Biosynthesis PC(22:4(7Z,10Z,13Z,16Z)/18:3(9Z,12Z,15Z))620
Phosphatidylcholine Biosynthesis PC(22:4(7Z,10Z,13Z,16Z)/18:4(6Z,9Z,12Z,15Z))620
Phosphatidylcholine Biosynthesis PC(22:4(7Z,10Z,13Z,16Z)/20:0)620
Phosphatidylcholine Biosynthesis PC(22:4(7Z,10Z,13Z,16Z)/20:1(11Z))620
Phosphatidylcholine Biosynthesis PC(22:4(7Z,10Z,13Z,16Z)/20:2(11Z,14Z))620
Phosphatidylcholine Biosynthesis PC(22:4(7Z,10Z,13Z,16Z)/20:3(5Z,8Z,11Z))620
Phosphatidylcholine Biosynthesis PC(22:4(7Z,10Z,13Z,16Z)/20:3(8Z,11Z,14Z))620
Phosphatidylcholine Biosynthesis PC(22:4(7Z,10Z,13Z,16Z)/20:4(5Z,8Z,11Z,14Z))620
Phosphatidylcholine Biosynthesis PC(22:4(7Z,10Z,13Z,16Z)/20:4(8Z,11Z,14Z,17Z))620
Phosphatidylcholine Biosynthesis PC(22:4(7Z,10Z,13Z,16Z)/20:5(5Z,8Z,11Z,14Z,17Z))620
Phosphatidylcholine Biosynthesis PC(22:4(7Z,10Z,13Z,16Z)/22:0)620
Phosphatidylcholine Biosynthesis PC(22:4(7Z,10Z,13Z,16Z)/22:1(13Z))620
Phosphatidylcholine Biosynthesis PC(22:4(7Z,10Z,13Z,16Z)/22:2(13Z,16Z))620
Phosphatidylcholine Biosynthesis PC(22:4(7Z,10Z,13Z,16Z)/22:4(7Z,10Z,13Z,16Z))620
Phosphatidylcholine Biosynthesis PC(22:4(7Z,10Z,13Z,16Z)/22:5(4Z,7Z,10Z,13Z,16Z))620
Phosphatidylcholine Biosynthesis PC(22:4(7Z,10Z,13Z,16Z)/22:5(7Z,10Z,13Z,16Z,19Z))620
Phosphatidylcholine Biosynthesis PC(22:4(7Z,10Z,13Z,16Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))620
Phosphatidylcholine Biosynthesis PC(22:4(7Z,10Z,13Z,16Z)/24:0)620
Phosphatidylcholine Biosynthesis PC(22:4(7Z,10Z,13Z,16Z)/24:1(15Z))620
Phosphatidylcholine Biosynthesis PC(22:5(4Z,7Z,10Z,13Z,16Z)/14:0)620
Phosphatidylcholine Biosynthesis PC(22:5(4Z,7Z,10Z,13Z,16Z)/14:1(9Z))620
Phosphatidylcholine Biosynthesis PC(22:5(4Z,7Z,10Z,13Z,16Z)/15:0)620
Phosphatidylcholine Biosynthesis PC(22:5(4Z,7Z,10Z,13Z,16Z)/16:0)620
Phosphatidylcholine Biosynthesis PC(22:5(4Z,7Z,10Z,13Z,16Z)/16:1(9Z))620
Phosphatidylcholine Biosynthesis PC(22:5(4Z,7Z,10Z,13Z,16Z)/18:0)620
Phosphatidylcholine Biosynthesis PC(22:5(4Z,7Z,10Z,13Z,16Z)/18:1(11Z))620
Phosphatidylcholine Biosynthesis PC(22:5(4Z,7Z,10Z,13Z,16Z)/18:1(9Z))620
Phosphatidylcholine Biosynthesis PC(22:5(4Z,7Z,10Z,13Z,16Z)/18:2(9Z,12Z))620
Phosphatidylcholine Biosynthesis PC(22:5(4Z,7Z,10Z,13Z,16Z)/18:3(6Z,9Z,12Z))620
Phosphatidylcholine Biosynthesis PC(22:5(4Z,7Z,10Z,13Z,16Z)/18:3(9Z,12Z,15Z))620
Phosphatidylcholine Biosynthesis PC(22:5(4Z,7Z,10Z,13Z,16Z)/18:4(6Z,9Z,12Z,15Z))620
Phosphatidylcholine Biosynthesis PC(22:5(4Z,7Z,10Z,13Z,16Z)/20:0)620
Phosphatidylcholine Biosynthesis PC(22:5(4Z,7Z,10Z,13Z,16Z)/20:1(11Z))620
Phosphatidylcholine Biosynthesis PC(22:5(4Z,7Z,10Z,13Z,16Z)/20:2(11Z,14Z))620
Phosphatidylcholine Biosynthesis PC(22:5(4Z,7Z,10Z,13Z,16Z)/20:3(5Z,8Z,11Z))620
Phosphatidylcholine Biosynthesis PC(22:5(4Z,7Z,10Z,13Z,16Z)/20:3(8Z,11Z,14Z))620
Phosphatidylcholine Biosynthesis PC(22:5(4Z,7Z,10Z,13Z,16Z)/20:4(5Z,8Z,11Z,14Z))620
Phosphatidylcholine Biosynthesis PC(22:5(4Z,7Z,10Z,13Z,16Z)/20:4(8Z,11Z,14Z,17Z))620
Phosphatidylcholine Biosynthesis PC(22:5(4Z,7Z,10Z,13Z,16Z)/20:5(5Z,8Z,11Z,14Z,17Z))620
Phosphatidylcholine Biosynthesis PC(22:5(4Z,7Z,10Z,13Z,16Z)/22:0)620
Phosphatidylcholine Biosynthesis PC(22:5(4Z,7Z,10Z,13Z,16Z)/22:1(13Z))620
Phosphatidylcholine Biosynthesis PC(22:5(4Z,7Z,10Z,13Z,16Z)/22:2(13Z,16Z))620
Phosphatidylcholine Biosynthesis PC(22:5(4Z,7Z,10Z,13Z,16Z)/22:4(7Z,10Z,13Z,16Z))620
Phosphatidylcholine Biosynthesis PC(22:5(4Z,7Z,10Z,13Z,16Z)/22:5(4Z,7Z,10Z,13Z,16Z))620
Phosphatidylcholine Biosynthesis PC(22:5(4Z,7Z,10Z,13Z,16Z)/22:5(7Z,10Z,13Z,16Z,19Z))620
Phosphatidylcholine Biosynthesis PC(22:5(4Z,7Z,10Z,13Z,16Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))620
Phosphatidylcholine Biosynthesis PC(22:5(4Z,7Z,10Z,13Z,16Z)/24:0)620
Phosphatidylcholine Biosynthesis PC(22:5(4Z,7Z,10Z,13Z,16Z)/24:1(15Z))620
Phosphatidylcholine Biosynthesis PC(22:5(7Z,10Z,13Z,16Z,19Z)/14:0)620
Phosphatidylcholine Biosynthesis PC(22:5(7Z,10Z,13Z,16Z,19Z)/14:1(9Z))620
Phosphatidylcholine Biosynthesis PC(22:5(7Z,10Z,13Z,16Z,19Z)/15:0)620
Phosphatidylcholine Biosynthesis PC(22:5(7Z,10Z,13Z,16Z,19Z)/16:0)620
Phosphatidylcholine Biosynthesis PC(22:5(7Z,10Z,13Z,16Z,19Z)/16:1(9Z))620
Phosphatidylcholine Biosynthesis PC(22:5(7Z,10Z,13Z,16Z,19Z)/18:0)620
Phosphatidylcholine Biosynthesis PC(22:5(7Z,10Z,13Z,16Z,19Z)/18:1(11Z))620
Phosphatidylcholine Biosynthesis PC(22:5(7Z,10Z,13Z,16Z,19Z)/18:1(9Z))620
Phosphatidylcholine Biosynthesis PC(22:5(7Z,10Z,13Z,16Z,19Z)/18:2(9Z,12Z))620
Phosphatidylcholine Biosynthesis PC(22:5(7Z,10Z,13Z,16Z,19Z)/18:3(6Z,9Z,12Z))620
Phosphatidylcholine Biosynthesis PC(22:5(7Z,10Z,13Z,16Z,19Z)/18:3(9Z,12Z,15Z))620
Phosphatidylcholine Biosynthesis PC(22:5(7Z,10Z,13Z,16Z,19Z)/18:4(6Z,9Z,12Z,15Z))620
Phosphatidylcholine Biosynthesis PC(22:5(7Z,10Z,13Z,16Z,19Z)/20:0)620
Phosphatidylcholine Biosynthesis PC(22:5(7Z,10Z,13Z,16Z,19Z)/20:1(11Z))620
Phosphatidylcholine Biosynthesis PC(22:5(7Z,10Z,13Z,16Z,19Z)/20:2(11Z,14Z))620
Phosphatidylcholine Biosynthesis PC(22:5(7Z,10Z,13Z,16Z,19Z)/20:3(5Z,8Z,11Z))620
Phosphatidylcholine Biosynthesis PC(22:5(7Z,10Z,13Z,16Z,19Z)/20:3(8Z,11Z,14Z))620
Phosphatidylcholine Biosynthesis PC(22:5(7Z,10Z,13Z,16Z,19Z)/20:4(5Z,8Z,11Z,14Z))620
Phosphatidylcholine Biosynthesis PC(22:5(7Z,10Z,13Z,16Z,19Z)/20:4(8Z,11Z,14Z,17Z))620
Phosphatidylcholine Biosynthesis PC(22:5(7Z,10Z,13Z,16Z,19Z)/20:5(5Z,8Z,11Z,14Z,17Z))620
Phosphatidylcholine Biosynthesis PC(22:5(7Z,10Z,13Z,16Z,19Z)/22:0)620
Phosphatidylcholine Biosynthesis PC(22:5(7Z,10Z,13Z,16Z,19Z)/22:1(13Z))620
Phosphatidylcholine Biosynthesis PC(22:5(7Z,10Z,13Z,16Z,19Z)/22:2(13Z,16Z))620
Phosphatidylcholine Biosynthesis PC(22:5(7Z,10Z,13Z,16Z,19Z)/22:4(7Z,10Z,13Z,16Z))620
Phosphatidylcholine Biosynthesis PC(22:5(7Z,10Z,13Z,16Z,19Z)/22:5(4Z,7Z,10Z,13Z,16Z))620
Phosphatidylcholine Biosynthesis PC(22:5(7Z,10Z,13Z,16Z,19Z)/22:5(7Z,10Z,13Z,16Z,19Z))620
Phosphatidylcholine Biosynthesis PC(22:5(7Z,10Z,13Z,16Z,19Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))620
Phosphatidylcholine Biosynthesis PC(22:5(7Z,10Z,13Z,16Z,19Z)/24:0)620
Phosphatidylcholine Biosynthesis PC(22:5(7Z,10Z,13Z,16Z,19Z)/24:1(15Z))620
Phosphatidylcholine Biosynthesis PC(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/14:0)620
Phosphatidylcholine Biosynthesis PC(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/14:1(9Z))620
Phosphatidylcholine Biosynthesis PC(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/15:0)620
Phosphatidylcholine Biosynthesis PC(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/16:0)620
Phosphatidylcholine Biosynthesis PC(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/16:1(9Z))620
Phosphatidylcholine Biosynthesis PC(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/18:0)620
Phosphatidylcholine Biosynthesis PC(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/18:1(11Z))620
Phosphatidylcholine Biosynthesis PC(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/18:1(9Z))620
Phosphatidylcholine Biosynthesis PC(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/18:2(9Z,12Z))620
Phosphatidylcholine Biosynthesis PC(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/18:3(6Z,9Z,12Z))620
Phosphatidylcholine Biosynthesis PC(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/18:3(9Z,12Z,15Z))620
Phosphatidylcholine Biosynthesis PC(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/18:4(6Z,9Z,12Z,15Z))620
Phosphatidylcholine Biosynthesis PC(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:0)620
Phosphatidylcholine Biosynthesis PC(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:1(11Z))620
Phosphatidylcholine Biosynthesis PC(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:2(11Z,14Z))620
Phosphatidylcholine Biosynthesis PC(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:3(5Z,8Z,11Z))620
Phosphatidylcholine Biosynthesis PC(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:3(8Z,11Z,14Z))620
Phosphatidylcholine Biosynthesis PC(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:4(5Z,8Z,11Z,14Z))620
Phosphatidylcholine Biosynthesis PC(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:4(8Z,11Z,14Z,17Z))620
Phosphatidylcholine Biosynthesis PC(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:5(5Z,8Z,11Z,14Z,17Z))620
Phosphatidylcholine Biosynthesis PC(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/22:0)620
Phosphatidylcholine Biosynthesis PC(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/22:1(13Z))620
Phosphatidylcholine Biosynthesis PC(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/22:2(13Z,16Z))620
Phosphatidylcholine Biosynthesis PC(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/22:4(7Z,10Z,13Z,16Z))620
Phosphatidylcholine Biosynthesis PC(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/22:5(4Z,7Z,10Z,13Z,16Z))620
Phosphatidylcholine Biosynthesis PC(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/22:5(7Z,10Z,13Z,16Z,19Z))620
Phosphatidylcholine Biosynthesis PC(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))620
Phosphatidylcholine Biosynthesis PC(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/24:0)620
Phosphatidylcholine Biosynthesis PC(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/24:1(15Z))620
Phosphatidylcholine Biosynthesis PC(24:0/14:0)620
Phosphatidylcholine Biosynthesis PC(24:0/14:1(9Z))620
Phosphatidylcholine Biosynthesis PC(24:0/15:0)620
Phosphatidylcholine Biosynthesis PC(24:0/16:0)620
Phosphatidylcholine Biosynthesis PC(24:0/16:1(9Z))620
Phosphatidylcholine Biosynthesis PC(24:0/18:0)620
Phosphatidylcholine Biosynthesis PC(24:0/18:1(11Z))620
Phosphatidylcholine Biosynthesis PC(24:0/18:1(9Z))620
Phosphatidylcholine Biosynthesis PC(24:0/18:2(9Z,12Z))620
Phosphatidylcholine Biosynthesis PC(24:0/18:3(6Z,9Z,12Z))620
Phosphatidylcholine Biosynthesis PC(24:0/18:3(9Z,12Z,15Z))620
Phosphatidylcholine Biosynthesis PC(24:0/18:4(6Z,9Z,12Z,15Z))620
Phosphatidylcholine Biosynthesis PC(24:0/20:0)620
Phosphatidylcholine Biosynthesis PC(24:0/20:1(11Z))620
Phosphatidylcholine Biosynthesis PC(24:0/20:2(11Z,14Z))620
Phosphatidylcholine Biosynthesis PC(24:0/20:3(5Z,8Z,11Z))620
Phosphatidylcholine Biosynthesis PC(24:0/20:3(8Z,11Z,14Z))620
Phosphatidylcholine Biosynthesis PC(24:0/20:4(5Z,8Z,11Z,14Z))620
Phosphatidylcholine Biosynthesis PC(24:0/20:4(8Z,11Z,14Z,17Z))620
Phosphatidylcholine Biosynthesis PC(24:0/20:5(5Z,8Z,11Z,14Z,17Z))620
Phosphatidylcholine Biosynthesis PC(24:0/22:0)620
Phosphatidylcholine Biosynthesis PC(24:0/22:1(13Z))620
Phosphatidylcholine Biosynthesis PC(24:0/22:2(13Z,16Z))620
Phosphatidylcholine Biosynthesis PC(24:0/22:4(7Z,10Z,13Z,16Z))620
Phosphatidylcholine Biosynthesis PC(24:0/22:5(4Z,7Z,10Z,13Z,16Z))620
Phosphatidylcholine Biosynthesis PC(24:0/22:5(7Z,10Z,13Z,16Z,19Z))620
Phosphatidylcholine Biosynthesis PC(24:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))620
Phosphatidylcholine Biosynthesis PC(24:0/24:0)620
Phosphatidylcholine Biosynthesis PC(24:0/24:1(15Z))620
Phosphatidylcholine Biosynthesis PC(24:1(15Z)/14:0)620
Phosphatidylcholine Biosynthesis PC(24:1(15Z)/14:1(9Z))620
Phosphatidylcholine Biosynthesis PC(24:1(15Z)/15:0)620
Phosphatidylcholine Biosynthesis PC(24:1(15Z)/16:0)620
Phosphatidylcholine Biosynthesis PC(24:1(15Z)/16:1(9Z))620
Phosphatidylcholine Biosynthesis PC(24:1(15Z)/18:0)620
Phosphatidylcholine Biosynthesis PC(24:1(15Z)/18:1(11Z))620
Phosphatidylcholine Biosynthesis PC(24:1(15Z)/18:1(9Z))620
Phosphatidylcholine Biosynthesis PC(24:1(15Z)/18:2(9Z,12Z))620
Phosphatidylcholine Biosynthesis PC(24:1(15Z)/18:3(6Z,9Z,12Z))620
Phosphatidylcholine Biosynthesis PC(24:1(15Z)/18:3(9Z,12Z,15Z))620
Phosphatidylcholine Biosynthesis PC(24:1(15Z)/18:4(6Z,9Z,12Z,15Z))620
Phosphatidylcholine Biosynthesis PC(24:1(15Z)/20:0)620
Phosphatidylcholine Biosynthesis PC(24:1(15Z)/20:1(11Z))620
Phosphatidylcholine Biosynthesis PC(24:1(15Z)/20:2(11Z,14Z))620
Phosphatidylcholine Biosynthesis PC(24:1(15Z)/20:3(5Z,8Z,11Z))620
Phosphatidylcholine Biosynthesis PC(24:1(15Z)/20:3(8Z,11Z,14Z))620
Phosphatidylcholine Biosynthesis PC(24:1(15Z)/20:4(5Z,8Z,11Z,14Z))620
Phosphatidylcholine Biosynthesis PC(24:1(15Z)/20:4(8Z,11Z,14Z,17Z))620
Phosphatidylcholine Biosynthesis PC(24:1(15Z)/20:5(5Z,8Z,11Z,14Z,17Z))620
Phosphatidylcholine Biosynthesis PC(24:1(15Z)/22:0)620
Phosphatidylcholine Biosynthesis PC(24:1(15Z)/22:1(13Z))620
Phosphatidylcholine Biosynthesis PC(24:1(15Z)/22:2(13Z,16Z))620
Phosphatidylcholine Biosynthesis PC(24:1(15Z)/22:4(7Z,10Z,13Z,16Z))620
Phosphatidylcholine Biosynthesis PC(24:1(15Z)/22:5(4Z,7Z,10Z,13Z,16Z))620
Phosphatidylcholine Biosynthesis PC(24:1(15Z)/22:5(7Z,10Z,13Z,16Z,19Z))620
Phosphatidylcholine Biosynthesis PC(24:1(15Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))620
Phosphatidylcholine Biosynthesis PC(24:1(15Z)/24:0)620
Phosphatidylcholine Biosynthesis PC(24:1(15Z)/24:1(15Z))620
Phosphatidylethanolamine Biosynthesis PE(14:0/14:0)516
Phosphatidylethanolamine Biosynthesis PE(14:0/14:1(9Z))516
Phosphatidylethanolamine Biosynthesis PE(14:0/15:0)516
Phosphatidylethanolamine Biosynthesis PE(14:0/16:0)516
Phosphatidylethanolamine Biosynthesis PE(14:0/16:1(9Z))516
Phosphatidylethanolamine Biosynthesis PE(14:0/18:0)516
Phosphatidylethanolamine Biosynthesis PE(14:0/18:1(11Z))516
Phosphatidylethanolamine Biosynthesis PE(14:0/18:1(9Z))516
Phosphatidylethanolamine Biosynthesis PE(14:0/18:2(9Z,12Z))516
Phosphatidylethanolamine Biosynthesis PE(14:0/18:3(6Z,9Z,12Z))516
Phosphatidylethanolamine Biosynthesis PE(14:0/18:3(9Z,12Z,15Z))516
Phosphatidylethanolamine Biosynthesis PE(14:0/18:4(6Z,9Z,12Z,15Z))516
Phosphatidylethanolamine Biosynthesis PE(14:0/20:0)516
Phosphatidylethanolamine Biosynthesis PE(14:0/20:1(11Z))516
Phosphatidylethanolamine Biosynthesis PE(14:0/20:2(11Z,14Z))516
Phosphatidylethanolamine Biosynthesis PE(14:0/20:3(5Z,8Z,11Z))516
Phosphatidylethanolamine Biosynthesis PE(14:0/20:3(8Z,11Z,14Z))516
Phosphatidylethanolamine Biosynthesis PE(14:0/20:4(5Z,8Z,11Z,14Z))516
Phosphatidylethanolamine Biosynthesis PE(14:0/20:4(8Z,11Z,14Z,17Z))516
Phosphatidylethanolamine Biosynthesis PE(14:0/20:5(5Z,8Z,11Z,14Z,17Z))516
Phosphatidylethanolamine Biosynthesis PE(14:0/22:0)516
Phosphatidylethanolamine Biosynthesis PE(14:0/22:1(13Z))516
Phosphatidylethanolamine Biosynthesis PE(14:0/22:2(13Z,16Z))516
Phosphatidylethanolamine Biosynthesis PE(14:0/22:4(7Z,10Z,13Z,16Z))516
Phosphatidylethanolamine Biosynthesis PE(14:0/22:5(4Z,7Z,10Z,13Z,16Z))516
Phosphatidylethanolamine Biosynthesis PE(14:0/22:5(7Z,10Z,13Z,16Z,19Z))516
Phosphatidylethanolamine Biosynthesis PE(14:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))516
Phosphatidylethanolamine Biosynthesis PE(14:0/24:0)516
Phosphatidylethanolamine Biosynthesis PE(14:0/24:1(15Z))516
Phosphatidylethanolamine Biosynthesis PE(14:1(9Z)/14:0)516
Phosphatidylethanolamine Biosynthesis PE(14:1(9Z)/14:1(9Z))516
Phosphatidylethanolamine Biosynthesis PE(14:1(9Z)/15:0)516
Phosphatidylethanolamine Biosynthesis PE(14:1(9Z)/16:0)516
Phosphatidylethanolamine Biosynthesis PE(14:1(9Z)/16:1(9Z))516
Phosphatidylethanolamine Biosynthesis PE(14:1(9Z)/18:0)516
Phosphatidylethanolamine Biosynthesis PE(14:1(9Z)/18:1(11Z))516
Phosphatidylethanolamine Biosynthesis PE(14:1(9Z)/18:1(9Z))516
Phosphatidylethanolamine Biosynthesis PE(14:1(9Z)/18:2(9Z,12Z))516
Phosphatidylethanolamine Biosynthesis PE(14:1(9Z)/18:3(6Z,9Z,12Z))516
Phosphatidylethanolamine Biosynthesis PE(14:1(9Z)/18:3(9Z,12Z,15Z))516
Phosphatidylethanolamine Biosynthesis PE(14:1(9Z)/18:4(6Z,9Z,12Z,15Z))516
Phosphatidylethanolamine Biosynthesis PE(14:1(9Z)/20:0)516
Phosphatidylethanolamine Biosynthesis PE(14:1(9Z)/20:1(11Z))516
Phosphatidylethanolamine Biosynthesis PE(14:1(9Z)/20:2(11Z,14Z))516
Phosphatidylethanolamine Biosynthesis PE(14:1(9Z)/20:3(5Z,8Z,11Z))516
Phosphatidylethanolamine Biosynthesis PE(14:1(9Z)/20:3(8Z,11Z,14Z))516
Phosphatidylethanolamine Biosynthesis PE(14:1(9Z)/20:4(5Z,8Z,11Z,14Z))516
Phosphatidylethanolamine Biosynthesis PE(14:1(9Z)/20:4(8Z,11Z,14Z,17Z))516
Phosphatidylethanolamine Biosynthesis PE(14:1(9Z)/20:5(5Z,8Z,11Z,14Z,17Z))516
Phosphatidylethanolamine Biosynthesis PE(14:1(9Z)/22:0)516
Phosphatidylethanolamine Biosynthesis PE(14:1(9Z)/22:1(13Z))516
Phosphatidylethanolamine Biosynthesis PE(14:1(9Z)/22:2(13Z,16Z))516
Phosphatidylethanolamine Biosynthesis PE(14:1(9Z)/22:4(7Z,10Z,13Z,16Z))516
Phosphatidylethanolamine Biosynthesis PE(14:1(9Z)/22:5(4Z,7Z,10Z,13Z,16Z))516
Phosphatidylethanolamine Biosynthesis PE(14:1(9Z)/22:5(7Z,10Z,13Z,16Z,19Z))516
Phosphatidylethanolamine Biosynthesis PE(14:1(9Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))516
Phosphatidylethanolamine Biosynthesis PE(14:1(9Z)/24:0)516
Phosphatidylethanolamine Biosynthesis PE(14:1(9Z)/24:1(15Z))516
Phosphatidylethanolamine Biosynthesis PE(15:0/14:0)516
Phosphatidylethanolamine Biosynthesis PE(15:0/14:1(9Z))516
Phosphatidylethanolamine Biosynthesis PE(15:0/15:0)516
Phosphatidylethanolamine Biosynthesis PE(15:0/16:0)516
Phosphatidylethanolamine Biosynthesis PE(15:0/16:1(9Z))516
Phosphatidylethanolamine Biosynthesis PE(15:0/18:0)516
Phosphatidylethanolamine Biosynthesis PE(15:0/18:1(11Z))516
Phosphatidylethanolamine Biosynthesis PE(15:0/18:1(9Z))516
Phosphatidylethanolamine Biosynthesis PE(15:0/18:2(9Z,12Z))516
Phosphatidylethanolamine Biosynthesis PE(15:0/18:3(6Z,9Z,12Z))516
Phosphatidylethanolamine Biosynthesis PE(15:0/18:3(9Z,12Z,15Z))516
Phosphatidylethanolamine Biosynthesis PE(15:0/18:4(6Z,9Z,12Z,15Z))516
Phosphatidylethanolamine Biosynthesis PE(15:0/20:0)516
Phosphatidylethanolamine Biosynthesis PE(15:0/20:1(11Z))516
Phosphatidylethanolamine Biosynthesis PE(15:0/20:2(11Z,14Z))516
Phosphatidylethanolamine Biosynthesis PE(15:0/20:3(5Z,8Z,11Z))516
Phosphatidylethanolamine Biosynthesis PE(15:0/20:3(8Z,11Z,14Z))516
Phosphatidylethanolamine Biosynthesis PE(15:0/20:4(5Z,8Z,11Z,14Z))516
Phosphatidylethanolamine Biosynthesis PE(15:0/20:4(8Z,11Z,14Z,17Z))516
Phosphatidylethanolamine Biosynthesis PE(15:0/20:5(5Z,8Z,11Z,14Z,17Z))516
Phosphatidylethanolamine Biosynthesis PE(15:0/22:0)516
Phosphatidylethanolamine Biosynthesis PE(15:0/22:1(13Z))516
Phosphatidylethanolamine Biosynthesis PE(15:0/22:2(13Z,16Z))516
Phosphatidylethanolamine Biosynthesis PE(15:0/22:4(7Z,10Z,13Z,16Z))516
Phosphatidylethanolamine Biosynthesis PE(15:0/22:5(4Z,7Z,10Z,13Z,16Z))516
Phosphatidylethanolamine Biosynthesis PE(15:0/22:5(7Z,10Z,13Z,16Z,19Z))516
Phosphatidylethanolamine Biosynthesis PE(15:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))516
Phosphatidylethanolamine Biosynthesis PE(15:0/24:0)516
Phosphatidylethanolamine Biosynthesis PE(15:0/24:1(15Z))516
Phosphatidylethanolamine Biosynthesis PE(16:0/14:0)516
Phosphatidylethanolamine Biosynthesis PE(16:0/14:1(9Z))516
Phosphatidylethanolamine Biosynthesis PE(16:0/15:0)516
Phosphatidylethanolamine Biosynthesis PE(16:0/16:0)516
Phosphatidylethanolamine Biosynthesis PE(16:0/16:1(9Z))516
Phosphatidylethanolamine Biosynthesis PE(16:0/18:0)516
Phosphatidylethanolamine Biosynthesis PE(16:0/18:1(11Z))516
Phosphatidylethanolamine Biosynthesis PE(16:0/18:1(9Z))516
Phosphatidylethanolamine Biosynthesis PE(16:0/18:2(9Z,12Z))516
Phosphatidylethanolamine Biosynthesis PE(16:0/18:3(6Z,9Z,12Z))516
Phosphatidylethanolamine Biosynthesis PE(16:0/18:3(9Z,12Z,15Z))516
Phosphatidylethanolamine Biosynthesis PE(16:0/18:4(6Z,9Z,12Z,15Z))516
Phosphatidylethanolamine Biosynthesis PE(16:0/20:0)516
Phosphatidylethanolamine Biosynthesis PE(16:0/20:1(11Z))516
Phosphatidylethanolamine Biosynthesis PE(16:0/20:2(11Z,14Z))516
Phosphatidylethanolamine Biosynthesis PE(16:0/20:3(5Z,8Z,11Z))516
Phosphatidylethanolamine Biosynthesis PE(16:0/20:3(8Z,11Z,14Z))516
Phosphatidylethanolamine Biosynthesis PE(16:0/20:4(5Z,8Z,11Z,14Z))516
Phosphatidylethanolamine Biosynthesis PE(16:0/20:4(8Z,11Z,14Z,17Z))516
Phosphatidylethanolamine Biosynthesis PE(16:0/20:5(5Z,8Z,11Z,14Z,17Z))516
Phosphatidylethanolamine Biosynthesis PE(16:0/22:0)516
Phosphatidylethanolamine Biosynthesis PE(16:0/22:1(13Z))516
Phosphatidylethanolamine Biosynthesis PE(16:0/22:2(13Z,16Z))516
Phosphatidylethanolamine Biosynthesis PE(16:0/22:4(7Z,10Z,13Z,16Z))516
Phosphatidylethanolamine Biosynthesis PE(16:0/22:5(4Z,7Z,10Z,13Z,16Z))516
Phosphatidylethanolamine Biosynthesis PE(16:0/22:5(7Z,10Z,13Z,16Z,19Z))516
Phosphatidylethanolamine Biosynthesis PE(16:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))516
Phosphatidylethanolamine Biosynthesis PE(16:0/24:0)516
Phosphatidylethanolamine Biosynthesis PE(16:0/24:1(15Z))516
Phosphatidylethanolamine Biosynthesis PE(16:1(9Z)/14:0)516
Phosphatidylethanolamine Biosynthesis PE(16:1(9Z)/14:1(9Z))516
Phosphatidylethanolamine Biosynthesis PE(16:1(9Z)/15:0)516
Phosphatidylethanolamine Biosynthesis PE(16:1(9Z)/16:0)516
Phosphatidylethanolamine Biosynthesis PE(16:1(9Z)/16:1(9Z))516
Phosphatidylethanolamine Biosynthesis PE(16:1(9Z)/18:1(11Z))516
Phosphatidylethanolamine Biosynthesis PE(16:1(9Z)/18:1(9Z))516
Phosphatidylethanolamine Biosynthesis PE(16:1(9Z)/18:2(9Z,12Z))516
Phosphatidylethanolamine Biosynthesis PE(16:1(9Z)/18:3(6Z,9Z,12Z))516
Phosphatidylethanolamine Biosynthesis PE(16:1(9Z)/18:3(9Z,12Z,15Z))516
Phosphatidylethanolamine Biosynthesis PE(16:1(9Z)/18:4(6Z,9Z,12Z,15Z))516
Phosphatidylethanolamine Biosynthesis PE(16:1(9Z)/20:0)516
Phosphatidylethanolamine Biosynthesis PE(16:1(9Z)/20:1(11Z))516
Phosphatidylethanolamine Biosynthesis PE(16:1(9Z)/20:2(11Z,14Z))516
Phosphatidylethanolamine Biosynthesis PE(16:1(9Z)/20:3(5Z,8Z,11Z))516
Phosphatidylethanolamine Biosynthesis PE(16:1(9Z)/20:3(8Z,11Z,14Z))516
Phosphatidylethanolamine Biosynthesis PE(16:1(9Z)/20:4(5Z,8Z,11Z,14Z))516
Phosphatidylethanolamine Biosynthesis PE(16:1(9Z)/20:4(8Z,11Z,14Z,17Z))516
Phosphatidylethanolamine Biosynthesis PE(16:1(9Z)/20:5(5Z,8Z,11Z,14Z,17Z))516
Phosphatidylethanolamine Biosynthesis PE(16:1(9Z)/22:0)516
Phosphatidylethanolamine Biosynthesis PE(16:1(9Z)/22:1(13Z))516
Phosphatidylethanolamine Biosynthesis PE(16:1(9Z)/22:2(13Z,16Z))516
Phosphatidylethanolamine Biosynthesis PE(16:1(9Z)/22:4(7Z,10Z,13Z,16Z))516
Phosphatidylethanolamine Biosynthesis PE(16:1(9Z)/22:5(4Z,7Z,10Z,13Z,16Z))516
Phosphatidylethanolamine Biosynthesis PE(16:1(9Z)/22:5(7Z,10Z,13Z,16Z,19Z))516
Phosphatidylethanolamine Biosynthesis PE(16:1(9Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))516
Phosphatidylethanolamine Biosynthesis PE(16:1(9Z)/24:0)516
Phosphatidylethanolamine Biosynthesis PE(16:1(9Z)/24:1(15Z))516
Phosphatidylethanolamine Biosynthesis PE(18:0/14:0)516
Phosphatidylethanolamine Biosynthesis PE(18:0/14:1(9Z))516
Phosphatidylethanolamine Biosynthesis PE(18:0/15:0)516
Phosphatidylethanolamine Biosynthesis PE(18:0/16:0)516
Phosphatidylethanolamine Biosynthesis PE(18:0/16:1(9Z))516
Phosphatidylethanolamine Biosynthesis PE(18:0/18:0)516
Phosphatidylethanolamine Biosynthesis PE(18:0/18:1(11Z))516
Phosphatidylethanolamine Biosynthesis PE(18:0/18:1(9Z))516
Phosphatidylethanolamine Biosynthesis PE(18:0/18:2(9Z,12Z))516
Phosphatidylethanolamine Biosynthesis PE(18:0/18:3(6Z,9Z,12Z))516
Phosphatidylethanolamine Biosynthesis PE(18:0/18:3(9Z,12Z,15Z))516
Phosphatidylethanolamine Biosynthesis PE(18:0/18:4(6Z,9Z,12Z,15Z))516
Phosphatidylethanolamine Biosynthesis PE(18:0/20:0)516
Phosphatidylethanolamine Biosynthesis PE(18:0/20:1(11Z))516
Phosphatidylethanolamine Biosynthesis PE(18:0/20:2(11Z,14Z))516
Phosphatidylethanolamine Biosynthesis PE(18:0/20:3(5Z,8Z,11Z))516
Phosphatidylethanolamine Biosynthesis PE(18:0/20:3(8Z,11Z,14Z))516
Phosphatidylethanolamine Biosynthesis PE(18:0/20:4(5Z,8Z,11Z,14Z))516
Phosphatidylethanolamine Biosynthesis PE(18:0/20:4(8Z,11Z,14Z,17Z))516
Phosphatidylethanolamine Biosynthesis PE(18:0/20:5(5Z,8Z,11Z,14Z,17Z))516
Phosphatidylethanolamine Biosynthesis PE(18:0/22:0)516
Phosphatidylethanolamine Biosynthesis PE(18:0/22:1(13Z))516
Phosphatidylethanolamine Biosynthesis PE(18:0/22:2(13Z,16Z))516
Phosphatidylethanolamine Biosynthesis PE(18:0/22:4(7Z,10Z,13Z,16Z))516
Phosphatidylethanolamine Biosynthesis PE(18:0/22:5(4Z,7Z,10Z,13Z,16Z))516
Phosphatidylethanolamine Biosynthesis PE(18:0/22:5(7Z,10Z,13Z,16Z,19Z))516
Phosphatidylethanolamine Biosynthesis PE(18:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))516
Phosphatidylethanolamine Biosynthesis PE(18:0/24:0)516
Phosphatidylethanolamine Biosynthesis PE(18:0/24:1(15Z))516
Phosphatidylethanolamine Biosynthesis PE(18:1(11Z)/14:0)516
Phosphatidylethanolamine Biosynthesis PE(18:1(11Z)/14:1(9Z))516
Phosphatidylethanolamine Biosynthesis PE(18:1(11Z)/15:0)516
Phosphatidylethanolamine Biosynthesis PE(18:1(11Z)/16:0)516
Phosphatidylethanolamine Biosynthesis PE(18:1(11Z)/16:1(9Z))516
Phosphatidylethanolamine Biosynthesis PE(18:1(11Z)/18:0)516
Phosphatidylethanolamine Biosynthesis PE(18:1(11Z)/18:1(11Z))516
Phosphatidylethanolamine Biosynthesis PE(18:1(11Z)/18:1(9Z))516
Phosphatidylethanolamine Biosynthesis PE(18:1(11Z)/18:2(9Z,12Z))516
Phosphatidylethanolamine Biosynthesis PE(18:1(11Z)/18:3(6Z,9Z,12Z))516
Phosphatidylethanolamine Biosynthesis PE(18:1(11Z)/18:3(9Z,12Z,15Z))516
Phosphatidylethanolamine Biosynthesis PE(18:1(11Z)/18:4(6Z,9Z,12Z,15Z))516
Phosphatidylethanolamine Biosynthesis PE(18:1(11Z)/20:0)516
Phosphatidylethanolamine Biosynthesis PE(18:1(11Z)/20:1(11Z))516
Phosphatidylethanolamine Biosynthesis PE(18:1(11Z)/20:2(11Z,14Z))516
Phosphatidylethanolamine Biosynthesis PE(18:1(11Z)/20:3(5Z,8Z,11Z))516
Phosphatidylethanolamine Biosynthesis PE(18:1(11Z)/20:3(8Z,11Z,14Z))516
Phosphatidylethanolamine Biosynthesis PE(18:1(11Z)/20:4(5Z,8Z,11Z,14Z))516
Phosphatidylethanolamine Biosynthesis PE(18:1(11Z)/20:4(8Z,11Z,14Z,17Z))516
Phosphatidylethanolamine Biosynthesis PE(18:1(11Z)/20:5(5Z,8Z,11Z,14Z,17Z))516
Phosphatidylethanolamine Biosynthesis PE(18:1(11Z)/22:0)516
Phosphatidylethanolamine Biosynthesis PE(18:1(11Z)/22:1(13Z))516
Phosphatidylethanolamine Biosynthesis PE(18:1(11Z)/22:2(13Z,16Z))516
Phosphatidylethanolamine Biosynthesis PE(18:1(11Z)/22:4(7Z,10Z,13Z,16Z))516
Phosphatidylethanolamine Biosynthesis PE(18:1(11Z)/22:5(4Z,7Z,10Z,13Z,16Z))516
Phosphatidylethanolamine Biosynthesis PE(18:1(11Z)/22:5(7Z,10Z,13Z,16Z,19Z))516
Phosphatidylethanolamine Biosynthesis PE(18:1(11Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))516
Phosphatidylethanolamine Biosynthesis PE(18:1(11Z)/24:0)516
Phosphatidylethanolamine Biosynthesis PE(18:1(11Z)/24:1(15Z))516
Phosphatidylethanolamine Biosynthesis PE(18:1(9Z)/14:0)516
Phosphatidylethanolamine Biosynthesis PE(18:1(9Z)/14:1(9Z))516
Phosphatidylethanolamine Biosynthesis PE(18:1(9Z)/15:0)516
Phosphatidylethanolamine Biosynthesis PE(18:1(9Z)/16:0)516
Phosphatidylethanolamine Biosynthesis PE(18:1(9Z)/16:1(9Z))516
Phosphatidylethanolamine Biosynthesis PE(18:1(9Z)/18:0)516
Phosphatidylethanolamine Biosynthesis PE(18:1(9Z)/18:1(11Z))516
Phosphatidylethanolamine Biosynthesis PE(18:1(9Z)/18:1(9Z))516
Phosphatidylethanolamine Biosynthesis PE(18:1(9Z)/18:2(9Z,12Z))516
Phosphatidylethanolamine Biosynthesis PE(18:1(9Z)/18:3(6Z,9Z,12Z))516
Phosphatidylethanolamine Biosynthesis PE(18:1(9Z)/18:3(9Z,12Z,15Z))516
Phosphatidylethanolamine Biosynthesis PE(18:1(9Z)/18:4(6Z,9Z,12Z,15Z))516
Phosphatidylethanolamine Biosynthesis PE(18:1(9Z)/20:0)516
Phosphatidylethanolamine Biosynthesis PE(18:1(9Z)/20:1(11Z))516
Phosphatidylethanolamine Biosynthesis PE(18:1(9Z)/20:2(11Z,14Z))516
Phosphatidylethanolamine Biosynthesis PE(18:1(9Z)/20:3(5Z,8Z,11Z))516
Phosphatidylethanolamine Biosynthesis PE(18:1(9Z)/20:3(8Z,11Z,14Z))516
Phosphatidylethanolamine Biosynthesis PE(18:1(9Z)/20:4(5Z,8Z,11Z,14Z))516
Phosphatidylethanolamine Biosynthesis PE(18:1(9Z)/20:4(8Z,11Z,14Z,17Z))516
Phosphatidylethanolamine Biosynthesis PE(18:1(9Z)/20:5(5Z,8Z,11Z,14Z,17Z))516
Phosphatidylethanolamine Biosynthesis PE(18:1(9Z)/22:0)516
Phosphatidylethanolamine Biosynthesis PE(18:1(9Z)/22:1(13Z))516
Phosphatidylethanolamine Biosynthesis PE(18:1(9Z)/22:2(13Z,16Z))516
Phosphatidylethanolamine Biosynthesis PE(18:1(9Z)/22:4(7Z,10Z,13Z,16Z))516
Phosphatidylethanolamine Biosynthesis PE(18:1(9Z)/22:5(4Z,7Z,10Z,13Z,16Z))516
Phosphatidylethanolamine Biosynthesis PE(18:1(9Z)/22:5(7Z,10Z,13Z,16Z,19Z))516
Phosphatidylethanolamine Biosynthesis PE(18:1(9Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))516
Phosphatidylethanolamine Biosynthesis PE(18:1(9Z)/24:0)516
Phosphatidylethanolamine Biosynthesis PE(18:1(9Z)/24:1(15Z))516
Phosphatidylethanolamine Biosynthesis PE(18:2(9Z,12Z)/14:0)516
Phosphatidylethanolamine Biosynthesis PE(18:2(9Z,12Z)/14:1(9Z))516
Phosphatidylethanolamine Biosynthesis PE(18:2(9Z,12Z)/15:0)516
Phosphatidylethanolamine Biosynthesis PE(18:2(9Z,12Z)/16:0)516
Phosphatidylethanolamine Biosynthesis PE(18:2(9Z,12Z)/16:1(9Z))516
Phosphatidylethanolamine Biosynthesis PE(18:2(9Z,12Z)/18:0)516
Phosphatidylethanolamine Biosynthesis PE(18:2(9Z,12Z)/18:1(11Z))516
Phosphatidylethanolamine Biosynthesis PE(18:2(9Z,12Z)/18:1(9Z))516
Phosphatidylethanolamine Biosynthesis PE(18:2(9Z,12Z)/18:2(9Z,12Z))516
Phosphatidylethanolamine Biosynthesis PE(18:2(9Z,12Z)/18:3(6Z,9Z,12Z))516
Phosphatidylethanolamine Biosynthesis PE(18:2(9Z,12Z)/18:3(9Z,12Z,15Z))516
Phosphatidylethanolamine Biosynthesis PE(18:2(9Z,12Z)/18:4(6Z,9Z,12Z,15Z))516
Phosphatidylethanolamine Biosynthesis PE(18:2(9Z,12Z)/20:0)516
Phosphatidylethanolamine Biosynthesis PE(18:2(9Z,12Z)/20:1(11Z))516
Phosphatidylethanolamine Biosynthesis PE(18:2(9Z,12Z)/20:2(11Z,14Z))516
Phosphatidylethanolamine Biosynthesis PE(18:2(9Z,12Z)/20:3(5Z,8Z,11Z))516
Phosphatidylethanolamine Biosynthesis PE(18:2(9Z,12Z)/20:3(8Z,11Z,14Z))516
Phosphatidylethanolamine Biosynthesis PE(18:2(9Z,12Z)/20:4(5Z,8Z,11Z,14Z))516
Phosphatidylethanolamine Biosynthesis PE(18:2(9Z,12Z)/20:4(8Z,11Z,14Z,17Z))516
Phosphatidylethanolamine Biosynthesis PE(18:2(9Z,12Z)/20:5(5Z,8Z,11Z,14Z,17Z))516
Phosphatidylethanolamine Biosynthesis PE(18:2(9Z,12Z)/22:0)516
Phosphatidylethanolamine Biosynthesis PE(18:2(9Z,12Z)/22:1(13Z))516
Phosphatidylethanolamine Biosynthesis PE(18:2(9Z,12Z)/22:2(13Z,16Z))516
Phosphatidylethanolamine Biosynthesis PE(18:2(9Z,12Z)/22:4(7Z,10Z,13Z,16Z))516
Phosphatidylethanolamine Biosynthesis PE(18:2(9Z,12Z)/22:5(4Z,7Z,10Z,13Z,16Z))516
Phosphatidylethanolamine Biosynthesis PE(18:2(9Z,12Z)/22:5(7Z,10Z,13Z,16Z,19Z))516
Phosphatidylethanolamine Biosynthesis PE(18:2(9Z,12Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))516
Phosphatidylethanolamine Biosynthesis PE(18:2(9Z,12Z)/24:0)516
Phosphatidylethanolamine Biosynthesis PE(18:2(9Z,12Z)/24:1(15Z))516
Phosphatidylethanolamine Biosynthesis PE(18:3(6Z,9Z,12Z)/14:0)516
Phosphatidylethanolamine Biosynthesis PE(18:3(6Z,9Z,12Z)/14:1(9Z))516
Phosphatidylethanolamine Biosynthesis PE(18:3(6Z,9Z,12Z)/15:0)516
Phosphatidylethanolamine Biosynthesis PE(18:3(6Z,9Z,12Z)/16:0)516
Phosphatidylethanolamine Biosynthesis PE(18:3(6Z,9Z,12Z)/16:1(9Z))516
Phosphatidylethanolamine Biosynthesis PE(18:3(6Z,9Z,12Z)/18:0)516
Phosphatidylethanolamine Biosynthesis PE(18:3(6Z,9Z,12Z)/18:1(11Z))516
Phosphatidylethanolamine Biosynthesis PE(18:3(6Z,9Z,12Z)/18:1(9Z))516
Phosphatidylethanolamine Biosynthesis PE(18:3(6Z,9Z,12Z)/18:2(9Z,12Z))516
Phosphatidylethanolamine Biosynthesis PE(18:3(6Z,9Z,12Z)/18:3(6Z,9Z,12Z))516
Phosphatidylethanolamine Biosynthesis PE(18:3(6Z,9Z,12Z)/18:3(9Z,12Z,15Z))516
Phosphatidylethanolamine Biosynthesis PE(18:3(6Z,9Z,12Z)/18:4(6Z,9Z,12Z,15Z))516
Phosphatidylethanolamine Biosynthesis PE(18:3(6Z,9Z,12Z)/20:0)516
Phosphatidylethanolamine Biosynthesis PE(18:3(6Z,9Z,12Z)/20:1(11Z))516
Phosphatidylethanolamine Biosynthesis PE(18:3(6Z,9Z,12Z)/20:2(11Z,14Z))516
Phosphatidylethanolamine Biosynthesis PE(18:3(6Z,9Z,12Z)/20:3(5Z,8Z,11Z))516
Phosphatidylethanolamine Biosynthesis PE(18:3(6Z,9Z,12Z)/20:3(8Z,11Z,14Z))516
Phosphatidylethanolamine Biosynthesis PE(18:3(6Z,9Z,12Z)/20:4(5Z,8Z,11Z,14Z))516
Phosphatidylethanolamine Biosynthesis PE(18:3(6Z,9Z,12Z)/20:4(8Z,11Z,14Z,17Z))516
Phosphatidylethanolamine Biosynthesis PE(18:3(6Z,9Z,12Z)/20:5(5Z,8Z,11Z,14Z,17Z))516
Phosphatidylethanolamine Biosynthesis PE(18:3(6Z,9Z,12Z)/22:0)516
Phosphatidylethanolamine Biosynthesis PE(18:3(6Z,9Z,12Z)/22:1(13Z))516
Phosphatidylethanolamine Biosynthesis PE(18:3(6Z,9Z,12Z)/22:2(13Z,16Z))516
Phosphatidylethanolamine Biosynthesis PE(18:3(6Z,9Z,12Z)/22:4(7Z,10Z,13Z,16Z))516
Phosphatidylethanolamine Biosynthesis PE(18:3(6Z,9Z,12Z)/22:5(4Z,7Z,10Z,13Z,16Z))516
Phosphatidylethanolamine Biosynthesis PE(18:3(6Z,9Z,12Z)/22:5(7Z,10Z,13Z,16Z,19Z))516
Phosphatidylethanolamine Biosynthesis PE(18:3(6Z,9Z,12Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))516
Phosphatidylethanolamine Biosynthesis PE(18:3(6Z,9Z,12Z)/24:0)516
Phosphatidylethanolamine Biosynthesis PE(18:3(6Z,9Z,12Z)/24:1(15Z))516
Phosphatidylethanolamine Biosynthesis PE(18:3(9Z,12Z,15Z)/14:0)516
Phosphatidylethanolamine Biosynthesis PE(18:3(9Z,12Z,15Z)/14:1(9Z))516
Phosphatidylethanolamine Biosynthesis PE(18:3(9Z,12Z,15Z)/15:0)516
Phosphatidylethanolamine Biosynthesis PE(18:3(9Z,12Z,15Z)/16:0)516
Phosphatidylethanolamine Biosynthesis PE(18:3(9Z,12Z,15Z)/16:1(9Z))516
Phosphatidylethanolamine Biosynthesis PE(18:3(9Z,12Z,15Z)/18:0)516
Phosphatidylethanolamine Biosynthesis PE(18:3(9Z,12Z,15Z)/18:1(11Z))516
Phosphatidylethanolamine Biosynthesis PE(18:3(9Z,12Z,15Z)/18:1(9Z))516
Phosphatidylethanolamine Biosynthesis PE(18:3(9Z,12Z,15Z)/18:2(9Z,12Z))516
Phosphatidylethanolamine Biosynthesis PE(18:3(9Z,12Z,15Z)/18:3(6Z,9Z,12Z))516
Phosphatidylethanolamine Biosynthesis PE(18:3(9Z,12Z,15Z)/18:3(9Z,12Z,15Z))516
Phosphatidylethanolamine Biosynthesis PE(18:3(9Z,12Z,15Z)/18:4(6Z,9Z,12Z,15Z))516
Phosphatidylethanolamine Biosynthesis PE(18:3(9Z,12Z,15Z)/20:0)516
Phosphatidylethanolamine Biosynthesis PE(18:3(9Z,12Z,15Z)/20:1(11Z))516
Phosphatidylethanolamine Biosynthesis PE(18:3(9Z,12Z,15Z)/20:2(11Z,14Z))516
Phosphatidylethanolamine Biosynthesis PE(18:3(9Z,12Z,15Z)/20:3(5Z,8Z,11Z))516
Phosphatidylethanolamine Biosynthesis PE(18:3(9Z,12Z,15Z)/20:3(8Z,11Z,14Z))516
Phosphatidylethanolamine Biosynthesis PE(18:3(9Z,12Z,15Z)/20:4(5Z,8Z,11Z,14Z))516
Phosphatidylethanolamine Biosynthesis PE(18:3(9Z,12Z,15Z)/20:4(8Z,11Z,14Z,17Z))516
Phosphatidylethanolamine Biosynthesis PE(18:3(9Z,12Z,15Z)/20:5(5Z,8Z,11Z,14Z,17Z))516
Phosphatidylethanolamine Biosynthesis PE(18:3(9Z,12Z,15Z)/22:0)516
Phosphatidylethanolamine Biosynthesis PE(18:3(9Z,12Z,15Z)/22:1(13Z))516
Phosphatidylethanolamine Biosynthesis PE(18:3(9Z,12Z,15Z)/22:2(13Z,16Z))516
Phosphatidylethanolamine Biosynthesis PE(18:3(9Z,12Z,15Z)/22:4(7Z,10Z,13Z,16Z))516
Phosphatidylethanolamine Biosynthesis PE(18:3(9Z,12Z,15Z)/22:5(4Z,7Z,10Z,13Z,16Z))516
Phosphatidylethanolamine Biosynthesis PE(18:3(9Z,12Z,15Z)/22:5(7Z,10Z,13Z,16Z,19Z))516
Phosphatidylethanolamine Biosynthesis PE(18:3(9Z,12Z,15Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))516
Phosphatidylethanolamine Biosynthesis PE(18:3(9Z,12Z,15Z)/24:0)516
Phosphatidylethanolamine Biosynthesis PE(18:3(9Z,12Z,15Z)/24:1(15Z))516
Phosphatidylethanolamine Biosynthesis PE(18:4(6Z,9Z,12Z,15Z)/14:0)516
Phosphatidylethanolamine Biosynthesis PE(18:4(6Z,9Z,12Z,15Z)/14:1(9Z))516
Phosphatidylethanolamine Biosynthesis PE(18:4(6Z,9Z,12Z,15Z)/15:0)516
Phosphatidylethanolamine Biosynthesis PE(18:4(6Z,9Z,12Z,15Z)/16:0)516
Phosphatidylethanolamine Biosynthesis PE(18:4(6Z,9Z,12Z,15Z)/16:1(9Z))516
Phosphatidylethanolamine Biosynthesis PE(18:4(6Z,9Z,12Z,15Z)/18:0)516
Phosphatidylethanolamine Biosynthesis PE(18:4(6Z,9Z,12Z,15Z)/18:1(11Z))516
Phosphatidylethanolamine Biosynthesis PE(18:4(6Z,9Z,12Z,15Z)/18:1(9Z))516
Phosphatidylethanolamine Biosynthesis PE(18:4(6Z,9Z,12Z,15Z)/18:2(9Z,12Z))516
Phosphatidylethanolamine Biosynthesis PE(18:4(6Z,9Z,12Z,15Z)/18:3(6Z,9Z,12Z))516
Phosphatidylethanolamine Biosynthesis PE(18:4(6Z,9Z,12Z,15Z)/18:3(9Z,12Z,15Z))516
Phosphatidylethanolamine Biosynthesis PE(18:4(6Z,9Z,12Z,15Z)/18:4(6Z,9Z,12Z,15Z))516
Phosphatidylethanolamine Biosynthesis PE(18:4(6Z,9Z,12Z,15Z)/20:0)516
Phosphatidylethanolamine Biosynthesis PE(18:4(6Z,9Z,12Z,15Z)/20:1(11Z))516
Phosphatidylethanolamine Biosynthesis PE(18:4(6Z,9Z,12Z,15Z)/20:2(11Z,14Z))516
Phosphatidylethanolamine Biosynthesis PE(18:4(6Z,9Z,12Z,15Z)/20:3(5Z,8Z,11Z))516
Phosphatidylethanolamine Biosynthesis PE(18:4(6Z,9Z,12Z,15Z)/20:3(8Z,11Z,14Z))516
Phosphatidylethanolamine Biosynthesis PE(18:4(6Z,9Z,12Z,15Z)/20:4(5Z,8Z,11Z,14Z))516
Phosphatidylethanolamine Biosynthesis PE(18:4(6Z,9Z,12Z,15Z)/20:4(8Z,11Z,14Z,17Z))516
Phosphatidylethanolamine Biosynthesis PE(18:4(6Z,9Z,12Z,15Z)/20:5(5Z,8Z,11Z,14Z,17Z))516
Phosphatidylethanolamine Biosynthesis PE(18:4(6Z,9Z,12Z,15Z)/22:0)516
Phosphatidylethanolamine Biosynthesis PE(18:4(6Z,9Z,12Z,15Z)/22:1(13Z))516
Phosphatidylethanolamine Biosynthesis PE(18:4(6Z,9Z,12Z,15Z)/22:2(13Z,16Z))516
Phosphatidylethanolamine Biosynthesis PE(18:4(6Z,9Z,12Z,15Z)/22:4(7Z,10Z,13Z,16Z))516
Phosphatidylethanolamine Biosynthesis PE(18:4(6Z,9Z,12Z,15Z)/22:5(4Z,7Z,10Z,13Z,16Z))516
Phosphatidylethanolamine Biosynthesis PE(18:4(6Z,9Z,12Z,15Z)/22:5(7Z,10Z,13Z,16Z,19Z))516
Phosphatidylethanolamine Biosynthesis PE(18:4(6Z,9Z,12Z,15Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))516
Phosphatidylethanolamine Biosynthesis PE(18:4(6Z,9Z,12Z,15Z)/24:0)516
Phosphatidylethanolamine Biosynthesis PE(18:4(6Z,9Z,12Z,15Z)/24:1(15Z))516
Phosphatidylethanolamine Biosynthesis PE(20:0/14:0)516
Phosphatidylethanolamine Biosynthesis PE(20:0/14:1(9Z))516
Phosphatidylethanolamine Biosynthesis PE(20:0/15:0)516
Phosphatidylethanolamine Biosynthesis PE(20:0/16:0)516
Phosphatidylethanolamine Biosynthesis PE(20:0/16:1(9Z))516
Phosphatidylethanolamine Biosynthesis PE(20:0/18:0)516
Phosphatidylethanolamine Biosynthesis PE(20:0/18:1(11Z))516
Phosphatidylethanolamine Biosynthesis PE(20:0/18:1(9Z))516
Phosphatidylethanolamine Biosynthesis PE(20:0/18:2(9Z,12Z))516
Phosphatidylethanolamine Biosynthesis PE(20:0/18:3(6Z,9Z,12Z))516
Phosphatidylethanolamine Biosynthesis PE(20:0/18:3(9Z,12Z,15Z))516
Phosphatidylethanolamine Biosynthesis PE(20:0/18:4(6Z,9Z,12Z,15Z))516
Phosphatidylethanolamine Biosynthesis PE(20:0/20:0)516
Phosphatidylethanolamine Biosynthesis PE(20:0/20:1(11Z))516
Phosphatidylethanolamine Biosynthesis PE(20:0/20:2(11Z,14Z))516
Phosphatidylethanolamine Biosynthesis PE(20:0/20:3(5Z,8Z,11Z))516
Phosphatidylethanolamine Biosynthesis PE(20:0/20:3(8Z,11Z,14Z))516
Phosphatidylethanolamine Biosynthesis PE(20:0/20:4(5Z,8Z,11Z,14Z))516
Phosphatidylethanolamine Biosynthesis PE(20:0/20:4(8Z,11Z,14Z,17Z))516
Phosphatidylethanolamine Biosynthesis PE(20:0/20:5(5Z,8Z,11Z,14Z,17Z))516
Phosphatidylethanolamine Biosynthesis PE(20:0/22:0)516
Phosphatidylethanolamine Biosynthesis PE(20:0/22:1(13Z))516
Phosphatidylethanolamine Biosynthesis PE(20:0/22:2(13Z,16Z))516
Phosphatidylethanolamine Biosynthesis PE(20:0/22:4(7Z,10Z,13Z,16Z))516
Phosphatidylethanolamine Biosynthesis PE(20:0/22:5(4Z,7Z,10Z,13Z,16Z))516
Phosphatidylethanolamine Biosynthesis PE(20:0/22:5(7Z,10Z,13Z,16Z,19Z))516
Phosphatidylethanolamine Biosynthesis PE(20:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))516
Phosphatidylethanolamine Biosynthesis PE(20:0/24:0)516
Phosphatidylethanolamine Biosynthesis PE(20:0/24:1(15Z))516
Phosphatidylethanolamine Biosynthesis PE(20:1(11Z)/14:0)516
Phosphatidylethanolamine Biosynthesis PE(20:1(11Z)/14:1(9Z))516
Phosphatidylethanolamine Biosynthesis PE(20:1(11Z)/15:0)516
Phosphatidylethanolamine Biosynthesis PE(20:1(11Z)/16:0)516
Phosphatidylethanolamine Biosynthesis PE(20:1(11Z)/16:1(9Z))516
Phosphatidylethanolamine Biosynthesis PE(20:1(11Z)/18:0)516
Phosphatidylethanolamine Biosynthesis PE(20:1(11Z)/18:1(11Z))516
Phosphatidylethanolamine Biosynthesis PE(20:1(11Z)/18:1(9Z))516
Phosphatidylethanolamine Biosynthesis PE(20:1(11Z)/18:2(9Z,12Z))516
Phosphatidylethanolamine Biosynthesis PE(20:1(11Z)/18:3(6Z,9Z,12Z))516
Phosphatidylethanolamine Biosynthesis PE(20:1(11Z)/18:3(9Z,12Z,15Z))516
Phosphatidylethanolamine Biosynthesis PE(20:1(11Z)/18:4(6Z,9Z,12Z,15Z))516
Phosphatidylethanolamine Biosynthesis PE(20:1(11Z)/20:0)516
Phosphatidylethanolamine Biosynthesis PE(20:1(11Z)/20:1(11Z))516
Phosphatidylethanolamine Biosynthesis PE(20:1(11Z)/20:2(11Z,14Z))516
Phosphatidylethanolamine Biosynthesis PE(20:1(11Z)/20:3(5Z,8Z,11Z))516
Phosphatidylethanolamine Biosynthesis PE(20:1(11Z)/20:3(8Z,11Z,14Z))516
Phosphatidylethanolamine Biosynthesis PE(20:1(11Z)/20:4(5Z,8Z,11Z,14Z))516
Phosphatidylethanolamine Biosynthesis PE(20:1(11Z)/20:4(8Z,11Z,14Z,17Z))516
Phosphatidylethanolamine Biosynthesis PE(20:1(11Z)/20:5(5Z,8Z,11Z,14Z,17Z))516
Phosphatidylethanolamine Biosynthesis PE(20:1(11Z)/22:0)516
Phosphatidylethanolamine Biosynthesis PE(20:1(11Z)/22:1(13Z))516
Phosphatidylethanolamine Biosynthesis PE(20:1(11Z)/22:2(13Z,16Z))516
Phosphatidylethanolamine Biosynthesis PE(20:1(11Z)/22:4(7Z,10Z,13Z,16Z))516
Phosphatidylethanolamine Biosynthesis PE(20:1(11Z)/22:5(4Z,7Z,10Z,13Z,16Z))516
Phosphatidylethanolamine Biosynthesis PE(20:1(11Z)/22:5(7Z,10Z,13Z,16Z,19Z))516
Phosphatidylethanolamine Biosynthesis PE(20:1(11Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))516
Phosphatidylethanolamine Biosynthesis PE(20:1(11Z)/24:0)516
Phosphatidylethanolamine Biosynthesis PE(20:1(11Z)/24:1(15Z))516
Phosphatidylethanolamine Biosynthesis PE(20:2(11Z,14Z)/14:0)516
Phosphatidylethanolamine Biosynthesis PE(20:2(11Z,14Z)/14:1(9Z))516
Phosphatidylethanolamine Biosynthesis PE(20:2(11Z,14Z)/15:0)516
Phosphatidylethanolamine Biosynthesis PE(20:2(11Z,14Z)/16:0)516
Phosphatidylethanolamine Biosynthesis PE(20:2(11Z,14Z)/16:1(9Z))516
Phosphatidylethanolamine Biosynthesis PE(20:2(11Z,14Z)/18:0)516
Phosphatidylethanolamine Biosynthesis PE(20:2(11Z,14Z)/18:1(11Z))516
Phosphatidylethanolamine Biosynthesis PE(20:2(11Z,14Z)/18:1(9Z))516
Phosphatidylethanolamine Biosynthesis PE(20:2(11Z,14Z)/18:2(9Z,12Z))516
Phosphatidylethanolamine Biosynthesis PE(20:2(11Z,14Z)/18:3(6Z,9Z,12Z))516
Phosphatidylethanolamine Biosynthesis PE(20:2(11Z,14Z)/18:3(9Z,12Z,15Z))516
Phosphatidylethanolamine Biosynthesis PE(20:2(11Z,14Z)/18:4(6Z,9Z,12Z,15Z))516
Phosphatidylethanolamine Biosynthesis PE(20:2(11Z,14Z)/20:0)516
Phosphatidylethanolamine Biosynthesis PE(20:2(11Z,14Z)/20:1(11Z))516
Phosphatidylethanolamine Biosynthesis PE(20:2(11Z,14Z)/20:2(11Z,14Z))516
Phosphatidylethanolamine Biosynthesis PE(20:2(11Z,14Z)/20:3(5Z,8Z,11Z))516
Phosphatidylethanolamine Biosynthesis PE(20:2(11Z,14Z)/20:3(8Z,11Z,14Z))516
Phosphatidylethanolamine Biosynthesis PE(20:2(11Z,14Z)/20:4(5Z,8Z,11Z,14Z))516
Phosphatidylethanolamine Biosynthesis PE(20:2(11Z,14Z)/20:4(8Z,11Z,14Z,17Z))516
Phosphatidylethanolamine Biosynthesis PE(20:2(11Z,14Z)/20:5(5Z,8Z,11Z,14Z,17Z))516
Phosphatidylethanolamine Biosynthesis PE(20:2(11Z,14Z)/22:0)516
Phosphatidylethanolamine Biosynthesis PE(20:2(11Z,14Z)/22:1(13Z))516
Phosphatidylethanolamine Biosynthesis PE(20:2(11Z,14Z)/22:2(13Z,16Z))516
Phosphatidylethanolamine Biosynthesis PE(20:2(11Z,14Z)/22:4(7Z,10Z,13Z,16Z))516
Phosphatidylethanolamine Biosynthesis PE(20:2(11Z,14Z)/22:5(4Z,7Z,10Z,13Z,16Z))516
Phosphatidylethanolamine Biosynthesis PE(20:2(11Z,14Z)/22:5(7Z,10Z,13Z,16Z,19Z))516
Phosphatidylethanolamine Biosynthesis PE(20:2(11Z,14Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))516
Phosphatidylethanolamine Biosynthesis PE(20:2(11Z,14Z)/24:0)516
Phosphatidylethanolamine Biosynthesis PE(20:2(11Z,14Z)/24:1(15Z))516
Phosphatidylethanolamine Biosynthesis PE(20:3(5Z,8Z,11Z)/14:0)516
Phosphatidylethanolamine Biosynthesis PE(20:3(5Z,8Z,11Z)/14:1(9Z))516
Phosphatidylethanolamine Biosynthesis PE(20:3(5Z,8Z,11Z)/15:0)516
Phosphatidylethanolamine Biosynthesis PE(20:3(5Z,8Z,11Z)/16:0)516
Phosphatidylethanolamine Biosynthesis PE(20:3(5Z,8Z,11Z)/16:1(9Z))516
Phosphatidylethanolamine Biosynthesis PE(20:3(5Z,8Z,11Z)/18:0)516
Phosphatidylethanolamine Biosynthesis PE(20:3(5Z,8Z,11Z)/18:1(11Z))516
Phosphatidylethanolamine Biosynthesis PE(20:3(5Z,8Z,11Z)/18:1(9Z))516
Phosphatidylethanolamine Biosynthesis PE(20:3(5Z,8Z,11Z)/18:2(9Z,12Z))516
Phosphatidylethanolamine Biosynthesis PE(20:3(5Z,8Z,11Z)/18:3(6Z,9Z,12Z))516
Phosphatidylethanolamine Biosynthesis PE(20:3(5Z,8Z,11Z)/18:3(9Z,12Z,15Z))516
Phosphatidylethanolamine Biosynthesis PE(20:3(5Z,8Z,11Z)/18:4(6Z,9Z,12Z,15Z))516
Phosphatidylethanolamine Biosynthesis PE(20:3(5Z,8Z,11Z)/20:0)516
Phosphatidylethanolamine Biosynthesis PE(20:3(5Z,8Z,11Z)/20:1(11Z))516
Phosphatidylethanolamine Biosynthesis PE(20:3(5Z,8Z,11Z)/20:2(11Z,14Z))516
Phosphatidylethanolamine Biosynthesis PE(20:3(5Z,8Z,11Z)/20:3(5Z,8Z,11Z))516
Phosphatidylethanolamine Biosynthesis PE(20:3(5Z,8Z,11Z)/20:3(8Z,11Z,14Z))516
Phosphatidylethanolamine Biosynthesis PE(20:3(5Z,8Z,11Z)/20:4(5Z,8Z,11Z,14Z))516
Phosphatidylethanolamine Biosynthesis PE(20:3(5Z,8Z,11Z)/20:4(8Z,11Z,14Z,17Z))516
Phosphatidylethanolamine Biosynthesis PE(20:3(5Z,8Z,11Z)/20:5(5Z,8Z,11Z,14Z,17Z))516
Phosphatidylethanolamine Biosynthesis PE(20:3(5Z,8Z,11Z)/22:0)516
Phosphatidylethanolamine Biosynthesis PE(20:3(5Z,8Z,11Z)/22:1(13Z))516
Phosphatidylethanolamine Biosynthesis PE(20:3(5Z,8Z,11Z)/22:2(13Z,16Z))516
Phosphatidylethanolamine Biosynthesis PE(20:3(5Z,8Z,11Z)/22:4(7Z,10Z,13Z,16Z))516
Phosphatidylethanolamine Biosynthesis PE(20:3(5Z,8Z,11Z)/22:5(4Z,7Z,10Z,13Z,16Z))516
Phosphatidylethanolamine Biosynthesis PE(20:3(5Z,8Z,11Z)/22:5(7Z,10Z,13Z,16Z,19Z))516
Phosphatidylethanolamine Biosynthesis PE(20:3(5Z,8Z,11Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))516
Phosphatidylethanolamine Biosynthesis PE(20:3(5Z,8Z,11Z)/24:0)516
Phosphatidylethanolamine Biosynthesis PE(20:3(5Z,8Z,11Z)/24:1(15Z))516
Phosphatidylethanolamine Biosynthesis PE(20:3(8Z,11Z,14Z)/14:0)516
Phosphatidylethanolamine Biosynthesis PE(20:3(8Z,11Z,14Z)/14:1(9Z))516
Phosphatidylethanolamine Biosynthesis PE(20:3(8Z,11Z,14Z)/15:0)516
Phosphatidylethanolamine Biosynthesis PE(20:3(8Z,11Z,14Z)/16:0)516
Phosphatidylethanolamine Biosynthesis PE(20:3(8Z,11Z,14Z)/16:1(9Z))516
Phosphatidylethanolamine Biosynthesis PE(20:3(8Z,11Z,14Z)/18:0)516
Phosphatidylethanolamine Biosynthesis PE(20:3(8Z,11Z,14Z)/18:1(11Z))516
Phosphatidylethanolamine Biosynthesis PE(20:3(8Z,11Z,14Z)/18:1(9Z))516
Phosphatidylethanolamine Biosynthesis PE(20:3(8Z,11Z,14Z)/18:2(9Z,12Z))516
Phosphatidylethanolamine Biosynthesis PE(20:3(8Z,11Z,14Z)/18:3(6Z,9Z,12Z))516
Phosphatidylethanolamine Biosynthesis PE(20:3(8Z,11Z,14Z)/18:3(9Z,12Z,15Z))516
Phosphatidylethanolamine Biosynthesis PE(20:3(8Z,11Z,14Z)/18:4(6Z,9Z,12Z,15Z))516
Phosphatidylethanolamine Biosynthesis PE(20:3(8Z,11Z,14Z)/20:0)516
Phosphatidylethanolamine Biosynthesis PE(20:3(8Z,11Z,14Z)/20:1(11Z))516
Phosphatidylethanolamine Biosynthesis PE(20:3(8Z,11Z,14Z)/20:2(11Z,14Z))516
Phosphatidylethanolamine Biosynthesis PE(20:3(8Z,11Z,14Z)/20:3(5Z,8Z,11Z))516
Phosphatidylethanolamine Biosynthesis PE(20:3(8Z,11Z,14Z)/20:3(8Z,11Z,14Z))516
Phosphatidylethanolamine Biosynthesis PE(20:3(8Z,11Z,14Z)/20:4(5Z,8Z,11Z,14Z))516
Phosphatidylethanolamine Biosynthesis PE(20:3(8Z,11Z,14Z)/20:4(8Z,11Z,14Z,17Z))516
Phosphatidylethanolamine Biosynthesis PE(20:3(8Z,11Z,14Z)/20:5(5Z,8Z,11Z,14Z,17Z))516
Phosphatidylethanolamine Biosynthesis PE(20:3(8Z,11Z,14Z)/22:0)516
Phosphatidylethanolamine Biosynthesis PE(20:3(8Z,11Z,14Z)/22:1(13Z))516
Phosphatidylethanolamine Biosynthesis PE(20:3(8Z,11Z,14Z)/22:2(13Z,16Z))516
Phosphatidylethanolamine Biosynthesis PE(20:3(8Z,11Z,14Z)/22:4(7Z,10Z,13Z,16Z))516
Phosphatidylethanolamine Biosynthesis PE(20:3(8Z,11Z,14Z)/22:5(4Z,7Z,10Z,13Z,16Z))516
Phosphatidylethanolamine Biosynthesis PE(20:3(8Z,11Z,14Z)/22:5(7Z,10Z,13Z,16Z,19Z))516
Phosphatidylethanolamine Biosynthesis PE(20:3(8Z,11Z,14Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))516
Phosphatidylethanolamine Biosynthesis PE(20:3(8Z,11Z,14Z)/24:0)516
Phosphatidylethanolamine Biosynthesis PE(20:3(8Z,11Z,14Z)/24:1(15Z))516
Phosphatidylethanolamine Biosynthesis PE(20:4(5Z,8Z,11Z,14Z)/14:0)516
Phosphatidylethanolamine Biosynthesis PE(20:4(5Z,8Z,11Z,14Z)/14:1(9Z))516
Phosphatidylethanolamine Biosynthesis PE(20:4(5Z,8Z,11Z,14Z)/15:0)516
Phosphatidylethanolamine Biosynthesis PE(20:4(5Z,8Z,11Z,14Z)/16:0)516
Phosphatidylethanolamine Biosynthesis PE(20:4(5Z,8Z,11Z,14Z)/16:1(9Z))516
Phosphatidylethanolamine Biosynthesis PE(20:4(5Z,8Z,11Z,14Z)/18:0)516
Phosphatidylethanolamine Biosynthesis PE(20:4(5Z,8Z,11Z,14Z)/18:1(11Z))516
Phosphatidylethanolamine Biosynthesis PE(20:4(5Z,8Z,11Z,14Z)/18:1(9Z))516
Phosphatidylethanolamine Biosynthesis PE(20:4(5Z,8Z,11Z,14Z)/18:2(9Z,12Z))516
Phosphatidylethanolamine Biosynthesis PE(20:4(5Z,8Z,11Z,14Z)/18:3(6Z,9Z,12Z))516
Phosphatidylethanolamine Biosynthesis PE(20:4(5Z,8Z,11Z,14Z)/18:3(9Z,12Z,15Z))516
Phosphatidylethanolamine Biosynthesis PE(20:4(5Z,8Z,11Z,14Z)/18:4(6Z,9Z,12Z,15Z))516
Phosphatidylethanolamine Biosynthesis PE(20:4(5Z,8Z,11Z,14Z)/20:0)516
Phosphatidylethanolamine Biosynthesis PE(20:4(5Z,8Z,11Z,14Z)/20:1(11Z))516
Phosphatidylethanolamine Biosynthesis PE(20:4(5Z,8Z,11Z,14Z)/20:2(11Z,14Z))516
Phosphatidylethanolamine Biosynthesis PE(20:4(5Z,8Z,11Z,14Z)/20:3(5Z,8Z,11Z))516
Phosphatidylethanolamine Biosynthesis PE(20:4(5Z,8Z,11Z,14Z)/20:3(8Z,11Z,14Z))516
Phosphatidylethanolamine Biosynthesis PE(20:4(5Z,8Z,11Z,14Z)/20:4(5Z,8Z,11Z,14Z))516
Phosphatidylethanolamine Biosynthesis PE(20:4(5Z,8Z,11Z,14Z)/20:4(8Z,11Z,14Z,17Z))516
Phosphatidylethanolamine Biosynthesis PE(20:4(5Z,8Z,11Z,14Z)/20:5(5Z,8Z,11Z,14Z,17Z))516
Phosphatidylethanolamine Biosynthesis PE(20:4(5Z,8Z,11Z,14Z)/22:0)516
Phosphatidylethanolamine Biosynthesis PE(20:4(5Z,8Z,11Z,14Z)/22:1(13Z))516
Phosphatidylethanolamine Biosynthesis PE(20:4(5Z,8Z,11Z,14Z)/22:2(13Z,16Z))516
Phosphatidylethanolamine Biosynthesis PE(20:4(5Z,8Z,11Z,14Z)/22:4(7Z,10Z,13Z,16Z))516
Phosphatidylethanolamine Biosynthesis PE(20:4(5Z,8Z,11Z,14Z)/22:5(4Z,7Z,10Z,13Z,16Z))516
Phosphatidylethanolamine Biosynthesis PE(20:4(5Z,8Z,11Z,14Z)/22:5(7Z,10Z,13Z,16Z,19Z))516
Phosphatidylethanolamine Biosynthesis PE(20:4(5Z,8Z,11Z,14Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))516
Phosphatidylethanolamine Biosynthesis PE(20:4(5Z,8Z,11Z,14Z)/24:0)516
Phosphatidylethanolamine Biosynthesis PE(20:4(5Z,8Z,11Z,14Z)/24:1(15Z))516
Phosphatidylethanolamine Biosynthesis PE(20:4(8Z,11Z,14Z,17Z)/14:0)516
Phosphatidylethanolamine Biosynthesis PE(20:4(8Z,11Z,14Z,17Z)/14:1(9Z))516
Phosphatidylethanolamine Biosynthesis PE(20:4(8Z,11Z,14Z,17Z)/15:0)516
Phosphatidylethanolamine Biosynthesis PE(20:4(8Z,11Z,14Z,17Z)/16:0)516
Phosphatidylethanolamine Biosynthesis PE(20:4(8Z,11Z,14Z,17Z)/16:1(9Z))516
Phosphatidylethanolamine Biosynthesis PE(20:4(8Z,11Z,14Z,17Z)/18:0)516
Phosphatidylethanolamine Biosynthesis PE(20:4(8Z,11Z,14Z,17Z)/18:1(11Z))516
Phosphatidylethanolamine Biosynthesis PE(20:4(8Z,11Z,14Z,17Z)/18:1(9Z))516
Phosphatidylethanolamine Biosynthesis PE(20:4(8Z,11Z,14Z,17Z)/18:2(9Z,12Z))516
Phosphatidylethanolamine Biosynthesis PE(20:4(8Z,11Z,14Z,17Z)/18:3(6Z,9Z,12Z))516
Phosphatidylethanolamine Biosynthesis PE(20:4(8Z,11Z,14Z,17Z)/18:3(9Z,12Z,15Z))516
Phosphatidylethanolamine Biosynthesis PE(20:4(8Z,11Z,14Z,17Z)/18:4(6Z,9Z,12Z,15Z))516
Phosphatidylethanolamine Biosynthesis PE(20:4(8Z,11Z,14Z,17Z)/20:0)516
Phosphatidylethanolamine Biosynthesis PE(20:4(8Z,11Z,14Z,17Z)/20:1(11Z))516
Phosphatidylethanolamine Biosynthesis PE(20:4(8Z,11Z,14Z,17Z)/20:2(11Z,14Z))516
Phosphatidylethanolamine Biosynthesis PE(20:4(8Z,11Z,14Z,17Z)/20:3(5Z,8Z,11Z))516
Phosphatidylethanolamine Biosynthesis PE(20:4(8Z,11Z,14Z,17Z)/20:3(8Z,11Z,14Z))516
Phosphatidylethanolamine Biosynthesis PE(20:4(8Z,11Z,14Z,17Z)/20:4(5Z,8Z,11Z,14Z))516
Phosphatidylethanolamine Biosynthesis PE(20:4(8Z,11Z,14Z,17Z)/20:4(8Z,11Z,14Z,17Z))516
Phosphatidylethanolamine Biosynthesis PE(20:4(8Z,11Z,14Z,17Z)/20:5(5Z,8Z,11Z,14Z,17Z))516
Phosphatidylethanolamine Biosynthesis PE(20:4(8Z,11Z,14Z,17Z)/22:0)516
Phosphatidylethanolamine Biosynthesis PE(20:4(8Z,11Z,14Z,17Z)/22:1(13Z))516
Phosphatidylethanolamine Biosynthesis PE(20:4(8Z,11Z,14Z,17Z)/22:2(13Z,16Z))516
Phosphatidylethanolamine Biosynthesis PE(20:4(8Z,11Z,14Z,17Z)/22:4(7Z,10Z,13Z,16Z))516
Phosphatidylethanolamine Biosynthesis PE(20:4(8Z,11Z,14Z,17Z)/22:5(4Z,7Z,10Z,13Z,16Z))516
Phosphatidylethanolamine Biosynthesis PE(20:4(8Z,11Z,14Z,17Z)/22:5(7Z,10Z,13Z,16Z,19Z))516
Phosphatidylethanolamine Biosynthesis PE(20:4(8Z,11Z,14Z,17Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))516
Phosphatidylethanolamine Biosynthesis PE(20:4(8Z,11Z,14Z,17Z)/24:0)516
Phosphatidylethanolamine Biosynthesis PE(20:4(8Z,11Z,14Z,17Z)/24:1(15Z))516
Phosphatidylethanolamine Biosynthesis PE(20:5(5Z,8Z,11Z,14Z,17Z)/14:0)516
Phosphatidylethanolamine Biosynthesis PE(20:5(5Z,8Z,11Z,14Z,17Z)/14:1(9Z))516
Phosphatidylethanolamine Biosynthesis PE(20:5(5Z,8Z,11Z,14Z,17Z)/15:0)516
Phosphatidylethanolamine Biosynthesis PE(20:5(5Z,8Z,11Z,14Z,17Z)/16:0)516
Phosphatidylethanolamine Biosynthesis PE(20:5(5Z,8Z,11Z,14Z,17Z)/16:1(9Z))516
Phosphatidylethanolamine Biosynthesis PE(20:5(5Z,8Z,11Z,14Z,17Z)/18:0)516
Phosphatidylethanolamine Biosynthesis PE(20:5(5Z,8Z,11Z,14Z,17Z)/18:1(11Z))516
Phosphatidylethanolamine Biosynthesis PE(20:5(5Z,8Z,11Z,14Z,17Z)/18:1(9Z))516
Phosphatidylethanolamine Biosynthesis PE(20:5(5Z,8Z,11Z,14Z,17Z)/18:2(9Z,12Z))516
Phosphatidylethanolamine Biosynthesis PE(20:5(5Z,8Z,11Z,14Z,17Z)/18:3(6Z,9Z,12Z))516
Phosphatidylethanolamine Biosynthesis PE(20:5(5Z,8Z,11Z,14Z,17Z)/18:3(9Z,12Z,15Z))516
Phosphatidylethanolamine Biosynthesis PE(20:5(5Z,8Z,11Z,14Z,17Z)/18:4(6Z,9Z,12Z,15Z))516
Phosphatidylethanolamine Biosynthesis PE(20:5(5Z,8Z,11Z,14Z,17Z)/20:0)516
Phosphatidylethanolamine Biosynthesis PE(20:5(5Z,8Z,11Z,14Z,17Z)/20:1(11Z))516
Phosphatidylethanolamine Biosynthesis PE(20:5(5Z,8Z,11Z,14Z,17Z)/20:2(11Z,14Z))516
Phosphatidylethanolamine Biosynthesis PE(20:5(5Z,8Z,11Z,14Z,17Z)/20:3(5Z,8Z,11Z))516
Phosphatidylethanolamine Biosynthesis PE(20:5(5Z,8Z,11Z,14Z,17Z)/20:3(8Z,11Z,14Z))516
Phosphatidylethanolamine Biosynthesis PE(20:5(5Z,8Z,11Z,14Z,17Z)/20:4(5Z,8Z,11Z,14Z))516
Phosphatidylethanolamine Biosynthesis PE(20:5(5Z,8Z,11Z,14Z,17Z)/20:4(8Z,11Z,14Z,17Z))516
Phosphatidylethanolamine Biosynthesis PE(20:5(5Z,8Z,11Z,14Z,17Z)/20:5(5Z,8Z,11Z,14Z,17Z))516
Phosphatidylethanolamine Biosynthesis PE(20:5(5Z,8Z,11Z,14Z,17Z)/22:0)516
Phosphatidylethanolamine Biosynthesis PE(20:5(5Z,8Z,11Z,14Z,17Z)/22:1(13Z))516
Phosphatidylethanolamine Biosynthesis PE(20:5(5Z,8Z,11Z,14Z,17Z)/22:2(13Z,16Z))516
Phosphatidylethanolamine Biosynthesis PE(20:5(5Z,8Z,11Z,14Z,17Z)/22:4(7Z,10Z,13Z,16Z))516
Phosphatidylethanolamine Biosynthesis PE(20:5(5Z,8Z,11Z,14Z,17Z)/22:5(4Z,7Z,10Z,13Z,16Z))516
Phosphatidylethanolamine Biosynthesis PE(20:5(5Z,8Z,11Z,14Z,17Z)/22:5(7Z,10Z,13Z,16Z,19Z))516
Phosphatidylethanolamine Biosynthesis PE(20:5(5Z,8Z,11Z,14Z,17Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))516
Phosphatidylethanolamine Biosynthesis PE(20:5(5Z,8Z,11Z,14Z,17Z)/24:0)516
Phosphatidylethanolamine Biosynthesis PE(20:5(5Z,8Z,11Z,14Z,17Z)/24:1(15Z))516
Phosphatidylethanolamine Biosynthesis PE(22:0/14:0)516
Phosphatidylethanolamine Biosynthesis PE(22:0/14:1(9Z))516
Phosphatidylethanolamine Biosynthesis PE(22:0/15:0)516
Phosphatidylethanolamine Biosynthesis PE(22:0/16:0)516
Phosphatidylethanolamine Biosynthesis PE(22:0/16:1(9Z))516
Phosphatidylethanolamine Biosynthesis PE(22:0/18:0)516
Phosphatidylethanolamine Biosynthesis PE(22:0/18:1(11Z))516
Phosphatidylethanolamine Biosynthesis PE(22:0/18:1(9Z))516
Phosphatidylethanolamine Biosynthesis PE(22:0/18:2(9Z,12Z))516
Phosphatidylethanolamine Biosynthesis PE(22:0/18:3(6Z,9Z,12Z))516
Phosphatidylethanolamine Biosynthesis PE(22:0/18:3(9Z,12Z,15Z))516
Phosphatidylethanolamine Biosynthesis PE(22:0/18:4(6Z,9Z,12Z,15Z))516
Phosphatidylethanolamine Biosynthesis PE(22:0/20:0)516
Phosphatidylethanolamine Biosynthesis PE(22:0/20:1(11Z))516
Phosphatidylethanolamine Biosynthesis PE(22:0/20:2(11Z,14Z))516
Phosphatidylethanolamine Biosynthesis PE(22:0/20:3(5Z,8Z,11Z))516
Phosphatidylethanolamine Biosynthesis PE(22:0/20:3(8Z,11Z,14Z))516
Phosphatidylethanolamine Biosynthesis PE(22:0/20:4(5Z,8Z,11Z,14Z))516
Phosphatidylethanolamine Biosynthesis PE(22:0/20:4(8Z,11Z,14Z,17Z))516
Phosphatidylethanolamine Biosynthesis PE(22:0/20:5(5Z,8Z,11Z,14Z,17Z))516
Phosphatidylethanolamine Biosynthesis PE(22:0/22:0)516
Phosphatidylethanolamine Biosynthesis PE(22:0/22:1(13Z))516
Phosphatidylethanolamine Biosynthesis PE(22:0/22:2(13Z,16Z))516
Phosphatidylethanolamine Biosynthesis PE(22:0/22:4(7Z,10Z,13Z,16Z))516
Phosphatidylethanolamine Biosynthesis PE(22:0/22:5(4Z,7Z,10Z,13Z,16Z))516
Phosphatidylethanolamine Biosynthesis PE(22:0/22:5(7Z,10Z,13Z,16Z,19Z))516
Phosphatidylethanolamine Biosynthesis PE(22:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))516
Phosphatidylethanolamine Biosynthesis PE(22:0/24:0)516
Phosphatidylethanolamine Biosynthesis PE(22:0/24:1(15Z))516
Phosphatidylethanolamine Biosynthesis PE(22:1(13Z)/14:0)516
Phosphatidylethanolamine Biosynthesis PE(22:1(13Z)/14:1(9Z))516
Phosphatidylethanolamine Biosynthesis PE(22:1(13Z)/15:0)516
Phosphatidylethanolamine Biosynthesis PE(22:1(13Z)/16:0)516
Phosphatidylethanolamine Biosynthesis PE(22:1(13Z)/16:1(9Z))516
Phosphatidylethanolamine Biosynthesis PE(22:1(13Z)/18:0)516
Phosphatidylethanolamine Biosynthesis PE(22:1(13Z)/18:1(11Z))516
Phosphatidylethanolamine Biosynthesis PE(22:1(13Z)/18:1(9Z))516
Phosphatidylethanolamine Biosynthesis PE(22:1(13Z)/18:2(9Z,12Z))516
Phosphatidylethanolamine Biosynthesis PE(22:1(13Z)/18:3(6Z,9Z,12Z))516
Phosphatidylethanolamine Biosynthesis PE(22:1(13Z)/18:3(9Z,12Z,15Z))516
Phosphatidylethanolamine Biosynthesis PE(22:1(13Z)/18:4(6Z,9Z,12Z,15Z))516
Phosphatidylethanolamine Biosynthesis PE(22:1(13Z)/20:0)516
Phosphatidylethanolamine Biosynthesis PE(22:1(13Z)/20:1(11Z))516
Phosphatidylethanolamine Biosynthesis PE(22:1(13Z)/20:2(11Z,14Z))516
Phosphatidylethanolamine Biosynthesis PE(22:1(13Z)/20:3(5Z,8Z,11Z))516
Phosphatidylethanolamine Biosynthesis PE(22:1(13Z)/20:3(8Z,11Z,14Z))516
Phosphatidylethanolamine Biosynthesis PE(22:1(13Z)/20:4(5Z,8Z,11Z,14Z))516
Phosphatidylethanolamine Biosynthesis PE(22:1(13Z)/20:4(8Z,11Z,14Z,17Z))516
Phosphatidylethanolamine Biosynthesis PE(22:1(13Z)/20:5(5Z,8Z,11Z,14Z,17Z))516
Phosphatidylethanolamine Biosynthesis PE(22:1(13Z)/22:0)516
Phosphatidylethanolamine Biosynthesis PE(22:1(13Z)/22:1(13Z))516
Phosphatidylethanolamine Biosynthesis PE(22:1(13Z)/22:2(13Z,16Z))516
Phosphatidylethanolamine Biosynthesis PE(22:1(13Z)/22:4(7Z,10Z,13Z,16Z))516
Phosphatidylethanolamine Biosynthesis PE(22:1(13Z)/22:5(4Z,7Z,10Z,13Z,16Z))516
Phosphatidylethanolamine Biosynthesis PE(22:1(13Z)/22:5(7Z,10Z,13Z,16Z,19Z))516
Phosphatidylethanolamine Biosynthesis PE(22:1(13Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))516
Phosphatidylethanolamine Biosynthesis PE(22:1(13Z)/24:0)516
Phosphatidylethanolamine Biosynthesis PE(22:1(13Z)/24:1(15Z))516
Phosphatidylethanolamine Biosynthesis PE(22:2(13Z,16Z)/14:0)516
Phosphatidylethanolamine Biosynthesis PE(22:2(13Z,16Z)/14:1(9Z))516
Phosphatidylethanolamine Biosynthesis PE(22:2(13Z,16Z)/15:0)516
Phosphatidylethanolamine Biosynthesis PE(22:2(13Z,16Z)/16:0)516
Phosphatidylethanolamine Biosynthesis PE(22:2(13Z,16Z)/16:1(9Z))516
Phosphatidylethanolamine Biosynthesis PE(22:2(13Z,16Z)/18:0)516
Phosphatidylethanolamine Biosynthesis PE(22:2(13Z,16Z)/18:1(11Z))516
Phosphatidylethanolamine Biosynthesis PE(22:2(13Z,16Z)/18:1(9Z))516
Phosphatidylethanolamine Biosynthesis PE(22:2(13Z,16Z)/18:2(9Z,12Z))516
Phosphatidylethanolamine Biosynthesis PE(22:2(13Z,16Z)/18:3(6Z,9Z,12Z))516
Phosphatidylethanolamine Biosynthesis PE(22:2(13Z,16Z)/18:3(9Z,12Z,15Z))516
Phosphatidylethanolamine Biosynthesis PE(22:2(13Z,16Z)/18:4(6Z,9Z,12Z,15Z))516
Phosphatidylethanolamine Biosynthesis PE(22:2(13Z,16Z)/20:0)516
Phosphatidylethanolamine Biosynthesis PE(22:2(13Z,16Z)/20:1(11Z))516
Phosphatidylethanolamine Biosynthesis PE(22:2(13Z,16Z)/20:2(11Z,14Z))516
Phosphatidylethanolamine Biosynthesis PE(22:2(13Z,16Z)/20:3(5Z,8Z,11Z))516
Phosphatidylethanolamine Biosynthesis PE(22:2(13Z,16Z)/20:3(8Z,11Z,14Z))516
Phosphatidylethanolamine Biosynthesis PE(22:2(13Z,16Z)/20:4(5Z,8Z,11Z,14Z))516
Phosphatidylethanolamine Biosynthesis PE(22:2(13Z,16Z)/20:4(8Z,11Z,14Z,17Z))516
Phosphatidylethanolamine Biosynthesis PE(22:2(13Z,16Z)/20:5(5Z,8Z,11Z,14Z,17Z))516
Phosphatidylethanolamine Biosynthesis PE(22:2(13Z,16Z)/22:0)516
Phosphatidylethanolamine Biosynthesis PE(22:2(13Z,16Z)/22:1(13Z))516
Phosphatidylethanolamine Biosynthesis PE(22:2(13Z,16Z)/22:2(13Z,16Z))516
Phosphatidylethanolamine Biosynthesis PE(22:2(13Z,16Z)/22:4(7Z,10Z,13Z,16Z))516
Phosphatidylethanolamine Biosynthesis PE(22:2(13Z,16Z)/22:5(4Z,7Z,10Z,13Z,16Z))516
Phosphatidylethanolamine Biosynthesis PE(22:2(13Z,16Z)/22:5(7Z,10Z,13Z,16Z,19Z))516
Phosphatidylethanolamine Biosynthesis PE(22:2(13Z,16Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))516
Phosphatidylethanolamine Biosynthesis PE(22:2(13Z,16Z)/24:0)516
Phosphatidylethanolamine Biosynthesis PE(22:2(13Z,16Z)/24:1(15Z))516
Phosphatidylethanolamine Biosynthesis PE(22:4(7Z,10Z,13Z,16Z)/14:0)516
Phosphatidylethanolamine Biosynthesis PE(22:4(7Z,10Z,13Z,16Z)/14:1(9Z))516
Phosphatidylethanolamine Biosynthesis PE(22:4(7Z,10Z,13Z,16Z)/15:0)516
Phosphatidylethanolamine Biosynthesis PE(22:4(7Z,10Z,13Z,16Z)/16:0)516
Phosphatidylethanolamine Biosynthesis PE(22:4(7Z,10Z,13Z,16Z)/16:1(9Z))516
Phosphatidylethanolamine Biosynthesis PE(22:4(7Z,10Z,13Z,16Z)/18:0)516
Phosphatidylethanolamine Biosynthesis PE(22:4(7Z,10Z,13Z,16Z)/18:1(11Z))516
Phosphatidylethanolamine Biosynthesis PE(22:4(7Z,10Z,13Z,16Z)/18:1(9Z))516
Phosphatidylethanolamine Biosynthesis PE(22:4(7Z,10Z,13Z,16Z)/18:2(9Z,12Z))516
Phosphatidylethanolamine Biosynthesis PE(22:4(7Z,10Z,13Z,16Z)/18:3(6Z,9Z,12Z))516
Phosphatidylethanolamine Biosynthesis PE(22:4(7Z,10Z,13Z,16Z)/18:3(9Z,12Z,15Z))516
Phosphatidylethanolamine Biosynthesis PE(22:4(7Z,10Z,13Z,16Z)/18:4(6Z,9Z,12Z,15Z))516
Phosphatidylethanolamine Biosynthesis PE(22:4(7Z,10Z,13Z,16Z)/20:0)516
Phosphatidylethanolamine Biosynthesis PE(22:4(7Z,10Z,13Z,16Z)/20:1(11Z))516
Phosphatidylethanolamine Biosynthesis PE(22:4(7Z,10Z,13Z,16Z)/20:2(11Z,14Z))516
Phosphatidylethanolamine Biosynthesis PE(22:4(7Z,10Z,13Z,16Z)/20:3(5Z,8Z,11Z))516
Phosphatidylethanolamine Biosynthesis PE(22:4(7Z,10Z,13Z,16Z)/20:3(8Z,11Z,14Z))516
Phosphatidylethanolamine Biosynthesis PE(22:4(7Z,10Z,13Z,16Z)/20:4(5Z,8Z,11Z,14Z))516
Phosphatidylethanolamine Biosynthesis PE(22:4(7Z,10Z,13Z,16Z)/20:4(8Z,11Z,14Z,17Z))516
Phosphatidylethanolamine Biosynthesis PE(22:4(7Z,10Z,13Z,16Z)/20:5(5Z,8Z,11Z,14Z,17Z))516
Phosphatidylethanolamine Biosynthesis PE(22:4(7Z,10Z,13Z,16Z)/22:0)516
Phosphatidylethanolamine Biosynthesis PE(22:4(7Z,10Z,13Z,16Z)/22:1(13Z))516
Phosphatidylethanolamine Biosynthesis PE(22:4(7Z,10Z,13Z,16Z)/22:2(13Z,16Z))516
Phosphatidylethanolamine Biosynthesis PE(22:4(7Z,10Z,13Z,16Z)/22:4(7Z,10Z,13Z,16Z))516
Phosphatidylethanolamine Biosynthesis PE(22:4(7Z,10Z,13Z,16Z)/22:5(4Z,7Z,10Z,13Z,16Z))516
Phosphatidylethanolamine Biosynthesis PE(22:4(7Z,10Z,13Z,16Z)/22:5(7Z,10Z,13Z,16Z,19Z))516
Phosphatidylethanolamine Biosynthesis PE(22:4(7Z,10Z,13Z,16Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))516
Phosphatidylethanolamine Biosynthesis PE(22:4(7Z,10Z,13Z,16Z)/24:0)516
Phosphatidylethanolamine Biosynthesis PE(22:4(7Z,10Z,13Z,16Z)/24:1(15Z))516
Phosphatidylethanolamine Biosynthesis PE(22:5(4Z,7Z,10Z,13Z,16Z)/14:0)516
Phosphatidylethanolamine Biosynthesis PE(22:5(4Z,7Z,10Z,13Z,16Z)/14:1(9Z))516
Phosphatidylethanolamine Biosynthesis PE(22:5(4Z,7Z,10Z,13Z,16Z)/15:0)516
Phosphatidylethanolamine Biosynthesis PE(22:5(4Z,7Z,10Z,13Z,16Z)/16:0)516
Phosphatidylethanolamine Biosynthesis PE(22:5(4Z,7Z,10Z,13Z,16Z)/16:1(9Z))516
Phosphatidylethanolamine Biosynthesis PE(22:5(4Z,7Z,10Z,13Z,16Z)/18:0)516
Phosphatidylethanolamine Biosynthesis PE(22:5(4Z,7Z,10Z,13Z,16Z)/18:1(11Z))516
Phosphatidylethanolamine Biosynthesis PE(22:5(4Z,7Z,10Z,13Z,16Z)/18:1(9Z))516
Phosphatidylethanolamine Biosynthesis PE(22:5(4Z,7Z,10Z,13Z,16Z)/18:2(9Z,12Z))516
Phosphatidylethanolamine Biosynthesis PE(22:5(4Z,7Z,10Z,13Z,16Z)/18:3(6Z,9Z,12Z))516
Phosphatidylethanolamine Biosynthesis PE(22:5(4Z,7Z,10Z,13Z,16Z)/18:3(9Z,12Z,15Z))516
Phosphatidylethanolamine Biosynthesis PE(22:5(4Z,7Z,10Z,13Z,16Z)/18:4(6Z,9Z,12Z,15Z))516
Phosphatidylethanolamine Biosynthesis PE(22:5(4Z,7Z,10Z,13Z,16Z)/20:0)516
Phosphatidylethanolamine Biosynthesis PE(22:5(4Z,7Z,10Z,13Z,16Z)/20:1(11Z))516
Phosphatidylethanolamine Biosynthesis PE(22:5(4Z,7Z,10Z,13Z,16Z)/20:2(11Z,14Z))516
Phosphatidylethanolamine Biosynthesis PE(22:5(4Z,7Z,10Z,13Z,16Z)/20:3(5Z,8Z,11Z))516
Phosphatidylethanolamine Biosynthesis PE(22:5(4Z,7Z,10Z,13Z,16Z)/20:3(8Z,11Z,14Z))516
Phosphatidylethanolamine Biosynthesis PE(22:5(4Z,7Z,10Z,13Z,16Z)/20:4(5Z,8Z,11Z,14Z))516
Phosphatidylethanolamine Biosynthesis PE(22:5(4Z,7Z,10Z,13Z,16Z)/20:4(8Z,11Z,14Z,17Z))516
Phosphatidylethanolamine Biosynthesis PE(22:5(4Z,7Z,10Z,13Z,16Z)/20:5(5Z,8Z,11Z,14Z,17Z))516
Phosphatidylethanolamine Biosynthesis PE(22:5(4Z,7Z,10Z,13Z,16Z)/22:0)516
Phosphatidylethanolamine Biosynthesis PE(22:5(4Z,7Z,10Z,13Z,16Z)/22:1(13Z))516
Phosphatidylethanolamine Biosynthesis PE(22:5(4Z,7Z,10Z,13Z,16Z)/22:2(13Z,16Z))516
Phosphatidylethanolamine Biosynthesis PE(22:5(4Z,7Z,10Z,13Z,16Z)/22:4(7Z,10Z,13Z,16Z))516
Phosphatidylethanolamine Biosynthesis PE(22:5(4Z,7Z,10Z,13Z,16Z)/22:5(4Z,7Z,10Z,13Z,16Z))516
Phosphatidylethanolamine Biosynthesis PE(22:5(4Z,7Z,10Z,13Z,16Z)/22:5(7Z,10Z,13Z,16Z,19Z))516
Phosphatidylethanolamine Biosynthesis PE(22:5(4Z,7Z,10Z,13Z,16Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))516
Phosphatidylethanolamine Biosynthesis PE(22:5(4Z,7Z,10Z,13Z,16Z)/24:0)516
Phosphatidylethanolamine Biosynthesis PE(22:5(4Z,7Z,10Z,13Z,16Z)/24:1(15Z))516
Phosphatidylethanolamine Biosynthesis PE(22:5(7Z,10Z,13Z,16Z,19Z)/14:0)516
Phosphatidylethanolamine Biosynthesis PE(22:5(7Z,10Z,13Z,16Z,19Z)/14:1(9Z))516
Phosphatidylethanolamine Biosynthesis PE(22:5(7Z,10Z,13Z,16Z,19Z)/15:0)516
Phosphatidylethanolamine Biosynthesis PE(22:5(7Z,10Z,13Z,16Z,19Z)/16:0)516
Phosphatidylethanolamine Biosynthesis PE(22:5(7Z,10Z,13Z,16Z,19Z)/16:1(9Z))516
Phosphatidylethanolamine Biosynthesis PE(22:5(7Z,10Z,13Z,16Z,19Z)/18:0)516
Phosphatidylethanolamine Biosynthesis PE(22:5(7Z,10Z,13Z,16Z,19Z)/18:1(11Z))516
Phosphatidylethanolamine Biosynthesis PE(22:5(7Z,10Z,13Z,16Z,19Z)/18:1(9Z))516
Phosphatidylethanolamine Biosynthesis PE(22:5(7Z,10Z,13Z,16Z,19Z)/18:2(9Z,12Z))516
Phosphatidylethanolamine Biosynthesis PE(22:5(7Z,10Z,13Z,16Z,19Z)/18:3(6Z,9Z,12Z))516
Phosphatidylethanolamine Biosynthesis PE(22:5(7Z,10Z,13Z,16Z,19Z)/18:3(9Z,12Z,15Z))516
Phosphatidylethanolamine Biosynthesis PE(22:5(7Z,10Z,13Z,16Z,19Z)/18:4(6Z,9Z,12Z,15Z))516
Phosphatidylethanolamine Biosynthesis PE(22:5(7Z,10Z,13Z,16Z,19Z)/20:0)516
Phosphatidylethanolamine Biosynthesis PE(22:5(7Z,10Z,13Z,16Z,19Z)/20:1(11Z))516
Phosphatidylethanolamine Biosynthesis PE(22:5(7Z,10Z,13Z,16Z,19Z)/20:2(11Z,14Z))516
Phosphatidylethanolamine Biosynthesis PE(22:5(7Z,10Z,13Z,16Z,19Z)/20:3(5Z,8Z,11Z))516
Phosphatidylethanolamine Biosynthesis PE(22:5(7Z,10Z,13Z,16Z,19Z)/20:3(8Z,11Z,14Z))516
Phosphatidylethanolamine Biosynthesis PE(22:5(7Z,10Z,13Z,16Z,19Z)/20:4(5Z,8Z,11Z,14Z))516
Phosphatidylethanolamine Biosynthesis PE(22:5(7Z,10Z,13Z,16Z,19Z)/20:4(8Z,11Z,14Z,17Z))516
Phosphatidylethanolamine Biosynthesis PE(22:5(7Z,10Z,13Z,16Z,19Z)/20:5(5Z,8Z,11Z,14Z,17Z))516
Phosphatidylethanolamine Biosynthesis PE(22:5(7Z,10Z,13Z,16Z,19Z)/22:0)516
Phosphatidylethanolamine Biosynthesis PE(22:5(7Z,10Z,13Z,16Z,19Z)/22:1(13Z))516
Phosphatidylethanolamine Biosynthesis PE(22:5(7Z,10Z,13Z,16Z,19Z)/22:2(13Z,16Z))516
Phosphatidylethanolamine Biosynthesis PE(22:5(7Z,10Z,13Z,16Z,19Z)/22:4(7Z,10Z,13Z,16Z))516
Phosphatidylethanolamine Biosynthesis PE(22:5(7Z,10Z,13Z,16Z,19Z)/22:5(4Z,7Z,10Z,13Z,16Z))516
Phosphatidylethanolamine Biosynthesis PE(22:5(7Z,10Z,13Z,16Z,19Z)/22:5(7Z,10Z,13Z,16Z,19Z))516
Phosphatidylethanolamine Biosynthesis PE(22:5(7Z,10Z,13Z,16Z,19Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))516
Phosphatidylethanolamine Biosynthesis PE(22:5(7Z,10Z,13Z,16Z,19Z)/24:0)516
Phosphatidylethanolamine Biosynthesis PE(22:5(7Z,10Z,13Z,16Z,19Z)/24:1(15Z))516
Phosphatidylethanolamine Biosynthesis PE(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/14:0)516
Phosphatidylethanolamine Biosynthesis PE(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/14:1(9Z))516
Phosphatidylethanolamine Biosynthesis PE(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/15:0)516
Phosphatidylethanolamine Biosynthesis PE(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/16:0)516
Phosphatidylethanolamine Biosynthesis PE(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/16:1(9Z))516
Phosphatidylethanolamine Biosynthesis PE(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/18:0)516
Phosphatidylethanolamine Biosynthesis PE(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/18:1(11Z))516
Phosphatidylethanolamine Biosynthesis PE(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/18:1(9Z))516
Phosphatidylethanolamine Biosynthesis PE(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/18:2(9Z,12Z))516
Phosphatidylethanolamine Biosynthesis PE(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/18:3(6Z,9Z,12Z))516
Phosphatidylethanolamine Biosynthesis PE(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/18:3(9Z,12Z,15Z))516
Phosphatidylethanolamine Biosynthesis PE(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/18:4(6Z,9Z,12Z,15Z))516
Phosphatidylethanolamine Biosynthesis PE(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:0)516
Phosphatidylethanolamine Biosynthesis PE(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:1(11Z))516
Phosphatidylethanolamine Biosynthesis PE(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:2(11Z,14Z))516
Phosphatidylethanolamine Biosynthesis PE(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:3(5Z,8Z,11Z))516
Phosphatidylethanolamine Biosynthesis PE(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:3(8Z,11Z,14Z))516
Phosphatidylethanolamine Biosynthesis PE(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:4(5Z,8Z,11Z,14Z))516
Phosphatidylethanolamine Biosynthesis PE(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:4(8Z,11Z,14Z,17Z))516
Phosphatidylethanolamine Biosynthesis PE(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:5(5Z,8Z,11Z,14Z,17Z))516
Phosphatidylethanolamine Biosynthesis PE(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/22:0)516
Phosphatidylethanolamine Biosynthesis PE(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/22:1(13Z))516
Phosphatidylethanolamine Biosynthesis PE(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/22:2(13Z,16Z))516
Phosphatidylethanolamine Biosynthesis PE(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/22:4(7Z,10Z,13Z,16Z))516
Phosphatidylethanolamine Biosynthesis PE(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/22:5(4Z,7Z,10Z,13Z,16Z))516
Phosphatidylethanolamine Biosynthesis PE(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/22:5(7Z,10Z,13Z,16Z,19Z))516
Phosphatidylethanolamine Biosynthesis PE(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))516
Phosphatidylethanolamine Biosynthesis PE(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/24:0)516
Phosphatidylethanolamine Biosynthesis PE(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/24:1(15Z))516
Phosphatidylethanolamine Biosynthesis PE(24:0/14:0)516
Phosphatidylethanolamine Biosynthesis PE(24:0/14:1(9Z))516
Phosphatidylethanolamine Biosynthesis PE(24:0/15:0)516
Phosphatidylethanolamine Biosynthesis PE(24:0/16:0)516
Phosphatidylethanolamine Biosynthesis PE(24:0/16:1(9Z))516
Phosphatidylethanolamine Biosynthesis PE(24:0/18:0)516
Phosphatidylethanolamine Biosynthesis PE(24:0/18:1(11Z))516
Phosphatidylethanolamine Biosynthesis PE(24:0/18:1(9Z))516
Phosphatidylethanolamine Biosynthesis PE(24:0/18:2(9Z,12Z))516
Phosphatidylethanolamine Biosynthesis PE(24:0/18:3(6Z,9Z,12Z))516
Phosphatidylethanolamine Biosynthesis PE(24:0/18:3(9Z,12Z,15Z))516
Phosphatidylethanolamine Biosynthesis PE(24:0/18:4(6Z,9Z,12Z,15Z))516
Phosphatidylethanolamine Biosynthesis PE(24:0/20:0)516
Phosphatidylethanolamine Biosynthesis PE(24:0/20:1(11Z))516
Phosphatidylethanolamine Biosynthesis PE(24:0/20:2(11Z,14Z))516
Phosphatidylethanolamine Biosynthesis PE(24:0/20:3(5Z,8Z,11Z))516
Phosphatidylethanolamine Biosynthesis PE(24:0/20:3(8Z,11Z,14Z))516
Phosphatidylethanolamine Biosynthesis PE(24:0/20:4(5Z,8Z,11Z,14Z))516
Phosphatidylethanolamine Biosynthesis PE(24:0/20:4(8Z,11Z,14Z,17Z))516
Phosphatidylethanolamine Biosynthesis PE(24:0/20:5(5Z,8Z,11Z,14Z,17Z))516
Phosphatidylethanolamine Biosynthesis PE(24:0/22:0)516
Phosphatidylethanolamine Biosynthesis PE(24:0/22:1(13Z))516
Phosphatidylethanolamine Biosynthesis PE(24:0/22:2(13Z,16Z))516
Phosphatidylethanolamine Biosynthesis PE(24:0/22:4(7Z,10Z,13Z,16Z))516
Phosphatidylethanolamine Biosynthesis PE(24:0/22:5(4Z,7Z,10Z,13Z,16Z))516
Phosphatidylethanolamine Biosynthesis PE(24:0/22:5(7Z,10Z,13Z,16Z,19Z))516
Phosphatidylethanolamine Biosynthesis PE(24:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))516
Phosphatidylethanolamine Biosynthesis PE(24:0/24:0)516
Phosphatidylethanolamine Biosynthesis PE(24:0/24:1(15Z))516
Phosphatidylethanolamine Biosynthesis PE(24:1(15Z)/14:0)516
Phosphatidylethanolamine Biosynthesis PE(24:1(15Z)/14:1(9Z))516
Phosphatidylethanolamine Biosynthesis PE(24:1(15Z)/15:0)516
Phosphatidylethanolamine Biosynthesis PE(24:1(15Z)/16:0)516
Phosphatidylethanolamine Biosynthesis PE(24:1(15Z)/16:1(9Z))516
Phosphatidylethanolamine Biosynthesis PE(24:1(15Z)/18:0)516
Phosphatidylethanolamine Biosynthesis PE(24:1(15Z)/18:1(11Z))516
Phosphatidylethanolamine Biosynthesis PE(24:1(15Z)/18:1(9Z))516
Phosphatidylethanolamine Biosynthesis PE(24:1(15Z)/18:2(9Z,12Z))516
Phosphatidylethanolamine Biosynthesis PE(24:1(15Z)/18:3(6Z,9Z,12Z))516
Phosphatidylethanolamine Biosynthesis PE(24:1(15Z)/18:3(9Z,12Z,15Z))516
Phosphatidylethanolamine Biosynthesis PE(24:1(15Z)/18:4(6Z,9Z,12Z,15Z))516
Phosphatidylethanolamine Biosynthesis PE(24:1(15Z)/20:0)516
Phosphatidylethanolamine Biosynthesis PE(24:1(15Z)/20:1(11Z))516
Phosphatidylethanolamine Biosynthesis PE(24:1(15Z)/20:2(11Z,14Z))516
Phosphatidylethanolamine Biosynthesis PE(24:1(15Z)/20:3(5Z,8Z,11Z))516
Phosphatidylethanolamine Biosynthesis PE(24:1(15Z)/20:3(8Z,11Z,14Z))516
Phosphatidylethanolamine Biosynthesis PE(24:1(15Z)/20:4(5Z,8Z,11Z,14Z))516
Phosphatidylethanolamine Biosynthesis PE(24:1(15Z)/20:4(8Z,11Z,14Z,17Z))516
Phosphatidylethanolamine Biosynthesis PE(24:1(15Z)/20:5(5Z,8Z,11Z,14Z,17Z))516
Phosphatidylethanolamine Biosynthesis PE(24:1(15Z)/22:0)516
Phosphatidylethanolamine Biosynthesis PE(24:1(15Z)/22:1(13Z))516
Phosphatidylethanolamine Biosynthesis PE(24:1(15Z)/22:2(13Z,16Z))516
Phosphatidylethanolamine Biosynthesis PE(24:1(15Z)/22:4(7Z,10Z,13Z,16Z))516
Phosphatidylethanolamine Biosynthesis PE(24:1(15Z)/22:5(4Z,7Z,10Z,13Z,16Z))516
Phosphatidylethanolamine Biosynthesis PE(24:1(15Z)/22:5(7Z,10Z,13Z,16Z,19Z))516
Phosphatidylethanolamine Biosynthesis PE(24:1(15Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))516
Phosphatidylethanolamine Biosynthesis PE(24:1(15Z)/24:0)516
Phosphatidylethanolamine Biosynthesis PE(24:1(15Z)/24:1(15Z))516
Disorders of transmembrane transporters10243
SLC transporter disorders4537
Phosphatidylethanolamine Biosynthesis512
Phosphatidylcholine Biosynthesis PC(18:1(9Z)/24:1(15Z))620
Phosphatidylethanolamine Biosynthesis PE(16:1(9Z)/18:0)516
Phosphatidylcholine Biosynthesis PC(11D3/11D3)620
Phosphatidylcholine Biosynthesis PC(11D3/11D5)620
Phosphatidylcholine Biosynthesis PC(11D3/13D5)620
Phosphatidylcholine Biosynthesis PC(11D3/9D3)620
Phosphatidylcholine Biosynthesis PC(11D3/9D5)620
Phosphatidylcholine Biosynthesis PC(11D3/11M3)620
Phosphatidylcholine Biosynthesis PC(11D3/11M5)620
Phosphatidylcholine Biosynthesis PC(11D3/13M5)620
Phosphatidylcholine Biosynthesis PC(11D3/9M5)620
Phosphatidylcholine Biosynthesis PC(11D5/11D3)620
Phosphatidylcholine Biosynthesis PC(11D5/11D5)620
Phosphatidylcholine Biosynthesis PC(11D5/13D5)620
Phosphatidylcholine Biosynthesis PC(11D5/9D3)620
Phosphatidylcholine Biosynthesis PC(11D5/9D5)620
Phosphatidylcholine Biosynthesis PC(11D5/11M3)620
Phosphatidylcholine Biosynthesis PC(11D5/11M5)620
Phosphatidylcholine Biosynthesis PC(11D5/13M5)620
Phosphatidylcholine Biosynthesis PC(11D5/9M5)620
Phosphatidylcholine Biosynthesis PC(13D5/11D3)620
Phosphatidylcholine Biosynthesis PC(13D5/11D5)620
Phosphatidylcholine Biosynthesis PC(13D5/13D5)620
Phosphatidylcholine Biosynthesis PC(13D5/9D3)620
Phosphatidylcholine Biosynthesis PC(13D5/9D5)620
Phosphatidylcholine Biosynthesis PC(13D5/11M3)620
Phosphatidylcholine Biosynthesis PC(13D5/11M5)620
Phosphatidylcholine Biosynthesis PC(13D5/13M5)620
Phosphatidylcholine Biosynthesis PC(13D5/9M5)620
Phosphatidylcholine Biosynthesis PC(9D3/11D3)620
Phosphatidylcholine Biosynthesis PC(9D3/11D5)620
Phosphatidylcholine Biosynthesis PC(9D3/13D5)620
Phosphatidylcholine Biosynthesis PC(9D3/9D3)620
Phosphatidylcholine Biosynthesis PC(9D3/9D5)620
Phosphatidylcholine Biosynthesis PC(9D3/11M3)620
Phosphatidylcholine Biosynthesis PC(9D3/11M5)620
Phosphatidylcholine Biosynthesis PC(9D3/13M5)620
Phosphatidylcholine Biosynthesis PC(9D3/9M5)620
Phosphatidylcholine Biosynthesis PC(9D5/11D3)620
Phosphatidylcholine Biosynthesis PC(9D5/11D5)620
Phosphatidylcholine Biosynthesis PC(9D5/13D5)620
Phosphatidylcholine Biosynthesis PC(9D5/9D3)620
Phosphatidylcholine Biosynthesis PC(9D5/9D5)620
Phosphatidylcholine Biosynthesis PC(9D5/11M3)620
Phosphatidylcholine Biosynthesis PC(9D5/11M5)620
Phosphatidylcholine Biosynthesis PC(9D5/13M5)620
Phosphatidylcholine Biosynthesis PC(9D5/9M5)620
Phosphatidylcholine Biosynthesis PC(11M3/11D3)620
Phosphatidylcholine Biosynthesis PC(11M3/11D5)620
Phosphatidylcholine Biosynthesis PC(11M3/13D5)620
Phosphatidylcholine Biosynthesis PC(11M3/9D3)620
Phosphatidylcholine Biosynthesis PC(11M3/9D5)620
Phosphatidylcholine Biosynthesis PC(11M3/11M3)620
Phosphatidylcholine Biosynthesis PC(11M3/11M5)620
Phosphatidylcholine Biosynthesis PC(11M3/13M5)620
Phosphatidylcholine Biosynthesis PC(11M3/9M5)620
Phosphatidylcholine Biosynthesis PC(11M5/11D3)620
Phosphatidylcholine Biosynthesis PC(11M5/11D5)620
Phosphatidylcholine Biosynthesis PC(11M5/13D5)620
Phosphatidylcholine Biosynthesis PC(11M5/9D3)620
Phosphatidylcholine Biosynthesis PC(11M5/9D5)620
Phosphatidylcholine Biosynthesis PC(11M5/11M3)620
Phosphatidylcholine Biosynthesis PC(11M5/11M5)620
Phosphatidylcholine Biosynthesis PC(11M5/13M5)620
Phosphatidylcholine Biosynthesis PC(11M5/9M5)620
Phosphatidylcholine Biosynthesis PC(13M5/11D3)620
Phosphatidylcholine Biosynthesis PC(13M5/11D5)620
Phosphatidylcholine Biosynthesis PC(13M5/13D5)620
Phosphatidylcholine Biosynthesis PC(13M5/9D3)620
Phosphatidylcholine Biosynthesis PC(13M5/9D5)619
Phosphatidylcholine Biosynthesis PC(13M5/11M3)620
Phosphatidylcholine Biosynthesis PC(13M5/11M5)620
Phosphatidylcholine Biosynthesis PC(13M5/13M5)620
Phosphatidylcholine Biosynthesis PC(13M5/9M5)620
Phosphatidylcholine Biosynthesis PC(9M5/11D3)619
Phosphatidylcholine Biosynthesis PC(9M5/11D5)620
Phosphatidylcholine Biosynthesis PC(9M5/13D5)620
Phosphatidylcholine Biosynthesis PC(9M5/9D3)620
Phosphatidylcholine Biosynthesis PC(9M5/9D5)620
Phosphatidylcholine Biosynthesis PC(9M5/11M3)620
Phosphatidylcholine Biosynthesis PC(9M5/11M5)620
Phosphatidylcholine Biosynthesis PC(9M5/13M5)620
Phosphatidylcholine Biosynthesis PC(9M5/9M5)620
Phosphatidylethanolamine Biosynthesis PE(11D3/11D3)516
Phosphatidylethanolamine Biosynthesis PE(11D3/11D5)516
Phosphatidylethanolamine Biosynthesis PE(11D3/13D5)516
Phosphatidylethanolamine Biosynthesis PE(11D3/9D3)516
Phosphatidylethanolamine Biosynthesis PE(11D3/9D5)516
Phosphatidylethanolamine Biosynthesis PE(11D3/11M3)516
Phosphatidylethanolamine Biosynthesis PE(11D3/11M5)516
Phosphatidylethanolamine Biosynthesis PE(11D3/13M5)516
Phosphatidylethanolamine Biosynthesis PE(11D3/9M5)516
Phosphatidylethanolamine Biosynthesis PE(11D5/11D3)516
Phosphatidylethanolamine Biosynthesis PE(11D5/11D5)516
Phosphatidylethanolamine Biosynthesis PE(11D5/13D5)516
Phosphatidylethanolamine Biosynthesis PE(11D5/9D3)516
Phosphatidylethanolamine Biosynthesis PE(11D5/9D5)516
Phosphatidylethanolamine Biosynthesis PE(11D5/11M3)516
Phosphatidylethanolamine Biosynthesis PE(11D5/11M5)516
Phosphatidylethanolamine Biosynthesis PE(11D5/13M5)516
Phosphatidylethanolamine Biosynthesis PE(11D5/9M5)516
Phosphatidylethanolamine Biosynthesis PE(13D5/11D3)516
Phosphatidylethanolamine Biosynthesis PE(13D5/11D5)516
Phosphatidylethanolamine Biosynthesis PE(13D5/13D5)516
Phosphatidylethanolamine Biosynthesis PE(13D5/9D3)516
Phosphatidylethanolamine Biosynthesis PE(13D5/9D5)516
Phosphatidylethanolamine Biosynthesis PE(13D5/11M3)516
Phosphatidylethanolamine Biosynthesis PE(13D5/11M5)516
Phosphatidylethanolamine Biosynthesis PE(13D5/13M5)516
Phosphatidylethanolamine Biosynthesis PE(13D5/9M5)516
Phosphatidylethanolamine Biosynthesis PE(9D3/11D3)516
Phosphatidylethanolamine Biosynthesis PE(9D3/11D5)516
Phosphatidylethanolamine Biosynthesis PE(9D3/13D5)516
Phosphatidylethanolamine Biosynthesis PE(9D3/9D3)516
Phosphatidylethanolamine Biosynthesis PE(9D3/9D5)516
Phosphatidylethanolamine Biosynthesis PE(9D3/11M3)516
Phosphatidylethanolamine Biosynthesis PE(9D3/11M5)516
Phosphatidylethanolamine Biosynthesis PE(9D3/13M5)516
Phosphatidylethanolamine Biosynthesis PE(9D3/9M5)516
Phosphatidylethanolamine Biosynthesis PE(9D5/11D3)516
Phosphatidylethanolamine Biosynthesis PE(9D5/11D5)516
Phosphatidylethanolamine Biosynthesis PE(9D5/13D5)516
Phosphatidylethanolamine Biosynthesis PE(9D5/9D3)516
Phosphatidylethanolamine Biosynthesis PE(9D5/9D5)516
Phosphatidylethanolamine Biosynthesis PE(9D5/11M3)516
Phosphatidylethanolamine Biosynthesis PE(9D5/11M5)516
Phosphatidylethanolamine Biosynthesis PE(9D5/13M5)516
Phosphatidylethanolamine Biosynthesis PE(9D5/9M5)516
Phosphatidylethanolamine Biosynthesis PE(11M3/11D3)516
Phosphatidylethanolamine Biosynthesis PE(11M3/11D5)516
Phosphatidylethanolamine Biosynthesis PE(11M3/13D5)516
Phosphatidylethanolamine Biosynthesis PE(11M3/9D3)516
Phosphatidylethanolamine Biosynthesis PE(11M3/9D5)516
Phosphatidylethanolamine Biosynthesis PE(11M3/11M3)516
Phosphatidylethanolamine Biosynthesis PE(11M3/11M5)516
Phosphatidylethanolamine Biosynthesis PE(11M3/13M5)516
Phosphatidylethanolamine Biosynthesis PE(11M3/9M5)516
Phosphatidylethanolamine Biosynthesis PE(11M5/11D3)516
Phosphatidylethanolamine Biosynthesis PE(11M5/11D5)516
Phosphatidylethanolamine Biosynthesis PE(11M5/13D5)516
Phosphatidylethanolamine Biosynthesis PE(11M5/9D3)516
Phosphatidylethanolamine Biosynthesis PE(11M5/9D5)516
Phosphatidylethanolamine Biosynthesis PE(11M5/11M3)516
Phosphatidylethanolamine Biosynthesis PE(11M5/11M5)516
Phosphatidylethanolamine Biosynthesis PE(11M5/13M5)516
Phosphatidylethanolamine Biosynthesis PE(11M5/9M5)516
Phosphatidylethanolamine Biosynthesis PE(13M5/11D3)516
Phosphatidylethanolamine Biosynthesis PE(13M5/11D5)516
Phosphatidylethanolamine Biosynthesis PE(13M5/13D5)516
Phosphatidylethanolamine Biosynthesis PE(13M5/9D3)516
Phosphatidylethanolamine Biosynthesis PE(13M5/9D5)515
Phosphatidylethanolamine Biosynthesis PE(13M5/11M3)516
Phosphatidylethanolamine Biosynthesis PE(13M5/11M5)516
Phosphatidylethanolamine Biosynthesis PE(13M5/13M5)516
Phosphatidylethanolamine Biosynthesis PE(13M5/9M5)516
Phosphatidylethanolamine Biosynthesis PE(9M5/11D3)516
Phosphatidylethanolamine Biosynthesis PE(9M5/11D5)516
Phosphatidylethanolamine Biosynthesis PE(9M5/13D5)516
Phosphatidylethanolamine Biosynthesis PE(9M5/9D3)516
Phosphatidylethanolamine Biosynthesis PE(9M5/9D5)516
Phosphatidylethanolamine Biosynthesis PE(9M5/11M3)516
Phosphatidylethanolamine Biosynthesis PE(9M5/11M5)516
Phosphatidylethanolamine Biosynthesis PE(9M5/13M5)516
Phosphatidylethanolamine Biosynthesis PE(9M5/9M5)516
Defective SLC5A7 causes distal hereditary motor neuronopathy 7A (HMN7A)13
Phosphatidylcholine Biosynthesis PC(16:0/20:1(13Z))1120
Phosphatidylcholine Biosynthesis PC(18:0/20:1(13Z))1120
Phosphatidylcholine Biosynthesis PC(18:1(9Z)/20:1(13Z))1120
Phosphatidylcholine Biosynthesis PC(18:1(11Z)/20:1(13Z))1120
Phosphatidylcholine Biosynthesis PC(18:2(9Z,12Z)/20:1(13Z))1120
Phosphatidylcholine Biosynthesis PC(18:3(6Z,9Z,12Z)/20:1(13Z))1120
Phosphatidylcholine Biosynthesis PC(18:3(9Z,12Z,15Z)/20:1(13Z))1120
Phosphatidylcholine Biosynthesis PC(20:0/20:1(13Z))1120
Phosphatidylcholine Biosynthesis PC(20:1(11Z)/20:1(13Z))1120
Phosphatidylcholine Biosynthesis PC(20:1(13Z)/20:1(13Z))1120
Phosphatidylcholine Biosynthesis PC(20:1(13Z)/22:0)1120
Phosphatidylcholine Biosynthesis PC(20:1(13Z)/22:1(13Z))1120
superpathway of phosphatidylcholine biosynthesis818
Immune System91482
Innate Immune System41475
phosphatidylcholine resynthesis via glycerophosphocholine07
Fcgamma receptor (FCGR) dependent phagocytosis3211
Role of phospholipids in phagocytosis49
choline biosynthesis I221
phosphatidylcholine biosynthesis I010
phosphatidate metabolism, as a signaling molecule1114
choline biosynthesis II08
superpathway of choline biosynthesis1122
sinapate ester biosynthesis221
choline degradation I27
choline biosynthesis III912
superpathway of phospholipid biosynthesis II (plants)1731
phospholipases199
Glycerolipids and glycerophospholipids08
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis614
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(14:0/14:0) | PE(14:0/14:0)617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(14:0/i-15:0) | PE(14:0/i-15:0)613
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(14:0/16:0) | PE(14:0/16:0)617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(14:0/16:1(9Z)) | PE(14:0/16:1(9Z))617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(14:0/i-17:0) | PE(14:0/i-17:0)613
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(14:0/18:0) | PE(14:0/18:0)617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(14:0/18:1(9Z)) | PE(14:0/18:1(9Z))617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(14:0/18:1(11Z)) | PE(14:0/18:1(11Z))617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(14:0/18:2(9Z,12Z)) | PE(14:0/18:2(9Z,12Z))617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(14:0/18:3(6Z,9Z,12Z)) | PE(14:0/18:3(6Z,9Z,12Z))617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(14:0/18:3(9Z,12Z,15Z)) | PE(14:0/18:3(9Z,12Z,15Z))617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(14:0/20:0) | PE(14:0/20:0)617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(14:0/20:3(5Z,8Z,11Z)) | PE(14:0/20:3(5Z,8Z,11Z))617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(14:0/20:3(8Z,11Z,14Z)) | PE(14:0/20:3(8Z,11Z,14Z))617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(14:0/20:4(5Z,8Z,11Z,14Z)) | PE(14:0/20:4(5Z,8Z,11Z,14Z))617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(14:0/20:4(8Z,11Z,14Z,17Z)) | PE(14:0/20:4(8Z,11Z,14Z,17Z))617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(14:0/20:5(5Z,8Z,11Z,14Z,17Z)) | PE(14:0/20:5(5Z,8Z,11Z,14Z,17Z))617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(i-15:0/i-15:0) | PE(i-15:0/i-15:0)613
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(i-15:0/16:0) | PE(i-15:0/16:0)613
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(i-15:0/16:1(9Z)) | PE(i-15:0/16:1(9Z))613
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(i-15:0/i-17:0) | PE(i-15:0/i-17:0)613
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(i-15:0/18:0) | PE(i-15:0/18:0)613
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(i-15:0/18:1(9Z)) | PE(i-15:0/18:1(9Z))613
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(i-15:0/18:1(11Z)) | PE(i-15:0/18:1(11Z))613
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(i-15:0/18:2(9Z,12Z)) | PE(i-15:0/18:2(9Z,12Z))613
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(i-15:0/18:3(6Z,9Z,12Z)) | PE(i-15:0/18:3(6Z,9Z,12Z))613
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(i-15:0/18:3(9Z,12Z,15Z)) | PE(i-15:0/18:3(9Z,12Z,15Z))613
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(i-15:0/20:0) | PE(i-15:0/20:0)613
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(i-15:0/20:3(5Z,8Z,11Z)) | PE(i-15:0/20:3(5Z,8Z,11Z))613
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(i-15:0/20:3(8Z,11Z,14Z)) | PE(i-15:0/20:3(8Z,11Z,14Z))613
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(i-15:0/20:4(5Z,8Z,11Z,14Z)) | PE(i-15:0/20:4(5Z,8Z,11Z,14Z))613
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(i-15:0/20:4(8Z,11Z,14Z,17Z)) | PE(i-15:0/20:4(8Z,11Z,14Z,17Z))613
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(i-15:0/20:5(5Z,8Z,11Z,14Z,17Z)) | PE(i-15:0/20:5(5Z,8Z,11Z,14Z,17Z))613
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(16:0/16:0) | PE(16:0/16:0)617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(16:0/16:1(9Z)) | PE(16:0/16:1(9Z))617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(16:0/i-17:0) | PE(16:0/i-17:0)613
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(16:0/18:0) | PE(16:0/18:0)617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(16:0/18:1(9Z)) | PE(16:0/18:1(9Z))617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(16:0/18:1(11Z)) | PE(16:0/18:1(11Z))617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(16:0/18:2(9Z,12Z)) | PE(16:0/18:2(9Z,12Z))617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(16:0/18:3(6Z,9Z,12Z)) | PE(16:0/18:3(6Z,9Z,12Z))617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(16:0/18:3(9Z,12Z,15Z)) | PE(16:0/18:3(9Z,12Z,15Z))617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(16:0/20:0) | PE(16:0/20:0)617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(16:0/20:3(5Z,8Z,11Z)) | PE(16:0/20:3(5Z,8Z,11Z))617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(16:0/20:3(8Z,11Z,14Z)) | PE(16:0/20:3(8Z,11Z,14Z))617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(16:0/20:4(5Z,8Z,11Z,14Z)) | PE(16:0/20:4(5Z,8Z,11Z,14Z))617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(16:0/20:4(8Z,11Z,14Z,17Z)) | PE(16:0/20:4(8Z,11Z,14Z,17Z))617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(16:0/20:5(5Z,8Z,11Z,14Z,17Z)) | PE(16:0/20:5(5Z,8Z,11Z,14Z,17Z))617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(16:1(9Z)/16:1(9Z)) | PE(16:1(9Z)/16:1(9Z))617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(16:1(9Z)/i-17:0) | PE(16:1(9Z)/i-17:0)613
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(16:1(9Z)/18:0) | PE(16:1(9Z)/18:0)617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(16:1(9Z)/18:1(9Z)) | PE(16:1(9Z)/18:1(9Z))617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(16:1(9Z)/18:1(11Z)) | PE(16:1(9Z)/18:1(11Z))617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(16:1(9Z)/18:2(9Z,12Z)) | PE(16:1(9Z)/18:2(9Z,12Z))617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(16:1(9Z)/18:3(6Z,9Z,12Z)) | PE(16:1(9Z)/18:3(6Z,9Z,12Z))617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(16:1(9Z)/18:3(9Z,12Z,15Z)) | PE(16:1(9Z)/18:3(9Z,12Z,15Z))617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(16:1(9Z)/20:0) | PE(16:1(9Z)/20:0)617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(16:1(9Z)/20:3(5Z,8Z,11Z)) | PE(16:1(9Z)/20:3(5Z,8Z,11Z))617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(16:1(9Z)/20:3(8Z,11Z,14Z)) | PE(16:1(9Z)/20:3(8Z,11Z,14Z))617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(16:1(9Z)/20:4(5Z,8Z,11Z,14Z)) | PE(16:1(9Z)/20:4(5Z,8Z,11Z,14Z))617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(16:1(9Z)/20:4(8Z,11Z,14Z,17Z)) | PE(16:1(9Z)/20:4(8Z,11Z,14Z,17Z))617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(16:1(9Z)/20:5(5Z,8Z,11Z,14Z,17Z)) | PE(16:1(9Z)/20:5(5Z,8Z,11Z,14Z,17Z))617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(i-17:0/i-17:0) | PE(i-17:0/i-17:0)613
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(i-17:0/18:0) | PE(i-17:0/18:0)613
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(i-17:0/18:1(9Z)) | PE(i-17:0/18:1(9Z))613
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(i-17:0/18:1(11Z)) | PE(i-17:0/18:1(11Z))613
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(i-17:0/18:2(9Z,12Z)) | PE(i-17:0/18:2(9Z,12Z))613
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(i-17:0/18:3(6Z,9Z,12Z)) | PE(i-17:0/18:3(6Z,9Z,12Z))613
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(i-17:0/18:3(9Z,12Z,15Z)) | PE(i-17:0/18:3(9Z,12Z,15Z))613
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(i-17:0/20:0) | PE(i-17:0/20:0)613
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(i-17:0/20:3(5Z,8Z,11Z)) | PE(i-17:0/20:3(5Z,8Z,11Z))613
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(i-17:0/20:3(8Z,11Z,14Z)) | PE(i-17:0/20:3(8Z,11Z,14Z))613
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(i-17:0/20:4(5Z,8Z,11Z,14Z)) | PE(i-17:0/20:4(5Z,8Z,11Z,14Z))613
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(i-17:0/20:4(8Z,11Z,14Z,17Z)) | PE(i-17:0/20:4(8Z,11Z,14Z,17Z))613
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(i-17:0/20:5(5Z,8Z,11Z,14Z,17Z)) | PE(i-17:0/20:5(5Z,8Z,11Z,14Z,17Z))613
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(18:0/18:0) | PE(18:0/18:0)617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(18:0/18:1(9Z)) | PE(18:0/18:1(9Z))617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(18:0/18:1(11Z)) | PE(18:0/18:1(11Z))617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(18:0/18:2(9Z,12Z)) | PE(18:0/18:2(9Z,12Z))617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(18:0/18:3(6Z,9Z,12Z)) | PE(18:0/18:3(6Z,9Z,12Z))617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(18:0/18:3(9Z,12Z,15Z)) | PE(18:0/18:3(9Z,12Z,15Z))617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(18:0/20:0) | PE(18:0/20:0)617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(18:0/20:3(5Z,8Z,11Z)) | PE(18:0/20:3(5Z,8Z,11Z))617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(18:0/20:3(8Z,11Z,14Z)) | PE(18:0/20:3(8Z,11Z,14Z))617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(18:0/20:4(5Z,8Z,11Z,14Z)) | PE(18:0/20:4(5Z,8Z,11Z,14Z))617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(18:0/20:4(8Z,11Z,14Z,17Z)) | PE(18:0/20:4(8Z,11Z,14Z,17Z))617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(18:0/20:5(5Z,8Z,11Z,14Z,17Z)) | PE(18:0/20:5(5Z,8Z,11Z,14Z,17Z))617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(18:1(9Z)/18:1(9Z)) | PE(18:1(9Z)/18:1(9Z))617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(18:1(9Z)/18:1(11Z)) | PE(18:1(9Z)/18:1(11Z))617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(18:1(9Z)/18:2(9Z,12Z)) | PE(18:1(9Z)/18:2(9Z,12Z))617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(18:1(9Z)/18:3(6Z,9Z,12Z)) | PE(18:1(9Z)/18:3(6Z,9Z,12Z))617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(18:1(9Z)/18:3(9Z,12Z,15Z)) | PE(18:1(9Z)/18:3(9Z,12Z,15Z))617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(18:1(9Z)/20:0) | PE(18:1(9Z)/20:0)617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(18:1(9Z)/20:3(5Z,8Z,11Z)) | PE(18:1(9Z)/20:3(5Z,8Z,11Z))617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(18:1(9Z)/20:3(8Z,11Z,14Z)) | PE(18:1(9Z)/20:3(8Z,11Z,14Z))617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(18:1(9Z)/20:4(5Z,8Z,11Z,14Z)) | PE(18:1(9Z)/20:4(5Z,8Z,11Z,14Z))617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(18:1(9Z)/20:4(8Z,11Z,14Z,17Z)) | PE(18:1(9Z)/20:4(8Z,11Z,14Z,17Z))617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(18:1(9Z)/20:5(5Z,8Z,11Z,14Z,17Z)) | PE(18:1(9Z)/20:5(5Z,8Z,11Z,14Z,17Z))617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(18:1(11Z)/18:1(11Z)) | PE(18:1(11Z)/18:1(11Z))617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(18:1(11Z)/18:2(9Z,12Z)) | PE(18:1(11Z)/18:2(9Z,12Z))617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(18:1(11Z)/18:3(6Z,9Z,12Z)) | PE(18:1(11Z)/18:3(6Z,9Z,12Z))617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(18:1(11Z)/18:3(9Z,12Z,15Z)) | PE(18:1(11Z)/18:3(9Z,12Z,15Z))617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(18:1(11Z)/20:0) | PE(18:1(11Z)/20:0)617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(18:1(11Z)/20:3(5Z,8Z,11Z)) | PE(18:1(11Z)/20:3(5Z,8Z,11Z))617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(18:1(11Z)/20:3(8Z,11Z,14Z)) | PE(18:1(11Z)/20:3(8Z,11Z,14Z))617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(18:1(11Z)/20:4(5Z,8Z,11Z,14Z)) | PE(18:1(11Z)/20:4(5Z,8Z,11Z,14Z))617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(18:1(11Z)/20:4(8Z,11Z,14Z,17Z)) | PE(18:1(11Z)/20:4(8Z,11Z,14Z,17Z))617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(18:1(11Z)/20:5(5Z,8Z,11Z,14Z,17Z)) | PE(18:1(11Z)/20:5(5Z,8Z,11Z,14Z,17Z))617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(18:2(9Z,12Z)/18:2(9Z,12Z)) | PE(18:2(9Z,12Z)/18:2(9Z,12Z))617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(18:2(9Z,12Z)/18:3(6Z,9Z,12Z)) | PE(18:2(9Z,12Z)/18:3(6Z,9Z,12Z))617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(18:2(9Z,12Z)/18:3(9Z,12Z,15Z)) | PE(18:2(9Z,12Z)/18:3(9Z,12Z,15Z))617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(18:2(9Z,12Z)/20:0) | PE(18:2(9Z,12Z)/20:0)617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(18:2(9Z,12Z)/20:3(5Z,8Z,11Z)) | PE(18:2(9Z,12Z)/20:3(5Z,8Z,11Z))617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(18:2(9Z,12Z)/20:3(8Z,11Z,14Z)) | PE(18:2(9Z,12Z)/20:3(8Z,11Z,14Z))617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(18:2(9Z,12Z)/20:4(5Z,8Z,11Z,14Z)) | PE(18:2(9Z,12Z)/20:4(5Z,8Z,11Z,14Z))617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(18:2(9Z,12Z)/20:4(8Z,11Z,14Z,17Z)) | PE(18:2(9Z,12Z)/20:4(8Z,11Z,14Z,17Z))617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(18:2(9Z,12Z)/20:5(5Z,8Z,11Z,14Z,17Z)) | PE(18:2(9Z,12Z)/20:5(5Z,8Z,11Z,14Z,17Z))617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(18:3(6Z,9Z,12Z)/18:3(6Z,9Z,12Z)) | PE(18:3(6Z,9Z,12Z)/18:3(6Z,9Z,12Z))617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(18:3(6Z,9Z,12Z)/18:3(9Z,12Z,15Z)) | PE(18:3(6Z,9Z,12Z)/18:3(9Z,12Z,15Z))617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(18:3(6Z,9Z,12Z)/20:0) | PE(18:3(6Z,9Z,12Z)/20:0)617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(18:3(6Z,9Z,12Z)/20:3(5Z,8Z,11Z)) | PE(18:3(6Z,9Z,12Z)/20:3(5Z,8Z,11Z))617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(18:3(6Z,9Z,12Z)/20:3(8Z,11Z,14Z)) | PE(18:3(6Z,9Z,12Z)/20:3(8Z,11Z,14Z))617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(18:3(6Z,9Z,12Z)/20:4(5Z,8Z,11Z,14Z)) | PE(18:3(6Z,9Z,12Z)/20:4(5Z,8Z,11Z,14Z))617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(18:3(6Z,9Z,12Z)/20:4(8Z,11Z,14Z,17Z)) | PE(18:3(6Z,9Z,12Z)/20:4(8Z,11Z,14Z,17Z))617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(18:3(6Z,9Z,12Z)/20:5(5Z,8Z,11Z,14Z,17Z)) | PE(18:3(6Z,9Z,12Z)/20:5(5Z,8Z,11Z,14Z,17Z))617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(18:3(9Z,12Z,15Z)/18:3(9Z,12Z,15Z)) | PE(18:3(9Z,12Z,15Z)/18:3(9Z,12Z,15Z))617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(18:3(9Z,12Z,15Z)/20:0) | PE(18:3(9Z,12Z,15Z)/20:0)617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(18:3(9Z,12Z,15Z)/20:3(5Z,8Z,11Z)) | PE(18:3(9Z,12Z,15Z)/20:3(5Z,8Z,11Z))617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(18:3(9Z,12Z,15Z)/20:3(8Z,11Z,14Z)) | PE(18:3(9Z,12Z,15Z)/20:3(8Z,11Z,14Z))617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(18:3(9Z,12Z,15Z)/20:4(5Z,8Z,11Z,14Z)) | PE(18:3(9Z,12Z,15Z)/20:4(5Z,8Z,11Z,14Z))617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(18:3(9Z,12Z,15Z)/20:4(8Z,11Z,14Z,17Z)) | PE(18:3(9Z,12Z,15Z)/20:4(8Z,11Z,14Z,17Z))617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(18:3(9Z,12Z,15Z)/20:5(5Z,8Z,11Z,14Z,17Z)) | PE(18:3(9Z,12Z,15Z)/20:5(5Z,8Z,11Z,14Z,17Z))617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(20:0/20:0) | PE(20:0/20:0)617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(20:0/20:3(5Z,8Z,11Z)) | PE(20:0/20:3(5Z,8Z,11Z))617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(20:0/20:3(8Z,11Z,14Z)) | PE(20:0/20:3(8Z,11Z,14Z))617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(20:0/20:4(5Z,8Z,11Z,14Z)) | PE(20:0/20:4(5Z,8Z,11Z,14Z))617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(20:0/20:4(8Z,11Z,14Z,17Z)) | PE(20:0/20:4(8Z,11Z,14Z,17Z))617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(20:0/20:5(5Z,8Z,11Z,14Z,17Z)) | PE(20:0/20:5(5Z,8Z,11Z,14Z,17Z))617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(20:3(5Z,8Z,11Z)/20:3(5Z,8Z,11Z)) | PE(20:3(5Z,8Z,11Z)/20:3(5Z,8Z,11Z))617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(20:3(5Z,8Z,11Z)/20:3(8Z,11Z,14Z)) | PE(20:3(5Z,8Z,11Z)/20:3(8Z,11Z,14Z))617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(20:3(5Z,8Z,11Z)/20:4(5Z,8Z,11Z,14Z)) | PE(20:3(5Z,8Z,11Z)/20:4(5Z,8Z,11Z,14Z))617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(20:3(5Z,8Z,11Z)/20:4(8Z,11Z,14Z,17Z)) | PE(20:3(5Z,8Z,11Z)/20:4(8Z,11Z,14Z,17Z))617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(20:3(5Z,8Z,11Z)/20:5(5Z,8Z,11Z,14Z,17Z)) | PE(20:3(5Z,8Z,11Z)/20:5(5Z,8Z,11Z,14Z,17Z))617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(20:3(8Z,11Z,14Z)/20:3(8Z,11Z,14Z)) | PE(20:3(8Z,11Z,14Z)/20:3(8Z,11Z,14Z))617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(20:3(8Z,11Z,14Z)/20:4(5Z,8Z,11Z,14Z)) | PE(20:3(8Z,11Z,14Z)/20:4(5Z,8Z,11Z,14Z))617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(20:3(8Z,11Z,14Z)/20:4(8Z,11Z,14Z,17Z)) | PE(20:3(8Z,11Z,14Z)/20:4(8Z,11Z,14Z,17Z))617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(20:3(8Z,11Z,14Z)/20:5(5Z,8Z,11Z,14Z,17Z)) | PE(20:3(8Z,11Z,14Z)/20:5(5Z,8Z,11Z,14Z,17Z))617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(20:4(5Z,8Z,11Z,14Z)/20:4(5Z,8Z,11Z,14Z)) | PE(20:4(5Z,8Z,11Z,14Z)/20:4(5Z,8Z,11Z,14Z))617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(20:4(5Z,8Z,11Z,14Z)/20:4(8Z,11Z,14Z,17Z)) | PE(20:4(5Z,8Z,11Z,14Z)/20:4(8Z,11Z,14Z,17Z))617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(20:4(5Z,8Z,11Z,14Z)/20:5(5Z,8Z,11Z,14Z,17Z)) | PE(20:4(5Z,8Z,11Z,14Z)/20:5(5Z,8Z,11Z,14Z,17Z))617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(20:4(8Z,11Z,14Z,17Z)/20:4(8Z,11Z,14Z,17Z)) | PE(20:4(8Z,11Z,14Z,17Z)/20:4(8Z,11Z,14Z,17Z))617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(20:4(8Z,11Z,14Z,17Z)/20:5(5Z,8Z,11Z,14Z,17Z)) | PE(20:4(8Z,11Z,14Z,17Z)/20:5(5Z,8Z,11Z,14Z,17Z))617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(20:5(5Z,8Z,11Z,14Z,17Z)/20:5(5Z,8Z,11Z,14Z,17Z)) | PE(20:5(5Z,8Z,11Z,14Z,17Z)/20:5(5Z,8Z,11Z,14Z,17Z))617
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(14:0/14:1(9Z)) | PE(14:0/14:1(9Z))717
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(14:0/15:0) | PE(14:0/15:0)717
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(14:0/20:1(11Z)) | PE(14:0/20:1(11Z))717
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(14:0/22:0) | PE(14:0/22:0)717
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(14:1(9Z)/14:1(9Z)) | PE(14:1(9Z)/14:1(9Z))717
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(14:1(9Z)/15:0) | PE(14:1(9Z)/15:0)717
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(14:1(9Z)/16:0) | PE(14:1(9Z)/16:0)717
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(14:1(9Z)/18:0) | PE(14:1(9Z)/18:0)717
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(14:1(9Z)/18:1(9Z)) | PE(14:1(9Z)/18:1(9Z))717
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(14:1(9Z)/18:1(11Z)) | PE(14:1(9Z)/18:1(11Z))717
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(14:1(9Z)/18:2(9Z,12Z)) | PE(14:1(9Z)/18:2(9Z,12Z))717
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(14:1(9Z)/18:3(9Z,12Z,15Z)) | PE(14:1(9Z)/18:3(9Z,12Z,15Z))717
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(14:1(9Z)/20:1(11Z)) | PE(14:1(9Z)/20:1(11Z))717
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(14:1(9Z)/20:4(5Z,8Z,11Z,14Z)) | PE(14:1(9Z)/20:4(5Z,8Z,11Z,14Z))717
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(14:1(9Z)/22:0) | PE(14:1(9Z)/22:0)717
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(15:0/15:0) | PE(15:0/15:0)717
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(15:0/16:0) | PE(15:0/16:0)717
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(15:0/18:0) | PE(15:0/18:0)717
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(15:0/18:1(9Z)) | PE(15:0/18:1(9Z))717
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(15:0/18:1(11Z)) | PE(15:0/18:1(11Z))717
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(15:0/18:2(9Z,12Z)) | PE(15:0/18:2(9Z,12Z))717
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(15:0/18:3(9Z,12Z,15Z)) | PE(15:0/18:3(9Z,12Z,15Z))717
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(15:0/20:1(11Z)) | PE(15:0/20:1(11Z))717
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(15:0/20:4(5Z,8Z,11Z,14Z)) | PE(15:0/20:4(5Z,8Z,11Z,14Z))717
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(15:0/22:0) | PE(15:0/22:0)717
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(16:0/20:1(11Z)) | PE(16:0/20:1(11Z))717
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(16:0/22:0) | PE(16:0/22:0)717
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(18:0/20:1(11Z)) | PE(18:0/20:1(11Z))717
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(18:0/22:0) | PE(18:0/22:0)717
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(18:1(9Z)/20:1(11Z)) | PE(18:1(9Z)/20:1(11Z))717
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(18:1(9Z)/22:0) | PE(18:1(9Z)/22:0)717
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(18:1(11Z)/20:1(11Z)) | PE(18:1(11Z)/20:1(11Z))717
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(18:1(11Z)/22:0) | PE(18:1(11Z)/22:0)717
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(18:2(9Z,12Z)/20:1(11Z)) | PE(18:2(9Z,12Z)/20:1(11Z))717
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(18:2(9Z,12Z)/22:0) | PE(18:2(9Z,12Z)/22:0)717
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(18:3(9Z,12Z,15Z)/20:1(11Z)) | PE(18:3(9Z,12Z,15Z)/20:1(11Z))717
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(18:3(9Z,12Z,15Z)/22:0) | PE(18:3(9Z,12Z,15Z)/22:0)717
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(20:1(11Z)/20:1(11Z)) | PE(20:1(11Z)/20:1(11Z))717
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(20:1(11Z)/20:4(5Z,8Z,11Z,14Z)) | PE(20:1(11Z)/20:4(5Z,8Z,11Z,14Z))717
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(20:1(11Z)/22:0) | PE(20:1(11Z)/22:0)717
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(20:4(5Z,8Z,11Z,14Z)/22:0) | PE(20:4(5Z,8Z,11Z,14Z)/22:0)717
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(22:0/22:0) | PE(22:0/22:0)717
glycine betaine biosynthesis III (plants)19
16p11.2 proximal deletion syndrome039
10q11.21q11.23 copy number variation syndrome013
Diet-dependent trimethylamine/trimethylamine N-oxide metabolism112
superpathway of choline degradation to L-serine714
choline degradation27
phosphatidylcholine biosynthesis611
phosphatidylserine biosynthesis I12
plasmalogen biosynthesis1024
phosphatidate metabolism, as a signaling molecule1117
phospholipases1410
phosphatidylcholine resynthesis via glycerophosphocholine310
plasmalogen degradation28
superpathway of choline biosynthesis532
choline degradation IV211
choline-O-sulfate degradation416
choline degradation II18
choline degradation III14
choline degradation I713
phosphatidylcholine biosynthesis I816
L-carnitine degradation I417
phosphatidylcholine biosynthesis VI13
glycine betaine degradation I825
glycine betaine biosynthesis III (plants)29
glycine betaine biosynthesis II (Gram-positive bacteria)210
glycine betaine biosynthesis I (Gram-negative bacteria)221
choline biosynthesis I021
choline biosynthesis II09
choline biosynthesis III513
cell-surface glycoconjugate-linked phosphocholine biosynthesis311
superpathway of phosphatidylcholine biosynthesis019
choline biosynthesis411
phospholipids degradation26
phospholipid biosynthesis (Kennedy pathway)414
superpathway of phospholipid biosynthesis027
ester phospholipid biosynthesis021
Folic acid network070
Kennedy pathway012
One-carbon donor022
Neurotransmitter clearance in synaptic cleft022
Neurotransmitter release cycle021
Trans-sulfuration, one-carbon metabolism and related pathways053
Glycerophospholipid biosynthetic pathway3233
Methionine de novo and salvage pathway148
Biochemical pathways: part I0466
Kennedy pathway from sphingolipids011
One-carbon metabolism and related pathways038
Phosphatidylcholine catabolism14
MTHFR deficiency1515
Glycine betaine biosynthesis08
Choline biosynthesis I014
Choline biosynthesis III07

Protein Targets (38)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency1.25890.035520.977089.1251AID504332
muscarinic acetylcholine receptor M1Rattus norvegicus (Norway rat)Potency17.78280.00106.000935.4813AID943
ATP-dependent phosphofructokinaseTrypanosoma brucei brucei TREU927Potency0.16940.060110.745337.9330AID485368
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Solute carrier family 22 member 1Mus musculus (house mouse)IC50 (µMol)55.00000.28001.32753.9000AID678794
Solute carrier family 22 member 2Mus musculus (house mouse)IC50 (µMol)217.00002.80004.76678.0000AID678785
Neuronal acetylcholine receptor subunit alpha-3Rattus norvegicus (Norway rat)Ki42.25000.00000.352210.0000AID145685; AID146006; AID146162
Neuronal acetylcholine receptor subunit alpha-4Rattus norvegicus (Norway rat)Ki38.75000.00000.12345.5000AID145685; AID146486; AID146772
Neuronal acetylcholine receptor subunit alpha-2Rattus norvegicus (Norway rat)Ki34.00000.00000.04230.4500AID145685; AID145983
Neuronal acetylcholine receptor subunit beta-2Rattus norvegicus (Norway rat)Ki35.20000.00000.10825.5000AID145685; AID145983; AID146006; AID146486
Neuronal acetylcholine receptor subunit beta-3Rattus norvegicus (Norway rat)Ki42.00000.00000.05250.4500AID145685
Neuronal acetylcholine receptor subunit beta-4Rattus norvegicus (Norway rat)Ki41.50000.00000.296310.0000AID145685; AID146162; AID146772
Neuronal acetylcholine receptor subunit alpha-5Rattus norvegicus (Norway rat)Ki42.00000.00000.05250.4500AID145685
AcetylcholinesteraseHomo sapiens (human)IC50 (µMol)3,013.01000.00000.933210.0000AID32720
Sodium- and chloride-dependent creatine transporter 1Rattus norvegicus (Norway rat)IC50 (µMol)1.60001.60001.60001.6000AID52130
Neuronal acetylcholine receptor subunit alpha-6Rattus norvegicus (Norway rat)Ki42.00000.00000.05250.4500AID145685
Neuronal acetylcholine receptor subunit alpha-9Rattus norvegicus (Norway rat)Ki42.00000.00000.05250.4500AID145685
Neuronal acetylcholine receptor subunit alpha-7Rattus norvegicus (Norway rat)Ki42.00000.00000.73078.0000AID145685
Solute carrier family 22 member 1Rattus norvegicus (Norway rat)IC50 (µMol)925.00000.18003.68578.8000AID679826; AID681348
High affinity choline transporter 1Mus musculus (house mouse)IC50 (µMol)1.60001.60001.60001.6000AID52130
Neuronal acetylcholine receptor subunit alpha-10Rattus norvegicus (Norway rat)Ki42.00000.00000.05250.4500AID145685
Solute carrier family 22 member 2Rattus norvegicus (Norway rat)IC50 (µMol)804.50001.00004.446710.0000AID678970; AID681345
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, AcetylcholinesteraseMus musculus (house mouse)Kd930.000022.0000297.2000930.0000AID977611
Chain A, AcetylcholinesteraseMus musculus (house mouse)Kd930.000022.0000297.2000930.0000AID977611
Chain A, AcetylcholinesteraseMus musculus (house mouse)Kd930.000022.0000297.2000930.0000AID977611
Chain A, AcetylcholinesteraseMus musculus (house mouse)Kd930.000022.0000297.2000930.0000AID977611
Chain A, AcetylcholinesteraseMus musculus (house mouse)Kd930.000022.0000297.2000930.0000AID977611
Chain A, AcetylcholinesteraseMus musculus (house mouse)Kd930.000022.0000297.2000930.0000AID977611
Chain A, AcetylcholinesteraseMus musculus (house mouse)Kd930.000022.0000297.2000930.0000AID977611
Chain A, Putative Glycine Betaine-binding Abc Transporter ProteinSinorhizobium melilotiKd2.30002.30002.30002.3000AID977611
Chain A, PUTATIVE GLYCINE BETAINE-BINDING ABC TRANSPORTER PROTEINSinorhizobium melilotiKd2.30002.30002.30002.3000AID977611
Chain A, Glycine betaine/carnitine/choline-binding proteinBacillus subtilisKd28.00006.000017.000028.0000AID977611
Chain A, Glycine betaine/carnitine/choline-binding proteinBacillus subtilisKd28.00006.000017.000028.0000AID977611
Chain A, Glycine betaine/carnitine/choline-binding proteinBacillus subtilisKd28.00006.000017.000028.0000AID977611
Chain A, Glycine betaine/carnitine/choline-binding proteinBacillus subtilisKd28.00006.000017.000028.0000AID977611
Chain A, Choline-binding proteinBacillus subtilis subsp. subtilis str. JH642Kd30.500030.500030.500030.5000AID977611
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Solute carrier family 22 member 1Mus musculus (house mouse)Km42.000010.000010.000010.0000AID680371
Solute carrier family 22 member 2Homo sapiens (human)Km167.33330.02891.04072.6000AID678957; AID679159; AID681960
Solute carrier family 22 member 1 Homo sapiens (human)Activity3,540.00000.71005.30179.7000AID681117
Solute carrier family 22 member 1Rattus norvegicus (Norway rat)Km514.00000.27005.695010.0000AID678993; AID679188; AID679314; AID679825
Solute carrier family 22 member 2Rattus norvegicus (Norway rat)Km1,015.00009.40009.40009.4000AID679635; AID681589; AID681624
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (56)

Processvia Protein(s)Taxonomy
activation of cysteine-type endopeptidase activity involved in apoptotic processSolute carrier family 22 member 2Homo sapiens (human)
positive regulation of gene expressionSolute carrier family 22 member 2Homo sapiens (human)
organic cation transportSolute carrier family 22 member 2Homo sapiens (human)
monoatomic cation transportSolute carrier family 22 member 2Homo sapiens (human)
neurotransmitter transportSolute carrier family 22 member 2Homo sapiens (human)
serotonin transportSolute carrier family 22 member 2Homo sapiens (human)
body fluid secretionSolute carrier family 22 member 2Homo sapiens (human)
organic cation transportSolute carrier family 22 member 2Homo sapiens (human)
quaternary ammonium group transportSolute carrier family 22 member 2Homo sapiens (human)
prostaglandin transportSolute carrier family 22 member 2Homo sapiens (human)
amine transportSolute carrier family 22 member 2Homo sapiens (human)
putrescine transportSolute carrier family 22 member 2Homo sapiens (human)
spermidine transportSolute carrier family 22 member 2Homo sapiens (human)
acetylcholine transportSolute carrier family 22 member 2Homo sapiens (human)
choline transportSolute carrier family 22 member 2Homo sapiens (human)
dopamine transportSolute carrier family 22 member 2Homo sapiens (human)
norepinephrine transportSolute carrier family 22 member 2Homo sapiens (human)
xenobiotic transportSolute carrier family 22 member 2Homo sapiens (human)
epinephrine transportSolute carrier family 22 member 2Homo sapiens (human)
histamine transportSolute carrier family 22 member 2Homo sapiens (human)
serotonin uptakeSolute carrier family 22 member 2Homo sapiens (human)
histamine uptakeSolute carrier family 22 member 2Homo sapiens (human)
norepinephrine uptakeSolute carrier family 22 member 2Homo sapiens (human)
thiamine transmembrane transportSolute carrier family 22 member 2Homo sapiens (human)
purine-containing compound transmembrane transportSolute carrier family 22 member 2Homo sapiens (human)
amino acid import across plasma membraneSolute carrier family 22 member 2Homo sapiens (human)
dopamine uptakeSolute carrier family 22 member 2Homo sapiens (human)
L-arginine import across plasma membraneSolute carrier family 22 member 2Homo sapiens (human)
export across plasma membraneSolute carrier family 22 member 2Homo sapiens (human)
transport across blood-brain barrierSolute carrier family 22 member 2Homo sapiens (human)
L-alpha-amino acid transmembrane transportSolute carrier family 22 member 2Homo sapiens (human)
spermidine transmembrane transportSolute carrier family 22 member 2Homo sapiens (human)
L-arginine transmembrane transportSolute carrier family 22 member 2Homo sapiens (human)
cellular detoxificationSolute carrier family 22 member 2Homo sapiens (human)
xenobiotic transport across blood-brain barrierSolute carrier family 22 member 2Homo sapiens (human)
xenobiotic metabolic processSolute carrier family 22 member 1 Homo sapiens (human)
neurotransmitter transportSolute carrier family 22 member 1 Homo sapiens (human)
serotonin transportSolute carrier family 22 member 1 Homo sapiens (human)
establishment or maintenance of transmembrane electrochemical gradientSolute carrier family 22 member 1 Homo sapiens (human)
organic cation transportSolute carrier family 22 member 1 Homo sapiens (human)
quaternary ammonium group transportSolute carrier family 22 member 1 Homo sapiens (human)
prostaglandin transportSolute carrier family 22 member 1 Homo sapiens (human)
monoamine transportSolute carrier family 22 member 1 Homo sapiens (human)
putrescine transportSolute carrier family 22 member 1 Homo sapiens (human)
spermidine transportSolute carrier family 22 member 1 Homo sapiens (human)
acetylcholine transportSolute carrier family 22 member 1 Homo sapiens (human)
dopamine transportSolute carrier family 22 member 1 Homo sapiens (human)
norepinephrine transportSolute carrier family 22 member 1 Homo sapiens (human)
thiamine transportSolute carrier family 22 member 1 Homo sapiens (human)
xenobiotic transportSolute carrier family 22 member 1 Homo sapiens (human)
epinephrine transportSolute carrier family 22 member 1 Homo sapiens (human)
serotonin uptakeSolute carrier family 22 member 1 Homo sapiens (human)
norepinephrine uptakeSolute carrier family 22 member 1 Homo sapiens (human)
thiamine transmembrane transportSolute carrier family 22 member 1 Homo sapiens (human)
metanephric proximal tubule developmentSolute carrier family 22 member 1 Homo sapiens (human)
purine-containing compound transmembrane transportSolute carrier family 22 member 1 Homo sapiens (human)
dopamine uptakeSolute carrier family 22 member 1 Homo sapiens (human)
monoatomic cation transmembrane transportSolute carrier family 22 member 1 Homo sapiens (human)
transport across blood-brain barrierSolute carrier family 22 member 1 Homo sapiens (human)
(R)-carnitine transmembrane transportSolute carrier family 22 member 1 Homo sapiens (human)
acyl carnitine transmembrane transportSolute carrier family 22 member 1 Homo sapiens (human)
spermidine transmembrane transportSolute carrier family 22 member 1 Homo sapiens (human)
cellular detoxificationSolute carrier family 22 member 1 Homo sapiens (human)
xenobiotic transport across blood-brain barrierSolute carrier family 22 member 1 Homo sapiens (human)
acetylcholine catabolic process in synaptic cleftAcetylcholinesteraseHomo sapiens (human)
regulation of receptor recyclingAcetylcholinesteraseHomo sapiens (human)
osteoblast developmentAcetylcholinesteraseHomo sapiens (human)
acetylcholine catabolic processAcetylcholinesteraseHomo sapiens (human)
cell adhesionAcetylcholinesteraseHomo sapiens (human)
nervous system developmentAcetylcholinesteraseHomo sapiens (human)
synapse assemblyAcetylcholinesteraseHomo sapiens (human)
receptor internalizationAcetylcholinesteraseHomo sapiens (human)
negative regulation of synaptic transmission, cholinergicAcetylcholinesteraseHomo sapiens (human)
amyloid precursor protein metabolic processAcetylcholinesteraseHomo sapiens (human)
positive regulation of protein secretionAcetylcholinesteraseHomo sapiens (human)
retina development in camera-type eyeAcetylcholinesteraseHomo sapiens (human)
acetylcholine receptor signaling pathwayAcetylcholinesteraseHomo sapiens (human)
positive regulation of cold-induced thermogenesisAcetylcholinesteraseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (33)

Processvia Protein(s)Taxonomy
amine transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
acetylcholine transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
neurotransmitter transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
monoamine transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
organic anion transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
organic cation transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
prostaglandin transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
L-amino acid transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
pyrimidine nucleoside transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
choline transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
thiamine transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
putrescine transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
efflux transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
spermidine transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
quaternary ammonium group transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
toxin transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
xenobiotic transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
L-arginine transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
acetylcholine transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
neurotransmitter transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
dopamine:sodium symporter activitySolute carrier family 22 member 1 Homo sapiens (human)
norepinephrine:sodium symporter activitySolute carrier family 22 member 1 Homo sapiens (human)
protein bindingSolute carrier family 22 member 1 Homo sapiens (human)
monoamine transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
secondary active organic cation transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
organic anion transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
organic cation transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
prostaglandin transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
pyrimidine nucleoside transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
thiamine transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
putrescine transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
spermidine transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
quaternary ammonium group transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
toxin transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
identical protein bindingSolute carrier family 22 member 1 Homo sapiens (human)
xenobiotic transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
(R)-carnitine transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
amyloid-beta bindingAcetylcholinesteraseHomo sapiens (human)
acetylcholinesterase activityAcetylcholinesteraseHomo sapiens (human)
cholinesterase activityAcetylcholinesteraseHomo sapiens (human)
protein bindingAcetylcholinesteraseHomo sapiens (human)
collagen bindingAcetylcholinesteraseHomo sapiens (human)
hydrolase activityAcetylcholinesteraseHomo sapiens (human)
serine hydrolase activityAcetylcholinesteraseHomo sapiens (human)
acetylcholine bindingAcetylcholinesteraseHomo sapiens (human)
protein homodimerization activityAcetylcholinesteraseHomo sapiens (human)
laminin bindingAcetylcholinesteraseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (19)

Processvia Protein(s)Taxonomy
plasma membraneSolute carrier family 22 member 2Homo sapiens (human)
basal plasma membraneSolute carrier family 22 member 2Homo sapiens (human)
membraneSolute carrier family 22 member 2Homo sapiens (human)
basolateral plasma membraneSolute carrier family 22 member 2Homo sapiens (human)
apical plasma membraneSolute carrier family 22 member 2Homo sapiens (human)
extracellular exosomeSolute carrier family 22 member 2Homo sapiens (human)
presynapseSolute carrier family 22 member 2Homo sapiens (human)
plasma membraneSolute carrier family 22 member 1 Homo sapiens (human)
basal plasma membraneSolute carrier family 22 member 1 Homo sapiens (human)
membraneSolute carrier family 22 member 1 Homo sapiens (human)
basolateral plasma membraneSolute carrier family 22 member 1 Homo sapiens (human)
apical plasma membraneSolute carrier family 22 member 1 Homo sapiens (human)
lateral plasma membraneSolute carrier family 22 member 1 Homo sapiens (human)
presynapseSolute carrier family 22 member 1 Homo sapiens (human)
extracellular regionAcetylcholinesteraseHomo sapiens (human)
basement membraneAcetylcholinesteraseHomo sapiens (human)
extracellular spaceAcetylcholinesteraseHomo sapiens (human)
nucleusAcetylcholinesteraseHomo sapiens (human)
Golgi apparatusAcetylcholinesteraseHomo sapiens (human)
plasma membraneAcetylcholinesteraseHomo sapiens (human)
cell surfaceAcetylcholinesteraseHomo sapiens (human)
membraneAcetylcholinesteraseHomo sapiens (human)
neuromuscular junctionAcetylcholinesteraseHomo sapiens (human)
synaptic cleftAcetylcholinesteraseHomo sapiens (human)
synapseAcetylcholinesteraseHomo sapiens (human)
perinuclear region of cytoplasmAcetylcholinesteraseHomo sapiens (human)
side of membraneAcetylcholinesteraseHomo sapiens (human)
plasma membraneNeuronal acetylcholine receptor subunit alpha-9Rattus norvegicus (Norway rat)
plasma membraneNeuronal acetylcholine receptor subunit alpha-10Rattus norvegicus (Norway rat)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (77)

Assay IDTitleYearJournalArticle
AID504836Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation2002The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16
Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID588349qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID588378qHTS for Inhibitors of ATXN expression: Validation
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID344669Binding affinity to blood-brain barrier choline transporter in rat brain assessed as inhibition of [3H]choline uptake2008Bioorganic & medicinal chemistry letters, Oct-15, Volume: 18, Issue:20
bis-Pyridinium cyclophanes: novel ligands with high affinity for the blood-brain barrier choline transporter.
AID231912Ratio between the binding affinities towards rat alpha3-beta4 and alpha3-beta2 nACh receptor using [3H]EB as radioligand2004Bioorganic & medicinal chemistry letters, Apr-19, Volume: 14, Issue:8
Pharmacology of the agonist binding sites of rat neuronal nicotinic receptor subtypes expressed in HEK 293 cells.
AID678794TP_TRANSPORTER: inhibition of MPP+ uptake (MPP+: 1 uM) in Xenopus laevis oocytes2002Biochemical and biophysical research communications, Aug-23, Volume: 296, Issue:3
Functional characterization of mouse cation transporter mOCT2 compared with mOCT1.
AID70621Minimum concentration required to inhibit Escherichia coli ATCC 259222003Journal of medicinal chemistry, Sep-11, Volume: 46, Issue:19
Soft antimicrobial agents: synthesis and activity of labile environmentally friendly long chain quaternary ammonium compounds.
AID386623Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium uptake at human OCT1 expressed in HEK293 cells at 100 uM by confocal microscopy2008Journal of medicinal chemistry, Oct-09, Volume: 51, Issue:19
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
AID681957TP_TRANSPORTER: inhibition of MPP+ uptake (MPP+: 0.85 uM, Choline: 1000 uM) in Xenopus laevis oocytes1997Molecular pharmacology, Jun, Volume: 51, Issue:6
Cloning and functional expression of a human liver organic cation transporter.
AID68051Minimum concentration required to inhibit Enterococcus faecalis ATCC 292122003Journal of medicinal chemistry, Sep-11, Volume: 46, Issue:19
Soft antimicrobial agents: synthesis and activity of labile environmentally friendly long chain quaternary ammonium compounds.
AID52130In vitro ability to inhibit the transport of [3H]choline in to high affinity choline transport system HAChT1986Journal of medicinal chemistry, Mar, Volume: 29, Issue:3
Neurochemistry of aging. 1. Toxins for an animal model of Alzheimer's disease.
AID681966TP_TRANSPORTER: inhibition of TEA uptake (TEA: 75 uM, Choline: 1000 uM) in Xenopus laevis oocytes2001The Journal of biological chemistry, Nov-09, Volume: 276, Issue:45
Ventricular choline transport: a role for organic cation transporter 2 expressed in choroid plexus.
AID678957TP_TRANSPORTER: uptake in Xenopus laevis oocytes1997DNA and cell biology, Jul, Volume: 16, Issue:7
Cloning and characterization of two human polyspecific organic cation transporters.
AID682099TP_TRANSPORTER: no change in tissue distribution in Oct1 -/- mouse2001Molecular and cellular biology, Aug, Volume: 21, Issue:16
Reduced hepatic uptake and intestinal excretion of organic cations in mice with a targeted disruption of the organic cation transporter 1 (Oct1 [Slc22a1]) gene.
AID678785TP_TRANSPORTER: inhibition of MPP+ uptake (MPP+: 1 uM) in Xenopus laevis oocytes2002Biochemical and biophysical research communications, Aug-23, Volume: 296, Issue:3
Functional characterization of mouse cation transporter mOCT2 compared with mOCT1.
AID231911Ratio between the binding affinities towards rat alpha2-beta4 and alpha2-beta2 nACh receptor using [3H]-EB as radioligand2004Bioorganic & medicinal chemistry letters, Apr-19, Volume: 14, Issue:8
Pharmacology of the agonist binding sites of rat neuronal nicotinic receptor subtypes expressed in HEK 293 cells.
AID678993TP_TRANSPORTER: uptake in Xenopus laevis oocytes1999Molecular pharmacology, Dec, Volume: 56, Issue:6
Selectivity of the polyspecific cation transporter rOCT1 is changed by mutation of aspartate 475 to glutamate.
AID1556731Agonist activity at alpha7 nAChR in human SH-SY5Y cells assessed as release of intracellular calcium at 3 mM preincubated for 20 mins with alpha7 nAChR antagonist alpha-bungarotoxin and for 1 min with alpha7 nAChR PAM PNU120596 prior to compound addition 2019European journal of medicinal chemistry, Oct-01, Volume: 179Bis(het)aryl-1,2,3-triazole quinuclidines as α7 nicotinic acetylcholine receptor ligands: Synthesis, structure affinity relationships, agonism activity, [
AID679635TP_TRANSPORTER: uptake (electrogenesis) in Xenopus laevis oocytes2000The Journal of biological chemistry, Sep-22, Volume: 275, Issue:38
Mechanism of electrogenic cation transport by the cloned organic cation transporter 2 from rat.
AID146772Binding affinity towards rat Nicotinic acetylcholine receptor alpha4-beta4 expressed in HEK293 cells using [3H]EB as radioligand2004Bioorganic & medicinal chemistry letters, Apr-19, Volume: 14, Issue:8
Pharmacology of the agonist binding sites of rat neuronal nicotinic receptor subtypes expressed in HEK 293 cells.
AID32720Inhibition acetylcholinesterase (AChE) enzyme.1997Journal of medicinal chemistry, Dec-19, Volume: 40, Issue:26
Three-dimensional quantitative structure-activity relationships from molecular similarity matrices and genetic neural networks. 2. Applications.
AID146162Binding affinity towards rat Nicotinic acetylcholine receptor alpha3-beta4 expressed in HEK293 cells using [3H]EB as radioligand2004Bioorganic & medicinal chemistry letters, Apr-19, Volume: 14, Issue:8
Pharmacology of the agonist binding sites of rat neuronal nicotinic receptor subtypes expressed in HEK 293 cells.
AID680371TP_TRANSPORTER: uptake in Oct1-expressing BALB/3T3 cells2000Journal of lipid research, Nov, Volume: 41, Issue:11
Functional expression of a high affinity mammalian hepatic choline/organic cation transporter.
AID680376TP_TRANSPORTER: inhibition of carnitine uptake by Choline at 500uM in Octn2-HEK cells2000The Journal of biological chemistry, Dec-22, Volume: 275, Issue:51
Molecular and functional characterization of organic cation/carnitine transporter family in mice.
AID681348TP_TRANSPORTER: inhibition of TEA uptake (TEA: 50 uM) in OCT1-expressing MDCK cells2001Pharmaceutical research, Nov, Volume: 18, Issue:11
Distinct characteristics of organic cation transporters, OCT1 and OCT2, in the basolateral membrane of renal tubules.
AID70623Minimum concentration required to inhibit Escherichia coli ATCC 259222003Journal of medicinal chemistry, Sep-11, Volume: 46, Issue:19
Soft antimicrobial agents: synthesis and activity of labile environmentally friendly long chain quaternary ammonium compounds.
AID679825TP_TRANSPORTER: uptake (electrogenesis,-50mV) in Xenopus laevis oocytes1996The Journal of biological chemistry, Dec-20, Volume: 271, Issue:51
Electrogenic properties and substrate specificity of the polyspecific rat cation transporter rOCT1.
AID681712TP_TRANSPORTER: inhibition of Carnitine uptake (Carnitine: 0.025 uM, Choline: 2000 uM) in OCTN2-expressing HRPE cells1999The Journal of pharmacology and experimental therapeutics, Sep, Volume: 290, Issue:3
Functional characteristics and tissue distribution pattern of organic cation transporter 2 (OCTN2), an organic cation/carnitine transporter.
AID680370TP_TRANSPORTER: uptake in Xenopus laevis oocytes1999Hepatology (Baltimore, Md.), May, Volume: 29, Issue:5
Cloning and functional expression of a mouse liver organic cation transporter.
AID146486Binding affinity towards rat Nicotinic acetylcholine receptor alpha4-beta2 expressed in HEK293 cells using [3H]EB as radioligand2004Bioorganic & medicinal chemistry letters, Apr-19, Volume: 14, Issue:8
Pharmacology of the agonist binding sites of rat neuronal nicotinic receptor subtypes expressed in HEK 293 cells.
AID242872Maximal response against Nicotinic acetylcholine receptor alpha 72005Journal of medicinal chemistry, Jul-28, Volume: 48, Issue:15
Neuronal nicotinic acetylcholine receptors: structural revelations, target identifications, and therapeutic inspirations.
AID681945TP_TRANSPORTER: inhibition of TEA uptake (TEA: 5 uM, Choline: 500 uM) in OCT1-expressing HeLa cells1998The Journal of pharmacology and experimental therapeutics, Jul, Volume: 286, Issue:1
Functional characterization of an organic cation transporter (hOCT1) in a transiently transfected human cell line (HeLa).
AID145983Binding affinity towards rat nicotinic acetylcholine receptor alpha2-beta2 expressed in HEK293 cells using [3H]EB as radioligand2004Bioorganic & medicinal chemistry letters, Apr-19, Volume: 14, Issue:8
Pharmacology of the agonist binding sites of rat neuronal nicotinic receptor subtypes expressed in HEK 293 cells.
AID681998TP_TRANSPORTER: inhibition of TEA uptake (TEA: 5 uM, Choline: 1000 uM) in OCT2A-expressing HEK293 cells2002Journal of the American Society of Nephrology : JASN, Jul, Volume: 13, Issue:7
cDNA cloning, functional characterization, and tissue distribution of an alternatively spliced variant of organic cation transporter hOCT2 predominantly expressed in the human kidney.
AID163958Minimum concentration required to inhibit Pseudomonas aeruginosa ATCC 278532003Journal of medicinal chemistry, Sep-11, Volume: 46, Issue:19
Soft antimicrobial agents: synthesis and activity of labile environmentally friendly long chain quaternary ammonium compounds.
AID681117TP_TRANSPORTER: inhibition of TEA uptake in OCT1-expressing HeLa cells2003Molecular pharmacology, Mar, Volume: 63, Issue:3
Influence of molecular structure on substrate binding to the human organic cation transporter, hOCT1.
AID681628TP_TRANSPORTER: uptake in OCT2-expressing HEK-293 cells2001American journal of physiology. Renal physiology, Sep, Volume: 281, Issue:3
Interaction of cations, anions, and weak base quinine with rat renal cation transporter rOCT2 compared with rOCT1.
AID681624TP_TRANSPORTER: uptake in Xenopus laevis oocytes2001The Journal of biological chemistry, Nov-09, Volume: 276, Issue:45
Ventricular choline transport: a role for organic cation transporter 2 expressed in choroid plexus.
AID1556733Agonist activity at alpha7 nAChR in human SH-SY5Y cells assessed as increase in intracellular calcium release at 3 mM preincubated for 1 min with alpha7 nAchR PAM PNU120596 prior to compound addition by Fluo-3 AM staining-based fluorescence spectral scann2019European journal of medicinal chemistry, Oct-01, Volume: 179Bis(het)aryl-1,2,3-triazole quinuclidines as α7 nicotinic acetylcholine receptor ligands: Synthesis, structure affinity relationships, agonism activity, [
AID682270TP_TRANSPORTER: inhibition of TEA uptake (TEA: 20 uM, Choline: 5000 uM) in OCTN2-expressing HeLa cells1998Biochemical and biophysical research communications, May-29, Volume: 246, Issue:3
cDNA sequence, transport function, and genomic organization of human OCTN2, a new member of the organic cation transporter family.
AID681345TP_TRANSPORTER: inhibition of TEA uptake (TEA: 50 uM) in OCT2-expressing MDCK cells2001Pharmaceutical research, Nov, Volume: 18, Issue:11
Distinct characteristics of organic cation transporters, OCT1 and OCT2, in the basolateral membrane of renal tubules.
AID51964Rate of acetylation of 13.0+/-1.1 umol compound by 1 g of choline acetyltransferase (ChAc) by incubating for 10 minutes at 37 degrees Centigrade1984Journal of medicinal chemistry, Jun, Volume: 27, Issue:6
Acetylation of some novel hemicholinium compounds by soluble choline acetyltransferase: structure-activity relationships.
AID207555Minimum concentration required to inhibit Staphylococcus aureus ATCC 259232003Journal of medicinal chemistry, Sep-11, Volume: 46, Issue:19
Soft antimicrobial agents: synthesis and activity of labile environmentally friendly long chain quaternary ammonium compounds.
AID52133Inhibition of [3H]-choline brain uptake was determined by in situ brain perfusion studies in male rats2004Bioorganic & medicinal chemistry letters, Jun-21, Volume: 14, Issue:12
Molecular modeling studies on the active binding site of the blood-brain barrier choline transporter.
AID146006Binding affinity towards rat Nicotinic acetylcholine receptor alpha3-beta2 expressed in HEK293 cells using [3H]EB as radioligand2004Bioorganic & medicinal chemistry letters, Apr-19, Volume: 14, Issue:8
Pharmacology of the agonist binding sites of rat neuronal nicotinic receptor subtypes expressed in HEK 293 cells.
AID681960TP_TRANSPORTER: uptake in Xenopus laevis oocytes2001The Journal of biological chemistry, Nov-09, Volume: 276, Issue:45
Ventricular choline transport: a role for organic cation transporter 2 expressed in choroid plexus.
AID52115Apparent Michaelis-Menten Constant (Vmax) for the acetylation of compound1984Journal of medicinal chemistry, Jun, Volume: 27, Issue:6
Acetylation of some novel hemicholinium compounds by soluble choline acetyltransferase: structure-activity relationships.
AID679159TP_TRANSPORTER: uptake (electrogenesis) in Xenopus laevis oocytes1997DNA and cell biology, Jul, Volume: 16, Issue:7
Cloning and characterization of two human polyspecific organic cation transporters.
AID681589TP_TRANSPORTER: uptake in Xenopus laevis oocytes2001American journal of physiology. Renal physiology, Sep, Volume: 281, Issue:3
Interaction of cations, anions, and weak base quinine with rat renal cation transporter rOCT2 compared with rOCT1.
AID231914Ratio between the binding affinities towards rat alpha3-beta4 and forebrain nACh receptor using [3H]EB as radioligand2004Bioorganic & medicinal chemistry letters, Apr-19, Volume: 14, Issue:8
Pharmacology of the agonist binding sites of rat neuronal nicotinic receptor subtypes expressed in HEK 293 cells.
AID163955Minimum concentration required to inhibit Pseudomonas aeruginosa ATCC 278532003Journal of medicinal chemistry, Sep-11, Volume: 46, Issue:19
Soft antimicrobial agents: synthesis and activity of labile environmentally friendly long chain quaternary ammonium compounds.
AID678970TP_TRANSPORTER: inhibition of TEA uptake (TEA: 100 uM) in Xenopus laevis oocytes1999Biochimica et biophysica acta, Mar-04, Volume: 1417, Issue:2
Molecular mechanisms of organic cation transport in OCT2-expressing Xenopus oocytes.
AID679188TP_TRANSPORTER: uptake in Xenopus laevis oocytes2001The Journal of biological chemistry, Nov-09, Volume: 276, Issue:45
Ventricular choline transport: a role for organic cation transporter 2 expressed in choroid plexus.
AID231915Ratio between the binding affinities towards rat alpha4-beta4 and alpha4-beta2 nACh receptor using [3H]EB as radioligand2004Bioorganic & medicinal chemistry letters, Apr-19, Volume: 14, Issue:8
Pharmacology of the agonist binding sites of rat neuronal nicotinic receptor subtypes expressed in HEK 293 cells.
AID52113Apparent Michaelis-Menten Constant (KM) for the acetylation of compound was calculated from Linewear-Burke plots by incubating for 10 minutes at 37 degrees Centigrade1984Journal of medicinal chemistry, Jun, Volume: 27, Issue:6
Acetylation of some novel hemicholinium compounds by soluble choline acetyltransferase: structure-activity relationships.
AID207553Minimum concentration required to inhibit Staphylococcus aureus ATCC 259232003Journal of medicinal chemistry, Sep-11, Volume: 46, Issue:19
Soft antimicrobial agents: synthesis and activity of labile environmentally friendly long chain quaternary ammonium compounds.
AID682276TP_TRANSPORTER: inhibition of Carnitine uptake (Carnitine: 0.025 uM, Choline: 2000 uM) in OCTN2-expressing HRPE cells1999The Journal of pharmacology and experimental therapeutics, Sep, Volume: 290, Issue:3
Functional characteristics and tissue distribution pattern of organic cation transporter 2 (OCTN2), an organic cation/carnitine transporter.
AID680544TP_TRANSPORTER: inhibition of Carnitine uptake (Carnitine: 0.01 uM, Choline: 500 uM) in OCTN2-expressing HEK293 cells2001Molecular pharmacology, Feb, Volume: 59, Issue:2
Molecular and physiological evidence for multifunctionality of carnitine/organic cation transporter OCTN2.
AID682231TP_TRANSPORTER: inhibition of Guanidine uptake (Guanidine: 35 uM, Choline: 5000 uM) in OCT3-expressing HeLa cells1998The Journal of biological chemistry, Jun-26, Volume: 273, Issue:26
Cloning and functional characterization of a potential-sensitive, polyspecific organic cation transporter (OCT3) most abundantly expressed in placenta.
AID68053Minimum concentration required to inhibit Enterococcus faecalis ATCC 292122003Journal of medicinal chemistry, Sep-11, Volume: 46, Issue:19
Soft antimicrobial agents: synthesis and activity of labile environmentally friendly long chain quaternary ammonium compounds.
AID679314TP_TRANSPORTER: uptake in Xenopus laevis oocytes1996The Journal of biological chemistry, Dec-20, Volume: 271, Issue:51
Electrogenic properties and substrate specificity of the polyspecific rat cation transporter rOCT1.
AID145685Binding affinity towards rat forebrain nicotinic acetylcholine receptor using [3H]EB as radioligand2004Bioorganic & medicinal chemistry letters, Apr-19, Volume: 14, Issue:8
Pharmacology of the agonist binding sites of rat neuronal nicotinic receptor subtypes expressed in HEK 293 cells.
AID679207TP_TRANSPORTER: inhibition of TEA uptake (TEA: 500 uM, Choline: 5000 uM) in OCT1A expressing Xenopus laevis oocytes1997The Journal of biological chemistry, Jun-27, Volume: 272, Issue:26
Cloning and functional characterization of a rat renal organic cation transporter isoform (rOCT1A).
AID680408TP_TRANSPORTER: inhibition of TEA uptake (TEA: 60 uM, Choline: 5000 uM) in Xenopus laevis oocytes1999The Journal of pharmacology and experimental therapeutics, May, Volume: 289, Issue:2
Novel membrane transporter OCTN1 mediates multispecific, bidirectional, and pH-dependent transport of organic cations.
AID225720Binding affinity towards rat alpha2-beta4 nACh receptor expressed in HEK293 cells using [3H]EB as radioligand2004Bioorganic & medicinal chemistry letters, Apr-19, Volume: 14, Issue:8
Pharmacology of the agonist binding sites of rat neuronal nicotinic receptor subtypes expressed in HEK 293 cells.
AID679826TP_TRANSPORTER: inhibition of TEA uptake (TEA: 100 uM) in Xenopus laevis oocytes1999Biochimica et biophysica acta, Mar-04, Volume: 1417, Issue:2
Molecular mechanisms of organic cation transport in OCT2-expressing Xenopus oocytes.
AID681707TP_TRANSPORTER: inhibition of TEA uptake (TEA: 20 uM, Choline: 2500 uM) in OCTN2-expressing HRPE cells1999The Journal of pharmacology and experimental therapeutics, Sep, Volume: 290, Issue:3
Functional characteristics and tissue distribution pattern of organic cation transporter 2 (OCTN2), an organic cation/carnitine transporter.
AID483710Binding affinity to blood-brain barrier choline transporter in rat brain assessed as inhibition of [3H]choline uptake2010Bioorganic & medicinal chemistry letters, Jun-01, Volume: 20, Issue:11
Bis-azaaromatic quaternary ammonium salts as ligands for the blood-brain barrier choline transporter.
AID679824TP_TRANSPORTER: uptake in OCT1-expressing HEK293 cells1999Molecular pharmacology, Jul, Volume: 56, Issue:1
Selective substrates for non-neuronal monoamine transporters.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID977611Experimentally measured binding affinity data (Kd) for protein-ligand complexes derived from PDB2011Journal of molecular biology, Aug-05, Volume: 411, Issue:1
The crystal structure of the substrate-binding protein OpuBC from Bacillus subtilis in complex with choline.
AID977611Experimentally measured binding affinity data (Kd) for protein-ligand complexes derived from PDB2006The Journal of biological chemistry, Sep-29, Volume: 281, Issue:39
Substrate and product trafficking through the active center gorge of acetylcholinesterase analyzed by crystallography and equilibrium binding.
AID1811Experimentally measured binding affinity data derived from PDB2006The Journal of biological chemistry, Sep-29, Volume: 281, Issue:39
Substrate and product trafficking through the active center gorge of acetylcholinesterase analyzed by crystallography and equilibrium binding.
AID977611Experimentally measured binding affinity data (Kd) for protein-ligand complexes derived from PDB2008The Journal of biological chemistry, Nov-21, Volume: 283, Issue:47
Crystal structures of the choline/acetylcholine substrate-binding protein ChoX from Sinorhizobium meliloti in the liganded and unliganded-closed states.
AID977611Experimentally measured binding affinity data (Kd) for protein-ligand complexes derived from PDB2011The Biochemical journal, Jun-01, Volume: 436, Issue:2
Structures of the substrate-binding protein provide insights into the multiple compatible solute binding specificities of the Bacillus subtilis ABC transporter OpuC.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (18,773)

TimeframeStudies, This Drug (%)All Drugs %
pre-19908868 (47.24)18.7374
1990's2525 (13.45)18.2507
2000's2735 (14.57)29.6817
2010's3273 (17.43)24.3611
2020's1372 (7.31)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 64.78

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index64.78 (24.57)
Research Supply Index9.92 (2.92)
Research Growth Index4.55 (4.65)
Search Engine Demand Index217.73 (26.88)
Search Engine Supply Index3.65 (0.95)

This Compound (64.78)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials608 (3.10%)5.53%
Reviews894 (4.55%)6.00%
Case Studies481 (2.45%)4.05%
Observational38 (0.19%)0.25%
Other17,607 (89.70%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (156)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Randomised Controlled Trial Assessing the Effect of S-adenosylmethionine Plus Choline in Treatment of Patients With Alcoholic Liver Disease [NCT03938662]44 participants (Anticipated)Interventional2019-05-09Recruiting
[NCT01221896]100 participants (Anticipated)Observational2011-01-31Not yet recruiting
A Randomized, Double-blind, Placebo-controlled Phase IV Trial for an Evaluation of the Efficacy of Gliatiline® on Post-stroke Patients With Vascular Cognitive Impairment no Dementia [NCT01363648]Phase 4222 participants (Actual)Interventional2010-11-30Completed
Effect of Maternal Choline Intake on Maternal/Fetal Biomarkers of Choline Status [NCT01127022]82 participants (Actual)Interventional2009-01-31Completed
Evaluation of 11 C-Choline PET-CT for Detection of Hepatocellular Carcinoma [NCT01377220]Phase 230 participants (Anticipated)Interventional2011-06-30Not yet recruiting
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study Assessing the Efficacy, Safety and Tolerability of Diazoxide Choline Controlled-Release Tablet (DCCR) in Subjects Without Diabetes Mellitus Having Very High Fasting Triglyceride Levels, Wi [NCT01211847]Phase 244 participants (Actual)Interventional2010-10-31Completed
A Cancer Research UK Phase II Trial to Compare [11C]Choline and [18F]Choline Each Given as a Single Administration Via Intravenous Injection for Imaging Patients With Metastatic Prostate Cancer [NCT01132599]Phase 20 participants (Actual)Interventional2010-05-31Withdrawn
Diagnostic Value of 18F-fluorocholine PET/CT Imaging in Localization of Hyperfunctioning Parathyroid Tissue in Hyperparathyroidism [NCT03203668]1,000 participants (Anticipated)Interventional2013-01-01Recruiting
Evaluation of PET TDM FDG-Choline as a Decision-making Tool for Routine Care on Inclusion on the Liver Transplant List for Hepatocellular Carcinoma [NCT04792801]100 participants (Anticipated)Observational2021-06-22Recruiting
Pilot Study of 11C-Choline (11C-CH) PET in Assessing Post-treatment True Tumor Progression From Pseudo-progression in High-grade Gliomas [NCT02849171]8 participants (Actual)Interventional2016-07-31Completed
Characterizing Lymphangioleiomyomatosis (LAM) With 11C-Choline PET/CT [NCT05087134]Early Phase 150 participants (Anticipated)Interventional2021-11-30Not yet recruiting
Choline Nutritional Status: Development of a Biomarker Panel [NCT03726671]101 participants (Actual)Interventional2018-11-01Completed
Place of 68Ga-PSMA-11 PET-CT in the Therapeutic Decision at the End of the Initial Staging for High Risk Prostate Cancer Patients in Comparaison of 18F-Choline PET-CT [NCT03344822]Phase 2/Phase 333 participants (Anticipated)Interventional2018-01-02Not yet recruiting
Examination of the Lipid Metabolism of the Liver After Choline Substitution in Cystic Fibrosis [NCT03312140]10 participants (Actual)Interventional2014-11-06Completed
Reverse Triple Negative Immune Resistant Breast Cancer [NCT05076682]Phase 230 participants (Anticipated)Interventional2022-06-30Recruiting
Developing a Biomarker Panel to Assess Choline Nutritional Status [NCT03234062]16 participants (Actual)Interventional2018-02-15Completed
Evaluation of the Practice of the TEP Choline in Provence - Alps and Côte d'Azur at Patients With Prostate Cancer - Multicentre Retrospective Study. [NCT03201380]300 participants (Actual)Observational2014-11-01Active, not recruiting
Effects of Choline From Eggs vs. Supplements on the Generation of TMAO in Humans (EGGS) [NCT03039023]86 participants (Actual)Interventional2016-09-02Completed
A Dose Titration Study of Diazoxide Choline Controlled-Release Tablet (DCCR) in Patients With Prader-Willi Syndrome With a Double-Blind, Placebo-Controlled, Randomized Withdrawal Extension [NCT02034071]Phase 1/Phase 213 participants (Actual)Interventional2014-04-30Completed
A Multi-center, Randomized, Double-blind, Placebo-controlled, Phase IV Trial to Evaluate the Efficacy and Safety of Choline Alfoscerate in Patients With Mild to Moderate Alzheimer's Disease [NCT05383183]Phase 4630 participants (Anticipated)Interventional2022-01-13Recruiting
Phase 2 Study of Citocoline for Treatment in Fragile X-associated Tremor/Ataxia Syndrome [NCT02197104]Phase 210 participants (Actual)Interventional2015-01-31Completed
Choline PET/CT vs. MeAIB PET/CT. Better Detection of Bone and Lymph Node Metastases in Prostate Cancer Patients, PROSTAGE III [NCT02232672]0 participants (Actual)Interventional2016-11-30Withdrawn
A Multiple-Dose Pharmacokinetic Study of Diazoxide Choline Controlled-Release Tablet (DCCR) in Subjects With Elevated Fasting Triglyceride Levels [NCT01211860]Phase 19 participants (Actual)Interventional2010-10-31Completed
The Role of C-11 Choline PET in Patients With Prostate Cancer [NCT02852122]54 participants (Actual)Interventional2015-01-31Completed
Choline PET/CT vs. Dual Time Point FDG PET/CT. Better Detection of Bone and Lymph Node Metastasis in Prostate Cancer Patients, PROSTAGE II [NCT02232724]20 participants (Actual)Interventional2014-11-30Completed
Treatment With Acetyl-Choline Esterase Inhibitors in Children With Autism [NCT01098383]Phase 484 participants (Anticipated)Interventional2010-03-31Recruiting
Effects of Choline Supplementation on Fetal Growth in Gestational Diabetes Mellitus [NCT04302168]60 participants (Anticipated)Interventional2020-04-01Recruiting
Molecular Imaging of Plaque Vulnerability Using 18F-choline PET-MRI in Carotid Artery Atherosclerosis Patients [NCT02640313]Phase 314 participants (Anticipated)Interventional2015-12-31Recruiting
PSMA Specific [68Ga]-P137 Peptide Probe for PET Imaging in Prostate Cancer [NCT04560725]50 participants (Anticipated)Interventional2020-10-22Recruiting
Plasma TMAO and Choline Levels in Individuals With Metabolic Syndrome - Comparison Between Eggs and Choline Supplement Intake [NCT03877003]25 participants (Actual)Interventional2018-11-01Completed
Choline Supplementation as a Neurodevelopmental Intervention in Fetal Alcohol Spectrum Disorders [NCT02735473]Phase 246 participants (Actual)Interventional2016-06-30Completed
Early Identification of Affected Children and Nutritional Risk Factors for FASD in Ukraine [NCT03782935]600 participants (Actual)Interventional2006-06-30Completed
A Cross-over, Randomized and Open-label Clinical Trial to Evaluate the Effects of Food on the Bioavailability of CKD-337 After a Single Oral Dose in Healthy Male Subjects [NCT03382756]Phase 116 participants (Actual)Interventional2017-10-12Completed
The Impact Of Choline Administration On Oxidative Stress And Clinical Outcome Of Patients With Non-Alcoholic Fatty Liver Disease NAFLD [NCT05200156]100 participants (Anticipated)Interventional2022-02-01Recruiting
Clinical Medication Development for Bipolar Disorder and Alcohol Use Disorders [NCT02582905]Phase 496 participants (Actual)Interventional2016-05-31Completed
A Phase 1, Randomized, Open-Label, 2-Way Crossover Study to Assess the Single-Dose Pharmacokinetics of ALXN1840 Enteric-Coated Tablets at 2 Dose Strengths in Healthy Adult Subjects [NCT05303324]Phase 148 participants (Actual)Interventional2019-07-04Completed
Short Term Choline Supplementation and Cardiovascular Health in Adults [NCT03327805]20 participants (Actual)Interventional2019-04-01Completed
CDP-Choline and Working Memory After TBI: A Neuroimaging Study. [NCT00727246]Phase 219 participants (Actual)Interventional2009-03-31Completed
Study of Efficacy and Tolerance of Treatment With DHA, Choline and Vitamin E in Children With Non-alcoholic Steatohepatitis [NCT01934777]Phase 360 participants (Actual)Interventional2013-10-31Completed
Effect of Choline Fenofibrate (SLV348) on Macular Edema Measured by Optical Coherence Tomography in Subjects With Diabetic Macular Edema - a One-year, Placebo-Controlled, Randomized Study [NCT00683176]Phase 2110 participants (Actual)Interventional2008-09-30Completed
To Investigate Whether Choline Supplementation in Children With CF Will Correct Biochemical Markers of Choline Deficiency and Improve Plasma Indices of Methylation Capacity and Redox Status and Result in Decreased Pro-inflammatory Cytokines [NCT00686361]34 participants (Actual)Interventional2007-10-31Completed
A Randomized, Open-label, Multi-dose Crossover Study Assessing the Pharmacokinetic Profiles of Diazoxide Choline Coated Versus Uncoated Formulations in Healthy Volunteers [NCT00688857]Phase 112 participants (Anticipated)Interventional2008-05-31Completed
Clinical Trial of Biomarkers for Predicting Immunotherapy Response in Hepatocellular Carcinoma [NCT04965454]Phase 280 participants (Anticipated)Interventional2022-03-28Recruiting
Whole Body Bone Scan vs 18F-Choline PET/CT, Better Detection of Bone Metastases in Prostate Cancer Patients, PROSTAGE I [NCT02232685]143 participants (Actual)Interventional2014-09-30Completed
A Study on the Diagnostic Value of the Methacholine Choline Provocation Test in the Asthmatic Population [NCT05870436]1,100 participants (Anticipated)Observational2023-05-19Recruiting
Neurobehavioral and Immune Effects of Citicoline in Youth Alcohol Use Disorder [NCT05870111]Phase 248 participants (Anticipated)Interventional2024-02-29Not yet recruiting
Clinical Value of 18F -Fluorocholine (18F-FCH) PET in Localizing Parathyroid Lesions: Comparison With 99mTc-sestamibi (MIBI) Scan. [NCT03555487]Phase 3103 participants (Actual)Interventional2015-05-05Completed
A Multi-center, Randomized, Double-blind, Placebo-controlled, Phase IV Trial to Evaluate the Efficacy and Safety of Choline Alfoscerate Compared to Placebo in Mild Cognitive Impairment Patients With Cerebrovascular Disease [NCT05050604]Phase 4418 participants (Anticipated)Interventional2021-09-30Not yet recruiting
A Multi-center, Randomized, Double-blind, Placebo-controlled, Phase IV Trial to Evaluate the Efficacy and Safety of Choline Alfoscerate Compared to Placebo in Patients With Degenerative Mild Cognitive Impairment(ESCALADE) [NCT05041790]Phase 4418 participants (Anticipated)Interventional2021-09-30Not yet recruiting
Effects of CDP-Choline on Gating and Cognitive Deficits in First Episode Schizophrenia [NCT02088983]Phase 240 participants (Anticipated)Interventional2014-04-30Not yet recruiting
Supplemental Citicoline Administration to Reduce Lung Injury Efficacy Trial (SCARLET) [NCT05881135]Phase 1/Phase 280 participants (Anticipated)Interventional2023-06-06Recruiting
Clinical Assessment of the Benefits of the Combination Inuline, Choline and Silymarin in Mitigating the Symptomatology in Patients With Irritable Bowel Syndrome [NCT03174561]50 participants (Anticipated)Interventional2017-05-01Recruiting
An Open-Label Study to Assess the Preliminary Efficacy and Safety of DCCR (Diazoxide Choline) Extended-Release Tablets in Patients With Genetic Obesities [NCT05532020]Phase 230 participants (Anticipated)Interventional2023-01-31Not yet recruiting
Efficacy of Phosphatidylcholine in Addition to Behavior Therapy by Clinical Pharmacist in the Management of Non Alcoholic Fatty Liver (NAFLD) [NCT04411862]Phase 3100 participants (Actual)Interventional2016-01-02Completed
Interventions to Test the Alpha7 Nicotinic Receptor Model in Schizophrenia [NCT00509067]Phase 243 participants (Actual)Interventional2007-11-30Completed
A 3-month, Randomized, Placebo-controlled, Double-masked, Multi-center Study to Evaluate the Safety and Efficacy of Topical Ocular UNR844-Cl in Subjects With Presbyopia [NCT03809611]Phase 2125 participants (Actual)Interventional2019-04-26Completed
A Pilot Study of Use of 11C-Choline PET-CT in the Metastatic Evaluation of Patients With Newly Diagnosed High Risk Adenocarcinoma of the Prostate [NCT00804245]Phase 118 participants (Actual)Interventional2008-08-31Completed
Detecting Recurrent Prostate Cancer With 11C-choline Positron Emission Tomography: An Expanded Access Study [NCT02531672]0 participants Expanded AccessNo longer available
[NCT02648906]Phase 4128 participants (Anticipated)Interventional2015-07-31Recruiting
11C-choline PET/CT Based Helical Tomotherapy as Innovative Treratment Approach for Bone Metastases in Prostate Cancer Patients. [NCT06179706]20 participants (Actual)Observational2015-10-27Completed
Testing Whether Choline Normalizes Lipid Metabolism in APOE4 Carriers [NCT05880849]Phase 114 participants (Anticipated)Interventional2023-06-26Recruiting
A Randomized, Open-Label, Single- and Multiple-Dose, Four-Way Parallel Study Comparing the Fed and Fasted Pharmacokinetics of Two Dose Levels of Diazoxide Choline Controlled-Release Tablet (DCCR) in Healthy VolunteersVOLUNTEERS [NCT00901823]Phase 10 participants (Actual)Interventional2011-03-31Withdrawn(stopped due to Did not support the planned development of DCCR in the new indication)
Choline Nutrition in Children With Cystic Fibrosis [NCT01070446]34 participants (Actual)Interventional2007-10-31Completed
A Pilot C11-Choline PET-CT Imaging Study in Patients With Locally Advanced Esophageal Cancer [NCT01051479]Phase 122 participants (Actual)Interventional2010-03-31Completed
Early Access Program for ALXN1840 in Patients With Wilson Disease [NCT05686564]0 participants Expanded AccessNo longer available
Pilot Study to Determine Uptake and Biodistribution of 18F-fluorocholine in Histiocytic Disorders by PET Imaging and Biopsy Measurement [NCT02608619]3 participants (Actual)Observational2015-11-30Completed
ABT-335 (Choline Fenofibrate)Reverse Cholesterol Transport (RCT) Study [NCT00673881]Phase 1/Phase 225 participants (Actual)Interventional2008-03-31Completed
Complex Imaging Assessment of Steatosis in Patients Under Treatment With Combination Silimarin, Phyllanthus Niruri and Choline [NCT02669641]Phase 450 participants (Anticipated)Interventional2016-01-31Recruiting
Performance of 18F-Fluorocholine Positron Emission Tomography With Computed Tomography in Patients With 18F-Fluorocholine-avid Lesions: A Basket Trial [NCT04150458]Phase 32,000 participants (Anticipated)Interventional2022-11-30Enrolling by invitation
Superselective Citicoline And Verapamil for Ischemic Neuroprotection and Greater Effective Response (SCAVINGER) in the Kentucky Regional Population: A Clinical and Translational Study [NCT02823106]Phase 10 participants (Actual)Interventional2016-08-31Withdrawn(stopped due to Study put on clinical hold by FDA. Sponsor decided to no pursue the study.)
A Randomized, Double-Blind, Placebo-Controlled Study Assessing the Efficacy and Safety of Diazoxide Choline in Non-Diabetic Hypertriglyceridemic Subjects [NCT00696475]Phase 280 participants (Anticipated)Interventional2008-06-30Completed
A Phase 1, Randomized, 2-period, 2-sequence, Crossover With Parallel-group Extension, Open-label Study to Compare the Relative Bioavailability of 2 Oral Formulations of ALXN1840 in Healthy Adult Participants [NCT04610580]Phase 148 participants (Actual)Interventional2021-01-31Completed
Comparison of Novel PET/CT Imaging Agents and MRS/MRI in Metastatic and High Risk Prostate Cancer: An Inter-SPORE Collaboration [NCT00987376]Phase 18 participants (Actual)Interventional2003-11-30Completed
Safety and Efficacy of Neostigmine Infusion as Adjuvant Therapy in Sepsis and Septic Shock [NCT04130230]Phase 250 participants (Anticipated)Interventional2019-03-06Recruiting
Effect of Choline Source and Gut Microbiota Composition on Trimethylamine-N-oxide Response in Humans [NCT04255368]44 participants (Actual)Interventional2017-11-09Completed
Effect of Oral Choline Supplementation on Postoperative Pain [NCT00720343]Phase 454 participants (Actual)Interventional2009-02-28Terminated(stopped due to PI left the institution.)
CARNIVAL Study: Gut Flora Dependent Metabolism of Dietary CARNItine and Phosphatidylcholine and cardioVAscuLar Disease [NCT01731236]Early Phase 1100 participants (Anticipated)Interventional2011-02-11Enrolling by invitation
A Pilot Study of Nuclear Factor-kappa B (NFkB) Inhibition During Induction Chemotherapy for Patients With Acute Myelogenous Leukemia (AML) [NCT00156299]Phase 115 participants (Actual)Interventional2003-03-31Terminated(stopped due to Replaced by another study)
Predictive Role of [11C] Choline PET/CT on Survival in Prostate Cancer Patients With Biochemical Failure. [NCT06168890]195 participants (Actual)Observational2014-02-04Completed
Choline Supplementation in Children With Fetal Alcohol Spectrum Disorders [NCT01911299]Phase 255 participants (Actual)Interventional2013-05-31Completed
Evaluation of the Incidence of Choline-PET Detected Nodal Metastases Among Newly Diagnosed Prostate Cancer Patients With Presumed Absence of Nodal and Distant Metastases. [NCT01769950]120 participants (Anticipated)Interventional2013-01-31Recruiting
Choline to Improve Malnutrition and Enhance Cognition [NCT06154174]1,500 participants (Anticipated)Interventional2023-12-05Recruiting
F-choline PET in Early Response Assessment for Castration Resistant Prostatic Cancer Treated by Abiraterone Acetate or Enzalutamide [NCT01981707]Phase 2/Phase 312 participants (Actual)Interventional2013-12-31Terminated(stopped due to enrollment default)
A Placebo-Controlled, Phase I, Single-center Evaluation of the Single-dose Pharmacokinetics Study of Azilsartan Trimethylethanolamine [NCT01985152]Phase 162 participants (Anticipated)Interventional2013-09-30Recruiting
A Retrospective Analysis of the Diagnostic Performance of 11C-choline PET/CT for Detection of Hyperfunctioning Parathyroid Glands After Prior Negative or Discordant Imaging in Primary Hyperparathyroidism [NCT04608253]36 participants (Actual)Observational2015-01-01Completed
A Prospective Single-Arm Phase I/II Study Using 11C-Choline PET Scans for Dose Escalated Hypofractionated Image Guided Inversely Planned Intensity Modulated External Beam Radiotherapy With Boost to PET Defined Dominant Intraprostatic Lesions and as a Pred [NCT02004418]Phase 1/Phase 221 participants (Actual)Interventional2014-03-31Completed
Choline Supplementation as a Neurodevelopmental Intervention in Fetal Alcohol Spectrum Disorders Study [NCT05108974]Phase 260 participants (Anticipated)Interventional2021-10-22Recruiting
A Phase 1, Single-Center, Randomized, 3-Period Crossover Study to Evaluate the Relative Bioavailability of WTX101 in Healthy Subjects After Single Dose Administration of a Non-Coated Formulation With and Without a Proton Pump Inhibitor and With a Proton P [NCT05319899]Phase 118 participants (Actual)Interventional2014-01-20Completed
Phase III Trial Comparing 2 Diagnostic Strategies for Preoperative Localization of Parathyroid Adenoma in Primary Hyperparathyroidism:TEMP / CT With Tc99m-sestaMIBI or PET / CT With F18-choline in First Intention [NCT04040946]Phase 359 participants (Actual)Interventional2019-09-19Completed
Efficacy and Safety of S-adenosyl-l-methionine in Treatment of Alcoholic Hepatitis With Cholestasis [NCT02024295]Phase 4118 participants (Anticipated)Interventional2013-12-31Recruiting
Postnatal Choline Supplementation in Children With Prenatal Alcohol Exposure [NCT01149538]Phase 1/Phase 260 participants (Actual)Interventional2010-07-31Completed
Choline-PET: Exploratory Study Assessing the Potential Role of F-choline PET Imaging in New and Emerging Indications [NCT04999215]Phase 3500 participants (Anticipated)Interventional2022-08-01Recruiting
Short Term Choline Supplementation and Cardiometabolic Health in Adults [NCT04764162]16 participants (Actual)Interventional2020-12-15Active, not recruiting
Acute Choline Supplementation and Cardiovascular Health in Adults [NCT03646175]29 participants (Actual)Interventional2018-09-24Active, not recruiting
Phase Ib Trial of Low-Dose Selinexor (KPT-330) in Combination With Choline Salicylate (CS) for the Treatment of Patients With Non-Hodgkin Lymphoma (NHL), Hodgkin Lymphoma, Histiocytic/Dendritic Cell Neoplasms, or Multiple Myeloma [NCT04640779]Phase 139 participants (Anticipated)Interventional2021-02-08Recruiting
[NCT01007539]Phase 331 participants (Actual)Interventional2009-11-30Completed
Biological Investigations in Active Surveillance (BIAS) IGAR 2008 I 19 [NCT00676286]Phase 126 participants (Actual)Interventional2008-11-30Completed
[Al18F]PSMA137 PET/CT Imaging for PSMA-Positive Cancer Patients [NCT04693169]20 participants (Anticipated)Interventional2021-01-15Recruiting
Diagnostic Value of 18F-Choline PET/CT in Patients With a Thyroid Nodule With an Indeterminate Cytology: Pilot Study [NCT02784223]107 participants (Actual)Interventional2016-05-31Completed
A 5 Treatment Period Crossover Pharmacokinetic Study Evaluating Dose Proportionality and Food Effects of Diazoxide Choline Controlled-Release Tablet (DCCR) [NCT02893618]Phase 232 participants (Anticipated)Interventional2017-07-31Not yet recruiting
A Phase 1, Single-Center, Randomized, 3-Period Crossover Study in Healthy Volunteers to Evaluate the Absorption of WTX101 After Single Dose Administration of an Enteric Coated Formulation With and Without Food and a Non-Coated Formulation Coadministered W [NCT05319912]Phase 118 participants (Actual)Interventional2014-04-07Completed
Cancer Localization in the Prostate With F-18 Fluorocholine Positron Emission Tomography [NCT01310192]Phase 120 participants (Actual)Interventional2004-06-30Completed
Cytidine-5'-Diphosphate-choline Treatment in Amphetamine Type Stimulant-using Adolescents [NCT02630069]Phase 2160 participants (Anticipated)Interventional2015-03-31Recruiting
Human Requirements for the Nutrient Choline [NCT00065546]43 participants (Actual)Interventional2007-06-30Completed
Nutritional Support and Prophylaxis Doses of Azithromycin for Pregnant Women to Improve Birth Outcomes in the Peri-urban Slums of Karachi, Pakistan -a Randomized Controlled Trial [NCT04012177]1,884 participants (Actual)Interventional2019-07-22Active, not recruiting
The Effect of Maternal Choline Supplementation on Offspring Cognition in Adolescence: A 13 Year Follow-up of a Randomized Feeding Study [NCT05859126]26 participants (Anticipated)Interventional2023-07-31Not yet recruiting
A Phase 1, Randomized, 2-Period, 2-Sequence, Cross-over Study to Determine the Effect of ALXN1840 on the Metabolism of a CYP2C9 Substrate in Healthy Participants. [NCT04526197]Phase 136 participants (Actual)Interventional2020-07-07Completed
Citicoline Treatment of Methamphetamine Dependence [NCT00950352]Phase 3104 participants (Actual)Interventional2010-01-31Completed
Phospholipid Endoplasmic Reticulum Stress in Nonalcoholic Fatty Liver Disease [NCT01807910]Early Phase 10 participants (Actual)Interventional2013-10-31Withdrawn(stopped due to The study was not funded)
Evaluation of Clinical Effectiveness of Choline Alphoscerate for Older Adults With Major Depression and Subjective Memory Complaints: a Double-blinded, Placebo-controlled, Randomization, Multicenter Investigator-initiated Trial [NCT05257902]120 participants (Anticipated)Interventional2022-03-31Not yet recruiting
Glucocorticosteroid Therapy on Drug-induced Liver Injury: a Prospective Non-randomized Concurrent Control Trial [NCT04553003]Phase 480 participants (Anticipated)Interventional2020-08-01Recruiting
Prevention of TPN-Associated Hepatic Steatosis: A Placebo Controlled Trial [NCT00031135]Phase 248 participants (Anticipated)Interventional2001-09-30Terminated
Assessment of TMAO Formation With Egg Intake Versus Choline Supplement in a Healthy Population [NCT03142763]30 participants (Actual)Interventional2017-01-31Completed
A 12-week, Randomized, Double-blind, Parallel-group, Placebo-controlled Trial of Citicoline as an add-on Therapy Will be Conducted in 200 Outpatients With Bipolar I Disorder and Cocaine Dependence. [NCT00619723]Phase 4130 participants (Actual)Interventional2008-04-30Completed
A Randomized Phase II Study of Nuclear Factor-kappa B (NF-κB) Inhibition During Induction Chemotherapy for Patients With Acute Myelogenous Leukemia [NCT02144675]Phase 227 participants (Actual)Interventional2009-01-31Completed
A Phase 1, Randomized, 2-Period, 2-Sequence, Cross-over Study to Determine the Effect of ALXN1840 on the Metabolism of a CYP2B6 Substrate in Healthy Participants [NCT04526210]Phase 154 participants (Actual)Interventional2020-10-21Completed
A Head-to-head Comparison of MRI, CT, 18F-FDGal and 18F-choline in Patients With Hepatocellular Carcinoma [NCT05359939]50 participants (Anticipated)Interventional2023-01-16Recruiting
Comparison Between Standalone Succinyl Choline and Rocuronium After Pretreatment With Dexmedetomidine, in Rapid Sequence Induction. [NCT04709315]Phase 3240 participants (Anticipated)Interventional2020-10-01Enrolling by invitation
The Effect of Whole-Food Dietary Supplementation on Cognitive and Immune Functioning and Quality of Life in Healthy Older Adults [NCT01672359]97 participants (Actual)Interventional2011-05-31Completed
Dietary Allowance of Methyl Donor Nutrients to Minimize Risks of Non-alcoholic Fatty Liver Progression: Novel Diagnostic and Therapeutic Markers in Metabolomics of Gut Microbiome/Host Methyl Nutrition and the Working Mechanisms [NCT05291104]60 participants (Anticipated)Interventional2022-04-01Enrolling by invitation
Phase 2 Study of 11C- and 18F-Choline PET/MR Imaging in Patients With Unfavorable Intermediate to High-Risk Prostate Cancer [NCT02397408]Phase 218 participants (Actual)Interventional2015-04-09Completed
Improving Cognition and Gestational Duration With Targeted Nutrition [NCT05949190]1,600 participants (Anticipated)Interventional2023-08-18Recruiting
Twelve-Month Chronic Efficacy and Safety of Diepalrestat in Adult Subjects With Diabetic Peripheral Neuropathy (DPN), A Randomized, Double-Blind, Placebo-Controlled Study [NCT02332005]Phase 2/Phase 3330 participants (Actual)Interventional2014-11-30Completed
Detecting Recurrent Prostate Cancer With C-11 Choline Positron Emission Tomography: An Expanded Access Study [NCT02355054]0 participants Expanded AccessApproved for marketing
Choline Uptake Study [NCT03822169]18 participants (Actual)Interventional2019-02-05Completed
Citicoline Brain Injury Treatment Trial [NCT00545662]Phase 31,213 participants (Actual)Interventional2007-07-31Terminated(stopped due to Trial stopped due to futility.)
Effect of Choline Fenofibrate on Carotid Atherosclerosis Estimated by 3D Ultrasound in Patients With Type 2 Diabetes and Combined Dyslipidemia [NCT05365425]Phase 456 participants (Anticipated)Interventional2023-06-01Recruiting
A Phase 3, Randomized, Rater-Blinded, Multi-Center Study To Evaluate the Efficacy and Safety of ALXN1840 Administered For 48 Weeks Versus Standard of Care in Patients With Wilson Disease Aged 12 Years and Older [NCT03403205]Phase 3214 participants (Actual)Interventional2018-02-15Terminated(stopped due to Sponsor decision to terminate the program)
A Double-blind, Placebo-controlled Trial of Citicoline add-on Therapy in Patients With a History of Mania or Hypomania and Cocaine Abuse/Dependence [NCT00223236]Phase 344 participants (Actual)Interventional2010-07-31Completed
Citicoline in the Treatment of Acute Ischemic Stroke. An International Randomized Multicenter Placebo-controlled Study [NCT00331890]Phase 32,298 participants (Actual)Interventional2006-10-31Terminated(stopped due to With 2078 patients, a statistical stopping boundary has now been crossed)
Double-blind Trial of Phosphatidylcholine During Pregnancy and Infant Serum Choline Levels [NCT00332124]Phase 1351 participants (Actual)Interventional2006-06-30Completed
A Phase II Study of 12-O-tetradecanoylphorbol-13-acetate (TPA) Plus Dexamethasone & Choline Magnesium Trisalicylate in the Treatment of Patients With Relapsed/Refractory Acute Myelogenous Leukemia [NCT01009931]Phase 21 participants (Actual)Interventional2011-03-31Terminated(stopped due to Study was terminated early due to lack of experimental medication (supply issues))
An Exploratory Phase 2, Open-label, Single-arm, Efficacy and Imaging Study of Oral Enzalutamide (XTANDI) Androgen Receptor (AR)-Directed Therapy in Hormono-Sensitive Patients With Metastatic Prostate Cancer (Hormono-sensitive Patients) [NCT02815033]Phase 266 participants (Actual)Interventional2015-07-31Completed
A Randomized, Double-Blind, Placebo-controlled Clinical Trial of Choline Supplementation During Pregnancy to Mitigate Adverse Effects of Prenatal Alcohol Exposure on Growth and Cognitive Development [NCT04395196]Phase 2288 participants (Anticipated)Interventional2023-04-13Recruiting
Staging of Untreated Patients With Very High-risk and High-risk Prostate Carcinoma Utilizing Hybrid C11-choline PET/MR and Pelvic Multiparametric MRI for Personalized Precise Treatment: a Pilot Study [NCT03404648]Phase 319 participants (Actual)Interventional2017-11-01Completed
Biodistribution and Mechanism of Action of the 11C-labeled PET Tracer Sarcosine in Patients With Prostate Cancer as Well as Radiation Dosimetry, Plasma Pharmacokinetics and Biodistribution in Healthy Volunteers [NCT02462447]20 participants (Actual)Observational2015-06-30Completed
Maternal Choline Supplementation and Its Impact on Docosahexaenoic Acid Supply in Human Pregnancy [NCT03194659]40 participants (Anticipated)Interventional2017-10-05Recruiting
Interest of the F18-choline as a Second Line of the Tracer for Detection of Parathyroid Adenomas [NCT02432599]Phase 228 participants (Actual)Interventional2015-03-31Completed
[NCT00004697]15 participants Interventional1997-11-30Completed
Asthma in the Elderly: A Study of Choline Supplementation [NCT02371993]Phase 330 participants (Actual)Interventional2015-01-31Completed
The Effects of Choline,Vitamin C, Vitamin E and Ampelopsis Grossedentata Natural Extracts Supplementation on NASH Patients [NCT05052515]50 participants (Anticipated)Interventional2021-09-30Not yet recruiting
A Randomized, 3-Treatment, 3-Period, 6-Sequence, Crossover, Placebo- and Active-Controlled, Double-Blind for ALXN1840 (Open-Label for Moxifloxacin) Thorough QT/QTc Study to Evaluate ALXN1840 on Cardiac Repolarization in Healthy Adults [NCT04560816]Phase 157 participants (Actual)Interventional2020-07-24Completed
Citicoline for Alcohol Dependence [NCT02074735]Phase 462 participants (Actual)Interventional2014-04-30Completed
A Phase 2, Single-arm Pathologist-blinded 48-week Study Using Liver Biopsy Specimens to Assess Copper Concentration and Histopathologic Changes in ALXN1840-treated Patients With Wilson Disease Followed by an up to 48-weeks Extension Period [NCT04422431]Phase 231 participants (Actual)Interventional2020-12-02Completed
Double-blind Trial of Phosphatidylcholine Supplementation During Pregnancy: Impact on Attention and Social Withdrawal at 4 Years of Age [NCT03028857]Phase 1600 participants (Anticipated)Interventional2017-06-12Active, not recruiting
Nutritional Prevention of Exertional Muscle Dysfunction [NCT01722448]68 participants (Actual)Interventional2012-11-30Completed
Effects of Increased Maternal Choline Intake on Child Cognitive Development [NCT04987099]40 participants (Anticipated)Interventional2020-12-13Recruiting
Evaluation of Choline Fenofibrate (ABT-335) on Carotid Intima-Media Thickness (cIMT) in Subjects With Type IIb Dyslipidemia With Residual Risk in Addition to Atorvastatin Therapy (FIRST) Trial [NCT00616772]Phase 3682 participants (Actual)Interventional2008-02-29Completed
A Multicenter, Randomized, Double-Blind, Prospective Study Comparing the Safety and Efficacy of ABT-335 in Combination With Atorvastatin and Ezetimibe to Atorvastatin in Combination With Ezetimibe in Subjects With Combined (Atherogenic) Dyslipidemia [NCT00639158]Phase 3543 participants (Actual)Interventional2008-02-29Completed
Nahrungsergänzung Mit Cholin- Und Docosahexaensäure Bei Sehr Unreifen Frühgeborenen [NCT02509728]24 participants (Actual)Interventional2015-07-31Completed
Genomic and Imaging Study for Patients Undergoing Surgery for Liver Cancer [NCT01395030]Phase 264 participants (Actual)Interventional2011-08-15Completed
[NCT02395926]Phase 124 participants (Actual)Interventional2013-10-31Completed
The Effect of Choline Alfoscerate on Improvement of Cognitive Function in Elderly Patients With Diabetes [NCT03249259]Phase 336 participants (Actual)Interventional2016-03-10Completed
Pilot Study on the Association Choline Alphoscerate-Nimodipine in Patients With Subcortical Vascular Cognitive Impairment [NCT03228498]Phase 262 participants (Actual)Interventional2017-05-02Completed
A Pilot Study of Choline and Betaine Supplementation in Arsenic-exposed Individuals in Bangladesh [NCT01749982]Phase 460 participants (Actual)Interventional2012-12-31Completed
Expanded Access to 11C Choline PET/CT and 11C Choline PET/MR for Staging of Recurrent Prostate Cancer With Comparison Study of CT and MR Modalities [NCT02260817]Phase 3109 participants (Actual)Interventional2014-10-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00223236 (4) [back to overview]Young Mania Rating Scale(YMRS).
NCT00223236 (4) [back to overview]Cocaine Use Determined by Urine Analysis
NCT00223236 (4) [back to overview]Inventory of Depressive Symptomatology Self Report (IDS-SR).
NCT00223236 (4) [back to overview]Rey Auditory Verbal Learning Test(RAVLT)
NCT00509067 (3) [back to overview]Negative Symptoms Measured on Positive and Negative Syndrome Scale (PANSS)
NCT00509067 (3) [back to overview]Clinical Global Impression
NCT00509067 (3) [back to overview]MATRICS Verbal Learning and Memory
NCT00545662 (1) [back to overview]Functional and Cognitive Outcome
NCT00616772 (5) [back to overview]Rate of Change in Composite of Mean of the Mean Posterior-wall Intima-media Thickness (IMT)
NCT00616772 (5) [back to overview]Rate of Change in Mean of Maximal Posterior-wall Carotid Intima-media Thickness (cIMT)
NCT00616772 (5) [back to overview]Rate of Change in Mean Posterior-wall Carotid Intima-media Thickness (cIMT)
NCT00616772 (5) [back to overview]Rate of Change in Composite of Mean of Maximal Posterior-wall and Anterior-wall Intima-media Thickness (IMT)
NCT00616772 (5) [back to overview]Rate of Change in Composite of Mean of Maximal Posterior-wall Intima-media Thickness (IMT)
NCT00619723 (3) [back to overview]Percentage of Participants With Presence of a Cocaine-Positive Urine Screen
NCT00619723 (3) [back to overview]Depressive Symptoms Measured Using the Hamilton Rating Scale for Depression (HRSD)
NCT00619723 (3) [back to overview]Manic Symptoms Measured Using Young Mania Rating Scale (YMRS)
NCT00639158 (8) [back to overview]Mean Percent Change in Very Low-Density Lipoprotein Cholesterol (VLDL-C) From Baseline to Final Visit
NCT00639158 (8) [back to overview]Mean Percent Change in Non-High-Density Lipoprotein Cholesterol (Non-HDL-C) From Baseline to Final Visit
NCT00639158 (8) [back to overview]Mean Percent Change in High-Density Lipoprotein Cholesterol (HDL-C) From Baseline to Final Visit
NCT00639158 (8) [back to overview]Mean Percent Change in Apolipoprotein CIII (apoCIII) From Baseline to Final Visit
NCT00639158 (8) [back to overview]Mean Percent Change in Apolipoprotein B (apoB) From Baseline to Final Visit
NCT00639158 (8) [back to overview]Mean Percent Change in Apolipoprotein AI (apoAI) From Baseline to Final Visit
NCT00639158 (8) [back to overview]Median Percent Change in High-Sensitivity C-Reactive Protein (hsCRP) From Baseline to Final Visit
NCT00639158 (8) [back to overview]Median Percent Change in Triglycerides From Baseline to Final Visit
NCT00673881 (4) [back to overview]Mean Change in Calculated Low Density Lipoprotein Cholesterol
NCT00673881 (4) [back to overview]Mean Change in High Density Lipoprotein Cholesterol
NCT00673881 (4) [back to overview]Mean Change in Plasma Triglycerides
NCT00673881 (4) [back to overview]Total Cholesterol
NCT00727246 (2) [back to overview]Cognitive Composite Score for Group of Subjects With TBI and Unmatched Healthy Controls
NCT00727246 (2) [back to overview]Cognitive Composite Score for Group of Subjects With TBI and Healthy Controls Matched by Age, Education, and Treatment Group.
NCT00950352 (1) [back to overview]Methamphetamine Dependent Subjects Treated With Citicoline vs Placebo
NCT01149538 (5) [back to overview]Elicited Imitation Task Memory
NCT01149538 (5) [back to overview]Mullen Scales of Early Learning - Early Learning Composite
NCT01149538 (5) [back to overview]Evoked Response Potentials Microvolts
NCT01149538 (5) [back to overview]Evoked Response Potential - Negative Component Latency
NCT01149538 (5) [back to overview]Side Effects of Choline Bitartrate
NCT01395030 (5) [back to overview]Number of Participants Comprising Two Distinct PET/CT Imaging Phenotypes (High FCH Uptake vs. Low FCH Uptake) Between the Different Tumor Sub-classes
NCT01395030 (5) [back to overview]Statistical Significance of Molecular Pathways Associated With Choline Metabolism as Identified Through Gene Set Enrichment Analysis of Hepatocellular Carcinoma (HCC) Tumor Samples.
NCT01395030 (5) [back to overview]Fluorine-18 (18F) Fluoromethylcholine (FCH) PET/CT Parameters for Assessing Hepatocellular Carcinoma (HCC): Sensitivity/Specificity
NCT01395030 (5) [back to overview]Clinical Liver Disease Severity Based on Liver Fibrosis (Metavir) Stage
NCT01395030 (5) [back to overview]Fluorine-18 (18F) Fluoromethylcholine (FCH) PET/CT Parameters for Assessing Hepatocellular Carcinoma (HCC): Area Under the Receiver Operating Characteristic Curve.
NCT01749982 (3) [back to overview]Change in Urinary % Dimethyl Arsenic
NCT01749982 (3) [back to overview]Change in Urinary % Inorganic Arsenic
NCT01749982 (3) [back to overview]Change in Urinary % Monomethyl Arsenic
NCT02074735 (1) [back to overview]Heavy Drinking Days Per Week
NCT02144675 (1) [back to overview]Inhibition of NF-kB Target Transcripts and/or Inhibition of Drug Efflux in at Least 50% of Patients
NCT02197104 (1) [back to overview]FXTAS Rating Scale Score
NCT02260817 (15) [back to overview]Median PSA at Diagnosis of Arm 2 Participants
NCT02260817 (15) [back to overview]Median Primary Biopsy Gleason Score of Arm 2 Participants
NCT02260817 (15) [back to overview]Median Months to Biochemical Relapse of Arm 2 Participants
NCT02260817 (15) [back to overview]Additional Treatment and Type for Arm 2 Participants
NCT02260817 (15) [back to overview]Evidence of Metastatic Prostate Cancer
NCT02260817 (15) [back to overview]Count of Participants With Positive or Negative PET, CT, or MRI Modalities Resulting in Prostate Cancer (PCa) Confirmation
NCT02260817 (15) [back to overview]Specificity of 11C Choline PET Imaging Scans
NCT02260817 (15) [back to overview]Sensitivity of 11C Choline PET Imaging Scans
NCT02260817 (15) [back to overview]Negative Predictive Value (NPV) of 11C Choline PET Imaging Scans
NCT02260817 (15) [back to overview]Median PSA Velocity of Arm 2 Participants at PET Imaging
NCT02260817 (15) [back to overview]Median PSA of Arm 2 Participant at PET Imaging
NCT02260817 (15) [back to overview]Median PSA Doubling Time of Arm 2 Participants at PET Imaging
NCT02260817 (15) [back to overview]Positive Predictive Value (PPV) of 11C Choline PET Imaging Scans
NCT02260817 (15) [back to overview]Median Age at Primary Treatment
NCT02260817 (15) [back to overview]Median Age of Arm 2 Participant at PET Imaging
NCT02397408 (15) [back to overview]Mean Maximum Kinetic Parameters Reflecting F-18 Influx (K1max)
NCT02397408 (15) [back to overview]Mean Kinetic Parameters Reflecting Fluorocholine (FCH) Fluorine 18 FCH (F-18) Influx (K1)
NCT02397408 (15) [back to overview]Specificity of of Combined Positron Emission Tomography (PET) and Magnetic Resonance (MR) Imaging
NCT02397408 (15) [back to overview]Correlation of SUVmax of Primary Tumors With SUVavg
NCT02397408 (15) [back to overview]Correlation of SUVmax of Primary Tumors With Serum Prostate-specific Antigen (PSA) Level
NCT02397408 (15) [back to overview]Correlation of SUVmax of Primary Tumors With Post-surgical Cancer of the Prostate Risk Assessment (CAPRA) Scores
NCT02397408 (15) [back to overview]Sensitivity of Combined Positron Emission Tomography (PET) and Magnetic Resonance (MR) Imaging
NCT02397408 (15) [back to overview]Mean of the Standardized Uptake Value (SUVmax)
NCT02397408 (15) [back to overview]Comparison of SUVmax of Primary Tumors With Post-surgical Cancer of the Prostate Risk Assessment (CAPRA) Score Groups
NCT02397408 (15) [back to overview]Average Standardized Uptake Value (SUVavg)
NCT02397408 (15) [back to overview]Correlation of K1 of Primary Tumors With Average Standardized Uptake Value (SUVavg)
NCT02397408 (15) [back to overview]Correlation of K1 of Primary Tumors With K1max
NCT02397408 (15) [back to overview]Correlation of K1max of Primary Tumors With SUVavg
NCT02397408 (15) [back to overview]Correlation of K1max of Primary Tumors With SUVmax
NCT02397408 (15) [back to overview]Correlation of SUVmax of Primary Tumors With Pathological Stage
NCT02735473 (6) [back to overview]Elicited Imitation Memory Task - Short Delay Memory Measure: 9 Months
NCT02735473 (6) [back to overview]NIH Toolbox Flanker Task: 9 Months
NCT02735473 (6) [back to overview]Stanford-Binet Intelligence Scales: 9 Months
NCT02735473 (6) [back to overview]Minnesota Executive Function Scale: 9 Months
NCT02735473 (6) [back to overview]Child Behavior Checklist: 9 Months
NCT02735473 (6) [back to overview]Elicited Imitation Memory Task - Short Delay Memory Measure: 6 Months
NCT03039023 (10) [back to overview]Changes in Plasma Levels of Fasting Trimethylamine-N-oxide (TMAO), a Choline Metabolite
NCT03039023 (10) [back to overview]Changes in Lipid Profile, Triglycerides
NCT03039023 (10) [back to overview]Changes in Lipid Profile, Total Cholesterol
NCT03039023 (10) [back to overview]Changes in Lipid Profile, LDL
NCT03039023 (10) [back to overview]Changes in Levels of Fasting Trimethylamine-N-oxide (TMAO) in 24-hour Urine Collections
NCT03039023 (10) [back to overview]Changes in Lipid Profile, HDL
NCT03039023 (10) [back to overview]Changes in Plasma Levels of Fasting Betaine.
NCT03039023 (10) [back to overview]Changes in Plasma Levels of Fasting Carnitine.
NCT03039023 (10) [back to overview]Changes in Plasma Levels of Fasting Choline
NCT03039023 (10) [back to overview]Changes in Platelet Function With Increased Choline Intake
NCT03403205 (12) [back to overview]Change From Baseline in UWDRS Part III Functional Subscale Score at Week 48
NCT03403205 (12) [back to overview]Change From Baseline in UWDRS Part III Total Score at Week 48
NCT03403205 (12) [back to overview]Clinical Global Impression-Improvement Scale (CGI-I) Score at Week 48
NCT03403205 (12) [back to overview]Daily Mean Area Under The Effect-time Curve (AUEC) of Directly Measured Non-ceruloplasmin-bound Copper (dNCC) From 0 to 48 Weeks (dNCC AUEC0-48W)
NCT03403205 (12) [back to overview]Number of Participants With Treatment-emergent Adverse Events (TEAEs)
NCT03403205 (12) [back to overview]Percent Change From Baseline in cNCC or cNCCcorrected in Plasma at Week 48
NCT03403205 (12) [back to overview]Change From Baseline in UWDRS Part III Individual Items/Subscales (Speech, Handwriting, Arising From a Chair, and Gait) Score at Week 48
NCT03403205 (12) [back to overview]cNCC/cNCCcorrected Responder at Week 48
NCT03403205 (12) [back to overview]Absolute Change From Baseline in Calculated Non-Ceruloplasmin Bound Copper (cNCC) or Calculated Non-Ceruloplasmin Bound Copper Corrected (cNCCcorrected) in Plasma at Week 48
NCT03403205 (12) [back to overview]Change From Baseline in Clinical Global Impression Severity Scale (CGI-S) Score at Week 48
NCT03403205 (12) [back to overview]Change From Baseline in Model for End-Stage Liver Disease (MELD) Score at Week 48
NCT03403205 (12) [back to overview]Change From Baseline in the Unified Wilson Disease Rating Scale (UWDRS) Part II Total Score at Week 48
NCT03404648 (2) [back to overview]Number of Lesions Showing C11-Choline Uptake
NCT03404648 (2) [back to overview]Uptake Value of C11-choline
NCT03726671 (7) [back to overview]Difference in Choline Deficiency Signature
NCT03726671 (7) [back to overview]Comparison of Choline Pool Size Between Participants With Different Genotypes in Phosphatidylethanolamine-N-methyltransferase (PEMT) Single Nucleotide Polymorphism (SNP rs12325817)
NCT03726671 (7) [back to overview]Comparison of Choline Pool Size Between Participants With and Without Choline Metabolites Signature During Cho Depletion
NCT03726671 (7) [back to overview]Validation of Isotope Dilution Method to Assess Choline Pool Size by Magnetic Resonance Spectroscopy (MRS)
NCT03726671 (7) [back to overview]Ion Abundance (Intensity) of Metabolites as Indicators of the Intake of 25%, 50%, or 100% Choline in the Diet. The Ratio of the Intensity of Metabolite Signals for Each Dietary Group Can be Calculated and Correlated With the Level of Choline in the Diet
NCT03726671 (7) [back to overview]Ratio of Liver Choline Pool Size by Isotope Dilution
NCT03726671 (7) [back to overview]Change in Liver Fat Content Based on CAP Values
NCT03809611 (3) [back to overview]Number of Subjects With Adverse Events, Ocular Adverse Events, Deaths, Other Serious Adverse Events, or Adverse Events Leading to Study Drug Discontinuation
NCT03809611 (3) [back to overview]Change in Binocular Distance-corrected Near Visual Acuity (DCNVA) From Baseline
NCT03809611 (3) [back to overview]Number and Percentage of Subjects Aged 45 to 55 Years Achieving 75 or More Early Treatment Diabetic Retinopathy Study (ETDRS) Letters in Binocular DCNVA at Month 3
NCT04422431 (16) [back to overview]Number of Participants With Change From Baseline in NAS Steatosis Grading Score at Week 48 (Treatment Period)
NCT04422431 (16) [back to overview]Number of Participants With Change From Baseline in Nonalcoholic Steatohepatitis Clinical Research Network (NASH CRN) Fibrosis Stage at Week 48 (Treatment Period)
NCT04422431 (16) [back to overview]Clinical Global Impression-Improvement (CGI-I) Scale Score at Week 48 (Treatment Period)
NCT04422431 (16) [back to overview]Change From Baseline in a-SMA Content at Week 48 (Treatment Period)
NCT04422431 (16) [back to overview]Change From Baseline in CGI-S Scale Score at Week 48 (Treatment Period)
NCT04422431 (16) [back to overview]Change From Baseline in Hepatic Collagen Content at Week 48 (Treatment Period)
NCT04422431 (16) [back to overview]Change From Baseline in Hepatic Fat Content at Week 48 (Treatment Period)
NCT04422431 (16) [back to overview]Change From Baseline in Liver Cu Concentration at Week 48 (Treatment Period)
NCT04422431 (16) [back to overview]Change From Baseline in Mo in Liver Biopsy Specimen at Week 48 (Treatment Period)
NCT04422431 (16) [back to overview]Change From Baseline in NAS Total Score at Week 48 (Treatment Period)
NCT04422431 (16) [back to overview]Treatment Period: Number of Participants With Treatment-emergent Adverse Events (TEAEs)
NCT04422431 (16) [back to overview]Extension Period: Number of Participants With TEAEs
NCT04422431 (16) [back to overview]Treatment Period: Predose Trough Plasma Total Mo Concentration
NCT04422431 (16) [back to overview]Treatment Period: Predose Trough Plasma Total PUF Mo Concentration
NCT04422431 (16) [back to overview]Number of Participants With Change From Baseline in Ishak Fibrosis Score at Week 48 (Treatment Period)
NCT04422431 (16) [back to overview]Number of Participants With Change From Baseline in Metavir Fibrosis Score at Week 48 (Treatment Period)
NCT04526197 (6) [back to overview]Cmax Of Molybdenum With Coadministration Of Celecoxib
NCT04526197 (6) [back to overview]AUCt Of Molybdenum With Coadministration Of Celecoxib
NCT04526197 (6) [back to overview]AUCinf Of Molybdenum With Coadministration Of Celecoxib
NCT04526197 (6) [back to overview]Maximum Observed Plasma Concentration (Cmax) Of Celecoxib With And Without The Coadministration Of ALXN1840
NCT04526197 (6) [back to overview]Area Under The Plasma Concentration Versus Time Curve From Time 0 To The Last Quantifiable Concentration (AUCt) Of Celecoxib With And Without The Coadministration Of ALXN1840
NCT04526197 (6) [back to overview]Area Under The Plasma Concentration Versus Time Curve From Time 0 To Infinity (AUCinf) Of Celecoxib With And Without The Coadministration Of ALXN1840
NCT04526210 (10) [back to overview]Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
NCT04526210 (10) [back to overview]Maximum Observed Plasma Concentration (Cmax) of Bupropion With and Without the Coadministration of ALXN1840
NCT04526210 (10) [back to overview]AUCinf of Plasma Total Molybdenum With Coadministration of Bupropion
NCT04526210 (10) [back to overview]AUCinf of Hydroxybupropion With and Without the Coadministration of ALXN1840
NCT04526210 (10) [back to overview]Area Under the Plasma Concentration Versus Time Curve From Time 0 to the Last Quantifiable Concentration (AUCt) of Bupropion With and Without the Coadministration of ALXN1840
NCT04526210 (10) [back to overview]Cmax of Plasma Total Molybdenum With Coadministration of Bupropion
NCT04526210 (10) [back to overview]AUCt of Hydroxybupropion With and Without the Coadministration of ALXN1840
NCT04526210 (10) [back to overview]Area Under the Plasma Concentration Versus Time Curve From Time 0 to Infinity (AUCinf) of Bupropion With and Without the Coadministration of ALXN1840
NCT04526210 (10) [back to overview]Cmax of Hydroxybupropion With and Without the Coadministration of ALXN1840
NCT04526210 (10) [back to overview]AUCt of Plasma Total Molybdenum With Coadministration of Bupropion
NCT04560816 (14) [back to overview]Placebo-corrected Change From Baseline PR Interval (ΔΔPR)
NCT04560816 (14) [back to overview]Placebo-corrected Change From Baseline For QTcF (ΔΔQTcF) for ALXN1840 Using The By-time Point Analysis
NCT04560816 (14) [back to overview]Placebo-corrected Change From Baseline Heart Rate (ΔΔHR)
NCT04560816 (14) [back to overview]Placebo-corrected Change From Baseline QRS Interval (ΔΔQRS)
NCT04560816 (14) [back to overview]Number of Participants With Treatment-emergent T-wave Morphology Abnormalities and U-waves
NCT04560816 (14) [back to overview]Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
NCT04560816 (14) [back to overview]Change From Baseline QT Interval Using Fridericia's Formula (ΔQTcF)
NCT04560816 (14) [back to overview]Change From Baseline QRS Interval (ΔQRS)
NCT04560816 (14) [back to overview]Change From Baseline PR Interval (ΔPR)
NCT04560816 (14) [back to overview]Change From Baseline For Heart Rate (ΔHR)
NCT04560816 (14) [back to overview]ALXN1840 PK Parameter: Time To Maximum Observed Concentration (Tmax) Of Total Molybdenum And PUF Molybdenum Following a Single Oral Dose of ALXN1840
NCT04560816 (14) [back to overview]ALXN1840 PK Parameter: Maximum Observed Concentration (Cmax) Of Total Molybdenum And PUF Molybdenum Following a Single Oral Dose of ALXN1840
NCT04560816 (14) [back to overview]ALXN1840 PK Parameter: Area Under The Concentration Versus Time Curve From Time 0 To The Last Quantifiable Concentration (AUC0-t) Of Total Molybdenum And Plasma Ultrafiltrate (PUF) Molybdenum Following a Single Oral Dose of ALXN1840
NCT04560816 (14) [back to overview]ΔΔQTcF For Moxifloxacin Using The By-time Point Analysis
NCT05303324 (3) [back to overview]Area Under The Plasma Concentration Versus Time Curve From Time 0 (Dosing) to the Last Quantifiable Concentration (AUCt) of Total Molybdenum
NCT05303324 (3) [back to overview]Number of Participants With a Treatment-Emergent Adverse Event (TEAEs)
NCT05303324 (3) [back to overview]Maximum Observed (Plasma) Concentration (Cmax) of Total Molybdenum
NCT05319899 (3) [back to overview]Area Under the Plasma Concentration Versus Time Curve, From Time 0 to the Last Measurable Concentration (AUC0-t) of Total Molybdenum (Mo)
NCT05319899 (3) [back to overview]Maximum Measured Plasma Concentration (Cmax) of Total Mo
NCT05319899 (3) [back to overview]Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
NCT05319912 (3) [back to overview]Maximum Measured Plasma Concentration (Cmax) of Total Mo
NCT05319912 (3) [back to overview]Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
NCT05319912 (3) [back to overview]Area Under the Plasma Concentration Versus Time Curve, From Time 0 to the Last Measurable Concentration (AUC0-t) of Total Molybdenum (Mo)

Young Mania Rating Scale(YMRS).

The YMRS questionnaire has 11 items with scale range 0 to 4 for 7 items and 0 to 8 for 4 items. 0=normal and and 4 or 8 =most abnormal. The total possible score is 0 to 60, 0 being no symptom and 60 the worst symptom. The higher the score, the worse the mania symptoms are. Exit week is defined as the last week of treatment. It varied between 2 week an 12 weeks with an average exit week of 10 week and 7 week for the citicoline treatment and placebo groups, respectively. Allowing unequal week of treatment period in measuring outcome enables us to include most participants due to a low retention rate in the end of the study period, 12 weeks. The outcome was measured by change in scores between baseline and exit (exit - baseline). (NCT00223236)
Timeframe: Baseline to exit (exit score - baseline score)

Interventionunits on a scale (Mean)
Citicoline-2.00
Placebo-2.88

[back to top]

Cocaine Use Determined by Urine Analysis

Urine drug screens were administered at each visit to detect cocaine in urine. If negative according to urine analysis, it is determined as no cocaine use and if positive, cocaine use. Percentage of participants with no cocaine detected in urine at exit is an outcome measuring treatment effectiveness. Exit week is defined as the last week of treatment. It varied between 2 week an 12 weeks with an average exit week of 10 week and 7 week for the citicoline treatment and placebo groups, respectively. Allowing unequal week of treatment period in measuring outcome enables us to include most participants due to a low retention rate in the end of the study period, 12 weeks. (NCT00223236)
Timeframe: Biweekly (visit) urine drug screens

Interventionpercentage of participants no cocaine (Number)
Citicoline62.50
Placebo50.00

[back to top]

Inventory of Depressive Symptomatology Self Report (IDS-SR).

The IDS-SR is a 30 item self report used to assess the severity of depressive symptoms. The each item has a 4-likert scale, 0 to 3, with 3 representing the worst symptom. The total score of IDS-SR is calculated as a sum of each item score. The range of possible score is between 0 and 90, 0 as no symptom and 90 the worst symptom. The higher the score, the more severe the depression. Exit week is defined as the last week of treatment. It varied between 2 week an 12 weeks with an average exit week of 10 week and 7 week for the citicoline treatment and placebo groups, respectively. Allowing unequal week of treatment period in measuring outcome enables us to include most participants due to a low retention rate in the end of the tudy period, 12 weeks. The outcome was measured by change in scores between baseline and exit (exit - baseline). (NCT00223236)
Timeframe: Change in scores between baseline and exit (exit - baseline).

Interventionunits on scale (Mean)
Citicoline-20.54
Placebo-11.89

[back to top]

Rey Auditory Verbal Learning Test(RAVLT)

The RAVLT consists of 15 nouns read aloud for five consecutive trials with each trial followed by a free-recall trial. The total score is the total number of words recalled through the five trials. Normative RAVLT T-scores was used. the higher T score, the better memory. Exit week is defined as the last week of treatment. It varied between 2 week an 12 weeks with an average exit week of 10 week and 7 week for the citicoline treatment and placebo groups, respectively. Allowing unequal week of treatment period in measuring outcome enables us to include most participants due to a low retention rate in the end of the study period, 12 weeks. The outcome was measured by change in RAVLT T scores between baseline and exit (exit - baseline). (NCT00223236)
Timeframe: Change in T scores between baseline and exit (exitT score - baseline T score).

InterventionT score (Mean)
Citicoline7.06
Placebo3.14

[back to top]

Negative Symptoms Measured on Positive and Negative Syndrome Scale (PANSS)

The score for each subject was the sum of the ratings for five items on the negative-symptom subscale of the PANSS: 1) blunted affect, 2) emotional withdrawal, 3) poor rapport, 4) passive/apathetic social withdrawal, and 5) lack of spontaneity and flow of conversation. Each item (symptom) is rated on a scale from 1 = absence of negative symptom to 7 = extreme negative symptom. The sum of the ratings for the five items range from 5 to 35, with higher scores indicating more severe symptoms. The primary outcome measure is the mean of the sum of these ratings across subjects. (NCT00509067)
Timeframe: Measured at Baseline and Weeks 4, 8, 12, and 16

,
Interventionunits on a scale (Mean)
BaselineWeek 4Week 8Week 12Week 16
Galantamine/CDP Choline17.6317.0613.9314.9313.93
Placebos for Galantamine/CDP Choline18.2917.0817.2617.3216.05

[back to top]

Clinical Global Impression

The score for each subject was the mean rating on the severity item. The score of the item ranged from 1 (normal) to 7 (among most severely ill). (NCT00509067)
Timeframe: Measured at Baseline and Weeks 4, 8, 12, and 16

,
Interventionunits on a scale (Mean)
BaselineWeek 4Week 8Week 12Week 16
Galantamine and CDP-choline Group4.3243.673.873.8
Placebo Group4.383.924.0443.68

[back to top]

MATRICS Verbal Learning and Memory

The measure of verbal learning and memory is the Hopkins Verbal Learning Test. The score for each subject is the sum of the total number of words recalled correctly for Trials 1, 2, and 3. The measure is the mean of these scores at baseline, Week 8, and Week 16. (NCT00509067)
Timeframe: Measured at Baseline and Weeks 8 and 16

,
Interventionraw scores (Mean)
BaselineWeek 8Week 16
Galantamine and CDP-choline Group20.521.823.0
Placebo Group20.621.220.4

[back to top]

Functional and Cognitive Outcome

The primary outcome of this study was analyzed using a global statistic of the Network Core Battery. There were 9 scales: California Verbal Learning Test II (CVLT-II); Controlled Oral Word Association Test (COWAT); Digit Span (DS); Glasgow Outcome Scale Extended (GOSE); Processing Speed Index (PSI); Stroop Test 1 and 2 (ST1&2); and Trail Making Test part A and B (TMT parts A and B). Each scale was assigned cut-off for good outcome: GOSE>7, CVLT>36, PSI>85, TMT part A <42, TMT part B<138.1, DS>7.15, ST1<60.29, ST2<151.47, COWAT>32.5. Logistic regression was used to estimate the global OR. (NCT00545662)
Timeframe: 90 days

,
Interventionpercentage of participants (Number)
Glasgow Outcome Scale - ExtendedCalifornia Verbal Learning TestProcessing Speed IndexTrail Making ATrail Making BDigit SpanStroop Task 1Stroop Task 2Controlled Oral Word Association Test
Control35.5660.4853.2861.9671.0584.0267.9566.5942.68
Treatment35.4357.7152.6864.9674.4486.5065.3168.2937.32

[back to top]

Rate of Change in Composite of Mean of the Mean Posterior-wall Intima-media Thickness (IMT)

Rate of change (mm/year) from baseline in composite of mean of the mean posterior-wall intima-media thickness (IMT) of the left and right common carotid artery, internal carotid artery, and carotid bifurcation. The statistical model used change from baseline as the dependent variable, with time of IMT assessment (in years) as one of the factors in the model. The between-group difference in the rate of change was based on the parameter coefficient for the time-by-treatment interaction. The within-group rate of change was obtained from estimate statements within the repeated measures analysis. IMT was measured using non-invasive ultrasound. (NCT00616772)
Timeframe: Baseline, 6 months, 12 months, 18 months, and 24 months

Interventionmm/year (Mean)
ABT-335 + Atorvastatin-0.010
Placebo + Atorvastatin-0.004

[back to top]

Rate of Change in Mean of Maximal Posterior-wall Carotid Intima-media Thickness (cIMT)

Rate of change (mm/year) from baseline in mean of maximal posterior-wall carotid intima-media thickness (cIMT) of the left and right common carotid artery. The statistical model used change from baseline as the dependent variable, with time of cIMT assessment (in years) as one of the factors in the model. The between-group difference in the rate of change was based on the parameter coefficient for the time-by-treatment interaction. The within-group rate of change was obtained from estimate statements within the repeated measures analysis. cIMT was measured using non-invasive ultrasound. (NCT00616772)
Timeframe: Baseline, 6 months, 12 months, 18 months, and 24 months

Interventionmm/year (Mean)
ABT-335 + Atorvastatin-0.005
Placebo + Atorvastatin-0.003

[back to top]

Rate of Change in Mean Posterior-wall Carotid Intima-media Thickness (cIMT)

Rate of change (mm/year) from baseline in mean of posterior-wall carotid intima-media thickness (cIMT) of the left and right common carotid artery. The statistical model used change from baseline as the dependent variable, with time of cIMT assessment (in years) as one of the factors in the model. The between-group difference in the rate of change was based on the parameter coefficient for the time-by-treatment interaction. The within-group rate of change was obtained from estimate statements within the repeated measures analysis. cIMT was measured using non-invasive ultrasound. (NCT00616772)
Timeframe: Baseline, 6 months, 12 months, 18 months, and 24 months

Interventionmm/year (Mean)
ABT-335 + Atorvastatin-0.006
Placebo + Atorvastatin0.000

[back to top]

Rate of Change in Composite of Mean of Maximal Posterior-wall and Anterior-wall Intima-media Thickness (IMT)

Rate of change (mm/year) from baseline in composite of mean of maximal posterior-wall and anterior-wall intima-media thickness (IMT) of the left and right common carotid artery, internal carotid artery, and carotid bifurcation. The statistical model used change from baseline as the dependent variable, with time of IMT assessment (in years) as one of the factors in the model. The between-group difference in the rate of change was based on the parameter coefficient for the time-by-treatment interaction. The within-group rate of change was obtained from estimate statements within the repeated measures analysis. IMT was measured using non-invasive ultrasound. (NCT00616772)
Timeframe: Baseline, 6 months, 12 months, 18 months, and 24 months

Interventionmm/year (Mean)
ABT-335 + Atorvastatin-0.003
Placebo + Atorvastatin-0.019

[back to top]

Rate of Change in Composite of Mean of Maximal Posterior-wall Intima-media Thickness (IMT)

Rate of change (mm/year) from baseline in composite of mean of maximal posterior-wall intima-media thickness (IMT) of the left and right common carotid artery, internal carotid artery, and carotid bifurcation. The statistical model used change from baseline as the dependent variable, with time of IMT assessment (in years) as one of the factors in the model. The between-group difference in the rate of change was based on the parameter coefficient for the time-by-treatment interaction. The within-group rate of change was obtained from estimate statements within the repeated measures analysis. IMT was measured using non-invasive ultrasound. (NCT00616772)
Timeframe: Baseline, 6 months, 12 months, 18 months, and 24 months

Interventionmm/year (Mean)
ABT-335 + Atorvastatin-0.014
Placebo + Atorvastatin-0.008

[back to top]

Percentage of Participants With Presence of a Cocaine-Positive Urine Screen

Cocaine use frequency was measured by the presence or absence of a cocaine-positive urine screen. Drug screens were obtained thrice-weekly for 12 weeks. All participants who completed the baseline assessment and at least one additional assessment were included in the primary analysis. Missing data were imputed as cocaine positive. (NCT00619723)
Timeframe: 12 weeks

Interventionpercentage of participants (Number)
Citicoline59.0
Placebo49.2

[back to top]

Depressive Symptoms Measured Using the Hamilton Rating Scale for Depression (HRSD)

As part of HRSD, the patient is rated by a clinician on 17 items that measure depressive symptom severity. The total score is calculated by summing the responses across all items. Lower scores (closer to 0) indicate the absence of depressive symptoms, while higher scores indicate the presence of depressive symptoms. Eight items are scored on a 5-point scale, ranging from 0 = not present to 4 = severe. Nine are scored from 0-2 (0 = not present; 2 = severe). The scale range of scores is 0-52. (NCT00619723)
Timeframe: 12 Weeks

Interventionunits on a scale (Mean)
Citicoline17.9
Placebo18.0

[back to top]

Manic Symptoms Measured Using Young Mania Rating Scale (YMRS)

The Young Mania Rating Scale (YMRS) is a clinician-rated scale that has 11 items and is based on the patient's subjective report of his or her clinical condition over the previous 48 hours. There are four items that are graded on a 0 to 8 scale (irritability, speech, thought content, and disruptive/aggressive behavior), while the remaining seven items are graded on a 0 to 4 scale. These four items are given twice the weight of the others to compensate for poor cooperation from severely ill patients. The total score is calculated by summing answers to all the item on the scale, with a higher score indicative of more severe mania symptoms. The scale total score ranges from 0 (absence of manic symptoms) to 60 (severe manic symptoms). (NCT00619723)
Timeframe: 12 weeks

Interventionunits on a scale (Mean)
Citicoline10.2
Placebo10.1

[back to top]

Mean Percent Change in Very Low-Density Lipoprotein Cholesterol (VLDL-C) From Baseline to Final Visit

[(Week 12 VLDL-C minus baseline VLDL-C)/baseline VLDL-C] x 100 (NCT00639158)
Timeframe: Baseline to 12 weeks (final visit)

InterventionPercent change (Mean)
ABT-335 + 40 mg Atorvastatin + 10 mg Ezetimibe-57.8
Placebo + 40 mg Atorvastatin + 10 mg Ezetimibe-41.1

[back to top]

Mean Percent Change in Non-High-Density Lipoprotein Cholesterol (Non-HDL-C) From Baseline to Final Visit

[(Week 12 non-HDL-C minus baseline non-HDL-C)/baseline non-HDL-C] x 100 (NCT00639158)
Timeframe: Baseline to 12 weeks (Final Visit)

InterventionPercent change (Mean)
ABT-335 + 40 mg Atorvastatin + 10 mg Ezetimibe-55.6
Placebo + 40 mg Atorvastatin + 10 mg Ezetimibe-51.0

[back to top]

Mean Percent Change in High-Density Lipoprotein Cholesterol (HDL-C) From Baseline to Final Visit

[(Week 12 HDL-C minus baseline HDL-C)/baseline HDL-C] x 100 (NCT00639158)
Timeframe: Baseline to 12 weeks (Final Visit)

InterventionPercent change (Mean)
ABT-335 + 40 mg Atorvastatin + 10 mg Ezetimibe13.0
Placebo + 40 mg Atorvastatin + 10 mg Ezetimibe4.2

[back to top]

Mean Percent Change in Apolipoprotein CIII (apoCIII) From Baseline to Final Visit

[(Week 12 apoCIII minus baseline apoCIII)/baseline apoCIII] x 100 (NCT00639158)
Timeframe: Baseline to 12 weeks (Final Visit)

InterventionPercent change (Mean)
ABT-335 + 40 mg Atorvastatin + 10 mg Ezetimibe-42.5
Placebo + 40 mg Atorvastatin + 10 mg Ezetimibe-25.3

[back to top]

Mean Percent Change in Apolipoprotein B (apoB) From Baseline to Final Visit

[(Week 12 apoB minus baseline apoB)/baseline apoB] x 100 (NCT00639158)
Timeframe: Baseline to 12 weeks (Final Visit)

InterventionPercent change (Mean)
ABT-335 + 40 mg Atorvastatin + 10 mg Ezetimibe-49.1
Placebo + 40 mg Atorvastatin + 10 mg Ezetimibe-44.7

[back to top]

Mean Percent Change in Apolipoprotein AI (apoAI) From Baseline to Final Visit

[(Week 12 apoAI minus baseline apoAI)/baseline apoAI] x 100 (NCT00639158)
Timeframe: Baseline to 12 weeks (Final Visit)

InterventionPercent change (Mean)
ABT-335 + 40 mg Atorvastatin + 10 mg Ezetimibe1.8
Placebo + 40 mg Atorvastatin + 10 mg Ezetimibe-1.3

[back to top]

Median Percent Change in High-Sensitivity C-Reactive Protein (hsCRP) From Baseline to Final Visit

[(Week 12 hsCRP minus baseline hsCRP)/baseline hSCRP] x 100 (NCT00639158)
Timeframe: Baseline to 12 weeks (Final Visit)

InterventionPercent change (Median)
ABT-335 + 40 mg Atorvastatin + 10 mg Ezetimibe-52.1
Placebo + 40 mg Atorvastatin + 10 mg Ezetimibe-40.3

[back to top]

Median Percent Change in Triglycerides From Baseline to Final Visit

[(Week 12 triglycerides minus baseline triglycerides)/baseline triglycerides] x 100 (NCT00639158)
Timeframe: Baseline to 12 Weeks (Final Visit)

InterventionPercent change (Median)
ABT-335 + 40 mg Atorvastatin + 10 mg Ezetimibe-57.3
Placebo + 40 mg Atorvastatin + 10 mg Ezetimibe-39.7

[back to top]

Mean Change in Calculated Low Density Lipoprotein Cholesterol

Mean change in calculated LDL, baseline (average Day 0, 1 10) to end-of-treatment (12 weeks treatment,average Day 95) (NCT00673881)
Timeframe: baseline to 12 weeks

Interventionmg/dL (Mean)
ABT 335-22.7

[back to top]

Mean Change in High Density Lipoprotein Cholesterol

Mean change in plasma high density plasma lipoprotein cholesterol (HDL-C)baseline (average Day 0, 1 10) to end-of-treatment (12 weeks treatment,Day 95) (NCT00673881)
Timeframe: Baseline to 12 weeks

Interventionmg/dL (Mean)
ABT 335-1.6

[back to top]

Mean Change in Plasma Triglycerides

Change in plasma triglyceride, baseline (average Day 0, 1 10) to end-of-treatment (12 weeks treatment,Day 95) (NCT00673881)
Timeframe: baseline to 12 weeks

Interventionmg/dL (Mean)
ABT 335-138.0

[back to top]

Total Cholesterol

Mean Change in total cholesterol from baseline to End-of-treatment (Day 95) (NCT00673881)
Timeframe: 12 weeks

Interventionmg/dL (Mean)
ABT 335-54.0

[back to top]

Cognitive Composite Score for Group of Subjects With TBI and Unmatched Healthy Controls

A mean index score created as a composite cognitive performance across domains. Purpose was to serve as a measure of overall cognitive functioning for data analysis. Higher T-scores indicate higher levels of cognitive functioning. Due to the small number of subjects in this study, this second analysis was completed using the same number of subjects in the TBI and control groups, but without matching so that a slightly larger number of subject's data could be utilized. Although analyses were run, due to the very small number of participants in this study, results should be considered with caution. (NCT00727246)
Timeframe: 6 weeks

InterventionT-score (Mean)
Participants With TBI Who Received CDP-Choline55.750
Participants With TBI Who Received Placebo50.167
Control Participants Who Received CDP-Choline53.000
Control Participants Who Received Placebo55.000

[back to top]

Cognitive Composite Score for Group of Subjects With TBI and Healthy Controls Matched by Age, Education, and Treatment Group.

.A mean index score created as a composite cognitive performance across domains. Purpose was to serve as a measure of overall cognitive functioning for data analysis. A higher T-score indicates a higher level of cognitive function. Due to matching criteria of age range, gender and education level, as well as the small number of subjects with TBI who complete the study (n = 5), matched groups required a reduction to 2 subjects per group for analysis as planned per protocol. Due to the small number of subjects in this study overall, although analyses were run, results should be considered with caution. (NCT00727246)
Timeframe: 6 weeks

InterventionT-score (Mean)
Participants With TBI Who Received CDP-Choline42.750
Participants With TBI Who Received Placebo50.500
Control Participants Who Received CDP-Choline49.500
Control Participants Who Received Placebo55.000

[back to top]

Methamphetamine Dependent Subjects Treated With Citicoline vs Placebo

Total Amount of Methamphetamine consumed by the participants after 8-9 weeks of treatment. Methamphetamine was assessed twice weekly. (NCT00950352)
Timeframe: 8 weeks, assessed twice weekly starting week1

Interventiontotal amount consumed in grams (Mean)
Citicoline0.3025
Placebo0.3850

[back to top]

Elicited Imitation Task Memory

The Elicited Imitation (EI) paradigm (P.J. Bauer, 1989, Dev. Psychology) was used to measure memory in the participants at baseline, 6 months, and 9 months. The measures were items recalled after a delay (delayed items) and pairs of items recalled after a delay (delayed pairs). The sample was split by age in the analysis (young vs. old) as reflected in the outcome data. Outcome data measures included here are the slopes of the regression lines reflecting change over the three timepoints, controlling for immediate memory performance on the EI task.The slopes are given, as opposed to the raw scores, because these were the values used in the growth curve analyses. Details of these analyses are included in Wozniak et al. (2015) AJCN, doi:10.3945/ajcn.114.099168. NOTE that the means presented below represent the simple slopes that estimate the change in task performance (% of items correct) per 6-month unit of time. To estimate change in task performance over 9 months, multiply by 1.5. (NCT01149538)
Timeframe: Baseline, 6 months, and 9 months

,
InterventionSlope (Mean)
Delayed-Items-YoungDelayed-Items-OldDelayed-Pairs-YoungDelayed-Pairs-OldImmed-Items-YoungImmed-Items-OldImmed-Pairs-YoungImmed-Pairs-Old
Choline Bitartrate14.24-.7118.972.698.482.598.7511.46
Placebo4.434.2310.397.7913.723.8920.015.50

[back to top]

Mullen Scales of Early Learning - Early Learning Composite

The Mullen Scales of Early Learning is a measure of global cognitive development and is a primary outcome measure. The Early Learning Composite is the total score for this measure. It is a scaled score with a mean of 100 and a standard deviation of 15 (higher scores indicate better global cognitive status; average range is 85-115; Impaired range is 70 or below; full range is typically 50 - 150, although minimum and maximum scores are dependent on age). See the Mullen Scales reference manual for more psychometric details. (NCT01149538)
Timeframe: Baseline and 9 months

,
Interventionunits on a scale (Mean)
Baseline9-month follow-up
Choline Bitartrate83.287.1
Placebo84.389.6

[back to top]

Evoked Response Potentials Microvolts

Evoked response potentials were measured for the memory task. Frontal positive slow-wave potential negative component amplitude data are included. (NCT01149538)
Timeframe: Baseline, 6 months, and 9 months

,
InterventionMircovolts (Mean)
Frontal Positive Slow Wave (PSW) - BaselineFrontal Positive Slow Wave (PSW) - 6 monthsFrontal Positive Slow Wave (PSW) - 9 monthsFrontal Neg Component Amplitude - BaselineFrontal Neg Component Amplitude - 6 monthsFrontal Neg Component Amplitude - 9 months
Choline Bitartrate-2.05-1.04-0.26-2.531.220.35
Placebo0.57-1.03-1.410.62-0.84-1.37

[back to top]

Evoked Response Potential - Negative Component Latency

Evoked Response Potential - negative component latency data are included. (NCT01149538)
Timeframe: Baseline, 6 months, and 9 months

,
InterventionMilliseconds (Mean)
Frontal Neg Component Latency at baselineFrontal Neg Component at 6 monthsFrontal Neg Component at 9 months
Choline Bitartrate2.2332.45-4.00
Placebo5.35-4.28-3.03

[back to top]

Side Effects of Choline Bitartrate

Side effects of choline bitartrate will be monitored by the study physician and the P.I. with physical examinations and telephone contact. (NCT01149538)
Timeframe: Baseline, 6 months, & 9 months

,
Interventionparticipants (Number)
Baseline energy level problems6 month energy level problems9 months energy level problemsBaseline pain6 month pain9 month painBaseline skin problems6 month skin problems9 month skin problemsBaseline Ear Nose Throat problems6 month Ear Nose Throat problems9 month Ear Nose Throat problemsBaseline headaches/dizziness6 month headaches/dizziness9 month headaches/dizzinessBaseline vision problems6 month vision problems9 month vision problemsBaseline cardiovascular6 month cardiovascular9 month cardiovascularBaseline respiratory problems6 month respiratory problems9 month respiratory problemsBaseline gastrointestinal problems6 month gastrointestinal problems9 month gastrointestinal problemsBaseline genitourinary problems6 month genitourinary problems9 month genitourinary problemsBaseline musculoskeletal problems6 month musculoskeletal problems9 month musculoskeletal problems6 month neurologic/psychiatric problems9 month neurologic/psychiatric problemsBaseline neurologic/psychiatric problemsBaseline allergic problems6 month allergic problems9 month allergic problems
Choline Bitartrate888333666111222200111666181818444000111111200
Placebo1099444655001222222111666141111988111999333

[back to top]

Number of Participants Comprising Two Distinct PET/CT Imaging Phenotypes (High FCH Uptake vs. Low FCH Uptake) Between the Different Tumor Sub-classes

HCC tumors were sub-classified using gene expression arrays into 3 distinct prognostically-relevant molecular sub-classes (S1,S2, S3, where S3 is associated with the most favorable clinical prognosis) based on Hoshida et. al (PMID 19723656). The number of tumors comprising two distinct PET/CT imaging phenotypes (high FCH uptake vs. low FCH uptake) was compared between the different sub-classes. (NCT01395030)
Timeframe: Up to study completion at an average of 2.5 years

InterventionParticipants (Count of Participants)
HCC sub-class S172229287HCC sub-class S272229287HCC sub-class S372229287Intrahepatic cholangiocarcinoma72229287Primary sarcoma72229287
High FCH uptakeLow FCH uptake
18F-fluoromethylcholine PET/CT7
18F-fluoromethylcholine PET/CT6
18F-fluoromethylcholine PET/CT4
18F-fluoromethylcholine PET/CT24
18F-fluoromethylcholine PET/CT8
18F-fluoromethylcholine PET/CT0
18F-fluoromethylcholine PET/CT1

[back to top]

Statistical Significance of Molecular Pathways Associated With Choline Metabolism as Identified Through Gene Set Enrichment Analysis of Hepatocellular Carcinoma (HCC) Tumor Samples.

Statistically significant enrichment by sets of genes corresponding to previously-defined molecular pathway signatures was assessed by gene set enrichment analysis (a publicly available algorithm) of whole-genome expression array data obtained from tumors previously characterized by FCH PET/CT. Statistical significance was based on a false discovery rate < 0.05. Tumors demonstrating high choline metabolism (defined by a tumor-liver ratio > 1.0 measured on PET) were assessed for enrichment by publicly-available gene sets. This particular analysis involved the entire Molecular Hallmarks gene signature collection (v6.0) as obtained from the Broad Institute Molecular Signature Database (MSigDB). (NCT01395030)
Timeframe: Up to study completion at an average of 2.5 years

Interventionfalse discovery rate (Number)
HALLMARK_OXIDATIVE_PHOSPHORYLATIONHALLMARK_ADIPOGENESISHALLMARK_PEROXISOMEHALLMARK_XENOBIOTIC_METABOLISMHALLMARK_FATTY_ACID_METABOLISMHALLMARK_BILE_ACID_METABOLISM
18F-fluoromethylcholine PET/CT0.0090.0120.0120.0140.0150.016

[back to top]

Fluorine-18 (18F) Fluoromethylcholine (FCH) PET/CT Parameters for Assessing Hepatocellular Carcinoma (HCC): Sensitivity/Specificity

Sensitivity and specificity estimated at a predefined point (ie. Youden's maxima) on the receiver operating characteristic curve for detecting hepatocellular carcinoma with prognostically favorable molecular features (Hoshida molecular sub-class S3) based on FCH PET/CT measurement of tumor maximum standardized uptake value (SUVmax) in patients who underwent subsequent tumor resection. (NCT01395030)
Timeframe: Up to study completion at an average of 2.5 years

Interventionpercentage of analyzed participants (Number)
Sensitivity for HCC sub-class S3Specificity for HCC sub-class S3
18F-fluoromethylcholine PET/CT10073

[back to top]

Clinical Liver Disease Severity Based on Liver Fibrosis (Metavir) Stage

Odds ratios and 95% confidence intervals for histologic liver fibrosis (Metavir) stage >= F1, >= F2, >= F3, and F4 at liver standardized uptake value (SUV) thresholds of 8.3, 8.0, 7.4, and 6.4, respectively. Reference: PMID 29315063. (NCT01395030)
Timeframe: Up to 1 year

Interventionodds ratio (Number)
Fibrosis stage >= F1Fibrosis stage >= F2Fibrosis stage >= F3Fibrosis stage F4
18F-fluoromethylcholine PET/CT3.035.295.566.67

[back to top]

Fluorine-18 (18F) Fluoromethylcholine (FCH) PET/CT Parameters for Assessing Hepatocellular Carcinoma (HCC): Area Under the Receiver Operating Characteristic Curve.

Area under the receiver operating characteristic curve for detecting resectable hepatocellular carcinoma with prognostically favorable molecular features (Hoshida molecular sub-class S3) based on FCH PET/CT measurement of tumor maximum standardized uptake value (SUVmax). (NCT01395030)
Timeframe: Up to study completion at an average of 2.5 years

Interventionunitless (Number)
All primary liver cancers (n=50)HCC only (n=41)
18F-fluoromethylcholine PET/CT0.870.80

[back to top]

Change in Urinary % Dimethyl Arsenic

(NCT01749982)
Timeframe: From baseline to 8 weeks after the start of the intervention (week 8 - baseline)

Interventionpercentage of total urinary arsenic (Median)
Placebo-5.8
Choline Bitartrate0.65
Betaine-0.87
Choline Bitartrate + Betaine5.45

[back to top]

Change in Urinary % Inorganic Arsenic

(NCT01749982)
Timeframe: From baseline to 8 weeks after the start of the intervention (week 8 - baseline)

Interventionpercentage of total urinary arsenic (Median)
Placebo3.0
Choline Bitartrate-0.87
Betaine-1.25
Choline Bitartrate + Betaine-1.7

[back to top]

Change in Urinary % Monomethyl Arsenic

(NCT01749982)
Timeframe: From baseline to 8 weeks after the start of the intervention (week 8 - baseline)

Interventionpercentage of total urinary arsenic (Median)
Placebo2.4
Choline Bitartrate0.24
Betaine-0.06
Choline Bitartrate + Betaine-3.2

[back to top]

Heavy Drinking Days Per Week

"Heavy drinking days are defined as 4 or more drinks for women, 5 or more drinks for men in a single day. Participants self-reported the type and amount of alcohol consumed during each assessment period. From this information, number of standard drinks per day was calculated using the following formula: (number of drinks) x (oz per drink) x (alcohol by volume or ABV). The average number of heavy drinking days was calculated by dividing the number of heavy drinking days per week by the number of days in the assessment period." (NCT02074735)
Timeframe: 12 weeks

Interventiondays/week (Mean)
Placebo0.23
Citicoline0.33

[back to top]

Inhibition of NF-kB Target Transcripts and/or Inhibition of Drug Efflux in at Least 50% of Patients

The clinical trial will be based on a sequential monitoring so that we will have a 90% confidence that choline magnesium trisalicylate (CMT) based modulation of NF-kB transcriptional targets and/or drug efflux occurs in at least 50% of patients. (NCT02144675)
Timeframe: 24 hours

InterventionParticipants (Count of Participants)
Arm I (Choline Magnesium Trisalicylate and Chemotherapy)13
Arm II (Chemotherapy)14

[back to top]

FXTAS Rating Scale Score

The FXTAS Rating Scale (FXTAS-RS), which was designed to measure the severity of motor signs in FXTAS patients, was administered to each participant. The FXTAS-RS was designed to measure the severity of motor signs of FXTAS, tremor, ataxia, and parkinsonism. The scale was developed from a combination of three separate measures: the Clinical Rating Scale for Tremor (CRST), the International Cooperative Ataxia Rating Scale (ICARS), and the Unified Parkinson's Disease Rating Scale (UPDRS). The resultant scale has 44 items and a possible total score of 0-226. A higher score indicates worse symptoms. For this study, improvement was defined as a 20% improvement on the FXTAS-RS. (NCT02197104)
Timeframe: 12 months

Interventionscore on a scale (Mean)
Citocoline45.8

[back to top]

Median PSA at Diagnosis of Arm 2 Participants

The Prostate-Specific Antigen (PSA) measurement of participants at their original prostate cancer diagnosis was collected at entry to this trial. It is reported as nanograms of PSA per milliliter (ng/mL) of blood. The Median of all reported PSAs is reported here. (NCT02260817)
Timeframe: The participants' primary PSA at diagnosis was collected upon study enrollment (approximately 1 week into study)

Interventionng/ml (Median)
11C-choline Comparison Study of CT and MR Modalities13.07

[back to top]

Median Primary Biopsy Gleason Score of Arm 2 Participants

"The median primary Biopsy Gleason Score for the Arm 2 participants' will be reported.~The Gleason Score is the grading system used to determine the aggressiveness of prostate cancer. Typical Gleason Scores range from 6-10. The higher the Gleason Score, the more likely that the cancer will grow and spread quickly.~Gleason scores 2-4 are typically found in smaller tumors located in the transitional zone (around the urethra).~The majority of treatable/treated cancers are of Gleason scores 5 - 7 and are detected due to biopsy after abnormal digital rectal exam or prostate specific antigen evaluation. The cancer is typically located in the peripheral zone usually the posterior portion.~Tumors with Gleason scores 8-10 tend to be advanced neoplasms that are unlikely to be cured." (NCT02260817)
Timeframe: The participants' primary Biopsy Gleason Score data was collected upon study enrollment (approximately 1 week into study)

Interventionunits on a scale (Median)
11C-choline Comparison Study of CT and MR Modalities7

[back to top]

Median Months to Biochemical Relapse of Arm 2 Participants

The median of the Arm 2 participants' data between initial treatment and biochemical relapse, occurring prior to study enrollment, measured in months, will be reported. (NCT02260817)
Timeframe: The participants' biochemical relapse data was collected upon study enrollment (approximately 1 week into study)

Interventionmonths (Median)
11C-choline Comparison Study of CT and MR Modalities40

[back to top]

Additional Treatment and Type for Arm 2 Participants

"A census of the additional treatments undergone by participants prior to enrollment in the study, if undergone, for the participants of Arm 2 will be reported.~None Androgen Deprivation Therapy (ADT) Radiation Therapy (RT) Electron Beam Radiation Therapy (EBRT) Lycopene (herbal treatment) Salvage Radiation Therapy (RT) Salvage Radical Prostatectomy (RP) Adjuvant Radiation Therapy (RT) Bilateral Pelvis Lymph Node Dissection" (NCT02260817)
Timeframe: The participants' additional primary treatment data was collected upon study enrollment (approximately 1 week into study)

InterventionParticipants (Count of Participants)
Adjuvant RTADTBilateral Pelvis Lymph Node DissectionEBRTLycopeneNoneSalvage RPSalvage RTSalvage RT + ADT
11C-choline Comparison Study of CT and MR Modalities31111131153

[back to top]

Evidence of Metastatic Prostate Cancer

"The CT and MRI images will be evaluated for evidence of metastatic prostate cancer. This Outcome is only measured for Arm 2 of this study.~True Positive: True positives will consist of evidence of metastatic prostate cancer on conventional CT or MRI images or on 11C-choline PET/CT or MRI images confirmed with biopsy, surgical pathology, or by response to treatment with androgen suppression or other medical or radiation therapy.~True Negative: True negatives will consist of negative images.~False Positive: False positive will consist of evidence of metastatic prostate cancer on conventional CT or MRI images or on 11C-choline PET/CT or MRI images, but without corresponding confirmation from biopsy, surgical pathology or response to treatment.~False Negative: False negative will consist of negative images, but with positive biopsy, surgical pathology or a response to treatment." (NCT02260817)
Timeframe: After 11C-choline PET CT scan and MRI scans, approximately 1 day. If surgery or response to treatment required to evaluate, approximately 1 to 3 months.

,
InterventionParticipants (Count of Participants)
True PositiveTrue NegativeFalse PositiveFalse Negative
11C-choline Comparison Study of CT and MR Modalities3610111
11C-choline for Staging of Recurrent Prostate Cancer0000

[back to top]

Count of Participants With Positive or Negative PET, CT, or MRI Modalities Resulting in Prostate Cancer (PCa) Confirmation

Comparison of the results of participants' imaging modalities and whether those imaging modalities resulted in confirmation of Prostate Cancer (PCa). This Outcome is only measured for Arm 2. (NCT02260817)
Timeframe: Approximately 1 day post-scan for patient results

InterventionParticipants (Count of Participants)
Positive PET, Negative CT, Negative MRIPositive PET, Positive CT, Negative MRIPositive PET, Negative CT, Positive MRIPositive PET, Positive CT, Positive MRI
11C-choline Comparison Study of CT and MR Modalities116118

[back to top]

Specificity of 11C Choline PET Imaging Scans

"The results of the population's 11C-choline PET CT scans and MRI scans will be evaluated for imaging specificity.~Specificity of 11C-choline PET/CT and MRI will be calculated as True Negative / (True Negative + False Positive).~This Outcome is only measured and reported for Arm 2." (NCT02260817)
Timeframe: Approximately 1 day post-scan for patient results

Intervention% correctly identified negatives (Number)
11C-choline Comparison Study of CT and MR Modalities47.61

[back to top]

Sensitivity of 11C Choline PET Imaging Scans

"The results of the population's 11C-choline PET CT scans and MRI scans will be evaluated for imaging sensitivity.~Sensitivity of 11C-choline PET/CT and MRI will be calculated as True Positive / (True Positive + False Negative).~This Outcome is only measured for Arm 2 of this study." (NCT02260817)
Timeframe: Approximately 1 day post-scan for patient results

Intervention% of correctly identified positives (Number)
11C-choline Comparison Study of CT and MR Modalities97.29

[back to top]

Negative Predictive Value (NPV) of 11C Choline PET Imaging Scans

"The results of the population's 11C-choline PET CT scans and MRI scans will be evaluated for the images' negative predictive value.~Negative Predictive Value of 11C-choline PET/CT and MRI will be calculated as True Negative / (True Negative + False Negative).~This Outcome is only measured for Arm 2." (NCT02260817)
Timeframe: Approximately 1 day post-scan for patient results

InterventionProbability of being disease-free (%) (Number)
11C-choline Comparison Study of CT and MR Modalities90.90

[back to top]

Median PSA Velocity of Arm 2 Participants at PET Imaging

The median PSA velocity (measured in ng/mL/month) of the Arm 2 participants will be reported. (NCT02260817)
Timeframe: The participants' PSA velocity was collected upon study enrollment (approximately 1 week into study)

Interventionng/mL/month (Median)
11C-choline Comparison Study of CT and MR Modalities0.09

[back to top]

Median PSA of Arm 2 Participant at PET Imaging

The median of the PSA of Arm 2 participants at study entry will be reported as nanograms of PSA per milliliter (ng/mL) of blood (NCT02260817)
Timeframe: The participants' PSA was collected upon study enrollment (approximately 1 week into study)

Interventionng/ml of blood (Median)
11C-choline Comparison Study of CT and MR Modalities3.58

[back to top]

Median PSA Doubling Time of Arm 2 Participants at PET Imaging

The median of the time, measured in months that an Arm 2 participant's PSA has doubled from initial diagnosis to PSA measured at study enrollment. (NCT02260817)
Timeframe: The participants' PSA doubling time was collected upon study enrollment (approximately 1 week into study)

Interventionmonths (Median)
11C-choline Comparison Study of CT and MR Modalities4.91

[back to top]

Positive Predictive Value (PPV) of 11C Choline PET Imaging Scans

"The results of the population's 11C-choline PET CT scans and MRI scans will be evaluated for the images' positive predictive value.~Positive Predictive Value of 11C-choline PET/CT and MRI will be calculated as True Positive / (True Positive + False Positive).~This Outcome is only measured for Arm 2." (NCT02260817)
Timeframe: Approximately 1 day post-scan for patient results

InterventionProbability of disease (%) (Number)
11C-choline Comparison Study of CT and MR Modalities76.59

[back to top]

Median Age at Primary Treatment

The median age at primary treatment for Arm 2 participants. (NCT02260817)
Timeframe: The participants' age at primary treatment was collected upon study enrollment (approximately 1 week into study)

Interventionyears (Median)
11C-choline Comparison Study of CT and MR Modalities63

[back to top]

Median Age of Arm 2 Participant at PET Imaging

The median age (at time of study) of participants of Arm 2 will be reported in years. (NCT02260817)
Timeframe: The participants' age at study entry was collected upon study enrollment (approximately 1 week into study)

Interventionyears (Median)
11C-choline Comparison Study of CT and MR Modalities69

[back to top]

Mean Maximum Kinetic Parameters Reflecting F-18 Influx (K1max)

The K1max values of primary tumors will be reported along with the standard deviation (NCT02397408)
Timeframe: Day 1

InterventionK1 (min-1) (Mean)
Choline PET/MR0.753

[back to top]

Mean Kinetic Parameters Reflecting Fluorocholine (FCH) Fluorine 18 FCH (F-18) Influx (K1)

The average K1 values of primary tumors will be reported along with the standard deviation (NCT02397408)
Timeframe: Day 1

InterventionK1 (min-1) (Mean)
Choline PET/MR0.562

[back to top]

Specificity of of Combined Positron Emission Tomography (PET) and Magnetic Resonance (MR) Imaging

Specificity (True Negative Rate) measures the ability of a 11C- and 18F-Choline PET/MR Imaging for Prostate Cancer to correctly identify patient status as respectively diseased or non-dis- eased and is reported as a percentage ranging from 0 -100 with higher percentages indicating a higher specificity to identify the prostate cancer using SUVmax. The specificity of the combined PET and MR imaging for prediction of pathologic extraprostatic extension will be reported. (NCT02397408)
Timeframe: Day 1

Interventionpercentage of true negatives (Number)
Choline PET/MR100

[back to top]

Correlation of SUVmax of Primary Tumors With SUVavg

A spearman rank correlation test was performed to test the correlation of SUVmax with SUVavg. Spearman's correlation coefficient (ρ) determines the strength and direction of the monotonic relationship between two variables. The Spearman correlation coefficient is reported in values from +1 to -1. A ρ= +1 indicates a perfect association of ranks, a ρ = zero indicates no association between ranks and a ρ = -1 indicates a perfect negative association of ranks. The closer ρ is to zero, the weaker the association between the ranks. (NCT02397408)
Timeframe: Day 1

InterventionSpearman's correlation coefficient (ρ) (Number)
Choline PET/MR0.65

[back to top]

Correlation of SUVmax of Primary Tumors With Serum Prostate-specific Antigen (PSA) Level

A spearman rank correlation test was performed to test the correlation of SUVmax with a patients baseline PSA. Spearman's correlation coefficient (ρ) determines the strength and direction of the monotonic relationship between two variables. The Spearman correlation coefficient is reported in values from +1 to -1. A ρ= +1 indicates a perfect association of ranks, a ρ = zero indicates no association between ranks and a ρ = -1 indicates a perfect negative association of ranks. The closer ρ is to zero, the weaker the association between the ranks. (NCT02397408)
Timeframe: Day 1

InterventionSpearman rank correlation coefficient (p (Number)
Choline PET/MR0.71

[back to top]

Correlation of SUVmax of Primary Tumors With Post-surgical Cancer of the Prostate Risk Assessment (CAPRA) Scores

The CAPRA is a 5 item questionnaire completed by the clinicians with a total score range from 0-10 calculated using points assigned to: age at diagnosis, PSA at diagnosis, Gleason score of the biopsy, clinical stage and percent of biopsy cores involved with cancer. A CAPRA score of 0 to 2 indicates low-risk, a score of 3 to 5 indicates intermediate-risk, and a score of 6 to 10 indicates high-risk. A spearman rank correlation test was performed to test the correlation of SUVmax with a patient's CAPRA score after surgery. Spearman's correlation coefficient (ρ) determines the strength and direction of the monotonic relationship between two variables. The Spearman correlation coefficient is reported in values from +1 to -1. A ρ= +1 indicates a perfect association of ranks, a ρ = zero indicates no association between ranks and a ρ = -1 indicates a perfect negative association of ranks. The closer ρ is to zero, the weaker the association between the ranks. (NCT02397408)
Timeframe: After surgery, Up to 6 months

InterventionSpearman rank correlation coefficient (p (Number)
Choline PET/MR0.72

[back to top]

Sensitivity of Combined Positron Emission Tomography (PET) and Magnetic Resonance (MR) Imaging

Sensitivity (True Positive Rate, TPR) measures the ability of a 11C- and 18F-Choline PET/MR Imaging for Prostate Cancer to correctly identify patient status as respectively diseased or non-dis- eased and is reported as a percentage ranging from 0 -100 with higher percentages indicating a higher sensitivity to identify the prostate cancer using SUVmax . The sensitivity of the combined PET and MR imaging for prediction of pathologic extraprostatic extension will be reported. (NCT02397408)
Timeframe: Day 1

Interventionpercentage of true positives (Number)
Choline PET/MR88

[back to top]

Mean of the Standardized Uptake Value (SUVmax)

The SUVmax values of primary tumors will be reported along with the standard deviation. Typically, a standardized uptake value (SUV), a quantity that incorporates the patient's size and the injected dose, that is more than 2.0 is considered to be suggestive of malignancy. (NCT02397408)
Timeframe: Day 1

InterventionSUV (Mean)
Choline PET/MR8.40

[back to top]

Comparison of SUVmax of Primary Tumors With Post-surgical Cancer of the Prostate Risk Assessment (CAPRA) Score Groups

The CAPRA is a 5 item questionnaire completed by the clinicians with a total score range from 0-10 calculated using points assigned to: age at diagnosis, PSA at diagnosis, Gleason score of the biopsy, clinical stage and percent of biopsy cores involved with cancer. A CAPRA score of 0 to 2 indicates low-risk, a score of 3 to 5 indicates intermediate-risk, and a score of 6 to 10 indicates high-risk. A Mann-Whitney U test was performed to compare the SUVmax with patients classified as intermediate-risk and high risk based on their CAPRA Score. Means and standard deviations will be reported. (NCT02397408)
Timeframe: After surgery, Up to 6 months

InterventionSUVmax (Mean)
Intermediate Risk GroupHigh Risk Group
Choline PET/MR9.536.24

[back to top]

Average Standardized Uptake Value (SUVavg)

The SUVavg values of primary tumors will be reported along with the standard deviation. Typically, a standardized uptake value (SUV), a quantity that incorporates the patient's size and the injected dose, that is more than 2.0 is considered to be suggestive of malignancy (NCT02397408)
Timeframe: Day 1

InterventionSUV (Mean)
Choline PET/MR6.10

[back to top]

Correlation of K1 of Primary Tumors With Average Standardized Uptake Value (SUVavg)

A spearman rank correlation test was performed to test the correlation of K1 with the SUVavg of primary tumors. Spearman's correlation coefficient (ρ) determines the strength and direction of the monotonic relationship between two variables. The Spearman correlation coefficient is reported in values from +1 to -1. A ρ= +1 indicates a perfect association of ranks, a ρ = zero indicates no association between ranks and a ρ = -1 indicates a perfect negative association of ranks. The closer ρ is to zero, the weaker the association between the ranks. (NCT02397408)
Timeframe: Day 1

InterventionSpearman's correlation coefficient (ρ) (Number)
Choline PET/MR0.76

[back to top]

Correlation of K1 of Primary Tumors With K1max

A spearman rank correlation test was performed to test the correlation of K1 with K1max. Spearman's correlation coefficient (ρ) determines the strength and direction of the monotonic relationship between two variables. The Spearman correlation coefficient is reported in values from +1 to -1. A ρ= +1 indicates a perfect association of ranks, a ρ = zero indicates no association between ranks and a ρ = -1 indicates a perfect negative association of ranks. The closer ρ is to zero, the weaker the association between the ranks. (NCT02397408)
Timeframe: Day 1

InterventionSpearman's correlation coefficient (ρ) (Number)
Choline PET/MR0.86

[back to top]

Correlation of K1max of Primary Tumors With SUVavg

A spearman rank correlation test was performed to test the correlation of K1max with SUVavg. Spearman's correlation coefficient (ρ) determines the strength and direction of the monotonic relationship between two variables. The Spearman correlation coefficient is reported in values from +1 to -1. A ρ= +1 indicates a perfect association of ranks, a ρ = zero indicates no association between ranks and a ρ = -1 indicates a perfect negative association of ranks. The closer ρ is to zero, the weaker the association between the ranks. (NCT02397408)
Timeframe: Day 1

InterventionSpearman's correlation coefficient (ρ) (Number)
Choline PET/MR0.60

[back to top]

Correlation of K1max of Primary Tumors With SUVmax

A spearman rank correlation test was performed to test the correlation of K1max with SUVmax. Spearman's correlation coefficient (ρ) determines the strength and direction of the monotonic relationship between two variables. The Spearman correlation coefficient is reported in values from +1 to -1. A ρ= +1 indicates a perfect association of ranks, a ρ = zero indicates no association between ranks and a ρ = -1 indicates a perfect negative association of ranks. The closer ρ is to zero, the weaker the association between the ranks. (NCT02397408)
Timeframe: Day 1

InterventionSpearman's correlation coefficient (ρ) (Number)
Choline PET/MR0.65

[back to top]

Correlation of SUVmax of Primary Tumors With Pathological Stage

The system of pathological staging is developed by the American Joint Committee on Cancer (AJCC) and is divided into 5 stages: stage 0 (zero) and stages I through IV (1 through 4). A spearman rank correlation test was performed to test the correlation of SUVmax with a patient's baseline pathological stage. Spearman's correlation coefficient (ρ) determines the strength and direction of the monotonic relationship between two variables. The Spearman correlation coefficient is reported in values from +1 to -1. A ρ= +1 indicates a perfect association of ranks, a ρ = zero indicates no association between ranks and a ρ = -1 indicates a perfect negative association of ranks. The closer ρ is to zero, the weaker the association between the ranks. (NCT02397408)
Timeframe: Day 1

InterventionSpearman rank correlation coefficient (p (Number)
Choline PET/MR0.59

[back to top]

Elicited Imitation Memory Task - Short Delay Memory Measure: 9 Months

Elicited Imitation memory paradigm - short delay memory measure at 9 months (NCT02735473)
Timeframe: Change from baseline to 9 months

Interventionchange in percentage correct (Mean)
Choline Bitartrate0.318
Placebo0.668

[back to top]

NIH Toolbox Flanker Task: 9 Months

NIH Toolbox Flanker Inhibitory and Control Task at 9 months; scores are fully-corrected t-scores (mean=40, standard deviation=10) (NCT02735473)
Timeframe: Change from baseline to 9 months in fully-corrected t-score points

InterventionPercentage change in fully-corrected t-s (Mean)
Choline Bitartrate0.091
Placebo-0.169

[back to top]

Stanford-Binet Intelligence Scales: 9 Months

Stanford-Binet Intelligence Scales at 9 months; scores are standardized scores (mean 100 points, standard deviation of 15 points) (NCT02735473)
Timeframe: Change from baseline to 9 months in IQ points

InterventionPercentage change in full-scale IQ point (Mean)
Choline Bitartrate0.198
Placebo0.008

[back to top]

Minnesota Executive Function Scale: 9 Months

Minnesota Executive Function Scale - Early Childhood Version at 9 months; scores are in t-scores (mean=50, standard deviation=10) (NCT02735473)
Timeframe: Change from baseline to 9 months in t-score points

InterventionPercentage change in overall score (Mean)
Choline Bitartrate0.007
Placebo0.017

[back to top]

Child Behavior Checklist: 9 Months

Child Behavior Checklist - parent report instrument at 9 months; scores are t-scores (mean=50, standard deviation=10) (NCT02735473)
Timeframe: Change from baseline to 9 months in t-score points

InterventionChange from baseline in t-score points (Mean)
Choline Bitartrate-1.9
Placebo-1.8

[back to top]

Elicited Imitation Memory Task - Short Delay Memory Measure: 6 Months

Elicited Imitation memory paradigm - short delay memory measure at 6 months; scores are in percentage correct. (NCT02735473)
Timeframe: Change from baseline to 6 months in percentage correct

Interventionchange in percentage correct (Mean)
Choline Bitartrate0.252
Placebo0.183

[back to top]

Changes in Plasma Levels of Fasting Trimethylamine-N-oxide (TMAO), a Choline Metabolite

Changes in levels of non-labeled TMAO from baseline to end-of-study (day 28) as measured by established techniques by mass spectrometry. (NCT03039023)
Timeframe: Baseline, 28 days

,,,,
InterventionuM (Median)
BaselineDay 28
Choline Bitartrate Tablets1.911.1
Egg Whites + Choline Bitartrate Tablets2.628.1
Hardboiled Eggs + Choline Bitartrate Tablets2.312.3
Phosphatidylcholine Capsules2.83.4
Whole Hardboiled Eggs2.02.3

[back to top]

Changes in Lipid Profile, Triglycerides

Changes in measured triglyceride levels between baseline and Day 28 (NCT03039023)
Timeframe: Baseline, Day 28

,,,,
Interventionmg/dL (Median)
BaselineDay 28
Choline Bitartrate Tablets10696
Egg Whites + Choline Bitartrate Tablets122109
Hardboiled Eggs + Choline Bitartrate Tablets10397
Phosphatidylcholine Capsules7484
Whole Hardboiled Eggs86100

[back to top]

Changes in Lipid Profile, Total Cholesterol

Changes in total cholesterol levels between baseline and Day 28 (NCT03039023)
Timeframe: Baseline, Day 28

,,,,
Interventionmg/dL (Median)
BaselineDay 28
Choline Bitartrate Tablets180172
Egg Whites + Choline Bitartrate Tablets186178
Hardboiled Eggs + Choline Bitartrate Tablets187198
Phosphatidylcholine Capsules175172
Whole Hardboiled Eggs156158

[back to top]

Changes in Lipid Profile, LDL

Changes in measured LDL levels between baseline and Day 28 (NCT03039023)
Timeframe: Baseline, Day 28

,,,,
Interventionmg/dL (Median)
BaselineDay 28
Choline Bitartrate Tablets9094
Egg Whites + Choline Bitartrate Tablets104101
Hardboiled Eggs + Choline Bitartrate Tablets108118
Phosphatidylcholine Capsules107106
Whole Hardboiled Eggs9186

[back to top]

Changes in Levels of Fasting Trimethylamine-N-oxide (TMAO) in 24-hour Urine Collections

Changes in levels of non-labeled TMAO from baseline to Day 28 measured by established mass spectrometry techniques. (NCT03039023)
Timeframe: Baseline, Day 28

,,,,
Interventionmg in 24 hours (Median)
BaselineDay 28
Choline Bitartrate Tablets26.2139.0
Egg Whites + Choline Bitartrate Tablets29.3186.9
Hardboiled Eggs + Choline Bitartrate Tablets27.5221.8
Phosphatidylcholine Capsules15.833.1
Whole Hardboiled Eggs24.328.5

[back to top]

Changes in Lipid Profile, HDL

Changes in measured HDL levels between baseline and Day 28 (NCT03039023)
Timeframe: Baseline, Day 28

,,,,
Interventionmg/dL (Median)
BaselineDay 28
Choline Bitartrate Tablets4951
Egg Whites + Choline Bitartrate Tablets4850
Hardboiled Eggs + Choline Bitartrate Tablets5756
Phosphatidylcholine Capsules6162
Whole Hardboiled Eggs4849

[back to top]

Changes in Plasma Levels of Fasting Betaine.

Fasting plasma levels of betaine from samples obtained at baseline and at day 28 were compared. (NCT03039023)
Timeframe: Baseline, Day 28

,,,,
InterventionuM (Median)
BaselineDay 28
Choline Bitartrate Tablets38.269.0
Egg Whites + Choline Bitartrate Tablets38.759.8
Hardboiled Eggs + Choline Bitartrate Tablets30.746.9
Phosphatidylcholine Capsules33.646.3
Whole Hardboiled Eggs28.139.7

[back to top]

Changes in Plasma Levels of Fasting Carnitine.

Fasting plasma levels of carnitine from samples obtained at baseline and at day 28 were compared. (NCT03039023)
Timeframe: Baseline, Day 28

,,,,
InterventionuM (Median)
BaselineDay 28
Choline Bitartrate Tablets21.218.7
Egg Whites + Choline Bitartrate Tablets21.118.9
Hardboiled Eggs + Choline Bitartrate Tablets21.515.6
Phosphatidylcholine Capsules23.420.8
Whole Hardboiled Eggs19.119.4

[back to top]

Changes in Plasma Levels of Fasting Choline

Fasting plasma levels of choline from samples obtained at baseline and at day 28 were compared. (NCT03039023)
Timeframe: Baseline, Day 28

,,,,
InterventionuM (Median)
BaselineDay 28
Choline Bitartrate Tablets7.512.9
Egg Whites + Choline Bitartrate Tablets9.512.8
Hardboiled Eggs + Choline Bitartrate Tablets8.514.0
Phosphatidylcholine Capsules7.610.6
Whole Hardboiled Eggs8.310.9

[back to top]

Changes in Platelet Function With Increased Choline Intake

The activation and functioning of platelets within a single subject will be compared before and after increased choline intake. (NCT03039023)
Timeframe: Baseline, Day 28

,,,,
Interventionaggregation percentage (Median)
BaselineDay 28
Choline Bitartrate Tablets2.612.8
Egg Whites + Choline Bitartrate Tablets3.029.4
Hardboiled Eggs + Choline Bitartrate Tablets2.312.3
Phosphatidylcholine Capsules2.83.4
Whole Hardboiled Eggs2.63.6

[back to top]

Change From Baseline in UWDRS Part III Functional Subscale Score at Week 48

UWDRS Part III Functional Subscale consists of speech, handwriting, arising from chair, and gait from UWDRS Part III. The standardized score of the first 3 items ranges from 0 (normal) to 10 (worst), and standardized transformed score of gait ranges from 0 (normal) to 10 (worst). The average of these scores was used to create the Part III Functional Subscale with a range of 0 (normal) - 10 (worst) with higher scores indicating more functional disability. (NCT03403205)
Timeframe: Baseline, Week 48

Interventionunits on a scale (Mean)
Cohort 1: ALXN1840-0.165
Cohort 1: SoC Therapy-0.102
Cohort 2: ALXN1840-0.090
Cohort 2: SoC Therapy0.227

[back to top]

Change From Baseline in UWDRS Part III Total Score at Week 48

The UWDRS is a clinical rating scale designed to evaluate the neurological manifestations of Wilson Disease (WD). The UWDRS comprises 3 parts: UWDRS Part I (level of consciousness, item 1), UWDRS Part II (a patient-reported review of daily activity items [disability], items 2 to 11 [10 items in total]), and UWDRS Part III (a detailed neurological examination, items 12 to 34 [23 items in total]). The UWDRS Part I and III was assessed by a neurologist who was blinded to the treatment randomization. The UWDRS Part III total score was calculated as the sum of Question 12 to Question 34. The UWDRS Part III total score ranges from 0 (normal) to 175 (severe disease), with lower score indicating improvement in condition and a better outcome. Change from baseline was calculated as: postbaseline assessment value - baseline assessment value when both values were not missing. (NCT03403205)
Timeframe: Baseline, Week 48

Interventionunits on a scale (Mean)
Cohort 1: ALXN1840-2.24
Cohort 1: SoC Therapy-1.59
Cohort 2: ALXN1840-2.06
Cohort 2: SoC Therapy1.55

[back to top]

Clinical Global Impression-Improvement Scale (CGI-I) Score at Week 48

The CGI-I is a 7-point scale where the clinician assessed how much participant's illness improved or worsened relative to a Baseline state at the beginning of the intervention and rated as: 1, very much improved; 2, much improved; 3, minimally improved; 4, no change; 5, minimally worse; 6, much worse; or 7, very much worse. (NCT03403205)
Timeframe: Week 48

Interventionunits on a scale (Mean)
Cohort 1: ALXN18403.4
Cohort 1: SoC Therapy3.8
Cohort 2: ALXN18403.1
Cohort 2: SoC Therapy3.2

[back to top]

Daily Mean Area Under The Effect-time Curve (AUEC) of Directly Measured Non-ceruloplasmin-bound Copper (dNCC) From 0 to 48 Weeks (dNCC AUEC0-48W)

dNCC is the directly quantified copper not bound to ceruloplasmin, obtained by inductively coupled plasma mass spectrometry after immunocapture and removal of ceruloplasmin. Baseline was defined as last non-missing value on or before first study drug administration. Least square (LS) mean and standard error (SE) was calculated using analysis of covariance (ANCOVA). (NCT03403205)
Timeframe: Baseline to Week 48

Interventionmicromoles (µmol)*hours (hr)/liter (L) (Least Squares Mean)
Cohort 1: ALXN18402.50
Cohort 1: SoC Therapy0.87
Cohort 2: ALXN18404.76
Cohort 2: SoC Therapy0.96

[back to top]

Number of Participants With Treatment-emergent Adverse Events (TEAEs)

An AE was any untoward medical occurrence in a participant administered the study drug and which did not necessarily have a causal relationship with this treatment. TEAEs were defined as those AEs with onset after the first dose of randomized treatment or existing events that worsened in severity after the first dose of randomized treatment. A summary of all Serious Adverse Events and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section. (NCT03403205)
Timeframe: Baseline up to Week 48

InterventionParticipants (Count of Participants)
Cohort 1: ALXN184089
Cohort 1: SoC Therapy41
Cohort 2: ALXN184030
Cohort 2: SoC Therapy12

[back to top]

Percent Change From Baseline in cNCC or cNCCcorrected in Plasma at Week 48

"cNCC was calculated as follows: cNCC [µmol/L] = Plasma Total Cu [µg/L]-(3.15*ceruloplasmin [mg/L])/63.5 [µg/µmol]~For ALXN1840-treated participants, the cNCC in plasma was corrected for the amount of Cu bound to the ALXN1840 TPC using the square root-based cNCC correction method (cNCCcorrected) as follows:~cNCCcorrected = (√cNCC- 0.993)2√Mo, where Mo = molybdenum.~In the calculation of cNCC and cNCCcorrected the following rules apply:~For plasma total Cu concentration values < LLOQ, cNCC was considered missing (LLOQ value of plasma total Cu = 20 ng/mL);~Serum ceruloplasmin concentration values √cNCC." (NCT03403205)
Timeframe: Baseline, Week 48

Interventionpercent change (Mean)
Cohort 1: ALXN1840-7.7
Cohort 1: SoC Therapy104.6
Cohort 2: ALXN1840-64.0
Cohort 2: SoC Therapy-44.3

[back to top]

Change From Baseline in UWDRS Part III Individual Items/Subscales (Speech, Handwriting, Arising From a Chair, and Gait) Score at Week 48

UWDRS Part III individual items speech, handwriting, arising from chair, and gait are reported here. For speech (Question 12), original score ranges from 0 (normal) to 4 (unintelligible). For handwriting (Question 20), original score ranges from 0 (normal) to 4 (cannot hold a pen). For arising from chair (Question 27), original score ranges from 0 (normal) to 4 (unable to arise without help). For gait (Question 29), the original score (range: 0 [normal] to 10 [severe condition]) was calculated by summing subscores (0 [normal] to 4 [severe]) of Part A (Right and Left Leg dystonia), B (Ataxia), and C (Parkinsonism). (NCT03403205)
Timeframe: Baseline, Week 48

,,,
Interventionunits on a scale (Mean)
SpeechHandwritingArising from a chairGait
Cohort 1: ALXN1840-0.1-0.20.0-0.03
Cohort 1: SoC Therapy0.0-0.1-0.10.00
Cohort 2: ALXN1840-0.10.10.0-0.18
Cohort 2: SoC Therapy0.10.20.00.23

[back to top]

cNCC/cNCCcorrected Responder at Week 48

"cNCC/cNCCcorrected responder was defined as participants who achieved or maintained normalized cNCC/cNCCcorrected concentration (0.8-2.3 μmol) within (at or before) 48 weeks or reached a reduction of at least 25% in cNCC/cNCCcorrected within 48 weeks. Thus, a participant was considered a cNCC/cNCCcorrected responder if they met at least 1 of the following criteria:~Achieved normalized cNCC/cNCCcorrected concentration for 2 consecutive measurements within 48 weeks, for participants who had elevated cNCC concentrations at baseline;~Maintained normalized cNCC/cNCCcorrected concentration within 48 weeks, for participants who had normal cNCC concentrations at baseline;~Reached a reduction of at least 25% in cNCC/cNCCcorrected for 2 consecutive measurements within 48 weeks." (NCT03403205)
Timeframe: Week 48

InterventionParticipants (Count of Participants)
Cohort 1: ALXN1840101
Cohort 1: SoC Therapy39
Cohort 2: ALXN184033
Cohort 2: SoC Therapy13

[back to top]

Absolute Change From Baseline in Calculated Non-Ceruloplasmin Bound Copper (cNCC) or Calculated Non-Ceruloplasmin Bound Copper Corrected (cNCCcorrected) in Plasma at Week 48

"cNCC [µmol/L] = Plasma Total Copper (Cu) [micrograms (µg)/L]-(3.15*ceruloplasmin [milligrams (mg)/L])/63.5 [µg/µmol]~For ALXN1840-treated participants, cNCC in plasma was corrected for the amount of Cu bound to ALXN1840 tripartite complex (TPC) using square root-based cNCC correction method (cNCCcorrected):~cNCCcorrected = (√cNCC- 0.993)2√Mo, (Mo= molybdenum).~In calculation of cNCC and cNCCcorrected following rules apply:~For plasma total Cu concentration values √cNCC." (NCT03403205)
Timeframe: Baseline, Week 48

Interventionµmol/L (Mean)
Cohort 1: ALXN1840-0.72
Cohort 1: SoC Therapy0.64
Cohort 2: ALXN1840-1.95
Cohort 2: SoC Therapy-1.51

[back to top]

Change From Baseline in Clinical Global Impression Severity Scale (CGI-S) Score at Week 48

The CGI-S is a 7-point scale where the investigator rated severity of participant's illness at the time of assessment, relative to the investigator's past experience with participants who have the same diagnosis. Considering total clinical experience, a participant was assessed on severity of illness at time of rating as: 1, normal, not at all ill; 2, borderline ill; 3, mildly ill; 4, moderately ill; 5, markedly ill; 6, severely ill; or 7, extremely ill. (NCT03403205)
Timeframe: Baseline, Week 48

Interventionunits on a scale (Mean)
Cohort 1: ALXN1840-0.4
Cohort 1: SoC Therapy-0.1
Cohort 2: ALXN1840-0.6
Cohort 2: SoC Therapy-0.5

[back to top]

Change From Baseline in Model for End-Stage Liver Disease (MELD) Score at Week 48

"The MELD is a scoring system for assessing the severity of chronic liver disease in participants 12 years and older. The MELD score uses the participant's values for bilirubin, creatinine, and the international normalized ratio (INR). The initial MELD score (MELD[i]) is calculated according to the following formula:~MELD(i) = 3.78*ln[serum bilirubin (mg/dL)] + 11.2*ln[INR] + 9.57*ln[serum creatinine (mg/dL)] + 6.43.~Creatinine, bilirubin, and INR values less than 1.0 are set to 1.0 and creatinine values greater than 4.0 are set to 4.0 when calculating MELD(i). Additionally, creatinine, bilirubin, and INR are rounded to the 10th decimal place prior to performing the calculation. The initial MELD score is then rounded to the nearest integer. The MELD score ranges from 6 (least sick) - 40 (most sick), with higher values indicating more advanced disease." (NCT03403205)
Timeframe: Baseline, Week 48

Interventionunits on a scale (Mean)
Cohort 1: ALXN1840-0.1
Cohort 1: SoC Therapy0.1
Cohort 2: ALXN1840-0.7
Cohort 2: SoC Therapy0.2

[back to top]

Change From Baseline in the Unified Wilson Disease Rating Scale (UWDRS) Part II Total Score at Week 48

The UWDRS is a clinical rating scale designed to evaluate the neurological manifestations of Wilson Disease (WD). The UWDRS comprises 3 parts: UWDRS Part I (level of consciousness, item 1), UWDRS Part II (a patient-reported review of daily activity items [disability], items 2 to 11 [10 items in total]), and UWDRS Part III (a detailed neurological examination, items 12 to 34 [23 items in total]). The UWDRS Part II may be reported to a non-blinded member of the study team, by the participant, family member or caregiver. The UWDRS Part II total score was calculated as the sum of Question 2 to Question 11 (each question has range 0 [none] to 4 [severe]). The UWDRS Part II total score ranges from 0 (no disability) to 40 (severe disability), with lower score indicating improvement in condition and a better outcome. Change from baseline was calculated as: postbaseline assessment value - baseline assessment value when both values were not missing. (NCT03403205)
Timeframe: Baseline, Week 48

Interventionunits on a scale (Mean)
Cohort 1: ALXN1840-0.7
Cohort 1: SoC Therapy0.0
Cohort 2: ALXN1840-0.5
Cohort 2: SoC Therapy-1.8

[back to top]

Number of Lesions Showing C11-Choline Uptake

Measured by the mean number of lesions to show C11-Choline uptake. (NCT03404648)
Timeframe: Baseline

InterventionLesions (Mean)
High Risk Prostate Cancer Patients1.2

[back to top]

Uptake Value of C11-choline

Measured by maximum standardized uptake value (SUVmax) of indexed lesions. SUV is calculated as ratio of concentration of tissue reactivity divided by dose at time of injection divided by body weight. (NCT03404648)
Timeframe: Baseline

InterventionRatio (Mean)
High Risk Prostate Cancer Patients6.2

[back to top]

Difference in Choline Deficiency Signature

Plasma choline metabolites (micromolar): choline, dimethylglycine, betaine, phosphatidylcholine, sphingomyelin, trimethylamine-oxide, and homocysteine measured by targeted metabolomic profiling. The signature for choline deficiency is defined by choline <0.793 mmol/L or betaine <34.9 mmol/L. The levels of these metabolites at the end of each intervention will be compared. The association between choline metabolites and choline pool size will be investigated. (NCT03726671)
Timeframe: At the end of 2 weeks of respective Cho diet

Interventionpercentage participants with signature (Number)
25% Cho57
50% Cho47
100% Cho23

[back to top]

Comparison of Choline Pool Size Between Participants With Different Genotypes in Phosphatidylethanolamine-N-methyltransferase (PEMT) Single Nucleotide Polymorphism (SNP rs12325817)

DNA was collected and evaluated for the presence of the PEMT SNP rs12325817. Genotypes was measured by real time polymerase chain reaction (RT-PCR). The magnitude of changes in choline pool size as measured by IER at the end of each dietary intervention was compared among subjects with different genotypes in the PEMT SNP. Linear mixed model with repeated measures was performed for each group (healthy males, pre- and postmenopausal females) separately to study the genotype effect and genotype x diet interaction effect on choline pool size. (NCT03726671)
Timeframe: 24 hours following administration of choline-d9 on day 12 of respective dietary intervention

,,,,,,,,
Interventionisotopic enrichment ratio (uM/uM) (Mean)
Pre-Menopausal Females: Betaine IERPre-Menopausal Females: Choline IERPre-Menopausal Females: Phosphatidylcholine IERPost-Menopausal Females: Betaine IERPost-Menopausal Females: Choline IERPost-Menopausal Females: Phosphatidylcholine IERMales: Betaine IERMales: Choline IERMales: Phosphatidylcholine IER
100% Cho, rs12325817, CC0.02430.00040.01070.02320.00470.00960.02470.00610.0127
100% Cho, rs12325817, CG0.02130.00080.01050.01750.00190.00860.02010.00290.0094
100% Cho, rs12325817, GG0.02470.00010.010.020.00260.00960.02130.00410.0112
25% Cho, rs12325817, CC0.0259-0.00180.01130.02120.00140.00950.02640.00430.0131
25% Cho, rs12325817, CG0.0201-0.00180.0110.02-0.00010.0090.0250.00290.0135
25% Cho, rs12325817, GG0.0261-0.00110.0110.02650.00170.01270.0240.0030.013
50% Cho, rs12325817, CC0.0244-0.00040.0110.01360.00060.00710.04190.00970.0184
50% Cho, rs12325817, CG0.02240.00040.0110.02120.00070.010.02410.00280.0111
50% Cho, rs12325817, GG0.0262-0.00070.01150.0280.00440.01210.02220.00290.0123

[back to top]

Comparison of Choline Pool Size Between Participants With and Without Choline Metabolites Signature During Cho Depletion

The 25% Cho arm was selected because only at that intake level is sufficient depletion achieved. Participants with plasma choline <0.793 mmol/L or betaine <34.9 mmol/L were considered as choline depleted (showing signature), participants with plasma choline >=0.793 mmol/L and betaine >=34.9 mmol/L were considered as not choline depleted (not showing signature). Available choline pool size was determined by the dilution of the deuterated choline metabolites formed in liver and released to plasma as measured by isotopic enrichment ratio (IER). The IER for a given metabolite is defined as the concentration of a deuterated metabolite divided by the sum of deuterated and non-deuterated metabolite. (NCT03726671)
Timeframe: 24 hours following administration of choline-d9 on day 12 of 25% Cho diet

,
Interventionisotopic enrichment ratio (uM/uM) (Mean)
Betaine IERCholine IERPhosphatidylcholine IER
Signature Absent During Choline Depletion0.02410.00250.0118
Signature Present During Choline Depletion0.0234-0.00050.0115

[back to top]

Validation of Isotope Dilution Method to Assess Choline Pool Size by Magnetic Resonance Spectroscopy (MRS)

MRS is a direct measurement of liver choline content. Changes in liver choline by MRS should correlate with changes in liver choline inferred by calculation of isotope enrichment ratio (IER) of plasma metabolites. Pearson correlation coefficient used to study the correlation between data generated from the two types of measurements. (NCT03726671)
Timeframe: At the end of 2 weeks of respective Cho diet

InterventionmM (Mean)
25%Cho8.4
50% Cho7.8
100% Cho11.2

[back to top]

Ion Abundance (Intensity) of Metabolites as Indicators of the Intake of 25%, 50%, or 100% Choline in the Diet. The Ratio of the Intensity of Metabolite Signals for Each Dietary Group Can be Calculated and Correlated With the Level of Choline in the Diet

Metabolomics was conducted on plasma that was collected from individuals at the end of each 2-week diet period. UHPLC High Resolution Mass Spectrometry was used for differential profiling (PMID: 33415121). Supervised Orthogonal Partial Least Squares Discriminant Analysis was used to determine signals that differentiated the 25% choline dietary group from the 100% choline dietary group. Metabolites that differentiated the 25% and 100% choline dietary groups with variable importance to projection (VIP) >1 and p-value < 0.05 are reported. The signals for these metabolites were matched by retention time, exact mass, and MS/MS to standards run on the same platform. Because this is a differential profiling method (not quantitative), the mean and standard deviation of peak intensities detected on the untargeted platform are reported. Results are reported for the selected metabolites for the 25%, 50%, and 100% choline dietary groups. Ratios can be obtained by division of the intensity data. (NCT03726671)
Timeframe: At the end of 2 weeks of respective Cho diet

,,
InterventionIon abundance (intensity) (Mean)
L-CarnitinePropionylcarnitineValerylcarnitineGamma-Muricholic AcidKynurenateN-AcetylglycineDeoxycholic AcidL-OrnithineMethylimidazoleacetic AcidN6-Acetyl-L-lysineDL-2-Aminoadipic Acid
100% Cho1012630.3580011.8682582.082519.322739.4126644.26600931.152410.868510.5722522.452805.00
25% Cho1228784.33104096.4394263.174285.053200.2032411.20731438.142696.019875.6524100.043088.49
50% Cho1178435.5299820.2293531.644927.623186.6628421.55802858.852684.5310075.9324361.813065.37

[back to top]

Ratio of Liver Choline Pool Size by Isotope Dilution

The liver choline pool determined by the dilution of the deuterated choline metabolites formed in liver and released to plasma as measured by isotopic enrichment ratio (IER). The IER for a given metabolite is defined as the concentration of a deuterated metabolite divided by the sum of deuterated and non-deuterated metabolite. (NCT03726671)
Timeframe: 24 hours following administration of choline-d9 on day 12 of respective dietary intervention

,,
Interventionisotopic enrichment ratio (Mean)
Betaine IERCholine IERPhosphatidylcholine IER
100% Cho0.021840.001910.01017
25% Cho0.023570.000230.01158
50% Cho0.024030.001320.01130

[back to top]

Change in Liver Fat Content Based on CAP Values

Controlled attenuation parameter (CAP) as measured by Fibroscan is an ultrasound-based technique to measure liver fat. This method will be used with other biomarkers to indicate functional signs of choline status. (NCT03726671)
Timeframe: Day 1 and Day 15 of respective Cho diet

InterventiondB/m (Mean)
25% Cho0.0208
50% Cho0.6958
100% Cho0.0135

[back to top]

Number of Subjects With Adverse Events, Ocular Adverse Events, Deaths, Other Serious Adverse Events, or Adverse Events Leading to Study Drug Discontinuation

Frequency of treatment emergent adverse events and treatment emergent serious adverse events in all subjects. Adverse events were collected from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 120 days. (NCT03809611)
Timeframe: 4 months

,
InterventionParticipants (Count of Participants)
Any adverse events (AEs)Any ocular adverse eventsAny non-ocular adverse eventsAny severe adverse eventsAny ocular severe adverse eventsAny non-ocular severe adverse eventsAny study drug related adverse eventsAny study drug related ocular adverse eventsAny study drug related non-ocular adverse eventsAny adverse events leading to study drug disc.Any ocular AEs leading to study drug disc.Any non-ocular AEs leading to study drug disc.Any serious adverse eventsAny ocular serious adverse eventsAny non-ocular serious adverse eventsAny study drug related serious adverse eventsAny study drug related ocular serious AEsAny study drug related non-ocular serious AEsDeath
Placebo Ophthalmic Solution5420001100000000000
UNR844-Cl144110004040000000000

[back to top]

Change in Binocular Distance-corrected Near Visual Acuity (DCNVA) From Baseline

Change from baseline in binocular DCNVA in subjects aged 45 to 55 years at Month 3 after UNR844-Cl or placebo treatment. Low contrast (10% contrast) DCNVA at 40 cm is measured binocularly using an electronic visual acuity testing system. This assessment was performed with subjects corrected for any distance refractive errors. The system provided distance-corrected low contrast near visual acuity in an Early Treatment Diabetic Retinopathy Study (ETDRS) letter numerical score. High monocular DCNVA ETDRS letter scores represent good vision; Low monocular DCNVA ETDRS letter scores represent poor vision. (NCT03809611)
Timeframe: Baseline and at Month 3

Interventionnumber of letters read correctly (Least Squares Mean)
UNR844-Cl6.1
Placebo Ophthalmic Solution4.5

[back to top]

Number and Percentage of Subjects Aged 45 to 55 Years Achieving 75 or More Early Treatment Diabetic Retinopathy Study (ETDRS) Letters in Binocular DCNVA at Month 3

Change from baseline in binocular DCNVA in subjects aged 45 to 55 years at Month 3 after UNR844-Cl or placebo treatment. Low contrast (10% contrast) DCNVA at 40 cm is measured binocularly using an electronic visual acuity testing system. This assessment was performed with subjects corrected for any distance refractive errors. The system provided distance-corrected low contrast near visual acuity in an Early Treatment Diabetic Retinopathy Study (ETDRS) letter numerical score. High monocular DCNVA ETDRS letter scores represent good vision; Low monocular DCNVA ETDRS letter scores represent poor vision. (NCT03809611)
Timeframe: month 3

InterventionParticipants (Count of Participants)
UNR844-Cl10
Placebo Ophthalmic Solution6

[back to top]

Number of Participants With Change From Baseline in NAS Steatosis Grading Score at Week 48 (Treatment Period)

Steatosis from histology was evaluated by the steatosis component of the NAS, which was ranged from 0 to 3 where Score 0: < 5% (minimal); Score 1: 5 - 33% (mild); Score 2: 34 - 66% (moderate); and Score 3: > 66% (severe). Higher scores indicated greater steatosis. (NCT04422431)
Timeframe: Baseline, Week 48 (Treatment Period)

InterventionParticipants (Count of Participants)
Baseline71990409Week 4871990409
Score 1Score 2Score 0Score 3
ALXN184019
ALXN18406
ALXN18403
ALXN184015
ALXN18402
ALXN18401

[back to top]

Number of Participants With Change From Baseline in Nonalcoholic Steatohepatitis Clinical Research Network (NASH CRN) Fibrosis Stage at Week 48 (Treatment Period)

Fibrosis from histology was evaluated by NASH CRN Fibrosis Stage, which was scaled from 0 to 4 stages where Score 0: None; Score 1: Perisinusoidal or periportal - 1a - mild, zone 3, perisinusoidal; Score 1: Perisinusoidal or periportal - 1b - moderate, zone 3, perisinusoidal; Score 1: Perisinusoidal or periportal - 1c - portal/periportal; Score 2: Both perisinusoidal and portal/periportal; Score 3: Bridging fibrosis; and Score 4: Cirrhosis. Higher scores indicated greater fibrosis. (NCT04422431)
Timeframe: Baseline, Week 48 (Treatment Period)

InterventionParticipants (Count of Participants)
Baseline71990409Week 4871990409
Score 1bScore 1cScore 2Not evaluableScore 0Score 1aScore 3Score 4
ALXN18400
ALXN18407
ALXN18403
ALXN18408
ALXN18402
ALXN18401
ALXN18405
ALXN18406

[back to top]

Clinical Global Impression-Improvement (CGI-I) Scale Score at Week 48 (Treatment Period)

The CGI-I is a 7-point scale clinician assessment where 1= very much improved; 2 = much improved; 3 = minimally improved; 4 = no change; 5 = minimally worse; 6 = much worse; or 7 = very much worse. Higher scores indicated worsening of disease. (NCT04422431)
Timeframe: Week 48 (Treatment Period)

Interventionunits on a scale (Mean)
ALXN18403.1

[back to top]

Change From Baseline in a-SMA Content at Week 48 (Treatment Period)

Fibrosis from histology was evaluated by morphometric quantification of hepatic a-SMA content. (NCT04422431)
Timeframe: Baseline, Week 48 (Treatment Period)

Interventionpercentage of a-SMA (Mean)
ALXN18401.6002

[back to top]

Change From Baseline in CGI-S Scale Score at Week 48 (Treatment Period)

The CGI-S is a 7-point scale clinician assessment. Participants were assessed on severity of illness at the time of rating/assessment as follows: 1 = normal, not at all ill; 2 = borderline ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; or 7 = extremely ill. Higher scores indicated worsening of disease. (NCT04422431)
Timeframe: Baseline, Week 48 (Treatment Period)

Interventionunits on a scale (Mean)
ALXN1840-0.4

[back to top]

Change From Baseline in Hepatic Collagen Content at Week 48 (Treatment Period)

Fibrosis from histology was evaluated by morphometric quantification of hepatic collagen content. (NCT04422431)
Timeframe: Baseline, Week 48 (Treatment Period)

Interventionpercentage of collagen (Mean)
ALXN18408.5445

[back to top]

Change From Baseline in Hepatic Fat Content at Week 48 (Treatment Period)

Steatosis from histology was evaluated by morphometric quantification of hepatic fat content. (NCT04422431)
Timeframe: Baseline, Week 48 (Treatment Period)

Interventionpercentage of fat (Mean)
ALXN1840-0.2504

[back to top]

Change From Baseline in Liver Cu Concentration at Week 48 (Treatment Period)

Liver biopsy samples were taken for the assessment of liver Cu concentration. Multiple imputation was used to impute missing data at Week 48 due to any reason based on Baseline values. (NCT04422431)
Timeframe: Baseline, Week 48 (Treatment Period)

Interventionμg/g (Mean)
ALXN184092.8

[back to top]

Change From Baseline in Mo in Liver Biopsy Specimen at Week 48 (Treatment Period)

(NCT04422431)
Timeframe: Baseline, Week 48 (Treatment Period)

Interventionμg/g (Mean)
ALXN184069.6976

[back to top]

Change From Baseline in NAS Total Score at Week 48 (Treatment Period)

Inflammation was quantified by the NAS total score. The score is defined as the unweighted sum of the scores for steatosis (0 [minimal] to 3 [severe]), lobular inflammation (0 [none] to 3 [>4 foci / 200x field]), and hepatocellular ballooning (0 [none] to 2 [many]), thus ranging from 0 (no inflammation) to 8 (severe inflammation), with higher scores indicating more severe disease. (NCT04422431)
Timeframe: Baseline, Week 48 (Treatment Period)

Interventionunits on a scale (Mean)
ALXN18400.1

[back to top]

Treatment Period: Number of Participants With Treatment-emergent Adverse Events (TEAEs)

An adverse event (AE) was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. An SAE was an AE that met at least 1 of the following criteria: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization for the AE, persistent or significant disability/incapacity or substantial disruption of the ability to conduct normal life functions, congenital anomaly/birth defect (in the child of a participant who was exposed to the study drug), important medical event or reaction. The TEAEs were AEs with onset on or after the first study drug dose. A summary of all Serious Adverse Events and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section. (NCT04422431)
Timeframe: Day 1 (Treatment Period) up to Week 48 (Treatment Period)

InterventionParticipants (Count of Participants)
ALXN184030

[back to top]

Extension Period: Number of Participants With TEAEs

An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. An SAE was an AE that met at least 1 of the following criteria: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization for the AE, persistent or significant disability/incapacity or substantial disruption of the ability to conduct normal life functions, congenital anomaly/birth defect (in the child of a participant who was exposed to the study drug), important medical event or reaction. The TEAEs were AEs with onset on or after the first study drug dose. A summary of all Serious Adverse Events and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section. (NCT04422431)
Timeframe: Day 1 (Extension Period) up data cutoff date of 29 Jul 2022 (up to Week 86)

InterventionParticipants (Count of Participants)
ALXN18408

[back to top]

Treatment Period: Predose Trough Plasma Total Mo Concentration

(NCT04422431)
Timeframe: Predose up to 4 hours postdose at Week 6 (Day 43) and Week 36 (Day 253)

Interventionnanograms (ng)/milliliter (mL) (Mean)
Week 6Week 36
ALXN1840174.39131.19

[back to top]

Treatment Period: Predose Trough Plasma Total PUF Mo Concentration

(NCT04422431)
Timeframe: Predose up to 4 hours postdose at Week 6 (Day 43) and Week 36 (Day 253)

Interventionng/mL (Mean)
Week 6Week 36
ALXN18405.8887.843

[back to top]

Number of Participants With Change From Baseline in Ishak Fibrosis Score at Week 48 (Treatment Period)

Fibrosis from histology was evaluated by Ishak Fibrosis Score, which was ranged from 0 to 6 where Score 0: No fibrosis; Score 1: Fibrous expansion of some portal areas, with or without short fibrous septa; Score 2: Fibrous expansion of most portal areas, with or without short fibrous septa; Score 3: Fibrous expansion of most portal areas with occasional portal to portal (P-P) bridging; and Score 4: Fibrous expansion of portal areas with marked bridging (P-P) as well as portal central (P-C); Score 5: Marked bridging (P-P and/or P-C) with occasional nodules (incomplete cirrhosis); and Score 6: Cirrhosis, probable or definite. Higher scores indicated greater fibrosis. (NCT04422431)
Timeframe: Baseline, Week 48 (Treatment Period)

InterventionParticipants (Count of Participants)
Baseline71990409Week 4871990409
Score 3Score 0Score 1Score 2Score 4Score 5Score 6Not evaluable
ALXN18406
ALXN18402
ALXN18409
ALXN18401
ALXN18405
ALXN18404
ALXN18408
ALXN18403
ALXN18400

[back to top]

Number of Participants With Change From Baseline in Metavir Fibrosis Score at Week 48 (Treatment Period)

Fibrosis from histology was evaluated by Metavir Fibrosis Score, which was ranged from 0 to 4 where Score 0: No fibrosis; Score 1: Stellate enlargement of portal tract but without septa formation; Score 2: Enlargement of portal tract with rare septa formation; Score 3: Numerous septa without cirrhosis; and Score 4: Cirrhosis. Higher scores indicated greater fibrosis. (NCT04422431)
Timeframe: Baseline, Week 48 (Treatment Period)

InterventionParticipants (Count of Participants)
Baseline71990409Week 4871990409
Score 0Not evaluableScore 1Score 2Score 3Score 4
ALXN18408
ALXN18402
ALXN18401
ALXN18405
ALXN18404
ALXN18407
ALXN18400

[back to top]

Cmax Of Molybdenum With Coadministration Of Celecoxib

Blood samples were collected for PK analysis of total molybdenum (as a measure of ALXN1840) and plasma ultrafiltrate (PUF) molybdenum. Cmax is reported as ng/mL. (NCT04526197)
Timeframe: Baseline, up to 336 hours post-dose

Interventionng/mL (Mean)
Total MolybdenumPUF Molybdenum
Treatment B373.482.44

[back to top]

AUCt Of Molybdenum With Coadministration Of Celecoxib

Blood samples were collected for PK analysis of total molybdenum (as a measure of ALXN1840) and PUF molybdenum. AUCt is reported as h•ng/mL. (NCT04526197)
Timeframe: Baseline, up to 336 hours post-dose

Interventionh•ng/mL (Mean)
Total MolybdenumPUF Molybdenum
Treatment B192401796

[back to top]

AUCinf Of Molybdenum With Coadministration Of Celecoxib

Blood samples were collected for PK analysis of total molybdenum (as a measure of ALXN1840) and PUF molybdenum. AUCinf is reported as h•ng/mL. (NCT04526197)
Timeframe: Baseline, up to 336 hours post-dose

Interventionh•ng/mL (Mean)
Total MolybdenumPUF Molybdenum
Treatment B209102305

[back to top]

Maximum Observed Plasma Concentration (Cmax) Of Celecoxib With And Without The Coadministration Of ALXN1840

Blood samples were collected for pharmacokinetics (PK) analysis of celecoxib. Cmax is reported as nanograms (ng)/milliliter (mL). (NCT04526197)
Timeframe: Baseline, up to 336 hours post-dose

Interventionng/mL (Mean)
Treatment A637.1
Treatment B567.4

[back to top]

Area Under The Plasma Concentration Versus Time Curve From Time 0 To The Last Quantifiable Concentration (AUCt) Of Celecoxib With And Without The Coadministration Of ALXN1840

Blood samples were collected for pharmacokinetic (PK) analysis of celecoxib. Area Under The Plasma Concentration Versus Time Curve From Time 0 To The Last Quantifiable Concentration (AUCt) is reported as hours•ng/mL (h•ng/mL). (NCT04526197)
Timeframe: Baseline, up to 336 hours post-dose

Interventionh•ng/mL (Mean)
Treatment A6406
Treatment B6482

[back to top]

Area Under The Plasma Concentration Versus Time Curve From Time 0 To Infinity (AUCinf) Of Celecoxib With And Without The Coadministration Of ALXN1840

Blood samples were collected for pharmacokinetic (PK) analysis of celecoxib. Area Under The Plasma Concentration Versus Time Curve From Time 0 To Infinity (AUCinf) is reported as h•ng/mL. (NCT04526197)
Timeframe: Baseline, up to 336 hours post-dose

Interventionh•ng/mL (Mean)
Treatment A6743
Treatment B6869

[back to top]

Number of Participants With Treatment-Emergent Adverse Events (TEAEs)

An adverse event (AE) was defined as any untoward medical occurrence in a participant administered with the study drug and which did not necessarily have a causal relationship with the study drug. An AE could therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of study drug, whether or not related to study drug. A TEAE was defined as any AE that began or worsened on or after the first dose of treatment until the end of study (EOS) or early termination (ET). An AE that occurred during the washout period between drugs was considered treatment emergent to the last drug given. A summary of all Serious Adverse Events and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section. (NCT04526210)
Timeframe: Day 1 up to Day 15

Interventionparticipants (Number)
Treatment A: Bupropion HCl8
Treatment B: Bupropion HCl + ALXN184011

[back to top]

Maximum Observed Plasma Concentration (Cmax) of Bupropion With and Without the Coadministration of ALXN1840

(NCT04526210)
Timeframe: Pre-dose (Day 1) up to 336 hours post-dose

Interventionnanograms (ng)/milliliter (mL) (Geometric Mean)
Treatment A: Bupropion HCl98.64
Treatment B: Bupropion HCl + ALXN184098.02

[back to top]

AUCinf of Plasma Total Molybdenum With Coadministration of Bupropion

Plasma total molybdenum was assessed as surrogate measures for ALXN1840 PK following coadministration with bupropion HCl salt tablet (Treatment B) only. (NCT04526210)
Timeframe: Pre-dose (Day 1) up to 336 hours post-dose

Interventionhours*ng/mL (Geometric Mean)
Treatment B: Bupropion HCl + ALXN184016130

[back to top]

AUCinf of Hydroxybupropion With and Without the Coadministration of ALXN1840

(NCT04526210)
Timeframe: Pre-dose (Day 1) up to 336 hours post-dose

Interventionhours*ng/mL (Geometric Mean)
Treatment A: Bupropion HCl11960
Treatment B: Bupropion HCl + ALXN184011630

[back to top]

Area Under the Plasma Concentration Versus Time Curve From Time 0 to the Last Quantifiable Concentration (AUCt) of Bupropion With and Without the Coadministration of ALXN1840

(NCT04526210)
Timeframe: Pre-dose (Day 1) up to 336 hours post-dose

Interventionhours*ng/mL (Geometric Mean)
Treatment A: Bupropion HCl1021
Treatment B: Bupropion HCl + ALXN18401010

[back to top]

Cmax of Plasma Total Molybdenum With Coadministration of Bupropion

Plasma total molybdenum was assessed as surrogate measures for ALXN1840 PK following coadministration with bupropion HCl salt tablet (Treatment B) only. (NCT04526210)
Timeframe: Pre-dose (Day 1) up to 336 hours post-dose

Interventionng/mL (Geometric Mean)
Treatment B: Bupropion HCl + ALXN1840325.6

[back to top]

AUCt of Hydroxybupropion With and Without the Coadministration of ALXN1840

(NCT04526210)
Timeframe: Pre-dose (Day 1) up to 336 hours post-dose

Interventionhours*ng/mL (Geometric Mean)
Treatment A: Bupropion HCl11900
Treatment B: Bupropion HCl + ALXN184011560

[back to top]

Area Under the Plasma Concentration Versus Time Curve From Time 0 to Infinity (AUCinf) of Bupropion With and Without the Coadministration of ALXN1840

(NCT04526210)
Timeframe: Pre-dose (Day 1) up to 336 hours post-dose

Interventionhours*ng/mL (Geometric Mean)
Treatment A: Bupropion HCl1049
Treatment B: Bupropion HCl + ALXN18401039

[back to top]

Cmax of Hydroxybupropion With and Without the Coadministration of ALXN1840

(NCT04526210)
Timeframe: Pre-dose (Day 1) up to 336 hours post-dose

Interventionng/mL (Geometric Mean)
Treatment A: Bupropion HCl286.5
Treatment B: Bupropion HCl + ALXN1840284.3

[back to top]

AUCt of Plasma Total Molybdenum With Coadministration of Bupropion

Plasma total molybdenum was assessed as surrogate measures for ALXN1840 PK following coadministration with bupropion HCl salt tablet (Treatment B) only. (NCT04526210)
Timeframe: Pre-dose (Day 1) up to 336 hours post-dose

Interventionhours*ng/mL (Geometric Mean)
Treatment B: Bupropion HCl + ALXN184015010

[back to top]

Placebo-corrected Change From Baseline PR Interval (ΔΔPR)

Twelve-lead ECGs were extracted from approximately 25-hour continuous (Holter) recordings on Day -1 of Treatment Period 1 and Days 1 and 2 in each treatment period. (NCT04560816)
Timeframe: Baseline (average of samples taken at 45, -30, and -15 minutes before dosing), 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, and 24 (Day 2) hours postdose

,
Interventionms (Least Squares Mean)
Day 1, 0.5 hours postdoseDay 1, 1 hour postdoseDay 1, 2 hours postdoseDay 1, 3 hours postdoseDay 1, 4 hours postdoseDay 1, 5 hours postdoseDay 1, 6 hours postdoseDay 1, 7 hours postdoseDay 1, 8 hours postdoseDay 1, 10 hours postdoseDay 1, 12 hours postdoseDay 2, 24 hours postdose
ALXN1840-1.39-1.25-0.24-0.87-0.65-0.60-0.21-1.71-0.69-0.610.09-0.82
Moxifloxacin-2.60-3.03-2.31-3.99-3.28-3.11-2.09-3.10-3.24-3.28-1.62-2.37

[back to top]

Placebo-corrected Change From Baseline For QTcF (ΔΔQTcF) for ALXN1840 Using The By-time Point Analysis

"Twelve-lead electrocardiograms (ECGs) were extracted from approximately 25-hour continuous (Holter) recordings on Day -1 of Treatment Period 1 and Days 1 and 2 in each treatment period. Change from baseline in the QT interval was corrected for heart rate using Fridericia's formula (ΔQTcF). ΔQTcF was based on a mixed-effects model for repeated measures (MMRM) with ΔQTcF as the dependent variable; period, sequence, time, treatment, and time-by-treatment interaction as fixed effects; and baseline QTc and sex as covariates.~ΔΔQTc = LS mean ΔQTcF after ALXN1840 dosing minus LS mean ΔQTcF after placebo. If the upper bound of the confidence interval (CI) of ΔΔQTcF was < 10 ms for all postdose time points, ALXN1840 was concluded to not have a significant effect on QT interval prolongation." (NCT04560816)
Timeframe: Baseline (average of samples taken at -45, -30, and -15 minutes before dosing), 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, and 24 (Day 2) hours postdose

Interventionms (Least Squares Mean)
Day 1, 0.5 hours postdoseDay 1, 1 hour postdoseDay 1, 2 hours postdoseDay 1, 3 hours postdoseDay 1, 4 hours postdoseDay 1, 5 hours postdoseDay 1, 6 hours postdoseDay 1, 7 hours postdoseDay 1, 8 hours postdoseDay 1, 10 hours postdoseDay 1, 12 hours postdoseDay 2, 24 hours postdose
ALXN1840-0.21-0.310.07-0.64-1.08-0.90-0.710.25-0.930.760.052.30

[back to top]

Placebo-corrected Change From Baseline Heart Rate (ΔΔHR)

"Twelve-lead ECGs were extracted from approximately 25-hour continuous (Holter) recordings on Day -1 of Treatment Period 1 and Days 1 and 2 in each treatment period.~Least square mean difference and its 90% CI were calculated based on MMRM with fixed effects for period, sequence, timepoint, treatment, time-by-treatment interaction as fixed effect and baseline value and sex as covariates." (NCT04560816)
Timeframe: Baseline (average of samples taken at 45, -30, and -15 minutes before dosing), 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, and 24 (Day 2) hours postdose

,
Interventionbpm (Least Squares Mean)
Day 1, 0.5 hours postdoseDay 1, 1 hour postdoseDay 1, 2 hours postdoseDay 1, 3 hours postdoseDay 1, 4 hours postdoseDay 1, 5 hours postdoseDay 1, 6 hours postdoseDay 1, 7 hours postdoseDay 1, 8 hours postdoseDay 1, 10 hours postdoseDay 1, 12 hours postdoseDay 2, 24 hours postdose
ALXN1840-0.77-0.40-0.311.580.271.020.131.270.720.270.580.73
Moxifloxacin0.773.501.783.312.060.990.482.291.401.711.751.32

[back to top]

Placebo-corrected Change From Baseline QRS Interval (ΔΔQRS)

"Twelve-lead ECGs were extracted from approximately 25-hour continuous (Holter) recordings on Day -1 of Treatment Period 1 and Days 1 and 2 in each treatment period.~Least square mean difference and its 90% CI were calculated based on MMRM with fixed effects for period, sequence, timepoint, treatment, time-by-treatment interaction as fixed effect and baseline value and sex as covariates." (NCT04560816)
Timeframe: Baseline (average of samples taken at 45, -30, and -15 minutes before dosing), 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, and 24 (Day 2) hours postdose

,
Interventionms (Least Squares Mean)
Day 1, 0.5 hours postdoseDay 1, 1 hour postdoseDay 1, 2 hours postdoseDay 1, 3 hours postdoseDay 1, 4 hours postdoseDay 1, 5 hours postdoseDay 1, 6 hours postdoseDay 1, 7 hours postdoseDay 1, 8 hours postdoseDay 1, 10 hours postdoseDay 1, 12 hours postdoseDay 2, 24 hours postdose
ALXN18400.070.080.170.15-0.020.05-0.270.19-0.27-0.18-0.12-0.16
Moxifloxacin-0.010.10-0.01-0.13-0.15-0.07-0.40-0.08-0.10-0.15-0.20-0.20

[back to top]

Number of Participants With Treatment-emergent T-wave Morphology Abnormalities and U-waves

Twelve-lead ECGs were extracted from approximately 25-hour continuous (Holter) recordings on Day -1 of Treatment Period 1 and Days 1 and 2 in each treatment period. (NCT04560816)
Timeframe: Day 1 (after dosing) through 24 hours postdose

,,
InterventionParticipants (Count of Participants)
At least one treatment-emergent T-wave abnormalityAt least one treatment-emergent U-wave
ALXN184000
Moxifloxacin10
Placebo00

[back to top]

Number of Participants With Treatment-Emergent Adverse Events (TEAEs)

An adverse event (AE) was any untoward medical occurrence in a participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. TEAE was an AE that started during or after the first dose, or started prior to the first dose and increased in severity after the first dose. A related TEAE was defined as having a reasonable possibility the study intervention caused the AE as assessed by the investigator. Serious AEs were defined as any untoward medical occurrence that met at least 1 of the following serious criteria: resulted in death, was life-threatening, required in-patient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, other medically important serious event. (NCT04560816)
Timeframe: Day 1 (after dosing) through Day 70

,,
InterventionParticipants (Count of Participants)
Any TEAEAny serious TEAE (SAE)Any TEAE leading to deathAny related TEAE
ALXN18409004
Moxifloxacin6003
Placebo3000

[back to top]

Change From Baseline QT Interval Using Fridericia's Formula (ΔQTcF)

Twelve-lead ECGs were extracted from approximately 25-hour continuous (Holter) recordings on Day -1 of Treatment Period 1 and Days 1 and 2 in each treatment period. (NCT04560816)
Timeframe: Baseline (average of samples taken at 45, -30, and -15 minutes before dosing), 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, and 24 (Day 2) hours postdose

,,
Interventionms (Least Squares Mean)
Day 1, 0.5 hours postdoseDay 1, 1 hour postdoseDay 1, 2 hours postdoseDay 1, 3 hours postdoseDay 1, 4 hours postdoseDay 1, 5 hours postdoseDay 1, 6 hours postdoseDay 1, 7 hours postdoseDay 1, 8 hours postdoseDay 1, 10 hours postdoseDay 1, 12 hours postdoseDay 2, 24 hours postdose
ALXN1840-2.56-0.49-0.69-1.04-1.06-0.64-6.05-7.60-7.66-4.96-5.050.52
Moxifloxacin2.299.4710.2810.9610.039.544.002.051.491.700.943.48
Placebo-2.36-0.19-0.76-0.410.02-0.55-5.35-7.85-6.73-5.73-5.10-1.78

[back to top]

Change From Baseline QRS Interval (ΔQRS)

Twelve-lead ECGs were extracted from approximately 25-hour continuous (Holter) recordings on Day -1 of Treatment Period 1 and Days 1 and 2 in each treatment period. (NCT04560816)
Timeframe: Baseline (average of samples taken at 45, -30, and -15 minutes before dosing), 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, and 24 (Day 2) hours postdose

,,
Interventionms (Least Squares Mean)
Day 1, 0.5 hours postdoseDay 1, 1 hour postdoseDay 1, 2 hours postdoseDay 1, 3 hours postdoseDay 1, 4 hours postdoseDay 1, 5 hours postdoseDay 1, 6 hours postdoseDay 1, 7 hours postdoseDay 1, 8 hours postdoseDay 1, 10 hours postdoseDay 1, 12 hours postdoseDay 2, 24 hours postdose
ALXN1840-0.010.040.080.100.14-0.23-1.01-0.89-0.66-0.89-0.42-0.14
Moxifloxacin-0.080.06-0.10-0.190.01-0.35-1.13-1.16-0.48-0.87-0.50-0.18
Placebo-0.07-0.04-0.09-0.050.16-0.28-0.73-1.08-0.39-0.71-0.300.02

[back to top]

Change From Baseline PR Interval (ΔPR)

Twelve-lead ECGs were extracted from approximately 25-hour continuous (Holter) recordings on Day -1 of Treatment Period 1 and Days 1 and 2 in each treatment period. (NCT04560816)
Timeframe: Baseline (average of samples taken at 45, -30, and -15 minutes before dosing), 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, and 24 (Day 2) hours postdose

,,
Interventionms (Least Squares Mean)
Day 1, 0.5 hours postdoseDay 1, 1 hour postdoseDay 1, 2 hours postdoseDay 1, 3 hours postdoseDay 1, 4 hours postdoseDay 1, 5 hours postdoseDay 1, 6 hours postdoseDay 1, 7 hours postdoseDay 1, 8 hours postdoseDay 1, 10 hours postdoseDay 1, 12 hours postdoseDay 2, 24 hours postdose
ALXN1840-0.130.411.300.46-0.75-1.72-3.64-5.76-4.52-3.94-2.89-0.13
Moxifloxacin-1.33-1.37-0.77-2.66-3.38-4.22-5.52-7.16-7.07-6.61-4.60-1.68
Placebo1.261.661.541.32-0.10-1.12-3.43-4.05-3.83-3.34-2.980.69

[back to top]

Change From Baseline For Heart Rate (ΔHR)

Twelve-lead ECGs were extracted from approximately 25-hour continuous (Holter) recordings on Day -1 of Treatment Period 1 and Days 1 and 2 in each treatment period. (NCT04560816)
Timeframe: Baseline (average of samples taken at 45, -30, and -15 minutes before dosing), 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, and 24 (Day 2) hours postdose

,,
Interventionbpm (Least Squares Mean)
Day 1, 0.5 hours postdoseDay 1, 1 hour postdoseDay 1, 2 hours postdoseDay 1, 3 hours postdoseDay 1, 4 hours postdoseDay 1, 5 hours postdoseDay 1, 6 hours postdoseDay 1, 7 hours postdoseDay 1, 8 hours postdoseDay 1, 10 hours postdoseDay 1, 12 hours postdoseDay 2, 24 hours postdose
ALXN1840-0.27-0.02-0.120.410.515.857.075.594.697.715.762.32
Moxifloxacin1.273.871.972.142.305.827.436.615.379.156.932.92
Placebo0.500.380.19-1.170.244.836.954.323.977.445.181.60

[back to top]

ALXN1840 PK Parameter: Time To Maximum Observed Concentration (Tmax) Of Total Molybdenum And PUF Molybdenum Following a Single Oral Dose of ALXN1840

Blood samples for PK analysis of total molybdenum and PUF molybdenum were collected as close as possible to nominal time after completion of the ECG extraction period. (NCT04560816)
Timeframe: Pre-dose to 96 hours post-dose

Interventionhours (Median)
Total MolybdenumPlasma Ultrafiltrate Molybdenum
ALXN18405.006.00

[back to top]

ALXN1840 PK Parameter: Maximum Observed Concentration (Cmax) Of Total Molybdenum And PUF Molybdenum Following a Single Oral Dose of ALXN1840

Blood samples for PK analysis of total molybdenum and PUF molybdenum were collected as close as possible to nominal time after completion of the ECG extraction period. (NCT04560816)
Timeframe: Predose (0) to 96 hours post-dose

Interventionng/mL (Geometric Mean)
Total MolybdenumPlasma Ultrafiltrate Molybdenum
ALXN1840504.1127.9

[back to top]

ALXN1840 PK Parameter: Area Under The Concentration Versus Time Curve From Time 0 To The Last Quantifiable Concentration (AUC0-t) Of Total Molybdenum And Plasma Ultrafiltrate (PUF) Molybdenum Following a Single Oral Dose of ALXN1840

Blood samples for PK analysis of total molybdenum and PUF molybdenum were collected as close as possible to nominal time after completion of the ECG extraction period. (NCT04560816)
Timeframe: Predose (0) to 96 hours post-dose

Interventionh*ng/mL (Geometric Mean)
Total MolybdenumPlasma Ultrafiltrate Molybdenum
ALXN1840184501763

[back to top]

ΔΔQTcF For Moxifloxacin Using The By-time Point Analysis

"Assay sensitivity was evaluated using the by-time point analysis of the effect on ΔΔQTc of moxifloxacin.~If ΔΔQTcF was larger than 5 ms at 1, 2, and 3 hours postdose, assay sensitivity was considered to be demonstrated." (NCT04560816)
Timeframe: 1, 2, and 3 hours postdose at Day 1

Interventionms (Least Squares Mean)
Day 1, 1 hour postdoseDay 1, 2 hours postdoseDay 1, 3 hours postdose
Moxifloxacin9.6511.0411.37

[back to top]

Area Under The Plasma Concentration Versus Time Curve From Time 0 (Dosing) to the Last Quantifiable Concentration (AUCt) of Total Molybdenum

The PK data of plasma total molybdenum were analyzed in the scope of this study as a surrogate measure for ALXN1840. Whole blood samples were collected for the measurement of plasma concentrations of total molybdenum via ICP-MS. (NCT05303324)
Timeframe: Up to 240 hours postdose

Interventionhours*ng/mL (Mean)
ALXN1840 Treatment A7054.5
ALXN1840 Treatment B6990.5

[back to top]

Number of Participants With a Treatment-Emergent Adverse Event (TEAEs)

An adverse event (AE) was any untoward medical occurrence in a participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. TEAE was an AE that started during or after the first dose, or started prior to the first dose and increased in severity after the first dose. A related TEAE was defined as having a reasonable possibility the study intervention caused the AE as assessed by the investigator. Serious AEs (SAEs) were defined as any untoward medical occurrence that met at least 1 of the following serious criteria: resulted in death, was life-threatening, required in-patient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, other medically important serious event. A summary of all SAEs and Other AEs (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section. (NCT05303324)
Timeframe: Baseline up to Day 43

,,,
InterventionParticipants (Count of Participants)
Any TEAEAny serious TEAE (SAE)Any TEAE leading to deathAny related TEAE
Period 1: ALXN1840 Treatment A7004
Period 1: ALXN1840 Treatment B5000
Period 2: ALXN1840 Treatment A4001
Period 2: ALXN1840 Treatment B8001

[back to top]

Maximum Observed (Plasma) Concentration (Cmax) of Total Molybdenum

The pharmacokinetic (PK) data of plasma total molybdenum were analyzed in the scope of this study as a surrogate measure for ALXN1840. Whole blood samples were collected for the measurement of plasma concentrations of total molybdenum via inductively coupled plasma-mass spectroscopy (ICP-MS). (NCT05303324)
Timeframe: Up to 240 hours postdose

Interventionnanograms (ng)/milliliter (mL) (Mean)
ALXN1840 Treatment A173.10
ALXN1840 Treatment B174.27

[back to top]

Area Under the Plasma Concentration Versus Time Curve, From Time 0 to the Last Measurable Concentration (AUC0-t) of Total Molybdenum (Mo)

AUC0-t was calculated by the linear trapezoidal method. (NCT05319899)
Timeframe: Predose (0 hour) up to 192 hours postdose

Interventionhours*ng/mL (Mean)
Treatment A: ALXN1840 (Fasted)14531
Treatment B: Omeprazole + ALXN1840 (Fasted)18537
Treatment C: Omeprazole + ALXN1840 (Fed)14536

[back to top]

Maximum Measured Plasma Concentration (Cmax) of Total Mo

(NCT05319899)
Timeframe: Predose (0 hour) up to 192 hours postdose

Interventionng/mL (Mean)
Treatment A: ALXN1840 (Fasted)330
Treatment B: Omeprazole + ALXN1840 (Fasted)401
Treatment C: Omeprazole + ALXN1840 (Fed)385

[back to top]

Number of Participants With Treatment-Emergent Adverse Events (TEAEs)

An adverse event (AE) was defined as any untoward medical occurrence in a participant administered with the study drug and which did not necessarily have a causal relationship with the study drug. An AE could therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of study drug, whether or not related to study drug. A TEAE was defined as an AE that started or worsened at the time of or after study drug administration. An AE that occurred during the washout period between drugs was considered treatment emergent to the last drug given. A summary of all Serious Adverse Events and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section. (NCT05319899)
Timeframe: Day 1 through 14 days following final dose (up to Day 43)

InterventionParticipants (Count of Participants)
Treatment A: ALXN1840 (Fasted)6
Treatment B: Omeprazole + ALXN1840 (Fasted)5
Treatment C: Omeprazole + ALXN1840 (Fed)6

[back to top]

Maximum Measured Plasma Concentration (Cmax) of Total Mo

(NCT05319912)
Timeframe: Predose (0 hour) up to 192 hours postdose

Interventionng/mL (Mean)
Treatment A: ALXN1840 (Fasted)376
Treatment B: ALXN1840 (Fed)187
Treatment C: Omeprazole + ALXN1840 (Fasted)442

[back to top]

Number of Participants With Treatment-Emergent Adverse Events (TEAEs)

An adverse event (AE) was defined as any untoward medical occurrence in a participant administered with the study drug and which did not necessarily have a causal relationship with the study drug. An AE could therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of study drug, whether or not related to study drug. A TEAE was defined as an AE that started or worsened at the time of or after study drug administration. An AE that occurred during the washout period between drugs was considered treatment emergent to the last drug given. A summary of all Serious Adverse Events and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section. (NCT05319912)
Timeframe: Day 1 through 14 days following final dose (up to Day 43)

InterventionParticipants (Count of Participants)
Treatment A: ALXN1840 (Fasted)4
Treatment B: ALXN1840 (Fed)2
Treatment C: Omeprazole + ALXN1840 (Fasted)6

[back to top]

Area Under the Plasma Concentration Versus Time Curve, From Time 0 to the Last Measurable Concentration (AUC0-t) of Total Molybdenum (Mo)

AUC0-t was calculated by the linear trapezoidal method. (NCT05319912)
Timeframe: Predose (0 hour) up to 192 hours postdose

Interventionhours*ng/mL (Mean)
Treatment A: ALXN1840 (Fasted)16026
Treatment B: ALXN1840 (Fed)5740
Treatment C: Omeprazole + ALXN1840 (Fasted)19809

[back to top]